

US010220071B2

(12) **United States Patent**
Call et al.

(10) **Patent No.: US 10,220,071 B2**
(45) **Date of Patent: Mar. 5, 2019**

(54) **MICROCIN AND USES THEREOF**

(71) Applicant: **Washington State University**, Pullman, WA (US)

(72) Inventors: **Douglas R. Call**, Pullman, WA (US);
Lisa Orfe, Pullman, WA (US)

(73) Assignee: **Washington State University**, Pullman, WA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/992,874**

(22) Filed: **May 30, 2018**

(65) **Prior Publication Data**

US 2018/0264078 A1 Sep. 20, 2018

Related U.S. Application Data

(60) Division of application No. 15/268,666, filed on Sep. 19, 2016, now Pat. No. 10,022,423, which is a continuation-in-part of application No. 14/407,975, filed as application No. PCT/US2013/045937 on Jun. 14, 2013, now Pat. No. 9,492,500.

(60) Provisional application No. 61/660,616, filed on Jun. 15, 2012.

(51) **Int. Cl.**

A61K 39/02 (2006.01)
A61K 38/16 (2006.01)
A61K 35/74 (2015.01)
A01N 63/02 (2006.01)
A01N 63/00 (2006.01)
A01N 37/46 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 38/164** (2013.01); **A01N 37/46** (2013.01); **A01N 63/00** (2013.01); **A01N 63/02** (2013.01); **A61K 35/74** (2013.01)

(58) **Field of Classification Search**

CPC **A61K 38/164**
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,512,282 A 4/1996 Krivan et al.
9,492,500 B2 11/2016 Call et al.
2008/0200374 A1 8/2008 Severinov et al.

OTHER PUBLICATIONS

Eberhart et al., "Characterization of a Novel Microcin that kills Enterohemorrhagic *Escherichia coli* O157:H7 and O26", Appl. Environ. Microbiol., Jul. 6, 2012, vol. 78, No. 18, pp. 6592-6599. NCBI, GenBank Accession No. YP_006954414.1, "microcin protein [*Escherichia coli*]", Jun. 9, 2013.

Zschuttig et al., "Identification and characterization of microcin S, a new antibacterial peptide produced by probiotic *Escherichia coli* G3/10", PloS One, Mar. 30, 2012, vol. 7, No. 3, pp. 1-9.

Sawant et al., Proximity-dependent inhibition in *Escherichia coli* isolates from cattle, Appl. Environ. Microbiol., Feb. 4, 2011, vol. 77, No. 7, pp. 2345-2351.

Azpiroz et al., "Microcin H47 system: an *Escherichia coli* small genomic island with novel features", PloS One, Oct. 11, 2011, vol. 6, No. 10, pp. 1-7.

Ashkenazi et al. (Therapeutic Advances in Vaccines, vol. 1 (3) pp. 113-123, 2013).

Plotkin et al. (Vaccines WB Saunders Company, p. 571, 1988).

Primary Examiner — Albert M Navarro

(74) Attorney, Agent, or Firm — W&C IP

(57) **ABSTRACT**

Microcin MccPDI and bacteria harboring the mcpM gene which encodes MccPDI limit growth of and/or kill pathogenic bacteria such as pathogenic *Escherichia coli* (*E. coli*) and/or *Shigella* bacteria via proximity-dependent inhibition (PDI).

4 Claims, 17 Drawing Sheets

Specification includes a Sequence Listing.




Figure 1




Figure 2




Figure 3A




Figure 3B




Figure 4




Figure 5




Figure 6




Figure 7A




Figure 7B




Figure 8A




Figure 8B




Figure 9A




Figure 9B




Figure 10A




Figure 10B




Figure 11A

-115 B3 -97 B1 -77 B2 -58

GAAAACATACAAATTTTTTCACATATTTACATTTAATCACACAATTTCACTTTCATTACATTTTTG
 SEQ ID NO:62

F1 TTTACTTTTGGTTACATATY SEQ ID NO:63
 F2 TTTTCYTTTTGAAACCAAAT SEQ ID NO:64
 F3 TTATCTTTGTAGCACTTTCA SEQ ID NO:65
 F4 GTTACGGAATATTACATTGC SEQ ID NO:66
 C1 TTTACATTTTGAAACATCTA SEQ ID NO:67
 B1 TTTACATTTAATCACACAAT SEQ ID NO:68
 B2 TTCAC-TTTCATTACATTTT SEQ ID NO:69
 B3 TACAAATTTTTTCACATA SEQ ID NO:70

Figure 11B




Figure 12



Figure 13




Figure 14




Figure 15




Figure 16A




Figure 16B




Figure 17




Figure 18




Figure 19




Figure 20A

Figure 20B

1

MICROCIN AND USES THEREOF**CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a divisional application of USSN 15/268,666 filed Sep. 19, 2016, now U.S. Pat. No. 10,022,423, which was a Continuation-in-Part of USSN 14/407,975, filed Dec. 15, 2014, now U.S. Pat. No. 9,492,500, which was a National Stage Application based on the International Application No. PCT/US2013/045937 filed Jun. 14, 2013 which claims priority to U.S. Provisional Application 61/660,616 filed Jun. 15, 2012 .

This invention was made with government support under Grant Number 2011-67005-30021 awarded by the United States Department of Agriculture through the National Institute of Food and Agriculture. The government has certain rights in this invention.

ACKNOWLEDGEMENT OF FEDERAL FUNDING

Particular aspects of the present invention were, at least in part, supported by Grant Number 2010-04487 from the United States Department of Agriculture (USDA-AFRINIFA) and Grant Number 10-086 from the National Pork Board. The United States government and National Pork Board therefore may have certain rights in the invention.

FIELD OF THE INVENTION

Aspects of the invention relate generally to bacteria, bacteriocins (e.g., colicins or microcins) and proximity-dependent inhibition (PDI), and in more particular embodiments to compositions and methods for controlling and/or killing pathogenic bacteria (e.g., enterohemorrhagic and/or enterotoxigenic strains of *E. coli*), comprising use of a novel microcin.

BACKGROUND

Escherichia coli are commonly found in the gut of both humans and animals. Most *E. coli* are considered symbiotic; however, pathogenic strains have been isolated that are associated with foodborne illness in people and animals e.g., pathogenic *E. coli* K88 and K99 affect swine and calves, respectively. Transmission of pathogenic *E. coli* occurs through fecal contamination of food or water, and is commonly associated with the consumption of under-cooked meat, raw milk, or contaminated vegetables.

Pathogenic *E. coli* includes the Shiga-toxin producing strains known as STEC. Shiga-toxin is named for its resemblance to the Shiga-toxin produced by *Shigella dysenteriae*. STEC infection can be asymptomatic, or include symptoms of fever, watery diarrhea, severe abdominal pain, hemolytic uremic syndrome (HUS) and even death, with more severe cases typically being reported in young children or the elderly. Enterohaemorrhagic *E. coli* (EHEC) are a subset of STEC, characterized by their ability to form attaching and effacing intestinal lesions. Cattle are the main reservoir for EHEC, the bacteria living asymptotically in the cow intestine, although these bacteria have also been isolated from the intestinal tract of other domestic animals including sheep, pigs, goats, and dogs. These EHEC predominantly colonize the recto-anal junction of cattle, thereby increasing the risk of transmission to humans through fecal contamination. Numerous EHEC have been isolated including sero-

2

types O111, O145, O103, O26, and O157. According to the Centers for Disease Control and Prevention, O157:H7 is the most common serotype that causing *E. coli*-linked food poisoning in the United States. The infectious dose is estimated to be as low as 10-100 bacteria. EHEC infections can be difficult to treat and some antibiotics actually worsen symptoms of an EHEC infection by inducing Shiga-toxin production and increasing the risk of HUS.

The introduction of antibiotics as therapeutics in the mid-1940s was an important advancement for medicine in terms of reducing human morbidity and mortality. The subsequent emergence of antibiotic resistant bacteria, however, indicates that bacteria adapt to antibiotic pressure. Resistance can be acquired and maintained within a population through horizontal transfer of resistant genes, and/or through selection for mutations that confer resistance. Unfortunately, the use of antibiotics is widespread and invariably selects for resistance as continual exposure to the drugs inhibit susceptible strains and allows resistant strains to emerge and dominate a population. Selection for resistance occurs for all bacteria exposed to antibiotics, not just the specific pathogens that are being targeted. For example, when enrofloxacin was used to treat *E. coli* infections in poultry, it simultaneously selected for resistance in *Campylobacter jejuni*, which is another important food-borne pathogen. The increasing prevalence of resistant bacterial pathogens threatens the effectiveness of currently available antibiotics and presents a difficult challenge in human and animal medicine. The development of novel strategies to control pathogenic bacteria is necessary to 1) combat infection by existing strains and 2) provide alternatives so that antibiotic use, and hence the emergence of resistant strains, can be decreased.

Some bacteria have developed the ability to inhibit other bacteria, and further characterization of how this occurs could be helpful in the design of new anti-bacterial strategies. For example, cell-cell inhibition mechanisms have been documented in the literature and range from contact-dependent inhibition (1, 20) to production of narrow-spectrum antimicrobial proteins called bacteriocins. Bacteriocins typically restrict the growth of closely related bacteria (reviewed in (28, 31)). *E. coli* produce numerous bacteriocins (31), classified as either colicins or microcins (2, 11). Colicins are high-molecular weight, whereas microcins are typically <10 kDa. Microcins can be either chromosomally or plasmid encoded, whereas colicins have only been found on plasmids (13, 29, 30). Colicin production is usually correlated with an SOS response to stress (22, 34) and release of the colicin typically occurs through cell lysis. Microcins are secreted from intact cells (8, 27). Bacteriocins have been identified that kill competitors through pore formation, nuclease activity, or by inhibiting protein synthesis (3, 23-25).

Sawant et al. recently described a novel bacterial inhibition phenotype whereby defined strains of *E. coli* from cattle are able to inhibit growth of other *E. coli* strains including several strains of enterohemorrhagic *E. coli* (EHEC) and enterotoxigenic *E. coli* (ETEC) (32). During in vitro competition assays, susceptible strains declined an average 4-6 log in population size relative to their expected population density when grown as monocultures. The inhibition phenotype was called "proximity-dependent inhibition" (PDI) because of the apparent need for inhibitor and susceptible strains to be located in close physical proximity for the phenotype to be observed. Two different *E. coli* strains were described as expressing this trait (PDI⁺); multidrug resistant *E. coli*-25 and antibiotic susceptible *E. coli*-264. *E. coli*-25

and *E. coli*-264 do not affect the growth of each other, indicating that immunity is either conferred actively through the presence of an immunity mechanism, or passively through the absence of a receptor ligand found on susceptible cells.

Certain characteristics of the PDI phenotype resemble that of microcin production. For example, inhibition is effective against closely related species; PDI is not dependent on an SOS response; and production presumably does not kill the inhibitor strain (32). Nevertheless, microcins are soluble proteins and when Sawant et al. (32) employed a split-well experiment they demonstrated that close cell-cell proximity is required for the PDI phenotype to function. These findings suggest that the inhibition mechanism is not due to a soluble molecule unless the concentration is so low as to require close proximity to be effective (32).

The initial report of PDI provided a detailed description of the phenotype and a similar phenotype has been described between *Bibersteinia trehalosi* and *Mannheimia haemolytica* (4). Nevertheless, the exact mechanism of PDI and requisite genes for inhibition and immunity were not known at the time that the PDI was originally described. Progress in this field could aid the development of strategies to combat the emergence and spread of pathogenic bacteria, and to provide treatments for infection with pathogenic bacteria.

SUMMARY OF EXEMPLARY ASPECTS

Particular embodiments of the invention demonstrate, for the first time, that “proximity-dependent inhibition” (hereinafter “PDI”) results in death of the susceptible cells, and that PDI can be used for killing pathogenic *E. coli* in vitro on surfaces and materials of interest, and in vivo, and further the PDI can be used prophylactically and therapeutically.

Additional embodiments of the invention identify the PDI gene cluster, which resembles that of a class IIa microcin. The gene cluster includes ORFs putatively encoding proteins for microcin synthesis, immunity, and export. In addition, *tolC* is required for inhibition, thereby confirming that the microcin is secreted by a type I secretion system (T1SS).

According to further embodiments of the invention, the PDI phenotype is caused by a novel microcin, designated herein as MccPDI, and MccPDI is utilized in a number of different and beneficial applications. In some instances, the use of MccPDI and/or bacteria that produce MccPDI advantageously replaces the use of antibiotics.

Every strain from a genetically diverse panel of *E. coli* O157:H7 (n=25) and additional strains of *E. coli* serovar O26 were susceptible to the PDI phenotype. Live-dead staining was consistent with inhibition by killing of susceptible cells. Comparative genome analysis identified the genetic component of PDI, which is composed of a plasmid-borne (*Incl1*) operon encoding a putative microcin and associated genes for transport, immunity, and microcin activation. Transfer of the plasmid to a PDI⁻ strain resulted in transfer of the phenotype and deletion of the genes within the operon resulted in loss of the inhibition phenotype. Deletion of chromosomally encoded *tolC* also resulted in loss of the inhibitory phenotype and this confirmed that the putative microcin is most likely secreted via a type I secretion pathway. Deletion of an unrelated plasmid gene had no effect on the PDI phenotype. Quantitative RT-PCR demonstrated that microcin expression is correlated with logarithmic-phase growth.

According to yet further embodiments of the invention, the ability to inhibit a diversity of *E. coli* strains indicates

that this microcin has utility to influence gut community composition (Eberhart, L J, J N Ochoa, T E Besser, and D R Call. 2014. Microcin mccPDI reduces the prevalence of susceptible *Escherichia coli* in neonatal calves. Journal of Applied Microbiology doi: 10.1111/jam.12535), and substantial utility for control of important enteric pathogens.

In some aspects, the bacteria that are killed (lysed, inhibited, damaged, etc.) are any that have (carry, bear, include, contain, etc.) the OmpF protein in or as a component of their outer membrane. OmpF or “outer membrane protein F”, (or OmpF porin), is an integral membrane protein located in the outer membrane of *E. coli* bacteria. OmpF porin is found in a trimer formation and is a non-specific transport channel that allows passive diffusion of small, polar molecules (600-700 Da in size) through the cell’s outer membrane, e.g. water, ions, glucose, and other nutrients as well as waste products. Without being bound by theory, the microcin described herein appears to bind to OmpF when exerting its lethal effects.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. PDI is effective against a broad panel of O157:H7 and STEC O26 *E. coli* isolates. On average, susceptible populations were reduced greater than 5-logs following 24 h co-culture with *E. coli*-25. Clinical and bovine-biased O157 genotypes are indicated (33). *Klebsiella pneumoniae* was not inhibited by PDI and is included as a negative control. Error bars correspond to the standard error of the mean based on duplicate experiments.

FIG. 2. Schematic of the putative PDI sequence (~5 kb). Whole genome sequencing identified a large plasmid containing a unique region that is present in PDI⁺ strains but not PDI⁻ strains (GenBank accession JQ901381) (SEQ ID NO:). Bioinformatics identified five open reading frames putatively corresponding to genes for microcin synthesis (*mcpM* and *mcpA*), immunity (*mcpI*), and export (*mcpD* and *mcpB*).

FIGS. 3A-B. Targeted gene deletion results in the loss of the PDI phenotype. A. CFUs of PDI⁻ *E. coli*-186 following co-culture with wild-type *E. coli*-25 or *E. coli*-25 knockout mutants. Results are expressed as the difference in CFUs of the sensitive strain grown in co-culture and monoculture. B. Competitions with PDI⁺ *E. coli*-264 indicate which knockout mutants no longer exhibit immunity to PDI. Immunity to PDI is restored in the *mcpI* complemented clone. Results are expressed as the difference of log CFUs during co-culture and individual culture. Experiments were conducted in triplicate with error bars representing the standard error of the mean. *, statistically significant ANOVA (p-value <0.01 with Dunnett’s upper one-sided multiple-comparison test with control).

FIG. 4. Expression of *mcpM* by *E. coli*-25 is correlated with growth phase. Expression of *mcpM* was measured during 24 hr culture in M9. Closed circles are the mean normalized *mcpM* expression \pm SEM (n=2 replicates). Open circles are the mean colony forming units (CFU) \pm SEM (n=2 replicates).

FIG. 5. MccPDI-producing *E. coli*-25 inhibits the growth of susceptible *E. coli*-186 in neonatal calves. A competition index (CI) was calculated as $(X-Y)/(X+Y)$, where X is the CFU of *E. coli*-25 Δ *mcpM* Δ *mcpI* or *E. coli*-25 Δ *traM* colonies and Y is the CFU of *E. coli*-186 colonies. A CI approaching +1 indicates the *E. coli*-25 mutant is the dominant strain and a CI approaching -1 indicates *E. coli*-186 is dominant. The mean CI for the positive (black bars; *E. coli*-25 Δ *traM* and *E. coli*-186; n=7)) and negative control

5

(white bars; *E. coli*-25 Δ mcpM Δ mcpI and *E. coli*-186; n=4) calves on day one and day six. Error bars correspond to the standard error of the mean and the asterisk shows significant difference between MccPDI-producing and non-producing groups (P=0.003).

FIG. 6. The production of MccPDI contributes to the fitness of *E. coli*-25 within a calf. Each data point represents the percentage of the *E. coli*-25 mutant relative to the total lactose fermenting enteric CFU at the corresponding day post inoculation. Closed circles represent *E. coli*-25 Δ traM (n=7 calves) and open circles correspond to *E. coli*-25 Δ mcpM Δ mcpI (n=4 calves). Error bars represent the standard error of the mean.

FIGS. 7A and B. MccPDI-producing *E. coli*-25 is recovered more frequently from GI tissues. Bars represent the frequency of recovery for competing strains in each trial at four segments of the GI tract: A. MccPDI-producing *E. coli*-25 Δ traM (black) and *E. coli*-186 (grey), B. MccPDI-knockout *E. coli*-25 Δ mcpM Δ mcpI (black) and *E. coli*-186 (grey).

FIGS. 8A and B. Growth curves of *E. coli*-25, *E. coli* BW25113, and the MccPDI-resistant mutants Δ atpA, Δ atpF, Δ dsbA, Δ dsbB, Δ ompF, and Δ ompR when cultured in M9 minimal media (A) or LB media (B).

FIGS. 9A and B. The EnvZ/OmpR two-component regulatory system controls the MccPDI phenotype. (A) Competition assays between an MccPDI-producing strain (*E. coli*-25) and a target strain (BW25113) in M9 and LB with different concentrations of NaCl for 12 h. Results are expressed as the difference of mean log CFU during co-culture and mono-culture (n=3 independent replicates; error bars=SEM). (B) Δ envZ or Δ ompR strains no longer exhibit the MccPDI phenotype. Results are shown for competition assays between different knockouts or their complemented strains and BW25113 or BW25113 (vector control). Results are expressed as the difference of BW25113 log CFUs during co-culture and mono-culture for 12 h (error bars=SEM; 3 independent replicates). For complementation experiments the competition assays were performed in M9 with 34 μ g/ml chloramphenicol and 0.5 mM IPTG. *, significant ANOVA followed by a Dunnett's one-way multiple comparisons test versus control group (E25) (P<0.001).

FIGS. 10A and B. Transcriptional analysis (qPCR) of mcpM for *E. coli*-25 and Δ envZ strains in M9 media (error bars=SEM; 2 independent replicates). P<0.05 for all time points E25 Δ envZ versus WT at 8 h. GLM ANOVA followed by a Bonferroni multiple-comparison test. (B) Transcriptional analysis (qPCR) of nicpM for *E. coli*-25 cultured in LB or M9 media. Fold change is expressed relative to mcpM expression in LB at 24 h (error bars=SEM; 3 independent replicates). *P<0.01 based on ANOVA.

FIGS. 11A and B. McpM promoter region has multiple binding sites for phosphorylated OmpR. (A) Diagram of the 10 DNA fragments that were selected from within the promoter region of mcpM. Fragments 1-8 were obtained by PCR amplification with bars indicating the primer position. Fragments 9-10 were obtained by annealing complementary oligonucleotides. (B) Three putative OmpR binding sites (B1, B2 and B3) are shown. F1, F2, F3 and F4 are the OmpR binding sites from the promoter region of *E. coli* ompF and C1 is the OmpR binding site identified with the promoter region of *E. coli* ompC.

FIG. 12. CFU counts for *E. coli* BW25113 following competition with microcin-producing *E. coli*-25 and associated gene knockout and complemented strains. Results are

6

expressed as the difference in CFUs of the sensitive strain grown in co-culture and monoculture (error bars=SEM; 3 independent experiments).

FIG. 13. Amino acid sequence alignment of class II microcin precursors. MccPDEI (SEQ ID NO:24); McsS, microcin S (YP_006954535; SEQ ID NO:71); ColV, colicin V (CAA40746; SEQ ID NO:72); MccL, microcin L (AAP03989; SEQ ID NO:73); Mcc24, microcin 24 (AAA88772; SEQ ID NO:74); MccE492, microcin E492 (AAD04332; SEQ ID NO:75); MccH47, MchB protein (CAB54534; SEQ ID NO:76). The arrows indicate the cleavage sites corresponding to McpM that we identified in this study. The inverted triangles indicate the position of the four cysteines of McpM. Sequence alignments were generated using ClustalX 1.83. Parenthetical numbers on the right indicate the amino acid position relative to the N terminus of each sequence.

FIG. 14. Identification of McpM cleavage sites. Competition assays between the different site-specific mutants and BW25113 (vector ctrl). Results are expressed as the mean difference in CFU of the sensitive strain grown in co-culture and monoculture (error bars=SEM; 3 independent replicates). *, statistically significant ANOVA (P<0.01 with Dunnett's upper one-sided multiple-comparison test with control).

FIG. 15. Competition assays between the different residue-specific mutants and BW25113 (vector ctrl). Competition was performed in M9 medium with chloramphenicol (34 μ g/ml) and 0.5 mM IPTG for 12 h. Results are expressed as the difference in CFUs of the sensitive strain grown in co-culture and monoculture.

FIGS. 16A and B. Loss of leader sequences blocks function of McpM. (A) Schematic diagram of different deleted constructs where residue numbering corresponds to amino acids in the full length McpM (wt). ColV1-15 is the signal peptide sequence from colicin V. (B) Competition assays between the different deleted mutants and BW25113 (vector control). Results are expressed as the mean difference in CFU of the sensitive strain grown in co-culture and monoculture (error bars=SEM; 3 independent replicates).

FIG. 17. Cysteine residues 57 and 90 are required for McpM function. Competition assays between the 4 cysteine-residue mutants and BW25113 (vector control). Results are expressed as the difference in CFU of the sensitive strain grown in co-culture and monoculture (bars=SEM; 3 independent replicates). *, statistically significant ANOVA (P<0.01 with Dunnett's upper one-sided multiple-comparison test with control).

FIG. 18. Disulfide bond formation system in *E. coli* is not involved into the mcpM activity. CFUs of *E. coli* BW25113 following competition with wild-type E25 and different knockouts strains in the E25 background (single and double). Results are expressed as the difference in CFUs of the sensitive strain grown in co-culture and monoculture. Experiments were done in duplicate with error bars representing the standard error of the mean (SEM). *, statistically significant ANOVA (P<0.01 with Dunnett's upper one-sided multiple-comparison test with control).

FIG. 19. MccPDI induces membrane permeability in susceptible cells. DAPI staining of the fluorescent-labeled strains in mono-culture and co-culture for 2 h and 6 h. The strains were derived from E25 (E25 Δ traM and E25 Δ mcpM Δ mcpI), and the MccPDI target strain BW25113. The DAPI staining was consistent with increased membrane permeability given exposure to MccPDI.

FIGS. 20A and B. Recombinant McpM inhibits growth of susceptible *E. coli* independent of a McpM-producing *E. coli* strain. Plates containing (A) M9 agar media and (B) LB agar media are shown.

DETAILED DESCRIPTION

The genetic components that are responsible for the PDI phenotype observed from *E. coli*-25 and *E. coli*-264 are, for the first time, identified herein. This 4.8-kb cassette is present on pPDI (see Example 10 below) and is comprised of the genes *mcpM*, *mcpI*, *mcpA*, *mcpD*, and *mcpB* (see Example 9 below).

According to particular aspects, inhibition is mediated by the microcin encoded by *mcpM*, whose mature gene product is designated herein as MccPDI. The inventors demonstrate that a non-mccPDI strain called *E. coli*-82 is genetically very similar to *E. coli*-25 based on a technique called XbaI macrorestriction digest and pulsed-field gel electrophoresis. These two strains were sequenced using a 454 sequencing platform. The resulting sequences showed that the primary difference between the two strains was the presence of a large Inc11 plasmid. From this sequence, the inventors identified the mccPDI gene cassette. pPDI was subsequently marked with a kanamycin resistant cassette while simultaneously knocking out an unrelated genes, *traM* (Δ traM). This plasmid was subsequently transferred to the PDI⁻ strain, *E. coli*-4. Wild-type *E. coli*-4 does not exhibit the inhibitory phenotype, as indicated by competition assays with the susceptible *E. coli*-186 (Table 2; and see Example 6 herein below). *E. coli*-4 also exhibits susceptibility to PDI, based on CFU counts following co-culture with PDI⁺*E. coli*-264. Following transformation with pPDI Δ traM, *E. coli*-4 acquired the inhibitory phenotype and immunity (Table 2; and see Example 6). Together these results indicate PDI and self-immunity are encoded by the 98.8 kb plasmid (see Example 10 below).

To demonstrate the necessity for each gene in the operon for PDI function, genetic knockouts were constructed and used herein to show that disrupting any gene within the PDI operon blocked the inhibitory phenotype and, additionally, immunity to PDI was lost in the *mcpM* and *mcpI* mutants (FIG. 3). According to particular aspects, this indicated that all the genes were important for PDI, but immunity was dependent on only one or two genes. Due to the direct downstream location of *mcpI*, loss of immunity in the *mcpM* mutant was likely caused by a polar effect from Δ *mcpM*. This is consistent with the ability shown herein to complement immunity by the expression of *mcpI* alone. Although *mcpI* likely does not play a direct role in killing, it is necessary for self-immunity and for this reason is required for PDI. Deleting *traM*, a gene located ~20 Kb upstream of the PDI operon, did not affect either inhibition or immunity indicating that the methods used herein did not interfere with PDI. Furthermore, the *tolC*, *mcpB*, and *mcpD* mutants lost the ability to inhibit but retained immunity, consistent with a role in toxin transport.

According to particular aspects, and based on gene cluster and sequence analysis, MccPDI is best characterized as a Gram-negative class IIa microcin. The PDI gene cluster is relatively simple, consisting of two genes for export, one for immunity, one presumptively for microcin activation, and the microcin gene itself. Unlike class I and IIb microcins, which have several genes for post-translational modification, MccPDI only has one recognizable gene that is putatively required for microcin activation. The dedicated transport system involves the products of two plasmid-encoded

genes, *mcpB* and *mcpD*. These two PDI genes have homology with *hlyB* and *hlyD* of the *E. coli* α -hemolysin T1SS (9). This multicomponent export system has similar organization to transport systems for other class II microcins, including MccE492, MccL, and MccV (10, 18, 26). McpB contains the transmembrane domains and nucleotide-binding domains, including the highly conserved Walker A and B motifs and ABC signature, characteristic of the ABC-transporter superfamily of proteins (21). McpD is thought to act as a membrane fusion protein, forming a channel through the periplasm and connecting to the outer membrane protein TolC, the third component of class II microcin export machinery (7, 10, 18, 26). In total, these proteins form the export system allowing secretion of protein from the cytoplasm across the periplasmic space and into the extracellular medium. McpM has homology to other microcin precursors within the N-terminal sequence, which encodes a putative signal peptide (6) that is consistent with T1SS transport. The presence of a conserved double glycine suggests the McpM precursor contains an 18-residue signal peptide that is cleaved to produce a mature MccPDI. There is no apparent sequence identity with other microcins in the activity region (C-terminal sequence) (6).

This indicates that a unique receptor is probably involved with the uptake of MccPDI and that the mechanism of killing is different from other microcins. The fact that only *E. coli* and *Shigella* (data not shown) are currently known to be susceptible to this PDI (MccPDI) suggests target cell recognition occurs through a specific receptor, possibly only expressed in these species.

Class IIa microcin gene clusters are typically composed of only four genes: two necessary for microcin export, one for immunity, and one encoding the microcin. The PDI operon is unique because it also includes a gene presumably involved with microcin processing or export. Deleting *mcpA* in *E. coli*-25 interrupts the inhibitory phenotype but does not affect immunity. It is possible this mutant has downstream effects on the microcin transport system (i.e. a polar effect); however, not to be bound by theory, bioinformatic analysis suggests the protein product is likely to be involved with post-translational modification of McpM. McpA has similarity to McmM and MceF (both 29% identity) of the MccM and MccE492 gene clusters, respectively. Wilkens et al. (36) showed an *mceF* mutant had a non-inhibitory phenotype and the microcin product collected from cell lysate was found at a higher molecular weight than mature MccE492, suggesting the presence of an inactive microcin precursor. Consistent with a role in protein modification, McpA contains a CaaX amino terminal protease domain (PF02517) that functions in post-translation modification of proteins with the CaaX sequence motif (35). Furthermore, the McpM C-terminus putatively contains a modified terminal CaaX sequence, suggesting McpM may be processed either before or during transport, resulting in the fully mature MccPDI.

Although microcins are released extracellularly to inhibit competing bacteria, no antimicrobial compounds were detected through membrane-divided competitions or spent media assays in previous work (32). It is possible the PDI microcin requires contact between competing cells or some other signal to become active in the media. Alternatively, the methods used in the Examples section herein may interfere with the detection of a soluble microcin in these assays, or the concentration of secreted microcin is too low to have a biological effect except when inhibitor cells express the microcin in close proximity to susceptible strains. Without being bound by theory, it is likely that MccPDI interacts

with an outer membrane protein OmpF, which is highly conserved in all sequenced *E. coli* and *Shigella*. Data presented in Example 12 below shows that six genes (atpA, atpF, dsbA, dsbB, ompF, and ompR) were required for susceptibility to PDI, suggesting that OmpF acts as the receptor for MccPDI and the other genes required for sensitivity are necessary for expression and folding of OmpF, and/or they are required to translocate MccPDI across the cellular membrane.

Like other microcins, MccPDI is a low molecular weight protein that inhibits the growth of closely related species. Whereas the activity of some microcins extends to a range of Gram-negative bacteria including *Escherichia*, *Klebsiella*, *Salmonella*, and *Pseudomonas* (6), MccPDI has only been observed to inhibit *Escherichia*, and testing has also shown inhibition of *Shigella* but not *Salmonella* or *Klebsiella* (data not shown). In Examples presented below, the PDI⁺ strain *E. coli*-25 was competed against a panel of pathogenic *E. coli* O157:H7 (n=25) and *E. coli* O26 (n=3). All the strains were susceptible to killing (FIG. 1) and the average reduction following co-culture was greater than 5 logs. The degree of killing may actually be much greater as our methods to determine cell counts were limited to 2×10³ CFU/ml. Calculations for the degree of killing were determined using 2×10³ CFU/ml for instances where the susceptible population was undetectable. Nonetheless, PDI effectively kills greater than 99% of the competing population. Because many of these pathogens are significant in diseases of both animals and humans (33), MccPDI has application in clinical medicine, food safety and other fields. FIG. 4 shows that native mcpM transcription occurs primarily during rapid growth of the inhibitor population.

The invention provides methods and compositions for killing and/or for preventing or decreasing the adverse effects of pathogenic bacteria such as pathogenic *Escherichia coli* (*E. coli*). The methods involve contacting the pathogenic bacteria with the novel microcin described herein, microcin MccPDI, the amino acid sequence of which is presented in SEQ ID NO: 24. In some embodiments, the microcin MccPDI has undergone one or more cleavage events and comprises a sequence comprising residues 37-120 of SEQ ID NO: 24. The cleaved product may form multimers containing two, three, four, five, six, or more cleaved products as part of a disulfide-bonded complex. In exemplary embodiments, the product forms a dimer. The contact may be via a preparation of the microcin itself, or via a preparation of a bacterium encoding the microcin, as described in detail below.

A further aspect of the invention provides a composition comprising microcin MccPDI having one or more of a sequence of SEQ ID NO: 77 or a functional variant thereof and/or SEQ ID NO:24 or a functional variant thereof, wherein said functional variant has a sequence at least 95% identical to SEQ ID NO: 77 or SEQ ID NO:24; and an oxidizing agent. The composition may contain 5-30% oxidizing agent. In some embodiments, the composition contains 10% oxidizing agent or 20% oxidizing agent. An oxidizing agent is a compound that is capable removing an electron (e.g., addition of a hydrogen) from another chemical species in a redox reaction. Exemplary oxidizing agents include, but are not limited to, dimethyl sulfoxide (DMSO), sodium perborate, permanganate, hypochlorite, and hydrogen peroxide.

Hosts, Pathogens and Sources of Contamination

While most *E. coli* strains are harmless, some serotypes can cause serious and even deadly diseases in a host, either as the result of exposure to the pathogenic bacteria via direct

transmission from another infected host or by ingestion of or exposure to (e.g. handling) contaminated food products or from other sources of the bacteria (e.g. fomites). In particular, the targeted pathogenic bacteria include *E. coli* strains expressing the OmpF protein, which are known to be vulnerable to the MccPDI microcin. The methods and compositions are also effective for killing (e.g. lysing) or preventing or decreasing the adverse effects of pathogenic *Shigella* sp. Those of skill in the art will recognize that phylogenetic studies indicate that *Shigella* is more appropriately treated as a subgenus of *Escherichia*, and that certain strains generally considered *E. coli* (e.g. *E. coli* O157:H7) could be classified as *Shigella*. Herein, the phrases “pathogenic bacteria” and “pathogenic *E. coli*” encompasses both pathogenic *E. coli* and pathogenic *Shigella*, although the two may be discussed separately, for clarity and to accord with historic designations.

The term “pathogenic” refers to the ability of the bacterium to cause disease symptoms in one or more hosts. The targeted bacterium need not cause disease in all hosts that is it capable of colonizing. Successful colonization of some hosts by the bacterium may be entirely benign (asymptomatic, harmless, etc.). However, such non-susceptible hosts may serve as reservoirs of the pathogenic bacteria which, when transmitted to a susceptible host, cause disease. Herein, these two genera of hosts may be referred to as “disease susceptible hosts” and “non-disease susceptible hosts”, respectively, or simply as “susceptible hosts” and “non-susceptible hosts”. It will be understood that the methods of treatment described herein may be advantageously applied to both susceptible and non-susceptible hosts. For the susceptible hosts, treatment may prevent, cure (fully or partially) or ameliorate disease symptoms, or prevent or decrease adverse effects that would otherwise be caused by pathogenic bacteria. These beneficial effects are brought about by killing and/or damaging established pathogenic bacteria, or by preventing, slowing or minimizing the growth of pathogenic bacteria to which the host is newly exposed. For non-susceptible hosts, treatment may destroy or lessen the number of pathogenic bacteria that can colonize the host or that might otherwise colonize the host, but for intervention using the methods and compositions described herein, thereby lessening or eliminating transmission of the pathogenic bacteria to other disease susceptible and non-susceptible hosts.

Susceptible hosts that may be subject to diseases caused by pathogenic *E. coli* are usually endotherms and may be mammals. Such mammals include but are not limited to: primates (e.g. humans), livestock e.g. cattle, pigs, sheep goats, etc., especially neonates, juveniles, elderly or immune compromised individuals; etc. Alternatively, various avian species may also be subject to such infections, including but not limited to: chickens, turkeys, ducks, etc. Non-susceptible hosts that may act as reservoirs of pathogenic bacteria that are passed to susceptible hosts include substantially the same endotherms described above as susceptible hosts.

Further, pathogenic bacteria may be transmitted among members of a particular host group (e.g. from person to person, among cows in a herd, etc.) or even from one area of an individual host organism to another area of the same organism, e.g. pathogenic bacteria may be transmitted from the anus to the urethra via fecal contamination, causing urethral infection.

Particular combinations of susceptible hosts and pathogenic bacteria include the following exemplary animal pathogens of interest:

11

Poultry—avian pathogenic *E. coli* (APEC)
 Calves—*E. coli* K99 (which causes calf diarrhea)
 Swine—*E. coli* K88 (which causes post-weaning diarrhea)

For food safety:

E. coli O157:H7

The United States Department of Agriculture (USDA)

“Big 6” STEC *E. coli*

pathogens: *E. coli* serovars O26, O45, O103, O111, O121 and O145.

Diarrhoeagenic *E. coli* human pathogens:

various enteropathogenic *E. coli* (EPEC)

various enterohaemorrhagic *E. coli* (EHEC)

various enterotoxigenic *E. coli* (ETEC)

various enteroinvasive *E. coli* (EIEC; including *Shigella*)

various enteroaggregative *E. coli* (EAEC)

various so-called diffusely adherent *E. coli* (DAEC)

Extraintestinal *E. coli* (ExPEC) human pathogens:

uropathogenic *E. coli* (UPEC)

neonatal meningitis *E. coli* (NMEC)

Exemplary pathogenic *Shigella* species of interest which may be killed by the compositions and methods of the invention include but are not limited to: Serogroup A: *S. dysenteriae*, Serogroup B: *S. flexneri*, and Serogroup D: *S. sonnei*, and serotypes and serovars thereof.

In addition, contamination with pathogenic bacteria can occur via other routes of transmission such via fomites, (inanimate objects such as countertops, cutting boards, utensils, towels, money, clothing, dishes, toys, dirt, excreted feces, diapers, surfaces in barns and stockyards, etc.), or via unpasteurized milk, dairy products, juices, etc.; or via contaminated water (e.g. drinking water, ponds and lakes, swimming pools, etc.); or via contaminated animals, meat, or produce; or fruits, etc.

In some aspects, the methods of the invention involve contacting pathogenic bacteria with the microcin MccPDI. Accordingly, the invention provides i) substantially purified MccPDI microcin protein; and ii) substantially pure cultures of bacteria that produce the microcin protein.

Proteins and Nucleic Acids

In some aspects the invention provides MccPDI microcin protein and/or a gene that encodes the protein (e.g. SEQ ID NOS: 23 or 33 and 24) as well as proteins/polypeptides of the operon disclosed herein, and the genes which encode them (e.g. SEQ ID NOS: 25-32). In some embodiments, the microcin MccPDI has undergone one or more cleavage events and comprises a sequence comprising residues 37-120 of SEQ ID NO: 24 which is represented by SEQ ID NO:77. The cleaved product may form multimers containing two, three, four, five, six, or more cleaved products as part of a disulfide-bonded complex. In exemplary embodiments, the product forms a dimer.

Substantially purified MccPDI microcin protein may be produced either recombinantly, or from a native or naturally occurring source such as the bacteria described herein. Those of skill in the art are familiar with techniques for genetically engineering organisms to recombinantly produce or overproduce a protein of interest such as MccPDI. Generally, such techniques involve excision of a gene encoding the protein from a natural source e.g. using nucleases or by amplifying the gene e.g. via PCR using primers complementary to sequences that flank the gene of interest. The gene can then be inserted into and positioned within a vector (e.g. an expression vector such as a plasmid or virus) so that it is able to be expressed (transcribed into translatable mRNA). Typically, the gene that is to be transcribed is juxtaposed to one or more suitable control elements such as

12

promoters, enhancers, etc. that drive expression of the gene. Suitable vectors include but are not limited to: plasmids, adenoviral vectors, baculovirus vectors (e.g. so-called shuttle or “bacmid” vectors, and the like). Suitable vectors may be chosen or constructed to contain appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes, and other sequences. The vectors may also contain a plasmid or viral backbone.

Typically, the vector is used to genetically engineer or infect a host organism where the gene is transcribed and translated into protein. In the host, the gene may be expressed from the vector (transcribed extrachromosomally, also called “in trans”) and may be overexpressed, i.e. expressed at a level that is higher than normally occurs in its native bacterial host. Alternatively, the gene may be inserted into the chromosome of the host (“in cis”). Exemplary expression systems that may be utilized include but are not limited to bacteria (such as *E. coli*), yeast, baculovirus, plant, mammalian, and cell-free systems. Host bacteria may be heterologous, i.e. they may be non-native bacteria in which the gene is not present in nature. Alternatively, they may be native bacteria that are natural hosts, but which are genetically engineered to produce the microcin in greater abundance (at higher levels or concentrations) than in the native, non-engineered host. Exemplary heterologous bacterial hosts include but are not limited to: various *Lactobacillus* species such as *Lactobacillus casei*, *Lactobacillus acidophilus*, *Lactobacillus fermentum*, *Lactobacillus gasseri*, *Lactobacillus pentosus*, *Lactobacillus plantarum*, *Lactobacillus sporogenes*, *Lactobacillus brevis*, *Lactobacillus delbrueckii*, *Lactobacillus salivarius*, *Lactobacillus hilgardii*, *Lactobacillus lactis*, *Lactobacillus rhamnosus*, *Lactobacillus johnsonii*, *Lactobacillus leishmanis*, *Lactobacillus jensenii*, *Lactobacillus reuteri*, *Lactobacillus sakei*, *Lactobacillus cellobiosus*, *Lactobacillus crispatus*, *Lactobacillus curvatus*, *Lactobacillus caucasicus*, and *Lactobacillus helveticus*, and others taught, for example, in United States patent application 20090169582 (Chua), the complete contents of which is hereby incorporated by reference in entirety; and other types of bacterial, fungal and/or viral recombinant hosts. Mammalian cells available in the art for heterologous protein expression include lymphocytic cell lines (e.g., NSO), HEK293 cells, Chinese hamster ovary (CHO) cells, COS cells, HeLa cells, baby hamster kidney cells, oocyte cells, and cells from a transgenic animal, e.g., mammary epithelial cell. For details, see Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press (1989). Many established techniques used with vectors, including the manipulation, preparation, mutagenesis sequencing, and transfection of DNA, are described in *Current Protocols in Molecular Biology*, Second Edition, Ausubel et al. eds., John Wiley & Sons (1992).

The vector or chromosome from which the microcin is transcribed includes at least a genetic sequence encoding the microcin described herein and may comprise one or more additional genes of the operon described herein, i.e. genes mcpM (SEQ ID NO: 23), mcpI (SEQ ID NO: 25), mcpA (SEQ ID NO: 27), mcpD (SEQ ID NO: 29), and mcpB (SEQ ID NO: 31), each of which encodes a respective protein or functional variant thereof (see below for explanation of “variant”. The one or more (at least one) gene(s) in the vector or chromosome is/are expressible and are operably (functionally, expressibly) linked to one or more control or expression elements, e.g. promoters, enhancers, etc. in a manner that facilitates, causes or allows expression of the gene(s). In some aspects, the genes are present on a plasmid such as the plasmid with the nucleotide sequence shown in

13

SEQ ID NO: 33), or a plasmid with at least about 55, 60, 65, 70, 75, 80, 85, 90, or 95% or more (e.g. 96, 97, 98, 99%) identity. The plasmid may be located in a native host bacterium, e.g. E-25 (which is resistant to tetracycline, streptomycin and sulfa drugs) and/or E-264 (which is not antibiotic resistant).

The protein that is produced is the microcin MccPDI (or another protein encode by the operon as described above) or a physiologically active variant thereof. By “physiologically active variant” or “active variant” or “functional variant”, we mean a protein sequence that is able to kill pathogenic bacteria as described herein. The protein may have the sequence shown in SEQ ID NO: 24, or may include this sequence, or a sequence that shares at least about 95% identity to SEQ ID NO: 24 (e.g. that is about 95, 96, 97, 98 or 99% identical thereto, as determined by alignment methods that are well-known), but that retains the ability to kill and/or impede growth/reproduction of and/or colonization by pathogenic bacteria. Compared to the wild type microcin, such variants are at least about 50%, and usually about 55, 60, 65, 70, 75, 80, 85, 90, or 95% or more as potent re killing, impeding growth and/or colonization, etc. In some embodiments, the variant may be more potent than the native microcin.

The variants of MccPDI that may be used in the practice of the invention may include those in which one or more amino acids are substituted by conservative or non-conservative amino acids, as is understood in the art. Further, deletions or insertions may also be tolerated without impairing the function. In addition, the microcin may be included in a chimeric or fusion protein that includes other useful sequences, e.g. tagging sequences (e.g. histidine tags), various targeting sequences (e.g. sequences that promote secretion or target the protein to a subcellular apartment or to the membrane), other antimicrobial sequences (e.g. other microcins), and the like, as well as spacer or linking sequences. The sequence of the microcin may be altered to prevent or discourage proteolysis, to promote solubility, or in any other suitable manner.

Some aspects of the invention provide a microcin with a sequence such as that shown in SEQ ID NO: 24, but which is foreshortened by 18 amino acids at the amino terminus, i.e. the 18 amino terminal residues present in SEQ ID NO: 24 are absent in this sequence, which is shown below as SEQ ID NO: 35. As described above for SEQ ID 24, active variants of the sequence represented by SEQ ID NO: 35 are also encompassed by the invention.

(SEQ ID NO: 35)

```

N A N S N F E G G P R N D R S S G A R N S L G R N
A P T H I Y S D P S T V K C A N A V F S G M I G G
A I K G G P I G M A R G T I G G A V V G Q C L S D
H G S G N G S G N R G S S S S C S G N N V G G T C
N R .

```

Some aspects of the invention provide a microcin with a sequence such as that shown in SEQ ID NO: 24, but which is foreshortened by 36 amino acids at the amino terminus, i.e. the 36 amino terminal residues present in SEQ ID NO: 24 are absent in this sequence, which is shown below as SEQ ID NO: 77. As described above for SEQ ID 24, active variants of the sequence represented by SEQ ID NO: 77 are also encompassed by the invention. The protein may have the sequence shown in SEQ ID NO: 77, or may include this

14

sequence, or a sequence that shares at least about 95% identity to SEQ ID NO: 24 (e.g. that is about 95, 96, 97, 98 or 99% identical thereto).

(SEQ ID NO: 77)

```

R N S L G R N A P T H I Y S D P S T V K C A N A V
F S G M I G G A I K G G P I G M A R G T I G G A V
V G Q C L S D H G S G N G S G N R G S S S S C S G
N N V G G T C N R .

```

The invention also encompasses nucleic acid sequences that encode the microcin and active variants thereof as described herein. For example, the encoding sequence may be that which is represented in SEQ ID NO: 23, but this is not always the case. Variants of SEQ ID NO: 23, usually having at least about 95, 96, 97, 98, or 99% identity thereto, are also contemplated. However, those of skill in the art will recognize that the identity may be much lower (e.g. about 50, 55, 60, 65, 70, 75, 80, 85 or 90%) and the sequence may still encode a fully functional microcin, e.g. due to the redundancy of the genetic code.

Calculations of “homology” and/or “sequence identity” between two sequences may be performed as follows: The sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference (native) sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In an exemplary embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (1970, J. Mol. Biol. 48:444-453) algorithm that has been incorporated into the GAP program in the GCG software package, using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In an exemplary embodiment, the percent homology/identity between two nucleotide sequences is determined using the GAP program in the GCG software package, using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that may be used if the practitioner is uncertain about what parameters may be applied to determine if a molecule is within a sequence identity, or homology limitation of the invention) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty

of 4, and a frame shift gap penalty of 5. The percent identity/homology between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller ((1988) CABIOS, 4:11-17) that has been incorporated into the ALIGN program (version 2:0); using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The culturing and the maintenance of cultures of microorganisms such as the bacteria of the invention is carried out e.g. as described herein in the Examples section. Bacterial preparations may be lyophilized or freeze-dried.

The production of the substantially purified microcin protein is carried out by methods known to those of skill in the art, e.g. by collecting unpurified protein from a source such as the bacteria (or other expression system) that make the protein, and purifying and characterizing the protein using known steps, e.g. various separation techniques and identification techniques which include but are not limited to: centrifugation, column chromatography, affinity chromatography, electrophoresis, precipitation, sequencing, spectroscopy, etc. Preparations may be lyophilized or freeze-dried. By "substantially purified" we mean that the microcin is provided in a form that is at least about 75 wt %, preferably at least about 80 wt %, more preferably at least about 90 wt %, and most preferably at least about 95 wt % or more free from other macromolecules such as other peptides, proteins, nucleic acids, lipids, membrane fragments, etc., as is understood by those of skill in the art.

Compositions

The microcins and/or bacteria producing microcins (both of which may be referred to herein as "active agent(s) or "active ingredient(s)") of this invention will generally be used as a bactericidal active ingredient in a composition, i.e. a formulation, with at least one additional component such as a surfactant, a solid or liquid diluent, etc., which serves as a carrier. The formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, the mode of application and environmental factors at the site of use, e.g. such as surface type, (e.g. soil or solid substrate, etc.), moisture, temperature, etc. If the composition is to be administered to a host, the ingredients are selected so as to be physiologically compatible with the host. Useful formulations include both liquid and solid compositions. Liquid compositions include solutions (including emulsifiable concentrates), suspensions, emulsions (including microemulsions and/or suspoemulsions) and the like, which optionally can be thickened into gels. The general types of aqueous liquid compositions are soluble concentrate, suspension concentrate, capsule suspension, concentrated emulsion, microemulsion and suspoemulsion. The general types of nonaqueous liquid compositions are emulsifiable concentrate, microemulsifiable concentrate, dispersible concentrate and oil dispersion.

The general types of solid compositions are dusts, powders, granules, pellets, pills, pastilles, tablets, films, filled or layered films, coatings, impregnations, gels, cakes, and the like, which can be water-dispersible ("wettable") or water-soluble. Films and coatings formed from film-forming solutions or flowable suspensions may be useful for some applications. Active ingredients can be (micro) encapsulated and further formed into a suspension or solid formulation; alternatively the entire formulation of active ingredient can be encapsulated (or "overcoated"). Encapsulation can control or delay release of the active ingredient. An emulsifiable granule combines the advantages of both an emulsifiable

concentrate formulation and a dry granular formulation. High-strength compositions may be used as intermediates for further formulation.

Sprayable formulations are typically extended in a suitable medium before spraying. Liquid and solid formulations are formulated to be readily diluted in the spray medium, which may be aqueous-based, e.g. water. Spray volumes can range from about one to several thousand liters, sprayable formulations may be tank mixed with water or another suitable medium for treatment by aerial or ground application, e.g. of stockyards, barns, stables, stalls, bins containing produce, etc. Smaller volume spray formulations for use on smaller surfaces (e.g. countertops, for application to small quantities of food stuffs, etc.) are also contemplated.

The formulations will typically contain effective amounts of active ingredient in the range of about 1 to about 99 percent by weight.

Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and bicarbonate, and sodium sulfate. Typical solid diluents are described in Watkins et al., Handbook of Insecticide Dust Diluents and Carriers, 2nd Ed., Dorland Books, Caldwell, N.J., the complete contents of which is hereby incorporated by reference in entirety.

Liquid diluents include, for example, water, N,N-dimethylalkanamides (e.g., N,N-dimethylformamide), limonene, dimethyl sulfoxide, N-alkylpyrrolidones (e.g., N-methylpyrrolidinone), ethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g., white mineral oils, normal paraffins, isoparaffins), alkylbenzenes, alkyl-naphthalenes, glycerine, glycerol triacetate, sorbitol, aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes, alkyl-naphthalenes, ketones such as cyclohexanone, 2-heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone, acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, tridecyl acetate and isobornyl acetate, other esters such as alkylated lactate esters, dibasic esters and gamma-butyrolactone, and alcohols, which can be linear, branched, saturated or unsaturated, such as methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol, isobutyl alcohol, n-hexanol, 2-ethylhexanol, n-octanol, decanol, isodecyl alcohol, isooctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol and benzyl alcohol. Liquid diluents also include glycerol esters of saturated and unsaturated fatty acids (typically C₆-C₂₂), such as plant seed and fruit oils (e.g., oils of olive, castor, linseed, sesame, corn (maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel), animal-sourced fats (e.g., beef tallow, pork tallow, lard, cod liver oil, fish oil), and mixtures thereof. Liquid diluents also include alkylated fatty acids (e.g., methylated, ethylated, butylated) wherein the fatty acids may be obtained by hydrolysis of glycerol esters from plant and animal sources, and can be purified by distillation. Typical liquid diluents are described in Marsden, Solvents Guide, 2nd Ed., Interscience, New York, 1950, the complete contents of which is hereby incorporated by reference in entirety.

The solid and liquid compositions of the present invention may include one or more surfactants. When added to a liquid, surfactants (also known as "surface-active agents") generally modify, most often reduce, the surface tension of

the liquid. Depending on the nature of the hydrophilic and lipophilic groups in a surfactant molecule, surfactants can be useful as wetting agents, dispersants, emulsifiers or defoaming agents. Surfactants can be classified as nonionic, anionic or cationic. Exemplary suitable surfactants can be found, for example, in United States patent application 20130143940 to Long, the entire contents of which is hereby incorporated by reference. Also useful for the present compositions are mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants. Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in a variety of published references including McCutcheon's Emulsifiers and Detergents, annual American and International Editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, Encyclopedia of Surface Active Agents, Chemical Publ. Co., Inc., New York, 1964; and A. S. Davidson and B. Milwidsky, Synthetic Detergents, Seventh Edition, John Wiley and Sons, New York, 1987, the complete contents of each of which is hereby incorporated by reference in entirety.

Compositions of this invention may also contain formulation auxiliaries and additives, known to those skilled in the art as formulation aids (some of which may be considered to also function as solid diluents, liquid diluents or surfactants). Such formulation auxiliaries and additives may control: pH (buffers), foaming during processing (antifoams such polyorganosiloxanes), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), in-container microbial growth (antimicrobials), product freezing (antifreezes), color (dyes/pigment dispersions), wash-off (film formers or stickers), evaporation (evaporation retardants), and other formulation attributes. Film formers include, for example, polyvinyl acetates, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes. Examples of formulation auxiliaries and additives include those listed in McCutcheon's Volume 2: Functional Materials, annual International and North American editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co., the complete contents of which is hereby incorporated by reference in entirety.

The active agents described herein and any other active ingredients are typically incorporated into the present compositions by dissolving or suspending the active ingredient in a solvent or by grinding in a liquid or dry diluent. Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. The preparation may be lyophilized (freeze dried). If the solvent of a liquid composition intended for use as an emulsifiable concentrate is water-immiscible, an emulsifier is typically added to emulsify the active-containing solvent upon dilution with water. Active ingredient slurries, with particle diameters of up to 2,000 μm can be wet milled using media mills to obtain particles with average diameters below 3 μm . Aqueous slurries can be made into finished suspension concentrates (see, for example, U.S. Pat. No. 3,060,084, the complete contents of which is hereby incorporated by reference in entirety) or further processed by spray drying to form water-dispersible granules. Dry formulations usually require dry milling processes, which produce average particle diameters in the 2 to 10 μm range. Dusts and powders can be prepared by blending and usually grinding (such as with a hammer mill or fluid-energy mill). Granules and pellets can be prepared by spraying the active material upon preformed granular carriers or by agglomeration techniques. See Browning, "Agglomeration", Chemical Engineering, Dec.

4, 1967, pp 147-48, Perry's Chemical Engineer's Handbook, 4th Ed., McGraw-Hill, New York, 1963, pages 8-57 and following, and WO 91/13546. Pellets can be prepared as described in U.S. Pat. No. 4,172,714. Water-dispersible and water-soluble granules can be prepared as taught in U.S. Pat. No. 4,144,050, U.S. Pat. Nos. 3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S. Pat. No. 5,180,587, U.S. Pat. No. 5,232,701 and U.S. Pat. No. 5,208,030. Films can be prepared as taught in GB 2,095,558 and U.S. Pat. No. 3,299,566. For further information regarding the art of formulation, see T. S. Woods, "The Formulator's Toolbox—Product Forms for Modern Agriculture" in Pesticide Chemistry and Bioscience, The Food-Environment Challenge, T. Brooks and T. R. Roberts, Eds., Proceedings of the 9th International Congress on Pesticide Chemistry, The Royal Society of Chemistry, Cambridge, 1999, pp. 120-133. See also U.S. Pat. No. 3,235,361, Col. 6, line 16 through Col. 7, line 19 and Examples 10-41; U.S. Pat. No. 3,309,192, Col. 5, line 43 through Col. 7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167 and 169-182; U.S. Pat. No. 2,891,855, Col. 3, line 66 through Col. 5, line 17 and Examples 1-4; Klingman, Weed Control as a Science, John Wiley and Sons, Inc., New York, 1961, pp 81-96; Hance et al., Weed Control Handbook, 8th Ed., Blackwell Scientific Publications, Oxford, 1989; and Developments in formulation technology, PJB Publications, Richmond, U K, 2000. The complete contents of each of these references is hereby incorporated by reference in entirety.

In addition, the formulations may include other suitable active agents, e.g. other antimicrobial agents such as other microcins, antibiotics, etc.; or broadly defined antimicrobials such as antiseptics or heavy metals, etc.

Incorporation into Various Products

The active agents described herein may be incorporated into and/or used as an amendment to many different products, e.g. substrates and media which include but are not limited to: so-called "hand-sanitizing" preparations and soaps, gels, etc.; various sprays and washes; detergents and various cleaning agents; fabrics e.g. linings for materials such as diapers and other garments that may be contacted by feces; "booties" that are used to cover and protect shoes; disposable or non-disposable gloves; disposable or non-disposable food preparation surfaces, e.g. as sheets of material that can be placed on a cutting surface, or in a cutting surface itself; in storage apparatuses for implements used in food preparation (e.g. knife blocks, or holders, etc.); and others.

In some aspects, the active agents described herein are incorporated into packaging materials, e.g. packaging materials designed to contain meat or meat products or produce. For example, the packaging material may be impregnated with the active agent either during or after manufacture, or may be coated onto one or more surfaces of the material. The packaging material may be a film e.g. formed from a flexible polymer that may be transparent, or may be a rigid or semi-rigid container formed from e.g. plastic resin, styrofoam, wood, cardboard or pasteboard or other molded cellulose product, or made from some other so-called "natural" material. The packaging material may be in the form of "peanuts". The material may be biodegradable. United States patent applications 20120259295 (Bonutti) and 20030234466 (Rasmussen) and references cited therein, the complete contents of all of which are hereby incorporated by reference in entirety, discuss the preparation of various types of packaging materials.

The active agents may be incorporated into probiotic formulations. Such formulations may be designed or tailored

to suit the mode of administration and the host to which the probiotic is administered. For example, if the targeted host is a human, the active agents may be added to other known probiotic products (kefir, yogurts, "smoothies", etc.) and/or other ingredients that increase palatability may be added (e.g. flavorings, thickeners, coloring agents, etc.). The formulation may be chewable (e.g. a gum or tablet) or taken as a pill. Other organisms may also be present in the probiotic preparation e.g. lactic acid bacteria (LAB), bifidobacteria, yeasts and various bacilli. If the recipient host is a juvenile such as a calf, the probiotic may be a milk substitute formulation. If the recipient is a bird or fowl, the probiotic may be a formulation of drinking water. Probiotics may also be formulated as suppositories.

Methods and Uses

In some aspects, the invention provides methods of using the microcins and bacteria that produce the microcins described herein, for preventing or decreasing the transmission of pathogenic *Escherichia coli* (*E. coli*) bacteria from a first location to a second location, e.g. from a first host (that may or not be a susceptible host) or first contaminated area, to a second host or previously uncontaminated area. The second host may or may not be susceptible. The first location may be a "reservoir" host or area/location that is already colonized by the pathogenic bacteria. Alternatively, the first host or location may be likely to be colonized or possible to colonize.

Administration to Hosts

If the first location is a susceptible (or non-susceptible) first host, the method comprises administering to the first host the microcin described herein or a bacterium that contains and expresses a nucleotide sequence encoding the microcin. By "administering" we mean the deliberate, intentional, active introduction of the bacterium into the first host (i.e. the purposeful inoculation of the first host), usually by a human or by a device, instrument or machine designed and operated by a human. In other words, the bacterium is not inadvertently, passively or accidentally transmitted, or is not transmitted as the result of an act of nature, or as the result of contamination of a source of the bacteria. Generally, the "bacterium" that is deliberately administered is a substantially pure, genetically homogenous population of substantially identical bacteria, or part of a mixture of several types of such substantially pure bacteria (e.g. several different serotypes, serovars, or strains). The bacteria that are so administered are generally cultured in vitro for a time prior to administration, and the method may involve culturing the bacteria from a natural source, selecting a single colony for propagation, and propagating the bacteria to form a culture that is sufficiently large or populous to successfully inoculate a host.

Administration results in contact between pathogenic bacteria that reside in/on the first host and the killing or damaging, etc. of the pathogens. Alternatively, administration may be prophylactic, i.e. the first host is not already infected with the pathogen, and infection is prevented or decreased. If bacteria are administered, the step of administering may also result in colonization of a host that is treated with the administered bacteria, i.e. bacteria that have the gene encoding the microcin. Thus, in some aspects, the step of administering results in an alteration of the microflora (e.g. "gut" or "digestive tract" microflora) of the recipient host, and the bacteria thus are a "probiotic" as discussed elsewhere herein, competing for nutrition and attachment sites to within the host. "Digestive tract" includes e.g. the mouth, esophagus, stomach, small intestine and large intestine (which includes the cecum, colon and

rectum). In general, the amount of microcin that is administered in order to be effective is in the range of from about the amount of microcin would range between about 1 ug and 100 mg depending on the application and dilution factor; and the amount of bacteria that is administered in order to be effective is in the range of from about 10^3 to about 10^{12} , and is preferably in the range of from about 10^6 to about 10^9 . Those of skill in the art will recognize that variations may occur, depending e.g. on how much microcin is produced by the bacterial strain in question, by the species, size, age, etc. of the subject to whom the microcin and/or the bacteria (or other recombinant host that produces the microcin) is administered.

When the microcin is administered, it may be in any suitable form or incorporated into any suitable vehicle. Exemplary vehicles for administering the microcin include but are not limited to: liquids such as drinking water, formula, and the like; and solid or semi-solid forms such as suppositories, pills, tablets, etc. The vehicle may be a solid "slow release" vehicle. The vehicle may include or be contained within e.g. a permeable or semi-permeable bag or pouch which can be suspended or retained indefinitely in the gut of a host organism (e.g. a cow), from which the active agent leaches or is released over time. The bag or pouch may be biodegradable.

For avian hosts (e.g. chickens), an exemplary mode of administration is addition of microcin-producing bacteria to drinking water or feed. Administration in this manner may be termed "probiotic" because the goal is to encourage colonization of the bird's digestive system with the harmless, protective bacteria, although colonization is not a requirement for positive effects to accrue. The protective microcin-producing bacteria can destroy or kill and thus outcompete pathogenic bacteria encountered by the bird, preventing colonization by the pathogens, or a least decreasing the level of colonization of, and hence transmission from, the bird. If the microcin itself is added to the drinking water or feed, it will destroy or kill pathogenic bacteria encountered by the bird, preventing colonization by the pathogens, or a least decreasing the level of colonization of, and hence transmission from, the bird, and possibly allow other non-pathogenic bacteria to flourish.

Similar strategies may be employed for bovine hosts, e.g. addition of microcin-producing bacteria or the microcin itself to drinking water, feed, salt licks, calf formula, etc., or administration of the bacteria as a probiotic to encourage the establishment of microcin-producing bacteria as described herein, or to provide a protective shield against infection by pathogenic bacteria.

Application to Surfaces

Those of skill in the art will recognize that it is also beneficial to prevent (discourage, impede, lessen, decrease, etc.) transmission of pathogenic bacteria from non-host sources to possible hosts, e.g. to prevent transmission from surfaces or areas which harbor the pathogens. The invention also comprises methods of doing so by applying the microcin of the invention and/or bacteria encoding the microcin, to surfaces which harbor the pathogens, or which are suspected or harboring the pathogens, or which could become contaminated with pathogens. Applying or treating such surfaces may be accomplished by any of many methods, e.g. by spraying a preparation of the microcin or bacteria, by applying a composition comprising a powder or granules, etc. Suitable compositions are described above. In general, the amount of microcin that is applied to a surface in order to be effective is in the range of from between about 1 ug and 100 mg; and the amount of bacteria that is applied is in the

range of from about 10^3 to about 10^{12} , and is preferably in the range of from about 10^6 to about 10^9 .

Areas that are particularly prone to contamination with pathogenic bacteria include those which house of livestock or fowl. Such areas, especially commercial areas, may be treated using the compositions of the invention, especially spray formulations. The areas may or may not be associated with a commercial enterprise, e.g. they may be associated with for profit or non-profit farms, stables, etc. The areas may also be set aside for animals e.g. as reserves, zoos, stockyards etc., or may be located at veterinary facilities. The compositions of the invention may be applied to any suitable surface where the microcin may be useful to kill pathogenic bacteria, e.g. soil or grass, flooring, stalls, pens, milking carousels, feed lot surfaces, drinking and/or feeding containers, cages, crates, truck beds, etc. Exemplary animals which are housed in such areas and are potential hosts of pathogenic bacteria include but are not limited to: livestock e.g. horses, mares, mules, jacks, jennies, colts, cows, calves, yearlings, bulls, oxen, sheep, goats, lambs, kids, hogs, shoats, pigs, bison, and others; and avian species such as land and water fowl e.g. chickens, turkeys, ducks, geese, ostriches, guinea fowl, etc. The preparations of the invention may be applied to the animals themselves, or to specific areas of the animals, e.g. to feet, the anal area, etc.

In addition, the preparations of the invention may be applied to various products, especially products derived from animals that are susceptible to infection with and/or to disease caused by pathogenic bacteria. The preparations may be applied to or included in (mixed into), for example, meats or meat products (including both raw and so-called "ready to eat" meat and poultry products), eggs, hides, carcasses, horns, hooves, feathers, etc.

Diseases Prevented or Treated

The types of diseases and conditions that may be prevented or treated using the methods and compositions disclosed herein include any of those which are caused by pathogenic *E. coli*, including but are not limited to: food poisoning (e.g. in humans), gastroenteritis, diarrhea, urinary tract infections, neonatal meningitis, hemolytic-uremic syndrome, peritonitis, mastitis, septicemia and Gram-negative pneumonia, shigellosis, dysentery, etc. In some aspects, probiotic preparations are contemplated, e.g. liquid or solid preparations that are taken prophylactically to prevent or treat disease symptoms or so-called Traveler's diarrhea prior to or during travel.

Herein, where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described.

All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

It is noted that, as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements, or use of a "negative" limitation.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

Before exemplary embodiments of the present invention are described in greater detail, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

EXAMPLES

Example 1. Materials and Methods

Bacterial Strains, Media, and Culture Conditions.

E. coli strains (Table 1) were cultured in Luria-Bertani (LB) media (Fisher Scientific, Pittsburgh, Pa.) or in M9 minimal media (6 g/L Na_2HPO_4 , 3 g/L KH_2PO_4 , 0.5 g/L NaCl, 1 g/L NH_4Cl , 2 mg/L thiamine, 1 mM MgSO_4 0.1 mM CaCl_2 and 0.2% glucose) at 37° C. with shaking (200 rpm), unless stated otherwise. Components for the M9 media were purchased from Fisher Scientific (Pittsburgh, Pa.), Sigma-Aldrich (St. Louis, Mo.) and J.T. Baker Reagents and Chemicals (Phillipsburg, N.J.). Antibiotics were added to media at the following concentrations: ampicillin (amp) 100 $\mu\text{g/ml}$ (Fisher Biotech, Fair Lawn, N.J.); kanamycin (kan) 50 $\mu\text{g/ml}$ (Fisher Scientific, Pittsburgh, Pa.); nalidixic acid (nal) 30 $\mu\text{g/ml}$ (MP Biomedicals, Solon, Ohio); and tetracycline (tet) 50 $\mu\text{g/ml}$ (Fisher Scientific, Pittsburgh, Pa.). Strains that would otherwise be antibiotic susceptible were selected for nalidixic acid resistance through successive passage in LB media with increasing nalidixic acid concentrations until the strains were capable of growth at 30 $\mu\text{g/ml}$.

23

TABLE 1

<i>E. coli</i> strains and PCR primer sequences used in this work.			
Strain	Genotype/phenotype	Primers: Homologous extensions (H1 ^a and H2 ^b); PDI, rpoD, and mcpM loci	Ref.
		PDI fwd: TAGTTGCAGGGGCATAAGAA (SEQ ID NO: 1)	5
		PDI rev: AGGAAACGCAAACAGCAACT (SEQ ID NO: 2)	
		rpoD fwd: CAGGTTCAATGCTCCGTTGC (SEQ ID NO: 3)	10
<i>E. coli</i> -25	Wild-type, SSuT ^R , PDI ⁺	rpoD rev: GCGACCTTTCGCTTTGATGG SEQ ID NO: 4)	(17)
		mcpM fwd: CCGTAATGACCGTTCCAGT (SEQ ID NO: 5)	20
		mcpM rev: CCATTTCCACTACCATGATCT (SEQ ID NO: 6)	25
		H1: ATAACCCGTATCTTTACGTTGC CT TACGTTCA (SEQ ID NO: 7)	30
<i>E. coli</i> -25ΔtolC	SSuT ^R , Kan ^R , ΔtolC, PDI ⁻	H2: CTAGAATCCGCAATAATTTTAC AGTTTGAT (SEQ ID NO: 8)	This work
		H1: AATAACGTGATTGCATATTACT TATCTCAGGAGTTC (SEQ ID NO: 9)	40
<i>E. coli</i> -25ΔtraM	SSuT ^R , Kan ^R , ΔtraM, PDI ⁺	H2: ATCCCTGGAAGGACTACAACC TATGACCGAAAATAC (SEQ ID NO: 10)	This work
		H1: GTAATTTAATAAACATAGTAG CGCCCTCCATTATATCTAT (SEQ ID NO: 11)	45
<i>E. coli</i> -25ΔmcpM	SSuT ^R , Kan ^R , ΔmcpM, PDI ⁻	H2: AACGCACAAAATAACAAACAA CCGATAGGGGAAATATGAT (SEQ ID NO: 12)	This work
		H1: ATTATCTTTACTATATTTATAT ATGTTATCATTATAATG (SEQ ID NO: 13)	50
<i>E. coli</i> -25ΔmcpMA mcpI	SSuT ^R , Kan ^R , ΔmcpMAmcpI, PDI ⁻	H2: AACGCACAAAATAACAAACAA CCGATAGGGGAAATATGAT (SEQ ID NO: 14)	This work
<i>E. coli</i> -25ΔmcpMA mcpI+ pMcpI	SSuT ^R , Kan ^R , ΔmcpMAmcpI, PDI ⁻ , immune to PDI	H1: TGGTGATGAATTCCTGTCAAA (SEQ ID NO: 15)	60

24

TABLE 1-continued

<i>E. coli</i> strains and PCR primer sequences used in this work.			
Strain	Genotype/phenotype	Primers: Homologous extensions (H1 ^a and H2 ^b); PDI, rpoD, and mcpM loci	Ref.
<i>E. coli</i> -25ΔmcpB	SSuT ^R , Kan ^R , ΔmcpB, PDI ⁻	H2: TACCAGTTTCCACCGTCACA (SEQ ID NO: 16)	This work
		H1: TCAGCCATTCCCATAAATGAC GAGTATCAAGGTTGACG (SEQ ID NO: 17)	15
<i>E. coli</i> -25ΔmcpD	SSuT ^R , Kan ^R , ΔmcpD, PDI ⁻	H2: TTGACGGAAAGGTTACTTATTG TATTAATAAATAATG (SEQ ID NO: 18)	This work
		H1: GATATACATCTGACCTGTGTGA TGTTAAAGTTTTATACTA (SEQ ID NO: 19)	20
<i>E. coli</i> -25ΔmcpA	SSuT ^R , Kan ^R , ΔmcpA, PDI ⁻	H2: ATAGAAAAATAAGAACAATC TCCGCGAAATAGCATTATG (SEQ ID NO: 20)	This work
<i>E. coli</i> -4	Wild-type, SSuT ^R , PDI ⁻		(32)
<i>E. coli</i> -4pPDI	SSuT ^R , Kan ^R , pPDI, PDI ⁺		This work
<i>E. coli</i> -6	Wild-type, SSuT ^R , PDI ⁻		(32)
<i>E. coli</i> -82	Wild-type, SSuT ^R , PDI ⁻		This work
<i>E. coli</i> -186	Wild-type, Nal ^R , PDI ⁻		(32)
<i>E. coli</i> -264	Wild-type, Nal ^R , PDI ⁺		(32)
O157: H7 Sakai	Wild-type		(15)
<i>E. coli</i> K12	Nal ^R		(19)

^a*E. coli*-25 gene-specific sequences are shown. For gene deletion mutants, homologous extensions also had the kanamycin primer site: TGTGTAGGCTGGAGCTGCTTCG (SEQ ID NO: 21), 3' to the *E. coli*-25 specific sequence.

^b*E. coli*-25 gene-specific sequences are shown. For gene deletion mutants, homologous extensions also had the kanamycin primer site: CATATGAATATCCTCCTTA (SEQ ID NO: 22), 3' to the *E. coli*-25 specific sequence.

Competition Assays to Measure Inhibition Phenotype.

55 Bacterial strains were grown individually overnight in LB. Equal volumes of each competing strain were inoculated into fresh M9 media at a 1:200 dilution, for a final 1:100 dilution of total cells. Cultures were then incubated at 37° C. for 8 to 24 h. It was previously shown that the PDI phenotype does not differ significantly between 8 and 24 h competitions (32). Mixed cultures were then serially diluted, plated on LB supplemented with the appropriate antibiotic to select for each competing strain, and enumerated.

Live/Dead Staining and Flow Cytometry.

65 Viability assays were conducted using the Live/Dead® BacLight™ Bacterial Viability Kit (L34856, Molecular Probes, Invitrogen, Eugene, Oreg.). Cell cultures were

grown in M9 media for six hours at 37° C. and then 1 ml of each culture was collected by centrifugation, washed in 0.85% NaCl, and resuspended in 0.85% NaCl. Cells were then diluted 1:10 in 0.85% NaCl that contained 1.5 µl of 3.34 mM SYTO 9 and 1.5 µl of 30 mM propidium iodide. Samples were incubated at room temperature in the dark for 15 min. Flow cytometry was performed on a FACCalibur flow cytometer (BD Biosciences) and data was analyzed using FCS Express software (De Novo software, Thornton, Ontario, Canada). Initial parameters were established by analyzing cell suspensions with known live- and dead-cell populations. These bacterial suspensions were prepared as follows: cells were grown in M9 minimal media to late-log phase and 1 ml aliquots of the cultures were collected by centrifugation, washed in 0.85% NaCl, and resuspended in either 0.85% NaCl (live portion) or 70% isopropyl alcohol (dead portion). Samples were incubated at room temperature for 30 min, then processed and analyzed by flow cytometry as described above. Ratios of live to dead cells used for the standard were (live:dead): 0:100, 50:50, and 100:0. Gates specific to our *E. coli* (based on side and forward light scatter) were used to collect data on 50,000 cell events. Green versus red fluorescence was measured to distinguish between SYTO 9 stained live cells and propidium iodide-SYTO 9 stained dead cells. Nonspecific signal was excluded at the time of data acquisition.

Sequencing and Analysis.

Genomic extractions of *E. coli*-25, *E. coli*-82, and *E. coli*-264 were prepared using the DNeasy Blood & Tissue kit (Qiagen, Valencia, Calif.) according to the manufacturer's instructions. Sequencing was conducted at the Genomics Core Lab at Washington State University using a Roche 454 FLX Titanium Genome Sequencer to a depth of 24× represented by 399,076 reads. Sequences were assembled using Newbler (version 2.5.3). Annotation employed Glimmer version 3.02 for gene calling, and then the data was piped into CLC Genomics Workbench (CLC Bio, Cambridge, Mass.) where the resulting genes were screened against the current BLAST, SignalP and Pfam databases for functional predictions. The annotated sequence has been deposited in GenBank under (note: sequence submitted, accession number pending).

Site-Directed Gene Deletion.

Gene-specific knockouts were generated using the methods described by Datsenko and Wanner (5). Briefly, the gene of interest was replaced with a PCR-generated kanamycin resistance marker. PCR primers were designed to amplify the kanamycin resistance gene from the template plasmid pKD4. Each primer incorporated 36-50 nt of the region flanking the gene of interest (Table 1). PCR products were column purified (Qiagen, Valencia, Calif.), digested overnight at 37° C. with DpnI (New England Biolabs, Ipswich, Mass.), purified again, and suspended in 30 µl 10 mM Tris, pH 8.0. *E. coli*-25 carrying the λ Red plasmid pKD46 (Amp^R) were grown in SOB (2% bactotryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄) with 1 mM L-arabinose at 30° C. to an OD₆₀₀ of ~0.6. The cells were then made electrocompetent by washing twice with ice-cold water, once with 10% glycerol, and concentrating the cells 100-fold in 10% glycerol. Electrocompetent cells (50 µl) were pulsed with ~100 ng of PCR product using the Gene Pulsar 1 (Bio-Rad, Hercules, Calif.). SOC media (12) was immediately added to the cells that were then incubated 2 h at 30° C. Cells were plated on LB with kanamycin and incubated overnight at 30° C. to select for transformants. PCR amplification using primers within the kanamycin resistance gene combined with genomic

primers adjacent to the sequence of interest were used to verify that the resistance cassette integrated at the desired location.

Complementation of *mcpI* Knockout.

A pET100 TOPO® vector (Invitrogen, Grand Island, N.Y.) was used for inducible expression of the putative immunity gene. This gene was PCR amplified from *E. coli*-25 using primers that produce a 3' single-stranded overhang identical to the 5' end of the pET100 vector, allowing directional joining of our gene of interest and the vector. Ligation and transformation was conducted according to the instructions of the Champion™ pET Directional TOPO® Expression kit. Briefly, 2 µl of PCR product was added to 1 µl Salt Solution (provided in kit), 1 µl TOPO vector, and 2 sterile water. This reaction incubated at room temperature for 25 min and then was placed on ice for 30 min. An aliquot (3 µl) was added into 50 µl chemically competent Top10 *E. coli* and incubated on ice for 2 min. Cells were heat shocked for 30 sec at 42° C. then transferred to ice. SOC media (250 µl) was added and the cells were incubated 1 h at 37° C. Cells were then plated on LB agar containing ampicillin and incubated overnight at 37° C. Transformants were screened by PCR using the universal T7 forward and reverse primers to identify clones containing the pET100 vector with an insert. Five transformants were selected for sequencing to verify they contained the correct insert. Plasmid was then isolated using the PureYield™ Plasmid Miniprep System (Promega, Madison, Wis.) and transferred to a host cell by electroporation as described above. Transformants were selected by their growth on LB with ampicillin.

Transforming *E. coli*-4 with the PDI Plasmid.

The pPDIΔtraM plasmid was purified using the MiniPrep Express™ Matrix (MP Biomedicals, Solon, Ohio). *E. coli*-4 was then made electrocompetent and transformed (as described above for the gene deletion mutants) with pPDIΔtraM. Successful transformants were selected on LB with kanamycin and PCR verified for the presence of the PDI region.

Plasmid Mating Experiments.

E. coli-25ΔmcpM and *E. coli* K12 were grown overnight in LB media with kanamycin or nalidixic acid, respectively. Equal amounts of plasmid-bearing strain *E. coli*-25ΔmcpM were mixed with non-plasmid-bearing *E. coli* K12 and centrifuged for 3 min at 16,000×g. The cells were washed and concentrated 100-fold in 10 mM MgSO₄. Cell suspensions were then pipetted onto a nitrocellulose membrane placed on a non-selective LB-agar plate. Following 24 h incubation at 30° C., the cells were resuspended in sterile PBS and dilutions plated on LB-agar containing nalidixic acid and/or kanamycin. The conjugation efficiency was calculated by dividing the CFU of transconjugants by the CFU of donor cells. Plasmid profiles were prepared for a subset of transconjugants to confirm the presence of plasmid. Profiles were conducted as described by Kado and Liu (14). The same experiments, using kanamycin and tetracycline for selection, were then repeated using the K12 pPDIΔmcpM transconjugant and *E. coli*-6 to determine whether the plasmid is self-mobilizable.

RNA Isolation, First-Strand cDNA Synthesis, and Microcin RT-qPCR.

E. coli-25 encoding McpM was inoculated into 5 ml M9 minimal media containing tetracycline and incubated overnight at 37° C. One ml of overnight culture was inoculated into 300 ml of room temperature M9 media and incubated at 37° C. Aliquots containing approximately 10⁸-10⁹ cells were removed immediately after inoculation (0 h), and 2 h, 4 h,

6 h, 8 h, 10 h, 12 h, and 24 h post-inoculation. Cells were pelleted by centrifugation at 4° C. and total RNA was isolated and DNase treated using RiboPure-bacteria kit (Ambion) according to manufacturer instructions. RNA concentrations were determined using a NanoDrop ND-1000 spectrophotometer. RNA samples from a given time course experiment were diluted to the same concentration as the least concentrated sample. To assess DNA contamination in RNA samples prior to cDNA synthesis and expression analysis, equivalent RNA concentrations to be used in the corresponding cDNA RT-qPCR reactions were run under identical conditions used for RT-qPCR analysis using polymerase sigma subunit rpoD primers (Table 1). RNA samples with cycle threshold (Ct) values less than 37.5 cycles were again treated with DNase and Ct values reanalyzed prior to cDNA synthesis. First-strand cDNA synthesis was completed using 8 µl of RNA (2-20 ng/µl), random hexamers and SuperScript III reverse transcriptase (Invitrogen) in a final reaction volume of 20 µl according to manufacturer instructions. To verify the specificity of the mcpM primers (Table 1), a single PCR product of the correct size (213 bp) was detected in PDI⁺ strains but not in PDI⁻ strains when analyzed on agarose gels. rpoD primers, described above, amplified a single PCR product of the correct size (336 bp) when analyzed on agarose gels from all PDI⁺ and PDI⁻ *E. coli* strains tested. The amplification efficiency of primer sets was then determined using plasmid DNA encoding their respective targets under identical conditions used for RT-qPCR.

All RT-qPCR reactions were performed as a single-plex reaction in triplicate in 96-well plates. Positive controls and no template controls were included in duplicate for each primer set. Each reaction was performed using 2 µl of cDNA, 500 nM final concentration per primer, and SsoFastEva Green Supermix (Bio-Rad) in a final volume of 20 µl. All PCR reactions were performed on a CFX96 Real-Time PCR Detection System with version 2.1 software (Bio-Rad) with the following cycling conditions: 95° C. for 30 s, 40 cycles of 95° C. for 1 s, 55° C. for 5 s, and 72° C. for 15 s. Normalized ($\Delta\Delta C_t$) microcin expression was automatically computed using the Bio-Rad CFX Manager Software version 2.1 using rpoD as the reference gene.

Example 2. PDI is Effective Against a Broad Range of *E. coli*

In this Example, PDI was shown to be effective against a broad range of *E. coli*. Because *E. coli* O157:H7 is represented by a diversity of genetic types (33) we first determined if the PDI phenotype was effective against the representative panel of strains. Strains representing bovine-biased and clinical-biased genotypes (33) from both the U.S. and New Zealand were highly susceptible to the PDI phenotype with an average reduction >5 log compared to the population for their respective monocultures (FIG. 1). Three strains of *E. coli* O26 were also tested, and similar reductions were found in population numbers (FIG. 1).

Example 3. Live/Dead Staining Indicated that PDI is Bactericidal

In this example, Live/dead staining indicated that PDI is bactericidal. Although susceptible cells show a substantial reduction in their CFU/ml following competition with PDI⁺ strains, it was not clear if the effect is bacteriostatic or bactericidal. Live/dead staining was used in conjunction with flow-cytometry to address this question using *E. coli*-

25 and *E. coli* O157:H7 Sakai in mono- or co-culture. The percent of dead cells detected from the two mono-cultures was $0.50\pm 0.06\%$ and $0.11\pm 0.01\%$, respectively (mean \pm SEM). When co-cultured for six hours the percent of dead cells increased to $1.27\pm 0.09\%$ consistent with killing of *E. coli* O157:H7 Sakai. When this susceptible strain was co-cultured with a PDI⁻ strain (*E. coli*-6), the percentage of dead cells was $0.33\pm 0.03\%$. These results, which were based on 3 independently replicated assays, indicate that PDI functions by killing susceptible cells.

Example 4. The Microcin-Encoding Gene Cluster was Identified

In this example, the microcin-encoding gene cluster was identified. In addition to the two PDI⁺ strains, *E. coli*-82 was identified from earlier work (16) as genetically similar (no differences) to *E. coli*-25 based on Xba-I macro-restriction, pulsed-field gel electrophoresis (PFGE) profile (unpublished data). Despite having a comparable genetic profile, *E. coli*-82 does not express the PDI phenotype. Genome sequencing of these two strains allowed an in-depth comparison that identified one relatively large region of sequence difference that was located on a large plasmid in *E. coli*-25. Although previous work using a different method did not detect the presence of plasmids in *E. coli*-25 (32), these results were verified by plasmid purification (14) and subsequent Southern analysis probing for mcpA (data not shown). PCR amplification of the PDI locus (primers available in Table 1) confirmed this region is present in the PDI⁺ strains *E. coli*-25 and *E. coli*-264, but not the PDI⁻ strains *E. coli*-6, *E. coli*-82, or *E. coli*-186.

The *E. coli*-25 IncI1 microcin-containing plasmid is 98,809 bp with a G+C content of 49% and a coding density of 88%. Annotation of the 132 coding sequences revealed that most of the plasmid content is devoted to genes involved in transfer, including a *Ira* system and a *pil* system, or encodes proteins of unknown function. The novel region of interest is a locus of approximately 4,800 bp that encodes five genes (FIG. 2). Two genes, which we have designated mcpB and mcpD, encode homologs of HlyB and HlyD that are known to be the structural components of a microcin transfer system along with chromosomally encoded *tolC* (7, 10, 18, 26). *McpA*, which contains a CaaX protease domain (PF02517), is thought to be the “activity” protein that processes the microcin, encoded by mcpM, to its mature form prior to transfer from the cell. *mcpI* likely encodes an immunity protein. This novel sequence was also found in a recent GenBank submission of *E. coli* DEC10F (Accession AIGU01000076; version: AIGU01000076.1 GI:378122919; incorporated by reference herein in its entirety).

Example 5. Knockout Mutations from *E. coli*-25 Blocked PDI

This example shows that knockout mutations from *E. coli*-25 blocked PDI. Four of the five putative microcin genes (FIG. 2) were individually knocked out in *E. coli*-25 to analyze their role in PDI. The mcpI gene knockout was constructed as a double knockout, $\Delta mcpM \Delta mcpI$. Each region of interest was replaced with a kanamycin resistant cassette and verified by PCR for the correct insertion site. Subsequently each knockout mutant was put into competition with the PDI⁻ *E. coli*-186 to determine whether the deletion affected the PDI phenotype. CFU counts following co-culture in M9 minimal media showed that *E. coli*-186 was greatly inhibited by *E. coli*-25 but was no longer

inhibited by the Δ mcpD, Δ mcpB, Δ mcpM, Δ mcpM Δ mcpI, and Δ mcpA mutants (FIG. 3A). Conversely, each mutant was also competed with *E. coli*-264 to determine how each knockout affected immunity to PDI (FIG. 3B). Only the Δ mcpM and Δ mcpM Δ mcpI strains became susceptible to PDI indicating that the other knockout strains retained immunity. Immunity was fully restored when mcpI was complemented back into the Δ mcpM Δ mcpI strain, verifying that this gene is required for resistance to killing by PDI⁺ strains (FIG. 3B). Expression of mcpI in a PDI⁻ strain does not confer immunity, indicating this gene alone is insufficient to prevent inhibition from the microcin (data not shown).

Class II microcins are typically secreted by a T1SS and the presence of the putative ABC transporter and membrane-fusion genes, mcpB and mcpD, is consistent with this structure in *E. coli*-25. These secretion systems require co-expression of a chromosomally encoded TolC protein on the cell surface (7, 10, 18, 26). Consequently, a Δ tolC strain was constructed and this disrupted the ability of *E. coli*-25 to inhibit *E. coli*-186 (FIG. 3A) but it did not influence immunity (FIG. 3B). These results are consistent with the requirement for a T1SS for PDI function. To verify that the gene knockout procedure was not producing artifacts, a gene deletion in an unrelated region of the plasmid was also generated. As expected, deleting traM did not affect inhibition or immunity (FIG. 3).

Example 6. Transferring the PDI Plasmid to a Non-Inhibitor *E. coli* Conferred the Inhibitory Phenotype

This example shows that transferring the PDI plasmid to a non-inhibitor *E. coli* conferred the inhibitory phenotype. Although the above knockout mutants verified that the genes involved with PDI had been identified, it was desirable to confirm from the mutants that all the genes unique to PDI were included on pPDI. Generating the traM mutant in *E. coli*-25 provided a selectable marker on pPDI that did not interfere with the PDI phenotype (see above). Following transformation with pPDI Δ traM, *E. coli*-4 acquired the ability to inhibit susceptible strains, and immunity to inhibition by *E. coli*-264 (Table 2).

Table 2 shows competition results of wild-type *E. coli*-4 and *E. coli*-4 carrying the PDI plasmid verifies the PDI genes are present on the plasmid. CFUs of PDI⁻ *E. coli*-186 following co-culture with wild-type *E. coli*-4 or *E. coli*-4+pPDI verifies the plasmid confers the inhibitory phenotype. Immunity to PDI is also maintained on the plasmid, as indicated by the ability of *E. coli*-4+pPDI to survive co-culture with the PDI⁺ strain *E. coli*-264. Results are expressed as log CFUs/ml \pm the SEM of 3 replicates.

This data indicates that all the PDI-specific genes are present on pPDI. Nevertheless, there is a possibility that other chromosomally-encoded genes common to *E. coli*-25 and *E. coli*-264 are involved with PDI expression or function.

TABLE 2

Competition results of wild-type <i>E. coli</i> -4 and <i>E. coli</i> -4 carrying the PDI plasmid verified the PDI genes are present on the plasmid.		
Competition	Log ₁₀ (CFU)/ml	
	<i>E. coli</i> -4	Competitor
<i>E. coli</i> -4 (PDI ⁻)		
vs. <i>E. coli</i> -186 (PDI ⁻)	8.83 \pm 0.05	8.64 \pm 0.06
vs. <i>E. coli</i> -264 (PDI ⁺)	4.70 \pm 0.28	9.14 \pm 0.02
<i>E. coli</i> -4 + pPDI		
vs. <i>E. coli</i> -186 (PDI ⁻)	9.18 \pm 0.06	4.03 \pm 0.61
vs. <i>E. coli</i> -264 (PDI ⁺)	8.88 \pm 0.03	8.76 \pm 0.02

Example 7. The PDI Δ mcpM Plasmid was Shown to be Self-Transmissible

This example shows that the PDI Δ mcpM plasmid is self-transmissible. Filter mating experiments between the Δ mcpM mutant and *E. coli* K12 showed the PDI plasmid is mobile with a conjugation efficiency ranging between 4.81×10^{-6} and 3.66×10^{-6} . Plasmid profiles of K12 Kan^R verified the presence of a single plasmid of \sim 100 Kb, consistent with the PDI plasmid. Another series of conjugation experiments between the K12 transformants and *E. coli*-6 confirmed that the plasmid is self-transmissible. Using this assay conjugation of the PDI plasmid was not detected when there was a functional microcin system, presumably because recipient cells are killed.

Example 8. The Kinetics of the Expression of mcpM were Determined

This example shows the kinetics of the expression of mcpM. Expression of the PDI phenotype has been observed throughout log-phase growth, but this function appears to subside when cells enter stationary phase (32). This earlier work was limited by the analytic sensitivity of the phenotypic assay and thus to better describe the kinetics of microcin expression we employed a quantitative PCR assay. RT-qPCR data confirmed that expression of the microcin increases rapidly during the log-phase growth and drops off rapidly in stationary phase (FIG. 4).

Example 9. cDNA Sequences and Protein Sequences for mcpM, mcpI, mcpA, mcpD, and mcpB were Determined

This example shows the cDNA sequences and protein sequences encoded by mcpM, mcpI, mcpA, mcpD, and mcpB:

cDNA sequence and protein sequence for mcpM
(SEQ ID NOS: 23 and 24)

```

ATGGCAAATATAAGAGAATTAACCTTAGATGAGATAACGCTTGTGACGGG
AGGAACAGCAACTTTGAAGGTGGCCCCGTAATGACCGTTCCAGTGGGGC
TCGTAACCTCACTGGGTGCGAAACGCACCAACTCATATTTATAGTGATCCAA
GCACTGTAAAATGCGCTAACGCTGTATTTAGTGGAATGATTGGTGGTGCG
ATCAAAGGAGGTCCCATAGGAATGGCAAGAGGTACCATTGGTGGAGCCGT
TGTTGGTCAATGTCTCTCAGATCATGGTAGTGGAATGGAAGTGGTAACA

```

31

-continued

GAGGAAGTTCAGTAGTTGTTTCAGGTAATAATGTTGGCGGAACATGTAAC
CGATAA

M A N I R E L T L D E I T L V S G G N A N S N F E
G G P R N D R S S G A R N S L G R N A P T H I Y S
D P S T V K C A N A V F S G **M I G G A I K G G P I**
G **M A R G T I G G A V V G Q C L S D H G S G N G S**
G N R G S S S S C S G N N V G G T C N R Stop

cDNA sequence and protein sequence for mcpI
(SEQ ID NOS: 25 and 26)

ATGGAGGGCGCTACTATGTTTATTAATAATTACTTTCCTTTATATGTGGTTT
GTTACTGGGATTTGCACTATTGAGTGGCTCCTCTGTTATTGATTTATACT
GGTTTTCACTACCTTCCGAGTTTTCAAAGATTGTAGTCATGCTGATCACT
CTTTTTTCCACGGCAAGATTCATGGACTATATCATAGAAAAATAAGAAC
AATCTCCGCGAAATAG

M E G A T M F I K L L S F I C G L L L G F A L L S
G S S V I D L Y W F S L P S E F S K I V V **M L I T**
L F S T A R F **M D Y I I E K I R T I S A K** Stop

cDNA sequence and protein sequence for mcpA
(SEQ ID NOS: 27 and 28)

ATGAATGATAACATATATAAATATAGTAAAGATAATGCGATAGCGtTTCT
TCTACTTGTGTTTATATCAACAGTTGTGATATTCACACCGGCATTCACCA
TACAATATATTGGTTTGGATCTGGCATTTCCTTTGTCTTTATTACTGAA
ATTTAATGTCAACTTCATTTATATTTTTTACTTAAGAAGAATACCAGG
TTGTAATAATCACCATAAAGACAAATGCGAAAACATTAAGCTATTAGTAA
TATCATTTGCTGTGATTGCTCTCATGCAACTGCTTATTTTTGCTTATAGA
GACAATTTGAACAATAGTGAATCAACTTCACTTAATTGGATTGAAATATT
TATACTGGTCTGACAGTTCGGTATTATGAAGAAATTGTTTACCGAACAT
GTCTATTTCGGTCTTCTATGTACGACTTATAaAAAAAGAATTATTTAcCCCC
TGCGTGTGTACATCTTTAtTTTTCTGCCTGATGCATCCGAGTATTATAA
TGTGGCTGATCAAATTATTCTGTTTATTATGTCAATGTTATTGTTGAATA
TAAGGATTTGCAGTAAGGGGATTTTCTATCCAATGCTGTTACATGCGGGA
ATAAACGGCTTTGTTATATTGTTAAATATATTATAG

M N D N I Y K Y S K D N A I A F L L L V V I S T V
V I F T P A F T I Q Y I G L D L A F S F V F I T E
I L **M S T S F Y I F Y L R R I P G C K I T I K T N**
A K T L K L L V I S F A V I A L **M Q L L I F A Y R**
D N L N N S E S T S L N W I E I F I L V L T V P Y
Y E E I V Y R T C L F G L L C T T Y K K E L F T P
C V C T S L F F C L **M H P Q Y Y N V A D Q I I L F**
I **M S M L L L N I R I C S K G I F Y P M L L H A G**
I N G F V I L L N I L Stop

32

-continued

cDNA sequence and protein sequence for mcpD
(SEQ ID NOS: 29 and 30)

ATGAATATATTTCAGAAGTGAAGCAATAGAACATCATAATGACACTGAATA
5 TGGTGACATTATTTTACCAACATCATTTAGCCTATCCGTATGTGCAACAG
TTACATTATTTCATTATGTTAAGTCTGACTGTATTTCATATATTACGGTAGC
TATACAAGGAAAGCGCATCTTACAGGTATCGTCATGCCCTCATCAGGACT
10 GGTAATAATAATTCTCAATATGCAGGATATGTAACACAACGACTGTAT
CCGAAGGAGAACACGTAAGTGCAGGGACACAACCTCTATCATATAAGTGA
GAACATTATAACGGTAACGGAACGACTGGCACATTAGCAACGATGAGTATTTT
15 CCTGAAGACTCAGTATATTATGTTGGCTCCCAGCAATCCTTTGAGTCGC
GAGATAATAGTCAACAACAGGAAGCCATACGGCAAAGGATGATATCACTT
GAGCCGCAATAAGAAGTGCAGAACAAGACTTCAGCTTGCTGAACGTCA
20 GGCAGAACTGGCTATATCCGTATGGAACGCTATAAAAAATTGGCTGGTA
CGCATTATGTGTCAGATATCGAATTCACAGAAACAATTTGATGTTTCT
GCCGCTCAACAAAACGTTGAAGATCAGCGTCAGGGGCTTCTCCAGTTACA
25 TACTGCAATGGACACAGCCAAAGATGAACTAAATCATCTTATTGTTTCAGG
GGAAAAGCCGTAAAGCAGAACTCGACAGACAATTGCAGGTGCTAAAACAA
CAACAGGATGAACTCGCCGACAAGAAAAATTTACTACTGAGGGCTCCAGT
30 ATCCGGGACTATTGCTGCTGTACTGATCAAACAGGGGCAGTCTGTGAAAG
CATCTGAACCGGTATGACTCTCATTCCCGATAATGCTCATTTACAAATT
GAGCTTTATGCTACCAGCCAGAAAGCCGGTTTTATCCGACCAGGTCAACG
35 GGTATCTCTGAAGTTTTTCGGCCTTCCCTTATCAGAAATTTGGTATCCAGT
ACGGCACAATTCGTAAAATCAGTCATACGACTCTGGCTCCTTCCGACTTA
TTACCAGITTCACCCGTACATGGAAAGAAAACGAAGGGCATTATCGCGT
TATTGTTGAACCTGAAAATACATTTATATTTGCATACGGaAAAAAAGAAC
40 CGCTAAGACCAGGCATGACTCTGGAAGGAGACGTCAACCTTGATACTCGT
CATTTATGGGAATGGCTGACAGAGCCCCCTATGGAGCATGAAAGGAAATCT
GTAA

45 **M N I F R S E A I E H H N D T E Y G D I I L P T S**
F S L S V C A T V T L F I **M L S L T V F I Y Y G S**
Y T R K A H L T G I V **M P S S G L V K I I P Q Y A**
50 G Y V T Q L T V S E G E H V T A G T Q L Y H I S G
E H Y N G N G T G T L A T **M S I S L K T Q Y I M L**
A S Q Q S F E S R D N S Q Q Q E A I R Q R **M I S L**
55 E P Q I R S A E Q R L Q L A E R Q A E L A I S V **M**
E R Y K K L A G T H Y V S D I E F Q Q K Q I D V S
A A Q Q N V E D Q R Q G L L Q L H T A **M D T A K D**
60 E L N H L I V Q G K S R K A E L D R Q L Q V L K Q
Q Q D E L A G Q E K F T L R A P V S G T I A A V L
I K Q G Q S V K A S E P V **M T L I P D N A H L Q I**
65 E L Y A T S Q K A G F I R P G Q R V S L K F S A F

33

-continued

P Y Q K F G I Q Y G T I R K I S H T T L A P S D L
 L P V S P V T W K E N E G H Y R V I V E P E N T F
 I F A Y G K K E P L R P G M T L E G D V N L D T R
 H L W E W L T E P L W S M K G N L Stop

cDNA sequence and protein sequence for mcpB
 (SEQ ID NOS: 31 and 32)
 ATGGAATCAATAAACTGGAAAGTAAGGAAACAACCTACCCGTTATCCGTCA
 AACCGAATCAGCTGAATGCGGTCTGGCGTGTCTGGCTATGATTGCCTGCT
 GGCATGGACTGAAAACAGATTTATCGACATTACGGGAACGTTTCAATATA
 GGTATT CAGGGAATGACGCTACAAAGGTTGATCGAATGTGCAGCGTCCAT
 CCATTTATCATCACGTGCAGTTCGTCTGGAACCCGAAGATCTGAGGTGTC
 TTAATCTTCCATCTATTCTGCACTGGGATATGAACCATTTCTGCTGTTCTC
 CATAAAGTTCGGGAAACCGGTTATACATCCATGATCCGGACAGAGGAAA
 AATTACAATAAGTCTGTTGGACGCAGGTAAGCATTTTACAGGAGTGGCAC
 TGGAATTAACCTCCAGCCAGTGATTTACCCCCCGGAACGAGAGAAAAAAA
 TCCACCTGCGTCAACTGACAGGAAAACCCCGGGCTTTTAGCATCAATG
 ACaAAAATTATTATTTTTGCTCTGGCCCTTGAGATTCTGGCTTTAGGTGG
 TCCACTTCTTAATCAACTGGTAATTGATGAAGTTCTGGTTCGCAGCAGACA
 GAAGTCTATTGTATGTCAATTATAGTGGCACTACTGTTGTTATCACTCATA
 CAATTATTACTCTCCCTAGCACGACAATGGGCAACGATCAGTTTATCCGT
 CAATTTTAAACATGCAATGGACTGCCAGAGTTTTCCATCATCTTGTAAGAC
 TCCCTCTTGCATGGTTCGATGCCCCGAAGTAAAGGAAGTATTAATGCCCGT
 TTTGAAGCAGTAGATATAATCCAGCAGGCGCTGACAACGCAGGTTCTTGA
 AGGCATTCTGGATATGCTACTTATTGTGACTGCTCTTTCATGATGCTGT
 TGTATAGCCCAGGAATGACATTAATCGCAGTAATTGCAGCTATTATATAT
 GGCGCACTGAGAGCATTGTTGATCCGGCTTTACGGCAATCTGTTGAAGA
 TGTCTGGGATGCAGGAACTAAGGAGTCGGGGCATTCTCGAAACCTTA
 ACGGCATT CAGAGTCTGAGAATCAACGGTGTAACTATTACAGAGAAGCG
 GCCTGGCTGAACCTCAACGTTACCCGAGAAACACACAGCTACGCCAGAA
 TCGTTTACAAATGAGCTATGAACTGACGCATACACTGACGAAAGTGTAG
 TTTACGCCATTATTTTTGTGGCAGGGAGCAGTAGAAGTGTCTGGATGGGACA
 TTTACCGTGGGTATGTTGGTTGCTTACTTATCCTATCAGATGCGTTTTTTC
 ATCCAGTATAAGCAATCTGACTGATAACTTTTTTCTGGCGCATGCTTG
 ATGTTTATAACGAGAGACTTGCCGATATTGTGCTAACACCACAGGAAGGT
 CACCAGAATCAGCACCATTGGGCAAACATAATGAAACAATATCTGCAAG
 CCAGTACAGAGAACATAAATATGATAATACCCATCCACCATTACTTATCG
 aAAAAATAACATTTAGCCATAAGGGCGCAGATAAACCCATATTGGATAAC
 GCGTCACTAATGCTCTTTCCTGGAGAAATATTAGCAATAACAGGTAATC
 AGGATGTGGCAAATCAACATTGGTAAAGCTTATTCTTGAATTCATACAC
 CAAGTGAAGGAAGAATTAATGCATTTGGCATAACACATACATTCTGAT
 TATTTTCAGGTTCTGCAACGAATTGGCACTGTATTGCAAGATGACTATCT
 TTTCAAAGGTTCTATAGCTGATAATATAATGTTTTTTAGCGAAATTAGAG

34

-continued

ATCATGAACACATGCGTAAATGCGCAAGTCTGGCACTTATAGACAGTGAT
 ATTATGGCAATGCCAATGGGCTATCAACATTACTTGGAGAAACCGGAGGG
 5 GGACTTTCAGGTGGTCAGAAGCAACGTATTCTACTGGCAAGAGCACTGTA
 TAAAAAACCCGGTCTATTATTACTGGACGAAGCAACCAGTCATCTTGATG
 10 TGGAAGTGAATAGAAATAAGCCAGACATTACGCCAACTCGGATTCCTG
 TTCTGTTAATAGCTCATCGACCAGAAACAATAGCATCCGCAGACAGAGTT
 CTATCTGAGAGATGGTCACTTTTTCGGAAATAACATATCGACCTGCCAGAA
 15 CTCATAATATAAATAATCACCCCAACAGGAGGTGA
 M E S I N W K V R K Q L P V I R Q T E S A E C G L
 A C L A M I A C W H G L K T D L S T L R E R F N I
 20 G I Q G M T L Q R L I E C A A S I H L S S R A V R
 L E P E D L R C L N L P S I L H W D M N H F V V L
 H K V R G N R L Y I H D P D R G K I T I S L L D A
 25 G K H F T G V A L E L T P A S D F T P R N E R K K
 I H L R Q L T G K T P G L L A S M T K I I I F A L
 A L E I L A L G G P L L N Q L V I D E V L V A A D
 30 R S L L Y V I I V A L L L L S L I Q L L L S L A R
 Q W A T I S L S V N F N M Q W T A R V F H H L V R
 L P L A W F D A R S K G S I N A R F E A V D I I Q
 35 Q A L T T Q V L E G I L D M L L I V T A L C M M L
 L Y S P G M T L I A V I A A I I Y G A L R A L W Y
 P A L R Q S V E D V W D A G T K E S G H F L E T L
 40 N G I Q S L R I N G V T I H R E A A W L N L N V T
 R R N T Q L R Q N R L Q M S Y E L T H T L T E S V
 V S A I I L W Q G A V E V L D G T F T V G M L V A
 45 Y L S Y Q M R F S S S I S N L T D N F F S W R M L
 D V Y N E R L A D I V L T P Q E G H Q N Q H H W A
 N H N E T I S A S Q Y R E H K Y D N T H P P L L I
 50 E K I T F S H K G A D K P I L D N A S L M L F P G
 E I L A I T G K S G C G K S T L V K L I L G I H T
 P S E G R I N A F G I P H T H S D Y F Q V R Q R I
 55 G T V L Q D D Y L F K G S I A D N I M F F S E I R
 D H E H M R K C A S L A L I D S D I M A M P M G Y
 Q T L L G E T G G G L S G G Q K Q R I L L A R A L
 60 Y K K P G L L L L D E A T S H L D V E S E I E I S
 Q T L R Q L G I P V L L I A H R P E T I A S A D R
 V L Y L R D G H F S E I T Y R P A R T H N I N N H
 65 P N R R

Example 10. Sequence for Plasmid Containing the Unique 4.8-Kb Operon Region that is Present in PDI⁺ Strains but not PDI⁻ Strains (GenBank Accession: JQ901381)

This sequence for the plasmid containing the unique 4.8-kb operon region that is present in PDI⁺ strains but not PDI⁻ strains was determined (GenBank accession JQ901381) and is presented as SEQ ID NO: 33. The region covering *mcpM*, *mcpI*, *mcpA*, *mcpD*, and *mcpB* is presented as SEQ ID NO: 34. Within SEQ ID NO: 34, the nucleotide positions of individual operon components are as follows: *mcpM* (41253-43442); *mcpM* (43443-44695); *mcpA* (44798-45433); *mcpD* (45438-45654); and *mcpB* (45663-46026).

References for Background and Examples 1-10

1. Aoki, S. K., R. Pamma, A. D. Hemday, J. E. Bickham, B. A. Braaten, and D. A. Low. 2005. *Science* 309:1245-8.
2. Asensio, C., and J. C. Perez-Diaz. 1976. *Biochem Biophys Res Commun* 69:7-14.
3. Bullock, J. O., F. S. Cohen, J. R. Dankert, and W. A. Cramer. 1983. *J Biol Chem* 258:9908-12.
4. Dassanayake, R. P., D. R. Call, A. A. Sawant, N. C. Casavant, G. C. Weiser, D. P. Knowles, and S. Srikumaran. 2010. *Appl Environ Microbiol* 76:1008-13.
5. Datsenko, K. A., and B. L. Wanner. 2000. *Proc Natl Acad Sci USA* 97:6640-5.
6. Duquesne, S., D. Destoumieux-Garzon, J. Peduzzi, and S. Rebuffat. 2007. *Nat Prod Rep* 24:708-34.
7. Gaggero, C., F. Moreno, and M. Lavina. 1993. *J Bacteriol* 175:5420-7.
8. Garrido, M. C., M. Herrero, R. Kolter, and F. Moreno. 1988. *EMBO J* 7:1853-62.
9. Gentschev, I., G. Dietrich, and W. Goebel. 2002. *Trends Microbiol* 10:39-45.
10. Gilson, L., H. K. Mahanty, and R. Kolter. 1990. *EMBO J* 9:3875-84.
11. Gratia, A. 1925. *C. R. Soc. Biol. (Paris)* 93:1040-1041.
12. Hanahan, D. 1983. *J Mol Biol* 166:557-80.
13. Hardy, K. G., G. G. Meynell, J. E. Dowman, and B. G. Spratt. 1973. *Mol Gen Genet* 125:217-30.
14. Kado, C. I., and S. T. Liu. 1981. *J Bacteriol* 145:1365-73.
15. Kawamura, T. 1997. *Rinsho Byori* 45:865-8.
16. Khachatryan, A. R., T. E. Besser, and D. R. Call. 2008. *Appl Environ Microbiol* 74:391-5.
17. Khachatryan, A. R., D. D. Hancock, T. E. Besser, and D. R. Call. 2006. *Appl Environ Microbiol* 72:443-8.
18. Lagos, R., M. Baeza, G. Corsini, C. Hetz, E. Strahsburger, J. A. Castillo, C. Vergara, and O. Monasterio. 2001. *Mol Microbiol* 42:229-43.
19. Lederberg, J., and E. L. Tatum. 1946. *Nature* 158:558.
20. Lemonnier, M., B. R. Levin, T. Romeo, K. Garner, M. R. Baquero, J. Mercante, E. Lemichez, F. Baquero, and J. Blazquez. 2008. *Proc Biol Sci* 275:3-10.
21. Linton, K. J., and C. F. Higgins. 1998. *Mol Microbiol* 28:5-13.
22. Lwoff, A., F. Jacob, E. Ritz, and M. Gage. 1952. *C R Hebd Seances Acad Sci* 234:2308-10.
23. Martinez, M. C., C. Lazdunski, and F. Pattus. 1983. *EMBO J* 2:1501-7.
24. Nomura, M., and M. Nakamura. 1962. 7:306-9.
25. Ohno-Iwashita, Y., and K. Imahori. 1982. *J Biol Chem* 257:6446-51.
26. Pons, A. M., F. Delalande, M. Duarte, S. Benoit, I. Lanneluc, S. Sable, A. Van Dorsselaer, and G. Cottenceau. 2004. *Chemother* 48:505-13.
27. Pugsley, A. P., and S. T. Cole. 1986. *J Gen Microbiol* 132:2297-307.
28. Reeves, P. 1965. The Bacteriocins. *Bacteriol Rev* 29:24-45.
29. Riley, M. A., and D. M. Gordon. 1992. *J Gen Microbiol* 138:1345-52.
30. Riley, M. A., Y. Tan, and J. Wang. 1994. *Proc Natl Acad Sci USA* 91:11276-80.
31. Riley, M. A., and J. E. Wertz. 2002. *Annu Rev Microbiol* 56:117-37.
32. Sawant, A. A., N. C. Casavant, D. R. Call, and T. E. Besser. 2011. *Appl Environ Microbiol* 77:2345-51.
33. Shringi, S., A. Garcia, K. K. Lahmers, K. A. Potter, S. Muthupalani, A. G. Swennes, C. J. Hovde, D. R. Call, J. G. Fox, and T. E. Besser. 2012. *Infect Immun* 80:369-80.
34. Smarda, J. 1962. *Experientia* 18:271-3.
35. Trueblood, C. E., V. L. Boyartchuk, E. A. Picologlou, D. Rozema, C. D. Poulter, and J. Rine. 2000. *Mol Cell Biot* 20:4381-92.
36. Wilkens, M., J. E. Villanueva, J. Cofre, J. Chnaiderman, and R. Lagos. 1997. *J Bacteriol* 179:4789-94.

Example 11. Microcin MccPDI Reduces the Prevalence of Susceptible *Escherichia coli* in Neonatal Calves

MccPDI microcin producing *E. coli*-25 or the equivalent knockout strains were co-inoculated into calves with susceptible *E. coli*-186 to investigate the function of MccPDI in vivo. MccPDI-producing *E. coli*-25 out-competed *E. coli*-186 (P=0.003), consistent with MccPDI being responsible for antibiotic resistant *E. coli*-25 competitive advantage in calves. The increasing prevalence of antibiotic resistant bacteria presents a major challenge for both human and animal health. High levels of antimicrobial usage in livestock potentially plays an important role in amplifying and retaining antibiotic resistance genes in bacterial populations (6, 7, 13). Nevertheless, even in the absence of antibiotic use resistant bacteria can persist (2, 5, 8). A previous study showed that *E. coli* strains with resistance to streptomycin, sulfadiazine, and tetracycline (SSuT) were the dominant *E. coli* found in calves at the Washington State University (WSU) dairy (10). Mixtures of these SSuT *E. coli* isolates, including strain *E. coli*-25, demonstrated a fitness advantage in dairy calves and in broth culture over antibiotic susceptible strains (10). The mechanism allowing these strains to dominate in calves was unknown, but was not associated with antimicrobial resistance traits (9). Recently we showed *E. coli*-25 produces the novel microcin, MccPDI, that is responsible for killing susceptible *E. coli* in vitro. MccPDI-production allows *E. coli*-25 to inhibit a diversity of *E. coli*, including enterohemorrhagic (EHEC) and enterotoxigenic (ETEC) strains (4, 11). The spectrum of MccPDI activity makes *E. coli*-25 attractive as a probiotic against pathogenic bacteria with potential for prophylactic, therapeutic, and food safety applications. Consequently, we tested the hypothesis that an MccPDI-producing *E. coli*-25ΔtraM strain will limit colonization of dairy calves by the MccPDI-susceptible *E. coli*-186, while MccPDI-knockout strain, *E. coli*-25ΔmcpMΔmcpI would exhibit no selective advantage in vivo (4).

This study was conducted in the large animal isolation facilities at WSU under a WSU Institutional Animal Care and Use Committee approved protocol. Calves inoculated

with the same strains were housed in groups when possible. Bulk milk was fed two to three times daily with one feeding containing 1 tbsp. of milk non-antibiotic containing supplement (10). Calves were pre-screened for nalidixic acid-, kanamycin-, and chloramphenicol-resistant *E. coli* using methods described below. If resistant bacteria were detected the calf was not used in the study. Kanamycin- and chloramphenicol-resistant *E. coli*-25 mutants were generated (Table 1) to allow the use of calves that carried either kanamycin or chloramphenicol resistant flora, but did not carry both. Each calf (<3 days old) was orally inoculated with 10^9 CFU of each competing *E. coli* strain. Inoculum was prepared by pelleting overnight cultures of each strain, resuspending the cells in fresh LB, and mixing the cultures immediately before inoculation. If the inoculated strains were not detected at one day post-inoculation, a second dose was administered on day two. Day one refers to the day following the final inoculation. The trial included two groups of calves with group one (n=4) receiving MccPDI knockout *E. coli*-25 Δ mcpM Δ mcpI and *E. coli*-186 and group two (n=7) receiving MccPDI-producing *E. coli*-25 Δ traM and *E. coli*-186; chance enrollment of calves with incompatible antibiotic resistant flora led to rejection of more calves from group one.

Fecal samples were collected directly from the rectum of each calf immediately following inoculation (day 0) and each day for six days (10). Within 4 h of collection ten-fold serial dilutions of each sample were prepared in sterile PBS and plated on MacConkey agar to determine total colony forming units (CFUs) of lactose fermenting enteric bacteria with colony morphology consistent with *E. coli*. MacConkey agar supplemented with kanamycin (50 μ g/ml) and tetracycline (50 μ g/ml), chloramphenicol (34 μ g/ml) and tetracycline (50 μ g/ml), or nalidixic acid (30 μ g/ml) was used to enumerate the test strains present in the fecal samples. A competition index (CI) was calculated to compare the fitness of competing strains (FIG. 5). PCR was used to confirm the identity of the *E. coli*-25 mutants by pairing primers within the resistance cassette (3) with locus-specific primers (Table 3; n=368). The putative *E. coli*-186 isolates (n=172) recovered from the fecal samples were confirmed by pulsed-field gel electrophoresis analysis (1).

TABLE 3

<i>E. coli</i> strains and PCR primer sequences used in this work.			
<i>E. coli</i> Strain	Genotype/phenotype	Strain-specific primer	Ref.
25 Δ mcpM Δ mcpI	SSuT ^r Chlor ^r Δ mcpM Δ mcpI PDI ⁻	mcpM_mcpI fwd: CAAACAACCGATAGGGGAAA (SEQ IN NO: 36) c2: GATCTTCCGTCACAGGTAGG (SEQ IN NO: 37)	This work
25 Δ mcpM Δ mcpI	SSuT ^r Kan ^r Δ mcpM Δ mcpI PDI ⁻	mcpM_mcpI fwd: CAAACAACCGATAGGGGAAA (SEQ IN NO: 38) k2: CGGTGCCCTGAATGAATGAAGTGC (SEQ IN NO: 39)	(4)
25 Δ traM	SSuT ^r Chlor ^r Δ traM PDI ⁺	traM fwd: GTTCTGCCATCCTGCGTTAT (SEQ IN NO: 40)	This work

TABLE 3-continued

<i>E. coli</i> strains and PCR primer sequences used in this work.			
<i>E. coli</i> Strain	Genotype/phenotype	Strain-specific primer	Ref.
		c1: TTATACGCAAGGCGACAAGG (SEQ IN NO: 41)	
10 25 Δ traM	SSuT ^r Kan ^r Δ traM PDI ⁺	traM fwd: GTTCTGCCATCCTGCGTTAT (SEQ IN NO: 42) k1: CAGTCATAGCCGAATAGCCT (SEQ IN NO: 43)	(4)
15 186	Wild-type; Nal ^r PDI ⁻		(11)
20 O157: H7 6-E12057	Wild-type; Nal ^r Cip ^r	rfb fwd: AAGATTGCGCTGAAGCCTTT (SEQ IN NO: 36) rfb rvs: CATTGGCATCGTGTGGACAG (SEQ IN NO: 36)	(12)

25 At six days post-inoculation calves were euthanized and five to ten centimeter lengths of the cecum, spiral colon, descending colon, and rectal-anal junction (RAJ) were collected. All fecal matter was removed by rinsing the tissue in sterile PBS. A 6 mm sterile biopsy punch was used to collect a sample and make a 1:10 dilution (sa/vol) in PBS. The tissue was homogenized, serially diluted, and plated onto MacConkey agar supplemented with antibiotics.

30 A previous study with *E. coli*-25 indicated the microcin-producing strain *E. coli*-25 Δ traM should have a distinct advantage over the susceptible strain *E. coli*-186 (10). As expected, by day six, *E. coli*-25 Δ traM dominated *E. coli*-186 (CI=0.22, P=0.003; FIG. 1). In contrast, the microcin-knockout strain *E. coli*-25 Δ mcpM Δ mcpI was significantly less fit than *E. coli*-186 (CI=-0.95; FIG. 5). Notably, different treatment outcomes were asymmetric with the CI for *E. coli*-25 Δ traM (0.22) being a smaller magnitude than the competition index for *E. coli*-25 Δ mcpM Δ mcpI (-0.95). This could possibly be explained by the presence of native MccPDI-expressing strains that would also compete with *E. coli*-25 Δ traM while enhancing inhibition of the susceptible *E. coli*-25 Δ mcpM Δ mcpI.

45 If most native *E. coli* strains are susceptible to MccPDI, and if the MccPDI producing strain has a fitness advantage relative to non-producing strains of *E. coli*, then the MccPDI-producing strain should be found in greater numbers relative to the total *E. coli* population. We enumerated the CFU for the *E. coli*-25 mutants relative to the CFU lactose-fermenting enteric bacteria in the fecal samples. *E. coli*-25 Δ mcpM Δ mcpI accounted for <0.2% of the total lactose-fermenting enteric bacteria by day six, whereas *E. coli*-25 Δ traM consistently comprised >2% of this population throughout the trial (repeated measures ANOVA, P=0.01; FIG. 6). There was no difference between the total number of lactose-fermenting bacteria between the two groups (P=0.96). These results confirm the MccPDI-producing strain has a selective advantage over the non-producing strain in this model.

50 *E. coli* was consistently recovered from tissues of the lower gastrointestinal tract (GI). The inoculated strains, however, were typically only detected at counts just above the detection level. *E. coli*-25 Δ traM strain was recovered

more frequently compared to *E. coli*-186, whereas *E. coli*-25 Δ mcpM Δ mcpI was recovered at a frequency similar to the *E. coli*-186 strain (P=0.01 and P=0.052, respectively; paired t-test; FIGS. 7A and B). There were no apparent differences in the frequency of detection between tissues (ANOVA, P=0.41). These results are consistent with *E. coli*-25 Δ traM having an in vivo fitness advantage allowing better colonization within calves.

Sixteen arbitrarily selected *E. coli* from each calf were tested for strain identity. Of calves inoculated with *E. coli*-25 Δ traM and *E. coli*-186, we detected the expected strains in 5 and 6 calves, respectively. We only recovered the expected strains from 1 of 4 calves for the non-microcin treatment group.

Bacteriocin-producing bacteria present an attractive means to control pathogens in food animal production. *E. coli*-25 Δ traM reduces the shedding of *E. coli*-186 confirming that MccPDI is functional in vivo. Changing the timing and doses of *E. coli*-25 Δ traM may potentially improve the treatment effect because it is unknown when or at what concentration MccPDI functions in vivo. Future research should investigate the use of multiple bacteriocinogenic strains, increased doses, or pre-inoculation of *E. coli*-25 Δ traM to limit pathogenic *E. coli* populations in cattle.

References for Example 11

1. Broschat, S. L., D. R. Call, M. A. Davis, D. Meng, S. Lockwood, R. Ahmed, and T. E. Besser. 2010. *J Clin Microbiol* 48:4072-82.
2. Chalus-Dancla, E., G Gerbaud, M. Lagorce, J. P. Lafont, and P. Courvalin. 1987. *Antimicrob Agents Chemother* 31:784-8.
3. Datsenko, K. A., and B. L. Wanner. 2000. *Proc Natl Acad Sci USA* 97:6640-5.
4. Eberhart, L. J., J. R. Deringer, K. A. Brayton, A. A. Sawant, T. E. Besser, and D. R. Call. 2012. *Appl Environ Microbiol* 78:6592-9.
5. Enne, V. I., D. M. Livermore, P. Stephens, and L. M. Hall. 2001. *Lancet* 357:1325-8.
6. Hinton, M., D. J. Hampson, E. Hampson, and A. H. Linton. 1985. *J Hyg (Lond)* 95:77-85.
7. Jackson, C. R., P. J. Fedorka-Cray, J. B. Barrett, and S. R. Ladely. 2004. *Appl Environ Microbiol* 70:4205-10.
8. Khachatryan, A. R., T. E. Besser, D. D. Hancock, and D. R. Call. 2006 *Appl Environ Microbiol* 72:4583-8.
9. Khachatryan, A. R., D. D. Hancock, T. E. Besser, and D. R. Call. 2006. *Appl Environ Microbiol* 72:443-8.
10. Khachatryan, A. R., D. D. Hancock, T. E. Besser, and D. R. Call. 2004. *Appl Environ Microbiol* 70:752-7.
11. Sawant, A. A., N. C. Casavant, D. R. Call, and T. E. Besser. 2011. *Appl Environ Microbiol* 77:2345-51.
12. Shringi, S., A. Garcia, K. K. Lahmers, K. A. Potter, S. Muthupalani, A. G Swennes, C. J. Hovde, D. R. Call, J. G. Fox, and T. E. Besser. 2012. *Infect Immun* 80:369-80.
13. Singer, R. S., R. Finch, H. C. Wegener, R. Bywater, J. Walters, and M. Lipsitch. 2003. *Lancet Infect Dis* 3:47-51.

Example 12. Identification of a Receptor and Associated Proteins Required for MccPDI to Recognize and Inhibit Susceptible *E. coli*

The *E. coli* Keio Collection, a single-gene deletion library, was screened for mutants able to grow in the presence of the MccPDI producing strain *E. coli*-25. The Keio Collection includes individual gene knockouts for all non-essential

genes that are expressed by *E. coli* strain BW25113, which is also sensitive to PDI. Screening of the full library followed by verification experiments demonstrated that mutants of *atpA*, *atpF*, *dsbA*, *dsbB*, *ompF*, or *ompR* were no longer sensitive to PDI, indicating these genes are required for MccPDI function.

Materials and Methods

Strains and Culture Conditions.

E. coli-25 [streptomycinR, sulfadiazineR, tetracyclineR, (SSuTR)] (26), *E. coli* S17, *E. coli* BW25113 and the *E. coli* BW25113 gene-deletion library (Keio Collection, kanamycinR, Thermo Scientific) were used in this study. *E. coli* BW25113 was purchased from the *Coli* Genetic Stock Center (CGSC, Yale) and it is susceptible to antibiotics employed in the current study. To isolate this strain in a mixed culture, *E. coli* BW25113 was made nalidixic acid resistant by passaging 5 times with increasing concentrations until it was capable of growing in 30 μ g/ml nalidixic acid. Unless stated otherwise, all strains were cultured in either Luria Broth (LB) or M9 Minimal Media at 37 $^{\circ}$ C. shaking 250 rpm. Antibiotics were used at the following concentrations: tetracycline (50 μ g/ml), chloramphenicol (34 μ g/ml), kanamycin (50 ng/ml), nalidixic acid (30 μ g/ml) and ampicillin (100 μ g/ml).

Screening the Keio Collection for Loss of PDI.

The Keio collection of *E. coli* knockouts (Thermo Scientific) was employed to identify genes associated with susceptibility to MccPDI. Each mutant was grown overnight at 37 $^{\circ}$ C. without shaking in a 96-well plate containing 150 μ l fresh LB (50 ng/ml kanamycin) per well. A 10 ml culture of *E. coli*-25 was also started at this time in LB (50 μ g/ml tetracycline) and incubated at 37 C with shaking (250 rpm). The following day each mutant was individually placed into co-culture with *E. coli*-25 in a sterile, U-bottom 96-well plate with 200 μ l M9 minimal media per well. A 96-pin replicator (Boekel Scientific) was used to transfer overnight cultures (~1 μ l) of each strain for competition experiments. The replicator was sterilized 3X between each use by submerging pins into 70% ethanol and flaming. The *E. coli*-25 culture was poured into a sterile plastic trough and transferred in the same manner. Competition cultures were incubated overnight at 37 $^{\circ}$ C., shaking at 100 rpm. Approximately 24 h later co-cultures (~1 μ l) were transferred onto LB agar containing kanamycin or tetracycline to select for the Keio strains or *E. coli*-25, respectively. The plates were incubated at 37 $^{\circ}$ C. for at least 6 h. Growth on tetracycline verified the presence of *E. coli*-25 in the culture. No growth on kanamycin indicated that the Keio knockout strain being tested was still susceptible to PDI. Growth of a Keio mutant strain on the kanamycin plate indicated putative identification of gene knockouts that were no longer susceptible to PDI.

Competition Assays and Enumeration of Resistant *E. coli* Mutants.

To confirm detection of PDI-resistant strains from the Keio collection, prospective strains were grown overnight in LB with antibiotic selection. Each mutant strain culture was then added (10 μ l) with *E. coli*-25 culture (10 μ l) to 2 ml M9 media. These co-cultures were incubated at 37 $^{\circ}$ C. for 8 to 24 h. To determine the CFUs of each strain following competition, serial dilutions of the co-cultures were prepared in a 96-well plate containing sterile PBS and then spotted (5 μ l) onto LB agar supplemented with kanamycin or tetracycline. Agar plates (3 per enumerated dilution) were incubated overnight at 37 $^{\circ}$ C. and colonies were tallied for total colony forming units (cfu).

PCR Verification of the Knockout Mutants.

Primers corresponding to sequence up- and down-stream the deleted gene (Table 3) were designed to verify the location of the kanamycin cassette insertion. Reactions were carried out with an initial denaturing step at 95° C. for 4 min, followed by 30 cycles of 95° C. for 20 s, 55° C. for 20 s, 72° C. for 1 min 20 s, and a final extension at 72° C. for 5 min. The PCR products were evaluated using electrophoresis alongside an O'gene Ruler 1 Kb plus ladder (Thermo Scientific) to determine the amplicon sizes. The wild-type (non-mutant) *E. coli* BW25113 was included as a control in addition to a no-template negative control.

Regenerating Resistant Mutants in *E. coli* S17.

To validate the findings from the Keio library screen, we generated independent mutants in a PDI sensitive strain, *E. coli* S17. The methods used to create these mutants were previously described by Datsenko and Wanner (2000; Proc Natl Acad Sci USA 97:6640-5) and were the same used to create the Keio Collection (Baba et al. Mol Syst Biol 2:2006 0008). The new gene-deletion mutants were generated with the insertion of chloramphenicol resistance (cat) instead of a kanamycin cassette as was used for the Keio Collection. PCR primers were designed to amplify the chloramphenicol cassette from plasmid pKD3 and contained extensions identical to the sequence flanking the gene of interest (Table 3). *E. coli* S17 was transformed with the pKD46 plasmid, which facilitates homologous recombination between the gene of interest and the PCR amplicon. *E. coli* S17+pKD46 was grown in super optimal broth (2% bacto-trypton, 0.5% yeast extract, 8.56 mM NaCl, 2.5 mM KCL, 10 mM MgCl₂) with ampicillin and 0.1 mM arabinose to induce the proteins necessary for homologous recombination. These induced cells were then made competent and electroporated with the chloramphenicol amplicon containing the requisite flanking sequences. Transformed cells were recovered at 30° C. and were plated onto LB agar with chloramphenicol to select for successful deletion mutants. PCR was used to verify the insertion site of the chloramphenicol cassette (Table 3) using PCR conditions as describe above.

Growth Curves.

All strains, including the gene knockout mutants, were assessed for their ability to grow in M9 and LB media. Growth curves were run on a BioScreen C (Oy Growth Curves Ab Ltd). Each strain was grown individually overnight in LB media with antibiotic selection. These cultures were used to inoculate (1:1,000 dilution) M9 minimal media or LB broth without antibiotics. Cultures incubated for 24 h at 37° C. with continuous shaking and optical density (450-580 nm) measured every 30 min.

Fluorescent Labeling and Microscopy.

E. coli-25ΔmcpMΔmcpI, *E. coli*-25ΔtraM, and *E. coli*-186 were each transformed with a vector expressing cherry red fluorescent protein (pFPV-mCherry) or GFP (pFPV25). Competition assays (described above) were conducted with the fluorescently labeled cells; one with MccPDI-producing *E. coli*-25ΔtraM+pFPV-mCherry and PDI-susceptible *E. coli*-186+pFPV25, and another with MccPDI—nonproducing *E. coli*-25ΔmcpMΔmcpI+pFPV-mCherry and PDI-susceptible *E. coli*-186+pFPV25. Additionally, these competitions were repeated where each strain carried the opposite plasmid to ensure the results were not caused by either strain differentially expressing either fluorescent protein. Individual cultures were run as controls. Each culture was visualized at 24 h using a fluorescent scope at 60× magnification.

Results

Six *E. coli* mutants in the Keio Collection were resistant to PDI. The single gene deletion *E. coli* mutant library, called the Keio Collection, was used to identify genes putatively associated with susceptibility to MccPDI. Approximately 3,985 mutants were screened using a high-throughput 96-well plate method. Following two rounds of screening using these methods, six mutants were identified as potentially being resistant to inhibition by *E. coli*-25. These mutants were then placed into a 2 ml competition experiment (M9 media) with *E. coli*-25 and CFUs were subsequently enumerated after 24 h co-culture. Mutants that were able to grow to a population density >10⁵ CFU were considered resistant to PDI and these included the mutants with a deletion in *atpA*, *atpF*, *dsbA*, *dsbB*, *ompF*, or *ompR* (Table 4).

TABLE 4

Gene-knockout mutants that are no longer susceptible to killing by <i>E. coli</i> -25. PCR primer sequences amplify the gene of interest and were used to verify the specific knockouts. The CFUs represent the average of triplicate competition assays.			
Gene Disrupted	Primers: Gene-specific primers and flanking sequences (H1 ^a and H2 ^b)	Gene Function	Co-culture with <i>E. coli</i> -25 (CFU)
<i>atpA</i>	<p><i>atpA</i> fwd: TGCTGCGATGGAAAAACGTC (SEQ ID NO: 36)</p> <p><i>atpA</i> rvs: TTCTGGACGCTTGCGATCTT (SEQ ID NO: 37)</p> <p>H1: CTTGCAGACGTCTTGAGTCTTAAGGGGACTGGAGC (SEQ ID NO: 38)</p> <p>H2: GCCTGCGCCTGCCCTAAGGCAAGCCGACGACGT (SEQ ID NO: 39)</p>	ATP synthase, F1 complex, α subunit; also called <i>papA</i>	4.10 × 10 ⁵
<i>atpF</i>	<p><i>atpF</i> fwd: ATCGCTGTAGGTCTGGGTCT (SEQ ID NO: 40)</p> <p><i>atpF</i> rvs: ATGTCCTGCCAGCGTTCTAC (SEQ ID NO: 41)</p> <p>H1: AATATCAGAACGTTAACTAAATAGAGGCATTGTGCT (SEQ ID NO: 42)</p> <p>H2: CTACCGTAATAAATTCAGACATCAGCCCTCCCTCC (SEQ ID NO: 43)</p>	ATP synthase, F0 complex, β subunit; also called <i>papF</i>	6.51 × 10 ⁶

TABLE 4-continued

Gene-knockout mutants that are no longer susceptible to killing by <i>E. coli</i> -25. PCR primer sequences amplify the gene of interest and were used to verify the specific knockouts. The CFUs represent the average of triplicate competition assays.			
Gene	Primers: Gene-specific primers and flanking Disrupted sequences (H1 ^a and H2 ^b)	Gene Function	Co-culture with <i>E. coli</i> -25 (CFU)
dsbA	dsbA fwd: AGCGGCAGGATGCATTATCA (SEQ ID NO: 44) dsbA rvs: GGGAAGATTACTGGCTGCGA (SEQ ID NO: 45) H1: GTGAATATTCACGGGCTTTATGTAATTTACATTGAA (SEQ ID NO: 46) H2: AATTAACACCIATGTATTAATCGGAGAGAGTAGATC (SEQ ID NO: 47)	Periplasmic protein disulfide isomerase (disulfide bond formation)	2.37 × 10 ⁷
dsbB	dsbB fwd: CAATGGCAGATGAAGCGAGC (SEQ ID NO: 48) dsbB rvs: TGCAAATGGGCTGGATAGCA (SEQ ID NO: 49) H1: AACTGCGCACTCTATGCATATTGCAGGGAAATGATT (SEQ ID NO: 50) H2: CAGGAAAAAGCGCTCCCGCAGGAGCGCTGAAGGGA (SEQ ID NO: 51)	Disulfide oxidoreductase (disulfide bond formation) membrane protein; oxidizes periplasmic DsbA	3.97 × 10 ⁷
ompF	ompF fwd: CGCTATCAGGGTAACGGGAG (SEQ ID NO: 52) ompF rvs: AGCACTTTCACGGTAGCGAA (SEQ ID NO: 53) H1: GTTGTGAGAATCGATCTGGTTGATGATGTAGTCAAC (SEQ ID NO: 54) H2: GTGATCGTCCCTGCTCTGTTAGTAGCAGGTAAGTCA (SEQ ID NO: 55)	Outer membrane protein, porin	9.50 × 10 ⁶
ompR	ompR fwd: TGTTGCGAACCTTTGGGAGT (SEQ ID NO: 56) ompR rvs: AGCAAGGTGACGATGAGCAA (SEQ ID NO: 57) H1: GGGCAAATGAACTTCGTGGCGAGAAGCGCAATCGCC (SEQ ID NO: 58) H2: CTTACAAATTGTTGCGAACCTTTGGGAGTACAAACA (SEQ ID NO: 59)	Transcriptional regulatory protein OmpR; Response regulator for Cosmoregulation	2.12 × 10 ⁶

^a*E. coli* S17 gene-specific sequences are shown. For gene deletion mutants, flanking sequences also included the chloramphenicol primer site: TGTGTAGGCTGGAGCTGCTTCG, (SEQ ID NO: 60) 3' to the *E. coli* S17 specific sequence.

^b*E. coli*-25 gene-specific sequences are shown. For gene deletion mutants, flanking sequences also included the chloramphenicol primer site: CATATGAATATCCTCTTA, (SEQ ID NO: 61) 3' to the *E. coli* S17 specific sequence.

Example 13. Microcin PDI Regulation and Post-Translational Modifications are Unique Among Known Microcins

In this study, we used competition assays with gene knockout and complemented strains, QPCR assays, western blots and electrophoretic mobility assays to demonstrate that expression of the microcin PDI is induced in low osmolarity conditions and is regulated by the EnvZ/OmpR system through the binding of the phosphorylated OmpR to the mcpM promoter region. The phosphorylated OmpR may recognize three different binding sites within this promoter region. This system of regulation is similar to that of OmpF and unique from other described microcins. Site-directed mutagenesis revealed that the MccPDI precursor peptide includes two leader peptides that undergo sequential cleavage (positions G17/G18 and G35/A36) during export through the type I secretion system. Competition assays showed that these cleaved products are required for the PDI phenotype. MccPDI has four cysteines within the mature peptide and experimental data showed that the first two cysteines are necessary for the microcin PDI inhibition of susceptible cells. DAPI staining of fluorescently-labeled

45 strains showed that the microcin PDI likely induces membrane permeability of susceptible cells. Without being bound by theory, the data suggests that MccPDI forms a multimer within the periplasm of susceptible cells where it damages membrane integrity. Together these data combined with previous work indicates that MccPDI is unique amongst the microcins that have been described to date.

Introduction

50 Like bacteriocins from Gram-positive bacteria, microcins are generally derived from precursor peptides that are composed of a C-terminal core region and an N-terminal leader peptide. The leader peptide is typically cleaved during the process of export (Kolter & Moreno, 1992, Duquesne et al., 2007). For example, the Colicin V precursor protein (a class IIa microcin) includes a double-glycine leader peptide, consisting of 15 amino acid residues, which is cleaved during export by the CvaA/CvaB/TolC export machinery (Gilson et al., 1990) (Havarstein et al., 1994; Zhong et al., 1996).

65 Microcin PDI (MccPDI), a newly identified microcin, is of particular interest because it inhibits the growth of a broad diversity of *E. coli* including EHEC serotypes O157:H7 and O26 (Sawant et al., 2011). The inhibitory phenotype has been called "proximity-dependent inhibition" (PDI) because

inhibition only occurs when the microcin-producing cells are located in close proximity to sensitive cells (Sawant et al., 2011). Whole-genome sequence analysis has identified five open-reading frames: *mcpM* and *mcpA* (microcin synthesis), *mcpI* (immunity) and *mcpD* and *mcpB* (export) (Eberhart et al., 2012). The number and organization of the genes resembles that of the class IIa microcins. Gene deletions verified that five plasmid encoded genes and the chromosomally located *tolC* are responsible for the PDI phenotype. To date, however, gene regulation, protein maturation and protein function have not been determined for MccPDI.

In this study, we demonstrate that the expression of microcin MccPDI is responsive to extracellular osmolarity and is regulated by the EnvZ/OmpR system. Maturation of the MccPDI effector protein, *McpM*, involves two sequential cleavage events, and once exported it appears that *McpM* interacts with susceptible cells resulting in increased cell membrane permeability.

Material and Methods

Bacterial Strains, Media and Growth Conditions.

E. coli strains were cultured in LB-Lennox medium (LB broth) (Difco) or in M9 minimal medium (6 g/L Na₂HPO₄, 3 g/L KH₂PO₄, 0.5 g/L NaCl, 1 g/L NH₄Cl, 2 mg/L thiamine, 1 mM MgSO₄, 0.1 mM CaCl₂, and 0.2% glucose) at 37° C. with shaking (200 rpm). Unless otherwise indicated, antibiotics were added to media at the following concentrations: tetracycline (Tet), 50 µg/ml; chloramphenicol (Cm), 34 µg/ml; kanamycin (Kan), 50 µg/ml; nalidixic acid (Nal), 30 µg/ml; and ampicillin (Amp), 100 µg/ml. LB broth with different salt concentrations were made by mixing 10 g/L Bacto-tryptone, 5 g/L yeast extract and NaCl at indicated concentrations.

DNA Manipulation and Mutant Construction.

Extraction of *E. coli* genomic DNA was accomplished using a Dneasy® Blood & Tissue kit following the manufacturer's instruction (Qiagen). Plasmid DNA was purified using a QIAprep® Spin Miniprep Kit (Qiagen). Conventional PCR included DreamTaq® Green PCR Master Mix (Thermo Scientific) while preparative PCR was used for plasmid construction using Platinum PCR SuperMix High Fidelity (Invitrogen) according to the manufacturer's protocol. Deletion cassettes for chromosomal in-frame deletions were first generated using the splice-overlap-extension method (Heckman & Pease, 2007), which joins two 400-600 bp PCR fragments corresponding to genomic sequences flanking the gene(s) of interest. The deletion cassettes were subsequently cloned into a suicide plasmid (pDM4) by using standard cloning procedures (Milton et al., 1996) followed by confirmation with DNA sequencing. The resulting constructs were individually electroporated into *E. coli* S17-1 λpir, after which they were introduced by conjugation into MccPDI-producing *E. coli*-25. Mutant strains were selected on LB plates containing Cm and Tet followed by a 10% sucrose selection process. Gene deletion was confirmed by PCR using primers located just outside of the deleted sequence. Plasmids for complementation (pMMB207 and pCR2.1) and overexpression (pPAL7) were constructed by using standard cloning procedures and all inserts were fully sequenced to confirm construct assembly. For site-directed mutagenesis, primers were designed by using (EbaseChanger and were then used to generate point mutation plasmids with a Q5 Site-Directed Mutagenesis Kit (New England Biolabs) following the manufacturer's protocol. These constructs were introduced into their target strains by electroporation.

Competition Assays.

Bacterial strains were grown individually overnight in LB media with appropriate antibiotics. Equal volumes of each competing strain were inoculated at 1:200 into either fresh LB medium with different salt concentrations or M9 medium. The cultures were mixed and incubated at 37° C. for 12 h. When necessary, IPTG (100 µM unless specified otherwise) and antibiotics (chloramphenicol or ampicillin) were added during the competition. Monocultures of each competing strain were also prepared as controls by inoculation into the appropriate media at the same dilution. To estimate the number of colony forming units (CFUs) for each strain following competition, a 6×6 drop-plate method was employed (Chen et al., 2003) with triplicate counts for each competition experiment (technical replicates were averaged before analysis).

RNA Isolation and qPCR.

Expression was quantified for *mcpA*, *mcpB*, *mcpM*, *mcpI* and *tolC* at 4, 8, 12 and 24 h. Briefly, a cell pellet was collected by centrifugation from 1.0-1.5 Ml broth culture. This was resuspended in RNAwiz® reagent (350 µL; Bacteria Ribopure kit; Ambion). Primary organic extraction was carried out as per manufacturer's instructions. The RNA was treated with RQ1-RNase-free DNase (Promega) for 30 min at 37° C., followed by a second organic extraction using TRIzol LS (Invitrogen) as per manufacturer's instructions. The final RNA was quantified using a NanoDrop™ 2000 Spectrophotometer (Thermo Scientific). All RNA extractions were confirmed as "DNA free" by subjecting them to a qPCR reaction with primers for *rpoD* (without cDNA synthesis). Any samples for which a Ct value of <38 cycles was generated were treated a second time with DNase and were re-extracted as described above. RT reactions were performed utilizing iScript Supermix (BioRad) as per manufacturer's instructions with 500 ng of RNA in a total volume of 20 µL. The resultant cDNA was diluted 1:10 with the addition of 180 µL of ultra-pure water. Diluted cDNA (5 µL) was used as template in each qPCR reaction. qPCR reactions included SsoAdvance SYBR Mastermix (2×) (BioRad). Mastermix (10 µL) was combined with 5 µL of cDNA template and 200 nM of each primer in a final volume of 20 µL. All primer pairs were run using the same cycling parameters: initial denaturation at 95° C. for 2 min, followed by 40 cycles of 55° C. for 1 min and 95° C. for 15 s. Fluorescent signal was recorded during the annealing/extension step (55° C.). A melt-curve analysis was performed on all reactions starting at 75° C. and increasing 0.5° C./cycle, with a pause and fluorescence detection at each temperature for 5 s. All assays were run in triplicate and each condition was run in biological duplicate. *rpoD* served as the house-keeping gene for normalization purposes.

Electrophoretic Mobility Shift Assays (EMSA).

DNA fragments 1-8 (see results) were prepared by PCR and were then purified by using a QIAquick® PCR purification kit (Qiagen). Fragments 9-10 were obtained by annealing oligonucleotides in annealing buffer (10 mM Tris pH 8.0, 50 mM NaCl, 1 mM EDTA). Briefly, equal volumes of complementary oligonucleotides (at equimolar concentration) were mixed in a 1.5 ml microfuge tube and placed in a heat block at 95° C. for 5 min. The heat block along with the samples, was removed from the apparatus and allowed to cool for 1 h to room temperature. The resulting double-stranded DNA was separated on a 2.0% agarose gel and purified using QIAquick gel extraction kit (Qiagen). All fragments were quantified using a NanoDrop™ 2000 Spectrophotometer before EMSA experiments. The OmpR and XRE (control) proteins were expressed and purified using the Profinity eXact System. Concentration of purified pro-

teins was estimated using a micro-BCA protein assay kit (Thermo Scientific). The purified proteins were mixed with the DNA fragments at different concentrations in 20 μ L of binding buffer [10 mM Tris (pH 7.5), 100 mM KCl, 10 mM MgCl₂, 1 mM DTT, 5% glycerol]. Binding reactions were incubated at room temperature for 30 min before adding 5 μ L of 5 \times loading buffer. The samples were electrophoresed on 5% native TBE gels (BioRad) for 45 min at 100 V followed by staining with ethidium bromide.

Western Blot Analysis.

Protein samples from bacterial pellets and cell fractions were denatured in boiling water for 5 min in tricine sample buffer (BioRad). SDS-PAGE was used to separate proteins with either Any kD Tris-glycine precast gels or a 16.5% Tris-Tricine precast gels (BioRad) prior to western blotting. The Tris-Tricine gels were used to improve resolution for McpM. A Trans-Blot turbo transfer starter system (BioRad) was used to transfer proteins to a low-fluorescence polyvinylidene fluoride (LF-PVDF) membrane. Primary antibodies anti-Histag (1:2500, Novagen), anti-DnaK (1:5000, Abcam) were used with secondary goat anti-mouse antibody (1:5000, DyLight 488 conjugate) to visualize proteins on western blots. A ChemiDoc MP Imaging System (BioRad) was used to detect fluorescent signal.

Supernatant Protein Precipitation.

Bacterial strains were grown 10 h at 37 $^{\circ}$ C. (200 rpm) in M9 broth (50 ml) supplemented with appropriate antibiotics. Supernatants were filtered through 0.45- μ m PVDF syringe filters, and the proteins in the supernatant were precipitated by adding 20% (vol/vol) trichloroacetic acid (TCA) followed by incubation on ice for 1 h. Precipitated protein was pelleted by centrifugation (12,000 \times g for 1 h), washed with acetone for 15 min, dried, and suspended in Tricine sample buffer.

Fluorescent Labeling and DAPI Staining.

To construct pFPV-tdTomato, the *gfpmut3* gene in pFPV25.1 (Valdivia & Falkow, 1996) was replaced with the *tdTomato* gene (Clontech) using primers *tdtomato_XbaI* and *tdtomato_SphI*. Standard cloning procedures were used and sequencing was used to verify results. E25 Δ traM:kan and E25 Δ mcpM Δ mcpI:kan were transformed with the pFPV25.1-*gfpmut3* expressing green fluorescent protein (GFP), while target strain BW25113 was transformed with the pFPV-*tdtomato* expressing red fluorescent protein (tomato red). Competition assays (described above) were conducted with the fluorescently labeled cells, and individual monocultures were run as controls. After 2 h and 6 h incubations, 1 ml samples were taken from each of the cultures and 4,6-Diamidino-2-phenylindole dihydrochloride (DAPI) (Thermo Scientific) stain was added at a final concentration of 0.25 μ g/ml for 10 min at room temperature. The stained bacteria were pelleted by centrifugation for 1 min at 12,000 \times g and re-suspended into the same volume of PBS buffer. Cells were then immobilized onto poly-L-lysine coated glass slides (Sigma) for 20 min and covered with glass coverslips. Cells were observed and images were captured by using an inverted fluorescence microscope (EVOS, Advanced Microscopy Group).

Statistical Analysis.

All qPCR results were processed using the A-Act method (Livak & Schmittgen, 2001) with the resultant fold change/biological replicate analyzed using an ANOVA with a Bonferroni multiple comparison post-hoc test (NCSS 2007; LLC. Kaysville, Utah). Other comparisons were made by using ANOVA with a Dunnett's one-way multiple comparisons posthoc test (SigmaPlot version 12.5; Systat Software, Inc., San Jose, Calif.).

Results

MccPDI is Regulated by the EnvZ/OmpR Two-Component Regulatory System.

A previous study reported that inhibition by MccPDI was phenotypically obvious when strains were co-cultured in M9 medium (0.05% NaCl) but muted when co-cultured in LB medium (0.5% NaCl) (Sawant et al., 2011). Competition assays were performed here between a ccPDI producing strain (*E. coli*-25) and a target strain (BW25113) in M9 and LB with different concentrations of NaCl. We found that the MccPDI phenotype was significantly enhanced in LB containing low (0.05% NaCl) or no added salt (FIG. 9A). In contrast, when the concentration of NaCl in LB or M9 was increased (0.5% and 1%), inhibition was reduced correspondingly, indicating that MccPDI function or synthesis is responsive to changes in osmolarity. Consistent with the phenotype, qPCR analysis revealed that transcription of *mcpM* was significantly upregulated at 8 h in M9 when compared to LB (FIG. 10B). Transcription of other genes (*mcpI*, *mcpA*, and *mcpB*) within MccPDI gene cluster showed a similar pattern when cultured in LB and M9 media.

The *E. coli* EnvZ/OmpR two-component system responds to osmolarity changes in broth media (Forst & Roberts, 1994, Cai & Inouye, 2002). To determine if this system is involved with MccPDI regulation, *envZ* and *ompR* deletion strains were constructed in *E. coli*-25. Transcription of *mcpM* was down-regulated significantly, particularly at 4 h, for the E25 Δ *envZ* strain when compared to the isogenic control (FIG. 10A). Competition assays showed that the *envZ* or *ompR* gene knockouts abolished inhibition from MccPDI whereas complementation of each gene in the corresponding mutant restored the PDI phenotype (FIG. 9B). Furthermore, when the functionally important histidine residue (H243) of EnvZ was mutated to alanine, complementation using this mutant *envZ* sequence did not restore the inhibition phenotype (FIG. 10B). This data is consistent with MccPDI being regulated by osmolarity that is signaled through the EnvZ/OmpR two-component system.

Phosphorylated OmpR Binds to the Promoter Region of *mcpM*.

EnvZ is an osmotic sensor that regulates the phosphorylation state of the transcriptional factor OmpR (Qin et al., 2000). Phosphorylated OmpR controls the expression levels of outer membrane porin genes (*ompF* and *ompC*) and other virulence and fimbriae genes by binding their promoter region (Cai & Inouye, 2002, Feng et al., 2003, Jubelin et al., 2005). To determine if the OmpR binds to the promoter sequence of *mcpM*, a 200 bp DNA fragment located at position -10 bp to -210 bp (Pmic-10/-210) relative to the start codon of *mcpM* was mixed with recombinant OmpR and subjected to a mobility-shift assay. A concentration-dependent shift of the OmpR/DNA mixture was clearly evident and is consistent with OmpR binding to the *mcpM* promoter region. The negative control protein, XRE (expressed and purified identically to recombinant OmpR) did not bind the promoter of *mcpM*. A secondary control involving an unrelated DNA fragment (270 bp, *atpE*) displayed no gel shift after addition of purified OmpR. Sequence analysis showed that there is a non-coding region upstream from the ABC transporter genes (*mcpD* and *mcpB*) that could serve as another promoter sequence within the MccPDI gene cluster. No gel shift was observed for this 143 bp DNA fragment (PmicD-20/-163; relative to *mcpD* start codon), implying that the fragment PmicB-20/-163 does not contain a promoter cassette that can be recognized by OmpR.

Additionally, no gel shift was observed for another 201 bp DNA sequence (Pmic-233/-433; relative to mcpM start codon).

To determine if OmpR phosphorylation is required for binding to the mcpM promoter region, we mutated a conserved D55 residue of OmpR that is known to undergo transphosphorylation by EnvZ (Forst et al., 1994). This mutated OmpR recombinant protein was mixed with Pmic-10/-210 and the gel mobility shift assay showed no evidence of binding even when 900 ng of protein was added. Consistent with the data, the OmpR, purified from M9 media, which contained a reduced amount of phosphorylated OmpR, displayed reduced binding to the mcpM promoter region compared to the OmpR purified from LB media. Taken together, this data indicates that phosphorylated OmpR binds to the promoter region of mcpM.

mcpM promoter region includes more than one OmpR recognition site. To identify the sequence motif(s) that OmpR binds to within Pmic-10/-210, a series of truncated DNA fragments were prepared (FIG. 11A). OmpR bound DNA fragments 1-3, but not fragments 4 and 5, indicating that the region between -81 to -102 is necessary for OmpR binding. This is consistent for the gel shifts that were evident for fragments 6-8 and fragment 10, which contain the region between -81 to -102, whereas fragment 9 did not bind as expected. From a qualitative perspective, binding was reduced for fragments 3, 7 and 8 compared with fragments 1, 2, and 6 (the same batch of recombinant OmpR was used for all of these mixtures). This could be a staining artefact (less ethidium bromide intercalated into shorter strands of DNA), but this is also consistent with sequences -61 to -81 and -102 to -134 providing additional binding sites or stabilizing OmpR binding. The mcpM promoter region is rich in adenines and thymines and three possible binding sites (B1, B2 and B3) are highlighted based on the above data (FIG. 11B). A multiple sequence alignment showed that the three possible binding sites, especially B1, resemble the consensus OmpR binding sites for ompF and ompC (F1, F2, F3, F4 and C1) and include conserved nucleotides that are important for OmpR binding (Harlocker et al., 1995). Collectively, these data are consistent with the mcpM promoter region having multiple binding sites and that region B1 is likely the primary binding site for the OmpR protein. McpM is cleaved into three peptides. Eberhart et al. (2012) could not recover the MccPDI inhibition phenotype with complementation of Δ mcpM:Kan. They assumed this was due to a polar effect on the immunity protein, mcpI, owing to the proximal insertion of a kanamycin resistance gene. For this reason, we generated a new scarless knock-out of mcpM using the suicide vector pDM4 in the wild-type *E. coli*-25 strain. As expected, the inhibition phenotype was lost for the new knockout strain, but we were able to restore the phenotype upon in trans expression of mcpM driven by an IPTG-induced promoter (Ptac) in pMMB207 vector (FIG. 12). Importantly, western blot analysis showed three distinct protein products in the mcpM complemented strains. The upper band is the presumptive fulllength protein because its mass is consistent with the mass of the recombinant protein (also visible when synthesized in two MccPDI-susceptible strains, *E. coli* BW25113 and 186). Presumably, the middle and lower bands are cleaved forms of the full length protein. To exclude the possibility that the promoter (Ptac) affects the observed phenotype, we generated a recombinant mcpM construct with the native promoter (Pmic-1/-210+mcp/14). The new construct displayed the same phenotype as the previous construct (p207::mcpM) that was driven by Ptac promoter (FIG. 12).

McpM Undergoes Two Cleavage Events.

Class II microcins are typically generated from a precursor protein that harbors conserved leader peptides (Duquesne et al., 2007). Alignment of class IIa microcin precursors showed that a conserved double glycine is present in positions 17 and 18 of mcpM, consistent with the presence of an 18-residue leader peptide (FIG. 13). When the glycine residues were changed to proline (G17P and G18P) this resulted in loss of two protein bands relative to the wild-type strain. Changing only one glycine to alanine (G17A or G18A) did not prevent cleavage although the faint-low mass protein bands are consistent with reduced cleavage efficiency for the G17A mutation. Double mutations from glycine to alanine (G17A/G18A) abolished cleavage. Competition assays showed that these mutants are unable to inhibit sensitive strains (FIG. 14).

If changes to the double-glycine site (G17/G18) results in loss of a cleavage site, this would only explain one of the two proteins band differences. One possibility is that the smallest protein band is the cleaved product while the middle band is modified form of the cleaved product. Peptide sequencing after different protease treatments (trypsin, chymotrypsin, and elastase) and analysis using UPLC-MS/MS on an Q-Exactive Orbitrap instrument showed no evidence for post-translational modifications (Bioproximity), arguing that the middle band is not a modified form of the smaller protein (data not shown). Alternatively, a second double glycine (positions 26 and 27) or a glycine-alanine motif at positions 35 and 36 could be the second cleavage sites for McpM (FIG. 13). Mutations G26P and G27P had no effect on the cleavage while mutations G35P and A36D resulted in loss of the lower-mass protein band.

These data indicate that MccPDI has two leader peptides (1-18 and 19-36) and the protein undergoes two cleavage events during maturation which are likely sequential. A competition assay employing the mutated secondary cleavage site (G35P or A36D) displayed only partial inhibitory activity when compared with wild-type strain (FIG. 14). We also mutated other residues (R5, E11, V15, S16, N19, S33, R37 and G41) located within the two leader peptides and around the cleavage sites. Western blots showed that each mutant was processed normally, although E11A and V15A may have resulted in reduced synthesis of MccPDI. All mutants, except N19 exhibited comparable inhibition of a susceptible strain (FIG. 15).

Cleavage of McpM is Insufficient to Produce a Functional Protein.

We generated different constructs of mcpM that lack individual leader peptides (Δ 1-18 or Δ 19-36) or both (Δ 1-36; FIG. 16A). Neither the Δ 1-18 or Δ 1-36 strains inhibited sensitive strains (FIG. 16B). Furthermore, western blots showed very limited quantities of McpM from these strains compared to the wild-type strain. The Colicin V leader peptide shares ~50% amino acid identity with the primary leader sequence of McpM (FIG. 13). Consequently, we therefore replaced the primary leader peptide with the Colicin V leader peptide (ColV1-15/ Δ 1-18) (FIG. 16A), but this was not sufficient to recover wild-type phenotype (FIG. 16B) and very limited quantities of McpM were again detected by western blot.

Interestingly, the Δ 19-36 strain appeared to have a similar concentration of protein as the wild-type strain, but its inhibitory activity was severely reduced (FIG. 16B). It is possible that the reduced activity is due to loss of export owing to the missing second leader sequence. Nevertheless, a western blot demonstrated that the product was present in

TCA-precipitated culture supernatant. Both of the cleaved McpM products appeared to be present for the wild-type strain whereas no products were present for the secretion-negative Δ mcpB strain. While the A19-36 construct of McpM is exported, it appears to have lost most of its functional activity (FIG. 16B, last bar).

McpM Cleavage is Concomitant with Export.

Class II microcin export machinery displays a canonical structure consisting of three components. The ABC transporter and an accessory protein are encoded in the microcin gene cluster while the third component is the chromosome-encoded TolC (Vassiliadis et al., 2011). We verified that Δ mcpB and Δ mcpD strains lose the PDI phenotype and complementation restores it (FIG. 12). Sequence alignment shows that McpB contains three conserved domains including an N-terminal peptidase C39 domain, an ABC transporter transmembrane domain, and a C-terminal ABC transporter ATP-binding domain, which is consistent with the ABC transporter family. In trans expression of mcpM in a double knockout (Δ mcpM Δ mcpB) demonstrated that deletion of mcpB leads to the loss of McpM cleavage, confirming that the ABC transporter is responsible for cleavage of this protein. McpD is homologous to proteins of class II microcin export machinery and it likely serves as a connector between the ABC transporter and TolC (Gilson et al., 1990, Pons et al., 2004). In trans expression of mcpM in the double knockout Δ mcpM Δ mcpD did not affect production of full-length McpM, but cleavage was blocked as with the Δ mcpB strain, indicating that cleavage of McpM is concomitant with export.

The First Two Cysteines within the McpM are Necessary for Function.

In class IIa microcins, cysteine pairs are commonly associated with the formation of disulfide bonds (Duquesne et al., 2007). The McpM protein includes four cysteine residues (positions 57, 90, 109 and 118) and all are located within the mature peptide sequence (FIG. 13). To determine if these cysteine residues are involved in post-translational modifications, each was individually mutated to alanine using site-directed mutagenesis. Western blots demonstrated that these point mutations did not affect McpM synthesis or post-translational cleavage, but the PDI inhibitory phenotype was eliminated for C57A and C90A, whereas mutation of cysteines 3 and 4 (C109A and C118A) had no effect on function (FIG. 17). These results are consistent with the possibility that a disulfide bond is required between the cysteine residues located at positions 57 and 90 for McpM to be functional. DsbA and DsbB are thiol-redox enzymes that are responsible for disulfide-bond formation in *E. coli* (Inaba, 2009). Knockouts of dsbA and dsbB (Δ dsbA and Δ dsbB) in the wild-type E-25 strain did not result in loss of PDI phenotype (FIG. 18). Furthermore, a series of double-knockouts (Δ dsbA Δ dsbB and Δ dsbA Δ dsbD) or triple-knockout (Δ dsbA Δ dsbB Δ dsbD) eliminated the possible redundancy between the DsbA/DsbB and DsbC/DsbD pathways, but did not impact the killing phenotype strain (FIG. 18).

MccPDI Induces Membrane Permeability.

To probe how MccPDI exerts its inhibitory activity on target cells, we fluorescently labeled the mcpM-producing strain (GFP-labeled E25 Δ traM and E25 Δ mcpM Δ mcpI) and target strain (tdTomato-labeled *E. coli* BW25113) to distinguish the two populations. After co-culture for 2 and 6 h, the cell mixtures were stained with a low concentration of DAPI (0.25 μ g/ml). DAPI is normally used to stain fixed cells that have a permeabilized cell membrane. Although high concentration of DAPI can also be used to stain live cells, the

effectiveness of the stain is lower (Zink et al., 2003). MccPDI-susceptible cells were co-cultured with E25 Δ traM for 6 hours after which they were easily stained by using a low concentration of DAPI (FIG. 19, top right panel). As a control, the susceptible cells were co-cultured with E25 Δ mcpM Δ mcpI for 6 hours and after applying the same staining protocol, there was no DAPI staining observed (FIG. 19, bottom right panel). DAPI also did not stain either strain in monoculture (data not shown).

Discussion

Regulation of Microcin PDI.

Bacteriocin production is an inducible process that is affected by different environmental and nutritional factors (Drider et al., 2006). For example, expression of colicin genes is regulated by the SOS response regulon that responds to DNA damage (Walker, 1995, Gillor et al., 2008). Alternatively, regulation of microcin synthesis is more related to nutrient depletion or anoxic conditions (Duquesne et al., 2007). For example, production of many class I microcins (MccB17, MccC7/C51 and MccJ25) are upregulated when cells reach the stationary growth phase (Moreno et al., 2002). One notable exception is MccE492, which is only produced during the exponential growth phase (Corsini et al., 2002). Nitrogen starvation induces MccB17 production (Connell et al., 1987) and MccV production is initiated under iron-limiting conditions (Gilson et al., 1990).

MccPDI gene expression increases rapidly during log-phase growth and drops off as the population enters stationary phase (Eberhart et al., 2012). The PDI phenotype is enhanced significantly when these experiments are conducted in M9 media compared to LB media, arguing that differences between the media (e.g., salt concentrations) might affect microcin synthesis or function (Sawant et al., 2011). We demonstrated that osmolarity in the growth media regulates expression of the mcpM. This is a novel regulatory mechanism with respect to what is known about microcins, although osmolarity can influence bacteriocin production in Gram-positive bacteria (Uguen et al., 1999).

The EnvZ/OmpR two-component regulatory system plays a central role in mediating the response to osmotic stress in *E. coli* (Stock et al., 2000). Consequently, it was not surprising to find that osmolarity-sensitive expression of MccPDI is dependent on the EnvZ/OmpR system where the phosphorylated transcriptional regulator, OmpR, binds to the mcpM promoter region. Similarly, Hernandez-Chico et al (1986) reported that expression of MccB17 gene cluster was dependent on the OmpR transcriptional factor, but this regulation is growth-phase dependent. RNA polymerase sigma 70 factor (δ 70) is involved in MccB17 expression (Bohannon et al., 1991) while RNA polymerase sigma S (δ S) appears to regulate MccJ25 and mccC7/C51. The histonelike protein H-NS acted as a repressor of MccB17 and mccC7/C51 expression (Fomenko et al. 2001; Moreno et al., 2002).

The EnvZ/OmpR system also regulates synthesis of the outer membrane proteins OmpF and OmpC that enable bacteria to cope with fluctuations in osmolarity (Forst et al., 1989). Under high osmolarity conditions, EnvZ auto-phosphorylates and transfers the phosphoryl group to OmpR, producing the phosphorylated form OmpR-P. At low osmolarity OmpR-P is present in low concentrations. OmpR-P binds to the promoter regions of outer membrane porin genes ompF and ompC and differentially modulates their expression according to the concentration of cellular OmpR-P (Yoshida et al., 2002). There are several binding sites for OmpR-P within the promoter region of ompF. When present in low concentrations, OmpR-P only binds to the

high-affinity sites. Under high osmolarity conditions, OmpR-P concentration increases and binding occurs at low-affinity sites that result in reduced expression of *ompF* (Harlocker et al., 1995). Here, we show that regulation of *mcpM* is negatively correlated with osmolarity of the growth media (greater in M9 than LB). OmpR-P clearly binds the promoter region of *mcpM* whereas unphosphorylated OmpR does not. Consequently, the EnvZ/OmpR system is required for activation of MccPDI and we propose that *mcpM* transcriptional regulation mirrors that of *ompF* regulation. This conclusion is further supported by the finding of at least three putative binding sites in the MccPDI promoter region that resembles the consensus OmpR binding site for *ompF*.

Furthermore, Zhao et al. (2015) recently demonstrated that *McpM* interacts with OmpF and consequently, the concurrent expression of these traits in producer and susceptible cells likely maximizes the ability of the MccPDI-producing strains to inhibit susceptible competitors. *McpM* maturation. Functional microcins are usually derived from a precursor protein that is composed of a C-terminal structural region and an N-terminal leader peptide (Kolter Moreno, 1992). Enzymatic cleavage removes the leader peptide and the microcin may or may not undergo further post-translational modification. The Class II microcins have conserved leader peptides that range in size from 15 to 19 residues and harbor a double-glycine or glycinealanine cleavage site (Duquesne et al., 2007). In contrast, there is little sequence similarity between the leader peptides of Class I microcins. For example, the MccB17 precursor, a class I microcin, is processed at G26, but this cleavage site is not a typical sequence of the doubleglycine-type leader peptides as described for class II microcins (Davagnino et al., 1986).

MccPDI most closely resembles a Class IIa microcin based on its genetic organization (Eberhart et al., 2012). The complete microcin protein, *McpM*, contains a typical double-glycine cleavage site (G17G18) and a conserved leader peptide (residues 1-18) similar to other Class II microcins. *McpM* also harbors a second cleavage site (G35A36) corresponding to a second leader peptide sequence. To our knowledge, this is the first report of a microcin containing two leader peptides (1-18 and 19-36).

Leader peptides typically prevent microcin function (e.g., in the cytoplasm of the producing strain) or serve as a recognition site for export (Drider et al., 2006). For *McpM*, experimental evidence suggests that the first leader peptide, but not the second, is required for export. The first leader sequence may also serve to inhibit protein degradation because when absent we find only very small quantities of the modified *McpM* protein in the cell. We assume that the second cleavage event takes place during or after export. If the latter, this would be consistent with the hypothesis that the fully functional microcin is composed of a dimer or multimer of the two cleaved products.

Cysteine is the least abundant amino acid found in proteins (Brooks & Fresco, 2002) and it performs a variety of essential functions including binding metal ions and forming disulfide bonds that produce three-dimensional protein structures (Giles et al., 2003). For these reasons, if a protein contains an "even" number of cysteines and is predicted to function outside the cytoplasm, it is likely that cysteines form disulfide bonds (Berkmen, 2012). *McpM* has four cysteines within the mature protein, consistent with the prediction that disulfide bond formation occurs. Our experimental data showed that the first two cysteines are necessary for MccPDI inhibition. We also conducted competition assays in the presence of 5 mM DTT, a reducing agent that breaks disulfide bonds. Under these conditions, no inhibition

was observed (data not shown) although this type of experiment could have multiple confounding effects. There was no evidence in this study that Dsb-based enzymatic activity in the *McpM*-producing strain contributes to disulfide-bond formation, but other works shows that strains lacking DsbA or DsbB are less susceptible to MccPDI (Zhao et al., 2015). While a computational three dimensional model for *McpM* did not support the formation of an intra-molecular disulfide bond between cysteine 57 and cysteine 90 due to the physical distance between these sites (data not shown), the reduced killing activity observed when only one of the two cleaved forms is present suggests the possibility of inter-molecular disulfide-bond formation. If disulfide bonds are required for function, we surmise that they form after the mature *McpM* protein enters the susceptible cell where folding likely occurs in the periplasm.

For class IIa microcins, cysteines commonly form disulfide bonds in the mature peptide. The full-length MccB17 protein has four cysteine residues that form heterocyclic rings by an unusual post-translational modification of the mature microcin (Bayer et al., 1995), and mutational analysis suggests that the mature form of MccV has a disulfide bond between the cysteine residues at positions 76 and 87 (Zhang et al., 1995). In addition, using mass spectrometry Pons et al. (2004) detected the presence of two intramolecular disulfide bridges in the mature MccL.

After maturation and export, microcins inhibit susceptible bacteria through a variety of mechanisms. MccJ25 recognizes the outer membrane protein FhuA and requires the inner membrane proteins TonB, ExbB, ExbD and SbmA, for translocation (Destoumieux-Garzon et al., 2005, Salomon & Farias, 1993, Salomon & Farias, 1995). Once it reaches the cytoplasm, MccJ25 inhibits transcription by obstructing the RNA polymerase secondary channel (Wilson et al., 2003). MccB17 binds OmpF on the outer membrane and the inner protein SbmA mediates uptake into the cytoplasm, where MccB17 inhibits the DNA gyrase (Lavina et al., 1986).

Microcin C7/C51 requires OmpF and the inner-membrane ABC-transporter, Yej, to be actively transported through the inner membrane (Novikova et al., 2007). Within the target cell MccC7/C51 is cleaved to form a modified aspartyl adenylate that inhibits Asp-tRNA synthetase, thus blocking protein synthesis at the translation level (Kazakov et al., 2008, Metlitskaya et al., 2006). MccE492, MccM, and MccH47, all Class IIb microcins, are unable to inhibit the growth of strains carrying mutations in the *fepA*, *cir*, and *fiu* genes, consistent with the requirement for these iron-catecholate receptors (Thomas et al., 2004, Patzer et al., 2003).

The transport of class IIb microcins across the outer membrane is also TonB-dependent (Destoumieux-Garzon et al., 2006, Thomas et al., 2004). Once in the periplasm, MccE492 functions by inserting into the inner membrane and interfering with membrane potential (Lagos et al., 1993, Destoumieux-Garzon et al., 2003). This activity is facilitated by the inner membrane proteins ManY and ManZ (Bieler et al., 2006). MccH47 exerts its activity by inhibiting the ATP synthase (Trujillo et al., 2001). MccV causes channel formation and disruption of membrane potential by binding to the inner membrane receptor SdaC (Yang & Konisky, 1984, Gerard et al., 2005). Recently, it was shown that MccPDI interacts with the sole receptor OmpF (Zhao et al., 2015). In this study we further demonstrate that MccPDI undergoes two sequential cleavage events, with the mature microcin inducing membrane permeability in susceptible cells. Without being bound by theory, the following model is representative of MccPDI function. First, *McpM* precursor protein undergoes two cleavage events to produce two cleaved

forms during and possibly after export. The two cleaved peptides interact with OmpF of susceptible cells, cross the outer membrane using an unknown mechanism to access the periplasm where disulfide bridges facilitate the formation of multimers. The disulfide bonds are formed utilizing the target cells thio-redox systems, DsbA/B and/or DsbC/D, and once fully mature, the multimers permeabilize the susceptible-cells membrane leading to cell death.

References for Example 13

- Asensio, C. & J. C. Perez-Diaz, (1976) A new family of low molecular weight antibiotics from enterobacteria. *Biochem Biophys Res Commun* 69: 7-14.
- Baquero, F. & F. Moreno, (1984) The microcins. *FEMS Microbiology Letters* 23: 117-124.
- Bayer, A., S. Freund & G. Jung, (1995) Post-translational heterocyclic backbone modifications in the 43-peptide antibiotic microcin B17. Structure elucidation and NMR study of a ¹³C, ¹⁵N-labelled gyrase inhibitor. *Eur J Biochem* 234: 414-426.
- Berkmen, M., (2012) Production of disulfide-bonded proteins in *Escherichia coli*. *Protein Expr Purif* 82: 240-251.
- Bieler, S., F. Silva, C. Soto & D. Belin, (2006) Bactericidal activity of both secreted and nonsecreted microcin E492 requires the mannose permease. *J Bacteriol* 188: 7049-7061.
- Bohannon, D. E., N. Connell, J. Keener, A. Tormo, M. Espinosa-Urgel, M. M. Zambrano & R. Kolter, (1991) Stationary-phase-inducible "gearbox" promoters: differential effects of katF mutations and role of sigma 70. *J Bacteriol* 173: 4482-4492.
- Brooks, D. J. & J. R. Fresco, (2002) Increased frequency of cysteine, tyrosine, and phenylalanine residues since the last universal ancestor. *Mol Cell Proteomics* 1: 125-131.
- Cai, S. J. & M. Inouye, (2002) EnvZ-OmpR interaction and osmoregulation in *Escherichia coli*. *J Biol Chem* 277: 24155-24161.
- Chen, C. Y., G. W. Nace & P. L. Irwin, (2003) A 6x6 drop plate method for simultaneous colony counting and MPN enumeration of *Campylobacter jejuni*, *Listeria monocytogenes*, and *Escherichia coli*. *J Microbiol Methods* 55: 475-479.
- Connell, N., Z. Han, F. Moreno & R. Kolter, (1987) An *E. coli* promoter induced by the cessation of growth. *Mol Microbiol* 1: 195-201.
- Corsini, G., M. Baeza, O. Monasterio & R. Lagos, (2002) The expression of genes involved in microcin maturation regulates the production of active microcin E492. *Biochimie* 84: 539-544.
- Davagnino, J., M. Herrero, D. Furlong, F. Moreno & R. Kolter, (1986) The DNA replication inhibitor microcin B17 is a forty-three-amino-acid protein containing sixty percent glycine. *Proteins* 1: 230-238.
- Destoumieux-Garzon, D., S. Duquesne, J. Peduzzi, C. Goulard, M. Desmadril, L. Letellier, S. Rebuffat & P. Boulanger, (2005) The iron-siderophore transporter FhuA is the receptor for the antimicrobial peptide microcin J25: role of the microcin Val11-Pro16 beta-hairpin region in the recognition mechanism. *Biochem J* 389: 869-876.
- Destoumieux-Garzon, D., J. Peduzzi, X. Thomas, C. Djediat & S. Rebuffat, (2006) Parasitism of iron-siderophore receptors of *Escherichia coli* by the siderophore-peptide microcin E492m and its unmodified counterpart. *Biometals* 19: 181-191.
- Destoumieux-Garzon, D., X. Thomas, M. Santamaria, C. Goulard, M. Barthelemy, B. Boscher, Y. Bessin, G. Molle, A. M. Pons, L. Letellier, J. Peduzzi & S. Rebuffat, (2003) Microcin E492 antibacterial activity: evidence for a TonB-dependent inner membrane permeabilization on *Escherichia coli*. *Mol Microbiol* 49: 1031-1041.
- Drider, D., G. Fimland, Y. Hechard, L. M. McMullen & H. Prevost, (2006) The continuing story of class IIa bacteriocins. *Microbiol Mol Biol Rev* 70: 564-582.
- Duquesne, S., D. Destoumieux-Garzon, J. Peduzzi & S. Rebuffat, (2007) Microcins, geneencoded antibacterial peptides from enterobacteria. *Nat Prod Rep* 24: 708-734.
- Eberhart, L. J., J. R. Deringer, K. A. Brayton, A. A. Sawant, T. E. Besser & D. R. Call, (2012) Characterization of a novel microcin that kills enterohemorrhagic *Escherichia coli* O157:H7 and O26. *Appl Environ Microbiol* 78: 6592-6599.
- Feng, X., R. Oropeza & L. J. Kenney, (2003) Dual regulation by phospho-OmpR of ssrA/B gene expression in *Salmonella* pathogenicity island 2. *Mol Microbiol* 48: 1131-1143.
- Fomenko, D., A. Veselovskii & I. Khmel, (2001) Regulation of microcin C51 operon expression: the role of global regulators of transcription. *Res Microbiol* 152: 469-479.
- Forst, S., J. Delgado & M. Inouye, (1989) Phosphorylation of OmpR by the osmosensor EnvZ modulates expression of the ompF and ompC genes in *Escherichia coli*. *Proc Natl Acad Sci USA* 86: 6052-6056.
- Forst, S. A. & D. L. Roberts, (1994) Signal transduction by the EnvZ-OmpR phosphotransfer system in bacteria. *Res Microbiol* 145: 363-373.
- Gerard, F., N. Pradel & L. F. Wu, (2005) Bactericidal activity of colicin V is mediated by an innermembrane protein, SdaC, of *Escherichia coli*. *J Bacteriol* 187: 1945-1950.
- Giles, N. M., G. I. Giles & C. Jacob, (2003) Multiple roles of cysteine in biocatalysis. *Biochem Biophys Res Commun* 300: 1-4.
- Gillor, O., J. A. Vriezen & M. A. Riley, (2008) The role of SOS boxes in enteric bacteriocin regulation. *Microbiology* 154: 1783-1792.
- Gilson, L., H. K. Mahanty & R. Kolter, (1990) Genetic analysis of an MDR-like export system: the secretion of colicin V. *Embo J* 9: 3875-3884.
- Harlocker, S. L., L. Bergstrom & M. Inouye, (1995) Tandem binding of six OmpR proteins to the ompF upstream regulatory sequence of *Escherichia coli*. *J Biol Chem* 270: 26849-26856.
- Havarstein, L. S., H. Holo & I. F. Nes, (1994) The leader peptide of colicin V shares consensus sequences with leader peptides that are common among peptide bacteriocins produced by gram-positive bacteria. *Microbiology* 140 (Pt 9): 2383-2389.
- Heckman, K. L. & L. R. Pease, (2007) Gene splicing and mutagenesis by PCR-driven overlap extension. *Nat Protoc* 2: 924-932.
- Hernandez-Chico, C., J. L. San Millan, R. Kolter & F. Moreno, (1986) Growth phase and ompR regulation of transcription of microcin B17 genes. *J Bacteriol* 167: 1058-1065.
- Hibbing, M. E., C. Fuqua, M. R. Parsek & S. B. Peterson, (2010) Bacterial competition: surviving and thriving in the microbial jungle. *Nat Rev Microbiol* 8: 15-25.
- Inaba, K., (2009) Disulfide bond formation system in *Escherichia coli*. *J Biochem* 146: 591-597.
- Jubelin, G., A. Vianney, C. Beloin, J. M. Ghigo, J. C. Lazzaroni, P. Lejeune & C. Dorel, (2005) CpxR/OmpR

- interplay regulates curli gene expression in response to osmolarity in *Escherichia coli*. *J Bacteriol* 187: 2038-2049.
- Kazakov, T., G. H. Vondenhoff, K. A. Datsenko, M. Novikova, A. Metlitskaya, B. L. Wanner & K. Severinov, (2008) *Escherichia coli* peptidase A, B, or N can process translation inhibitor microcin C. *J Bacteriol* 190: 2607-2610.
- Kolter, R. & F. Moreno, (1992) Genetics of ribosomally synthesized peptide antibiotics. *Annu Rev Microbiol* 46: 141-163.
- Lagos, R., M. Wilkens, C. Vergara, X. Cecchi & O. Monasterio, (1993) Microcin E492 forms ion channels in phospholipid bilayer membrane. *FEBS Lett* 321: 145-148.
- Lavina, M., A. P. Pugsley & F. Moreno, (1986) Identification, mapping, cloning and characterization of a gene (sbmA) required for microcin B17 action on *Escherichia coli* K12. *J Gen Microbiol* 132: 1685-1693.
- Livak, K. J. & T. D. Schmittgen, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25: 402-408.
- Metlitskaya, A., T. Kazakov, A. Kommer, O. Pavlova, M. Praetorius-Ibba, M. Ibba, I. Krasheninnikov, V. Kolb, I. Khmel & K. Severinov, (2006) Aspartyl-tRNA synthetase is the target of peptide nucleotide antibiotic Microcin C. *J Biol Chem* 281: 18033-18042.
- Milton, D. L., R. O'Toole, P. Horstedt & H. Wolf-Watz, (1996) Flagellin A is essential for the virulence of *Vibrio anguillarum*. *J Bacteriol* 178: 1310-1319.
- Moreno, F., J. E. Gonzalez-Pastor, M. R. Baquero & D. Bravo, (2002) The regulation of microcin B, C and J operons. *Biochimie* 84: 521-529.
- Novikova, M., A. Metlitskaya, K. Datsenko, T. Kazakov, A. Kazakov, B. Wanner & K. Severinov, (2007) The *Escherichia coli* Yej transporter is required for the uptake of translation inhibitor microcin C. *J Bacteriol* 189: 8361-8365.
- Patzer, S. I., M. R. Baquero, D. Bravo, F. Moreno & K. Hantke, (2003) The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholatesiderophore receptors FepA, Cir, Fiu and Iron. *Microbiology* 149: 2557-2570.
- Pons, A. M., F. Delalande, M. Duarte, S. Benoit, I. Lanneluc, S. Sable, A. Van Dorsselaer & G. Cottenceau, (2004) Genetic analysis and complete primary structure of microcin L. *Antimicrob Agents Chemother* 48: 505-513.
- Qin, L., R. Dutta, H. Kurokawa, M. Ikura & M. Inouye, (2000) A monomeric histidine kinase derived from EnvZ, an *Escherichia coli* osmosensor. *Mol Microbiol* 36: 24-32.
- Rebuffat, S., (2011) Bacteriocins from Gram-Negative Bacteria: A Classification? In: Prokaryotic Antimicrobial Peptides. D. Drider & S. Rebuffat (eds). Springer New York, pp. 55-72.
- Riley, M. A. (2011) Bacteriocin-mediated competitive interactions of bacterial populations and communities. In: Prokaryotic antimicrobial peptides. D. Drider & S. Rebuffat (eds). Springer New York, pp. 13-26.
- Riley M. A. & J. E. Wertz, (2002) Bacteriocins: evolution, ecology, and application. *Annu Rev Microbiol* 56:117-137.
- Salomon, R. A. & R. N. Farias, (1993) The FhuA protein is involved in microcin 25 uptake. *J Bacteriol* 175: 7741-7742.
- Salomon, R. A. & R. N. Farias, (1995) The peptide antibiotic microcin 25 is imported through the TonB pathway and the SbmA protein. *J Bacteriol* 177: 3323-3325.

- Sawant, A. A., N. C. Casavant, D. R. Call & T. E. Besser, (2011) Proximity-dependent inhibition in *Escherichia coli* isolates from cattle. *Appl Environ Microbiol* 77: 2345-2351.
- Severinov, K., E. Semenova, A. Kazakov, T. Kazakov & M. S. Gelfand, (2007) Low-molecularweight post-translationally modified microcins. *Mol Microbiol* 65: 1380-1394.
- Severinov, K., E. Semenova & T. Kazakov, (2011) Class I microcins: Their structures activities, and mechanisms of resistance. In: Prokaryotic Antimicrobial Peptides: from Genes to Applications. New York: Springer, pp. 289-308.
- Stock, A. M., V. L. Robinson & P. N. Goudreau, (2000) Two-component signal transduction. *Annu Rev Biochem* 69: 183-215.
- Thomas, X., D. Destoumieux-Garzon, J. Peduzzi, C. Afonso, A. Blond, N. Birlirakis, C. Goulard, L. Dubost, R. Thai, J. C. Tabet & S. Rebuffat, (2004) Siderophore peptide, a new type of post-translationally modified antibacterial peptide with potent activity. *J Biol Chem* 279: 28233-28242.
- Trujillo, M., E. Rodriguez & M. Lavina, (2001) ATP synthase is necessary for microcin H47 antibiotic action. *Antimicrob Agents Chemother* 45: 3128-3131.
- Uguen, P., J. Hamelin, J. P. Le Pennec & C. Blanco, (1999) Influence of osmolarity and the presence of an osmoprotectant on *Lactococcus lactis* growth and bacteriocin production. *Appl Environ Microbiol* 65: 291-293.
- Valdivia, R. H. & S. Falkow, (1996) Bacterial genetics by flow cytometry: rapid isolation of *Salmonella typhimurium* acid-inducible promoters by differential fluorescence induction. *Mol Microbiol* 22: 367-378.
- Vassiliadis, G., D. Destoumieux-Garzon & J. Peduzzi, (2011) Class II Microcins. In: Prokaryotic Antimicrobial Peptides: from Genes to Applications. New York: Springer, pp. 309-330.
- Walker, G. C., (1995) SOS-regulated proteins in translesion DNA synthesis and mutagenesis. *Trends Biochem Sci* 20: 416-420.
- Wilson, K. A., M. Kalkum, J. Ottesen, J. Yuzenkova, B. T. Chait, R. Landick, T. Muir, K. Severinov & S. A. Darst, (2003) Structure of microcin J25, a peptide inhibitor of bacterial RNA polymerase, is a lassoed tail. *J Am Chem Soc* 125: 12475-12483.
- Yang, C. C. & J. Konisky, (1984) Colicin V-treated *Escherichia coli* does not generate membrane potential. *J Bacteriol* 158: 757-759.
- Yoshida, T., S. Cai & M. Inouye, (2002) Interaction of EnvZ, a sensory histidine kinase, with phosphorylated OmpR, the cognate response regulator. *Mol Microbiol* 46: 1283-1294.
- Zhang, L. H., M. J. Fath, H. K. Mahanty, P. C. Tai & R. Kolter, (1995) Genetic analysis of the colicin V secretion pathway. *Genetics* 141: 25-32.
- Zhao, Z., L. J. Eberhart, L. H. Orfe, S. Y. Lu, T. E. Besser & D. R. Call, (2015) Genome-Wide Screening Identifies Six Genes That Are Associated with Susceptibility to *Escherichia coli* Microcin PDI. *Appl Environ Microbiol* 81: 6953-6963.
- Zhong, X., R. Kolter & P. C. Tai, (1996) Processing of colicin V-1, a secretable marker protein of a bacterial ATP binding cassette export system, requires membrane integrity, energy, and cytosolic factors. *J Biol Chem* 271: 28057-28063.
- Zink, D., N. Sadoni & E. Stelzer, (2003) Visualizing chromatin and chromosomes in living cells. *Methods* 29: 42-50.

Example 14. McpM Functions as an Independent Protein

Based on our prior findings, it is clear that McpM is the “effector” protein for mcpM. This soluble protein is excreted via a type I secretion system where it interacts with the OmpF protein that is displayed on the surface of susceptible *E. coli*. We generated plasmid constructs that encode mcpM (“M” for full-length McpM and two additional versions “82” and “109” that lack signal peptides) with a histidine “tag” allowing purification of the recombinant protein using conventional chromatography techniques. The recombinant proteins were incubated at room temperature with 0%, 10% or 20% DMSO to enhance the efficiency of potential spontaneous disulfide-bond formation within

and between the recombinant protein molecules. These preparations were then “spotted” onto bacterial “lawns” composed of a mcpM-sensitive strain of *E. coli*. In FIG. 20A, faint zones of clearance are visible regardless of pre-incubation with 0%, 10% and 20% DMSO (see arrows; DMSO-only controls are at bottom of plate) and regardless of the construct that was used. FIG. 20B shows a similar experiment with six replicate spots of an independent batch of full-length, recombinant McpM that was pre-incubated in 20% DMSO. The variance in zone clearance between the FIGS. 20A and B is attributable to differences in recombinant protein concentration or in the agar media (M9 FIG. 20A, LB FIG. 20B). Regardless, these results demonstrate that the recombinant McpM inhibits growth of susceptible *E. coli* independent of a McpM-producing *E. coli* strain.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 77

<210> SEQ ID NO 1

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 1

tagttgcagg ggcataagaa

20

<210> SEQ ID NO 2

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 2

aggaaacgca aacagcaact

20

<210> SEQ ID NO 3

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 3

caggttcaat gctccgttgc

20

<210> SEQ ID NO 4

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 4

gcgacctttc gctttgatgg

20

<210> SEQ ID NO 5

<211> LENGTH: 19

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 5

-continued

ccgtaatgac cggtccagt 19

<210> SEQ ID NO 6
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 6

ccatttccac taccatgatc t 21

<210> SEQ ID NO 7
 <211> LENGTH: 32
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 7

ataaccgta tctttacgtt gccttacgtt ca 32

<210> SEQ ID NO 8
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 8

ctagaatccg caataat ttt acagtttgat 30

<210> SEQ ID NO 9
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 9

aataacgtga ttgcatatta cttatctcag gagttc 36

<210> SEQ ID NO 10
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 10

atccctggaa ggactacaac ctatgaccga aaatac 36

<210> SEQ ID NO 11
 <211> LENGTH: 40
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 11

gtaatttaat aaacatagta ggcacctcca ttatatctat 40

<210> SEQ ID NO 12
 <211> LENGTH: 40
 <212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 12

 aacgcacaaa ataacaaaca accgataggg gaaatatgat 40

<210> SEQ ID NO 13
 <211> LENGTH: 40
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 13

 attatcttta ctatatttat atatggtatc attcataatg 40

<210> SEQ ID NO 14
 <211> LENGTH: 40
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 14

 aacgcacaaa ataacaaaca accgataggg gaaatatgat 40

<210> SEQ ID NO 15
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 15

 tggatgatgaa ttcctgtcaa a 21

<210> SEQ ID NO 16
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 16

 taccagtttc acccgtcaca 20

<210> SEQ ID NO 17
 <211> LENGTH: 38
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 17

 tcagccattc ccataaatga cgagtatcaa ggttgacg 38

<210> SEQ ID NO 18
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 18

 ttgacggaaa ggttacttat tgtattaaataaatg 36

-continued

<210> SEQ ID NO 19
 <211> LENGTH: 40
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 19
 gatatacatc tgacctgtgt gatgttaaag tttatacta 40

<210> SEQ ID NO 20
 <211> LENGTH: 40
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 20
 atagaaaaaa taagaacaat ctccgcgaaa tagcattatg 40

<210> SEQ ID NO 21
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer site
 <400> SEQUENCE: 21
 tgtgtaggct ggagctgctt cg 22

<210> SEQ ID NO 22
 <211> LENGTH: 19
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer site
 <400> SEQUENCE: 22
 catatgaata tcctcetta 19

<210> SEQ ID NO 23
 <211> LENGTH: 356
 <212> TYPE: DNA
 <213> ORGANISM: Escherichia coli
 <400> SEQUENCE: 23
 atggcaaata taagagaatt aacttttagat gagataacgc ttgtcagcgg aggaacagca 60
 actttgaagg tggccccctg aatgaccggt ccagtggggc tcgtaactca ctgggtcgaa 120
 acgcaccaac tcatatttat agtgatccaa gcactgtaaa atgcgctaac gctgtattta 180
 gtggaatgat tgggtgtgcg atcaaaggag gtcccatagg aatggcaaga ggtaccattg 240
 gtggagccgt tgttggtaa tgtctctcag atcatggtag tggaaatgga agtggtaaca 300
 gaggaagttc cagtagttgt tcaggtaata atgttggcgg aacatgtaac cgataa 356

<210> SEQ ID NO 24
 <211> LENGTH: 120
 <212> TYPE: PRT
 <213> ORGANISM: Escherichia coli
 <400> SEQUENCE: 24
 Met Ala Asn Ile Arg Glu Leu Thr Leu Asp Glu Ile Thr Leu Val Ser
 1 5 10 15

-continued

Gly Gly Asn Ala Asn Ser Asn Phe Glu Gly Gly Pro Arg Asn Asp Arg
 20 25 30
 Ser Ser Gly Ala Arg Asn Ser Leu Gly Arg Asn Ala Pro Thr His Ile
 35 40 45
 Tyr Ser Asp Pro Ser Thr Val Lys Cys Ala Asn Ala Val Phe Ser Gly
 50 55 60
 Met Ile Gly Gly Ala Ile Lys Gly Gly Pro Ile Gly Met Ala Arg Gly
 65 70 75 80
 Thr Ile Gly Gly Ala Val Val Gly Gln Cys Leu Ser Asp His Gly Ser
 85 90 95
 Gly Asn Gly Ser Gly Asn Arg Gly Ser Ser Ser Ser Cys Ser Gly Asn
 100 105 110
 Asn Val Gly Gly Thr Cys Asn Arg
 115 120

<210> SEQ ID NO 25
 <211> LENGTH: 216
 <212> TYPE: DNA
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 25

atggaggcg ctactatggt tattaata ctttccttta tatgtggttt gttactggga 60
 tttgcactat tgagtggctc ctctgttatt gatttatact ggttttcact accttccgag 120
 ttttcaaaga ttgtagtcat gctgatcact cttttttcca cggcaagatt catggactat 180
 atcatagaaa aaataagaac aatctccgag aatag 216

<210> SEQ ID NO 26
 <211> LENGTH: 71
 <212> TYPE: PRT
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 26

Met Glu Gly Ala Thr Met Phe Ile Lys Leu Leu Ser Phe Ile Cys Gly
 1 5 10 15
 Leu Leu Leu Gly Phe Ala Leu Leu Ser Gly Ser Ser Val Ile Asp Leu
 20 25 30
 Tyr Trp Phe Ser Leu Pro Ser Glu Phe Ser Lys Ile Val Val Met Leu
 35 40 45
 Ile Thr Leu Phe Ser Thr Ala Arg Phe Met Asp Tyr Ile Ile Glu Lys
 50 55 60
 Ile Arg Thr Ile Ser Ala Lys
 65 70

<210> SEQ ID NO 27
 <211> LENGTH: 636
 <212> TYPE: DNA
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 27

atgaatgata acatatataa atatagtaaa gataatgcga tagcgtttct tctacttggt 60
 gttatatcaa cagttgtgat attcacaccg gcattcacca tacaatataat tggtttggat 120
 ctggcatttt cctttgtctt tattactgaa attttaatgt caacttcatt ttatattttt 180
 tacttaagaa gaataccagg ttgtaaaatc accataaaga caaatgcgaa aacattaaag 240
 ctattagtaa tatcatttgc tgtgattgct ctcatgcaac tgcttatttt tgcttataga 300

-continued

```

gacaatttga acaatagtga atcaacttca cttaattgga ttgaaatatt tatactggtc 360
ctgacagttc cgtattatga agaaattggt taccgaacat gtctattcgg tcttctatgt 420
acgacttata aaaaagaatt atttaccccc tgcgtgtgta catctttatt tttctgctg 480
atgcatccgc agtattataa tgtggctgat caaattattc tgtttattat gtcaatgtta 540
ttgttgaata taaggatttg cagtaagggg attttctatc caatgctggt acatgcggga 600
ataaacggct ttggtatatt gttaaatata ttatag 636

```

```

<210> SEQ ID NO 28
<211> LENGTH: 211
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli

```

```

<400> SEQUENCE: 28

```

```

Met Asn Asp Asn Ile Tyr Lys Tyr Ser Lys Asp Asn Ala Ile Ala Phe
1           5           10           15
Leu Leu Leu Val Val Ile Ser Thr Val Val Ile Phe Thr Pro Ala Phe
20           25           30
Thr Ile Gln Tyr Ile Gly Leu Asp Leu Ala Phe Ser Phe Val Phe Ile
35           40           45
Thr Glu Ile Leu Met Ser Thr Ser Phe Tyr Ile Phe Tyr Leu Arg Arg
50           55           60
Ile Pro Gly Cys Lys Ile Thr Ile Lys Thr Asn Ala Lys Thr Leu Lys
65           70           75           80
Leu Leu Val Ile Ser Phe Ala Val Ile Ala Leu Met Gln Leu Leu Ile
85           90           95
Phe Ala Tyr Arg Asp Asn Leu Asn Asn Ser Glu Ser Thr Ser Leu Asn
100          105          110
Trp Ile Glu Ile Phe Ile Leu Val Leu Thr Val Pro Tyr Tyr Glu Glu
115          120          125
Ile Val Tyr Arg Thr Cys Leu Phe Gly Leu Leu Cys Thr Thr Tyr Lys
130          135          140
Lys Glu Leu Phe Thr Pro Cys Val Cys Thr Ser Leu Phe Phe Cys Leu
145          150          155          160
Met His Pro Gln Tyr Tyr Asn Val Ala Asp Gln Ile Ile Leu Phe Ile
165          170          175
Met Ser Met Leu Leu Leu Asn Ile Arg Ile Cys Ser Lys Gly Ile Phe
180          185          190
Tyr Pro Met Leu Leu His Ala Gly Ile Asn Gly Phe Val Ile Leu Leu
195          200          205
Asn Ile Leu
210

```

```

<210> SEQ ID NO 29
<211> LENGTH: 1254
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

```

```

<400> SEQUENCE: 29

```

```

atgaatatat tcagaagtga agcaatagaa catcataatg aactgaata tggtagacatt 60
attttaccaa catcatttag cctatccgta tgtgcaacag ttacattatt cattatgtta 120
agtctgactg tattcatata ttacggtagc tatacaagga aagegcatct tacaggatc 180
gtcatgccct catcaggact ggtaaaaata attcctcaat atgcaggata tgtaacacaa 240
ctgactgtat ccgaaggaga acacgtaact gcaggacac aactctatca tataagtgga 300

```

-continued

```

gaacattata acggtaacgg aactggcaca ttagcaacga tgagtatttc cctgaagact 360
cagtatatta tgttgacctc ccagcaatcc tttgagtcgc gagataatag tcaacaacag 420
gaagccatac ggcaaaggat gatatcactt gagccgcaaa taagaagtgc agaacaaga 480
cttcagcttg ctgaacgtca ggcagaactg gctatatccg tcatggaacg ctataaaaaa 540
ttggctggta cgcattatgt gtcagatata gaattccaac agaaacaaat tgatgtttct 600
gccgctcaac aaaacgttga agatcagcgt caggggcttc tccagttaca tactgcaatg 660
gacacagcca aagatgaact aatcatctt attgttcagg ggaaaagccg taaagcagaa 720
ctcgacagac aattgcaggt gctaaaacaa caacaggatg aactcgccgg acaagaaaaa 780
tttacctga gggctccagt atccgggact attgctgctg tactgatcaa acaggggcag 840
tctgtgaaag catctgaacc ggtcatgact ctcatcccg ataatgctca ttacaaaatt 900
gagctttatg ctaccagcca gaaagccggg tttatccgac caggtcaacg ggtatctctg 960
aagttttcgg ccttcctta tcagaaattt ggtatccagt acggcacaat tcgtaaaatc 1020
agtcatacga ctctggetcc ttccgactta ttaccagttt cacccgtcac atggaaagaa 1080
aacgaagggc attatcgcgt tattgttgaa cctgaaaata catttatatt tgcatacggg 1140
aaaaaagaac cgctaagacc aggcattgact ctggaaggag acgtcaacct tgatactcgt 1200
catttatggg aatggctgac agagccccta tggagcatga aaggaaatct gtaa 1254

```

<210> SEQ ID NO 30

<211> LENGTH: 417

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 30

```

Met Asn Ile Phe Arg Ser Glu Ala Ile Glu His His Asn Asp Thr Glu
1           5           10           15
Tyr Gly Asp Ile Ile Leu Pro Thr Ser Phe Ser Leu Ser Val Cys Ala
          20           25           30
Thr Val Thr Leu Phe Ile Met Leu Ser Leu Thr Val Phe Ile Tyr Tyr
          35           40           45
Gly Ser Tyr Thr Arg Lys Ala His Leu Thr Gly Ile Val Met Pro Ser
          50           55           60
Ser Gly Leu Val Lys Ile Ile Pro Gln Tyr Ala Gly Tyr Val Thr Gln
65           70           75           80
Leu Thr Val Ser Glu Gly Glu His Val Thr Ala Gly Thr Gln Leu Tyr
          85           90           95
His Ile Ser Gly Glu His Tyr Asn Gly Asn Gly Thr Gly Thr Leu Ala
          100          105          110
Thr Met Ser Ile Ser Leu Lys Thr Gln Tyr Ile Met Leu Ala Ser Gln
          115          120          125
Gln Ser Phe Glu Ser Arg Asp Asn Ser Gln Gln Gln Glu Ala Ile Arg
          130          135          140
Gln Arg Met Ile Ser Leu Glu Pro Gln Ile Arg Ser Ala Glu Gln Arg
145          150          155          160
Leu Gln Leu Ala Glu Arg Gln Ala Glu Leu Ala Ile Ser Val Met Glu
          165          170          175
Arg Tyr Lys Lys Leu Ala Gly Thr His Tyr Val Ser Asp Ile Glu Phe
          180          185          190
Gln Gln Lys Gln Ile Asp Val Ser Ala Ala Gln Gln Asn Val Glu Asp
          195          200          205

```

-continued

Gln Arg Gln Gly Leu Leu Gln Leu His Thr Ala Met Asp Thr Ala Lys
 210 215 220
 Asp Glu Leu Asn His Leu Ile Val Gln Gly Lys Ser Arg Lys Ala Glu
 225 230 235 240
 Leu Asp Arg Gln Leu Gln Val Leu Lys Gln Gln Gln Asp Glu Leu Ala
 245 250 255
 Gly Gln Glu Lys Phe Thr Leu Arg Ala Pro Val Ser Gly Thr Ile Ala
 260 265 270
 Ala Val Leu Ile Lys Gln Gly Gln Ser Val Lys Ala Ser Glu Pro Val
 275 280 285
 Met Thr Leu Ile Pro Asp Asn Ala His Leu Gln Ile Glu Leu Tyr Ala
 290 295 300
 Thr Ser Gln Lys Ala Gly Phe Ile Arg Pro Gly Gln Arg Val Ser Leu
 305 310 315 320
 Lys Phe Ser Ala Phe Pro Tyr Gln Lys Phe Gly Ile Gln Tyr Gly Thr
 325 330 335
 Ile Arg Lys Ile Ser His Thr Thr Leu Ala Pro Ser Asp Leu Leu Pro
 340 345 350
 Val Ser Pro Val Thr Trp Lys Glu Asn Glu Gly His Tyr Arg Val Ile
 355 360 365
 Val Glu Pro Glu Asn Thr Phe Ile Phe Ala Tyr Gly Lys Lys Glu Pro
 370 375 380
 Leu Arg Pro Gly Met Thr Leu Glu Gly Asp Val Asn Leu Asp Thr Arg
 385 390 395 400
 His Leu Trp Glu Trp Leu Thr Glu Pro Leu Trp Ser Met Lys Gly Asn
 405 410 415

Leu

<210> SEQ ID NO 31
 <211> LENGTH: 2185
 <212> TYPE: DNA
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 31

atggaatcaa taaactggaa agtaaggaaa caactaccgg ttatccgtca aaccgaatca 60
 gctgaatgcg gtctggcgtg tctggctatg attgcctgct ggcattggact gaaaacagat 120
 ttatcgacat tacgggaacg tttcaatata ggtattcagg gaatgacgct acaaagggtg 180
 atcgaatgtg cagcgtccat ccatttatca tcacgtgcag ttcgtctgga acccgaagat 240
 ctgaggtgtc ttaatcttcc atctattctg cactgggata tgaaccattt cgtcgttctc 300
 cataaagttc ggggaaaccg gttatacatc catgatccgg acagaggaaa aattacaata 360
 agtctgttgg acgcaggtaa gcattttaca ggagtggcac tggaattaac tccagccagt 420
 gatttcaccc cccggaacga gagaaaaaaaa tccacctgcg tcaactgaca gggaaaaccc 480
 cggggccttt agcatcaatg acaaaaatta ttatttttgc tctggccctt gagattctgg 540
 ctttaggtgg tccacttctt aatcaactgg taattgatga agttctggtc gcagcagaca 600
 gaagtctatt gtatgtcatt atagtggcac tactgttgtt atcactcata caattattac 660
 tctccctagc acgacaatgg gcaacgatca gtttatccgt caattttaac atgcaatgga 720
 ctgccagagt tttccatcat cttgtaagac tcctcttgc atggttcgat gcccgagta 780
 aaggaagtat taatgcccg tttgaagcag tagatataat ccagcaggcg ctgacaacgc 840
 aggttcttga aggcattctg gatatgctac ttattgtgac tgctcttgc atgatgctgt 900

-continued

```

tgtatagccc aggaatgaca ttaatcgag taattgcagc tattatataat ggcgactga 960
gagcattgtg gtatccggct ttacggcaat ctgttgaaga tgtctgggat gcaggaacta 1020
aggagtccgg gcattttctc gaaaccctta acggcattca gaggctgaga atcaacgggtg 1080
taactattca cagagaagcg gcctggctga acctcaacgt taccgcaga aacacacagc 1140
tacgccagaa tcgtttacaa atgagctatg aactgacgca tacactgacg gaaagtgtag 1200
tttcagccat tttttgtgg cagggagcag tagaagtgtc ggatgggaca tttaccgtgg 1260
gtatgttggg tgcttactta tcctatcaga tgcgtttttc atccagtata agcaatctga 1320
ctgataactt ttttctctgg cgcattgctg atgtttataa cgagagactt gccgatattg 1380
tgctaacacc acaggaaggt caccagaatc agcaccattg ggcaaaccat aatgaaacaa 1440
tatctgcaag ccagtacaga gaacataaat atgataatac ccatccacca ttacttatcg 1500
aaaaataaac atttagccat aagggcgagc ataaacccat attggataac gcgtcactaa 1560
tgctctttcc tggagaaata ttagcaataa caggtaaatac aggatgtggc aaatcaacat 1620
tggtaaagct tattcttggg attcatacac caagtgaagg aagaattaat gcatttggca 1680
taccacatac acattctgat tttttcagg ttcgtcaacg aattggcact gtattgcaag 1740
atgactatct tttcaaaggt tctatagctg ataataaat gttttttagc gaaattagag 1800
atcatgaaca catgcgtaaa tgcgcaagtc tggcacttat agacagtgat attatggcaa 1860
tgccaatggg ctatcaacat tacttggaga aaccggaggg ggactttcag gtggtcagaa 1920
gcaacgtatt ctactggcaa gagcactgta taaaaaacc ggtctattat tactggacga 1980
agcaaccagt catcttgatg tggaaagtga aatagaaata agccagacat tacgccaaact 2040
cggattcctg ttctgttaat agctcatcga ccagaaacaa tagcatccgc agacagagtt 2100
ctatctgaga gatggctact tttcggaaat aacatatacga cctgccagaa ctcataatat 2160
aaataatcac cccaacagga ggtga 2185

```

<210> SEQ ID NO 32

<211> LENGTH: 729

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 32

```

Met Glu Ser Ile Asn Trp Lys Val Arg Lys Gln Leu Pro Val Ile Arg
1           5           10          15
Gln Thr Glu Ser Ala Glu Cys Gly Leu Ala Cys Leu Ala Met Ile Ala
20          25          30
Cys Trp His Gly Leu Lys Thr Asp Leu Ser Thr Leu Arg Glu Arg Phe
35          40          45
Asn Ile Gly Ile Gln Gly Met Thr Leu Gln Arg Leu Ile Glu Cys Ala
50          55          60
Ala Ser Ile His Leu Ser Ser Arg Ala Val Arg Leu Glu Pro Glu Asp
65          70          75          80
Leu Arg Cys Leu Asn Leu Pro Ser Ile Leu His Trp Asp Met Asn His
85          90          95
Phe Val Val Leu His Lys Val Arg Gly Asn Arg Leu Tyr Ile His Asp
100         105         110
Pro Asp Arg Gly Lys Ile Thr Ile Ser Leu Leu Asp Ala Gly Lys His
115         120         125
Phe Thr Gly Val Ala Leu Glu Leu Thr Pro Ala Ser Asp Phe Thr Pro
130         135         140

```


-continued

Arg	Asn	Glu	Arg	Lys	Lys	Ile	His	Leu	Arg	Gln	Leu	Thr	Gly	Lys	Thr
145					150					155					160
Pro	Gly	Leu	Leu	Ala	Ser	Met	Thr	Lys	Ile	Ile	Ile	Phe	Ala	Leu	Ala
				165				170						175	
Leu	Glu	Ile	Leu	Ala	Leu	Gly	Gly	Pro	Leu	Leu	Asn	Gln	Leu	Val	Ile
			180					185					190		
Asp	Glu	Val	Leu	Val	Ala	Ala	Asp	Arg	Ser	Leu	Leu	Tyr	Val	Ile	Ile
		195					200					205			
Val	Ala	Leu	Leu	Leu	Leu	Ser	Leu	Ile	Gln	Leu	Leu	Leu	Ser	Leu	Ala
	210					215					220				
Arg	Gln	Trp	Ala	Thr	Ile	Ser	Leu	Ser	Val	Asn	Phe	Asn	Met	Gln	Trp
225					230					235					240
Thr	Ala	Arg	Val	Phe	His	His	Leu	Val	Arg	Leu	Pro	Leu	Ala	Trp	Phe
				245					250					255	
Asp	Ala	Arg	Ser	Lys	Gly	Ser	Ile	Asn	Ala	Arg	Phe	Glu	Ala	Val	Asp
			260					265					270		
Ile	Ile	Gln	Gln	Ala	Leu	Thr	Thr	Gln	Val	Leu	Glu	Gly	Ile	Leu	Asp
		275					280					285			
Met	Leu	Leu	Ile	Val	Thr	Ala	Leu	Cys	Met	Met	Leu	Leu	Tyr	Ser	Pro
	290					295					300				
Gly	Met	Thr	Leu	Ile	Ala	Val	Ile	Ala	Ala	Ile	Ile	Tyr	Gly	Ala	Leu
305					310					315					320
Arg	Ala	Leu	Trp	Tyr	Pro	Ala	Leu	Arg	Gln	Ser	Val	Glu	Asp	Val	Trp
				325					330					335	
Asp	Ala	Gly	Thr	Lys	Glu	Ser	Gly	His	Phe	Leu	Glu	Thr	Leu	Asn	Gly
			340					345						350	
Ile	Gln	Ser	Leu	Arg	Ile	Asn	Gly	Val	Thr	Ile	His	Arg	Glu	Ala	Ala
		355					360					365			
Trp	Leu	Asn	Leu	Asn	Val	Thr	Arg	Arg	Asn	Thr	Gln	Leu	Arg	Gln	Asn
	370					375					380				
Arg	Leu	Gln	Met	Ser	Tyr	Glu	Leu	Thr	His	Thr	Leu	Thr	Glu	Ser	Val
385					390					395					400
Val	Ser	Ala	Ile	Ile	Leu	Trp	Gln	Gly	Ala	Val	Glu	Val	Leu	Asp	Gly
				405					410					415	
Thr	Phe	Thr	Val	Gly	Met	Leu	Val	Ala	Tyr	Leu	Ser	Tyr	Gln	Met	Arg
			420					425					430		
Phe	Ser	Ser	Ser	Ile	Ser	Asn	Leu	Thr	Asp	Asn	Phe	Phe	Ser	Trp	Arg
		435					440					445			
Met	Leu	Asp	Val	Tyr	Asn	Glu	Arg	Leu	Ala	Asp	Ile	Val	Leu	Thr	Pro
	450					455					460				
Gln	Glu	Gly	His	Gln	Asn	Gln	His	His	Trp	Ala	Asn	His	Asn	Glu	Thr
465					470					475					480
Ile	Ser	Ala	Ser	Gln	Tyr	Arg	Glu	His	Lys	Tyr	Asp	Asn	Thr	His	Pro
				485					490					495	
Pro	Leu	Leu	Ile	Glu	Lys	Ile	Thr	Phe	Ser	His	Lys	Gly	Ala	Asp	Lys
			500					505					510		
Pro	Ile	Leu	Asp	Asn	Ala	Ser	Leu	Met	Leu	Phe	Pro	Gly	Glu	Ile	Leu
		515					520					525			
Ala	Ile	Thr	Gly	Lys	Ser	Gly	Cys	Gly	Lys	Ser	Thr	Leu	Val	Lys	Leu
	530					535					540				
Ile	Leu	Gly	Ile	His	Thr	Pro	Ser	Glu	Gly	Arg	Ile	Asn	Ala	Phe	Gly
545					550					555					560

-continued

Ile	Pro	His	Thr	His	Ser	Asp	Tyr	Phe	Gln	Val	Arg	Gln	Arg	Ile	Gly
				565					570					575	
Thr	Val	Leu	Gln	Asp	Asp	Tyr	Leu	Phe	Lys	Gly	Ser	Ile	Ala	Asp	Asn
			580					585					590		
Ile	Met	Phe	Phe	Ser	Glu	Ile	Arg	Asp	His	Glu	His	Met	Arg	Lys	Cys
		595					600					605			
Ala	Ser	Leu	Ala	Leu	Ile	Asp	Ser	Asp	Ile	Met	Ala	Met	Pro	Met	Gly
		610				615					620				
Tyr	Gln	Thr	Leu	Leu	Gly	Glu	Thr	Gly	Gly	Gly	Leu	Ser	Gly	Gly	Gln
625					630					635					640
Lys	Gln	Arg	Ile	Leu	Leu	Ala	Arg	Ala	Leu	Tyr	Lys	Lys	Pro	Gly	Leu
				645					650					655	
Leu	Leu	Leu	Asp	Glu	Ala	Thr	Ser	His	Leu	Asp	Val	Glu	Ser	Glu	Ile
			660					665					670		
Glu	Ile	Ser	Gln	Thr	Leu	Arg	Gln	Leu	Gly	Ile	Pro	Val	Leu	Leu	Ile
		675					680					685			
Ala	His	Arg	Pro	Glu	Thr	Ile	Ala	Ser	Ala	Asp	Arg	Val	Leu	Tyr	Leu
		690					695				700				
Arg	Asp	Gly	His	Phe	Ser	Glu	Ile	Thr	Tyr	Arg	Pro	Ala	Arg	Thr	His
705					710					715					720
Asn	Ile	Asn	Asn	His	Pro	Asn	Arg	Arg							
				725											

<210> SEQ ID NO 33

<211> LENGTH: 98809

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 33

```

gatctaaagc agaaaaatct gcttttaaaa atagatttta tttttttgac gcaggccaag    60
attaacttat tagaggtatc agtgaggagg cactggaaga gaagagatcg ttgtaatgct    120
tttcaaatta acgtaaagcg ggtatatttc ggctgttatt agctgtgcag aggggtggcac    180
tctgtggagc aaagcggcga aagccggacg gcagaatgcy ccataaggca ttcaggagag    240
atggcatgta cgggcagtaa gtcagaagac tgaagatggt ccggaagcca taaaaggaaa    300
acccccacta tctttcttac gaacttggcg gaacgacgaa agatagtggg ggcctcacag    360
aatacgggta aagtataatg aaaccgtacc agagattcaa ccctgtgcag tgtataaata    420
cacggcacia tcgctccgcc ataagcgaca gcttgtggca ggtctgaaga atactccata    480
taacgcagta cactggagtc agttagcacc cgaagagcag atccgtttct gggaagacta    540
tgaagcggga agggcgacca ctttctcggg tgaaccggaa aggaagcgca cgaagcgtcg    600
tcgtggtgag cactccacca aacccaaatg cgaaaatccg tcttggatc gtctgagcg    660
ctataaggcg ctgagcgggc agctcgggca cgctacaac cgtctggtga aaaaggaccc    720
ggtgaccggc gagcagagcc tgcgcatgca catgtctctg cactcttttt acgtgcagaa    780
acgaaactat gccggctcga aatatgcttt ccgtccggaa aaacaacgcc tctcagatgc    840
cgtctggccg gttctggtea gcttcagtga tgcgggcaca cataccgtag gcatgagtgt    900
ttcccgtctg gccagagaaa tcagcccga agacagcaag gggaaggtta tccgggaact    960
ggaagtgacg gtctcccgcc tttcccgttt gctggccgaa caggtagctt ttggtgtgct   1020
gggtgtttca gaggaacccc tgtgggaccg tgaaccccgc cagcgtctgc cacgttacgt   1080
ctggataaca ccggcaggct ggcagatgct gggcgtcgac atggtaaac ttcacgaaca   1140

```

-continued

gcagcagaaa	cgactgctg	aaagtgaaat	ccgccagcag	ctcattcggg	aaggtgttct	1200
gcgtgaggat	gaagatatct	ccgtacatgc	ggccagaaaa	cgctggatc	tgcagcgag	1260
tcaggatgcg	ctgaaacacc	gtcgtgcgaa	agcagcagcc	agtaagcgcg	ccagacgcct	1320
gaagaaactg	cctgcccacc	agcagattca	tgagatggca	gagtatctca	ggaagcgtct	1380
gcctccggat	gaagcctatt	tttgttccga	tgaccatctg	aagcgaatgg	ccatcagggg	1440
gttgcgtcag	cttgaactga	cgctggctgc	cccgccaccg	cactagacag	caccattccc	1500
tcagcactga	atcatcacca	gcccctccgg	ggctttcggc	gctggttccg	ctcagcccaa	1560
aatccgcagt	aatcacctta	aatcccctca	gaggggcata	tctgcccata	aaaccacgca	1620
tcagtcatca	gaacatggcc	acgttgtttc	agttatccac	ataaatccgc	aaataaagaa	1680
ctttaagaag	ctgcaaacct	gaaacagcaa	acctgcaata	tagtcttaac	cccattatct	1740
aatcccctgc	gttgcttcgc	cgcagggaaa	gtctttatct	ctgaaaccac	tgtgaacaaa	1800
tacaaagagg	ccttcgcttg	cagcggccag	ggccacgcgc	ctcagaatct	aaaagcacct	1860
cccacgctaa	cgcgcggggc	ccgaccctca	ccattcagaa	accacagcaa	aaaaacatca	1920
ggaataaaaa	cgccacacaa	acgcagcacc	gtgcctacc	ctcataactg	aaaagcgagg	1980
ccgccccgc	ccgaaggcg	ggaacaacat	cgcttttaat	tatgaatgtt	gtaactaagc	2040
attcccctcg	ctgtcagctt	tctggctgga	agtatcgagt	acacgctcgt	aagcggccct	2100
cacggcccgc	taacgcggag	atacggcccg	acttcgggta	aaccctcgtc	gggaccactc	2160
cgaccgcgca	cagaagctct	ctcatggctg	aaagcgggta	tggttagca	gggtgggaat	2220
gggataggcg	aaatctatca	atcagtaccg	gcttacgcgc	ggcttcggcg	gttttactcc	2280
ggtatcatat	gaaacaatgg	agtaccgctt	tccatgcgcg	tggegcggca	tctgttaaca	2340
atcaatactt	ttatcattat	tatcaggaaa	aaattgatcg	tctgaataaa	aatatatgaa	2400
tgataaaaaa	gagagataca	tatcttccga	gctgtcagat	aaaactcaac	tttctgtttt	2460
gcgcagtata	gttggatggg	gctatgaaaa	aataagacat	tctctggggc	gaccagggca	2520
acttgaaaga	gcgattgcat	ccggggagtt	aatcccgtgt	cctttaaaaa	ctcctgtcga	2580
tacactatgg	acgcgatcgg	tgatttactg	gcaggactgg	atatcccat	catggatacc	2640
atctgattct	cgccaatgta	cgatagattt	ctataagcca	ggctactatc	gtggtttaga	2700
acgatgtcat	atggttgttc	ccgaagttca	gaatctgatt	agcaaagaag	atattcctca	2760
ttttcgtgt	gatatcaccg	atattcaggg	tatctccgca	tcgaaatctg	agatgtatga	2820
tattggtgac	atattatgaat	ttcctctact	gagatgcctt	gggctgggta	ccccggtaaa	2880
tgaagaacat	ctcagagaaa	atatgcagta	ctgggagtta	aggctccatc	gaatgcgctt	2940
tgetgaatat	ccgtggactg	agcgtaaact	gtattggctg	aatgaagggt	gctcacatca	3000
ttttgcagct	gcccgttatc	aggcatgccg	tctgggaatt	tctgttccgc	ttacgggcag	3060
attgagtcgc	ttccatgtaa	acatgcagat	ggtttcagct	ttatgtcagc	aatggcacct	3120
gtttgctatt	cctgcagatg	aacggttagc	ctgctttttc	agggcgatga	ttgcctttga	3180
atgccatttt	ggtaattcag	aattacctcg	gaatatgcac	aatactataa	agtcaggagt	3240
caactcaaaa	ctcgtttggc	ttgaacgtgg	tcatacaaa	gcagacattg	ttgcagatgt	3300
acttgccaca	gcaggtttcc	ctgattttgg	ggatcaattg	aagctgctgg	ctaccagcag	3360
cctgcaaaaa	acacataagc	tggcctgaaa	ggaatacttc	acaatgaata	tcattgtgtt	3420
ggtaacctgc	tgttatcgtg	atgaaattac	cgctcaattt	tttcggttga	cgcggtctgt	3480
tcctgcagtg	ttttcatctt	tagcttctgt	ttttccctta	ctgccagcca	gcgtctggca	3540

-continued

ttctgcgc	at	cgattctga	tacctgacct	gctggtagtc	catccagtcc	ataacgaggg	3600
ataacctg	cgga	cagcagtagc	cagcagatat	acctgtcggg	tggtgatgca	ggatattgca	3660
caggaccatt	catccagtgt	cagttctgtc	tcagggtggt	ctgtcaggaa	tgccggcaaaa		3720
tcattgggta	tgccaatttt	cagtggaaga	aatccccgc	tttctgcgcg	aagatgggga		3780
aacagagact	taactttttc	cacgcaattg	tgagtaaatt	catgagtcca	atgaggctgg		3840
cgtggaaaac	ggcgtctttt	tctttttttc	ttactggcag	aagcttcagg	gggatgagta		3900
tcgacggcag	gagaactgct	tcccacagat	actggatctt	ccatctttac	cgtctctgaa		3960
cgtgcgataa	cacctgtttt	ttcagataag	gaagggggta	aaagagtgcg	acgttttttc		4020
accataatga	tgggtgtttt	cttttcttcc	tgatatttcc	ccataaaaaac	ctctacgatg		4080
tgttcttata	taataatata	tatcatattt	tcacaattaa	cataatatct	tcgttaagaa		4140
aataacagaa	caaaatttgt	tgttttttta	tgacaggcat	gaaatgagcc	agcataatta		4200
tattaatcat	tatcccaa	at	gagcttttgt	atttgcctcat	tcgggatggg	tggatatttt	4260
aagttatata	tactgtatca	ttctcaggta	atcgttccat	taaatcagaa	actacgggct		4320
gtaaccagtc	agtgacttca	cttacatact	gatgccattc	gggatgcctg	gaggccagat		4380
ccatcactcg	tgtaaccceg	gacggacgat	caatgcccaa	tttagttaa	atgttcgaga		4440
tataattatg	agcatcaagt	tcaactctga	tatcccttgc	tgcttctatt	atttctaaat		4500
attctccacc	caatccgtcc	agtgggacat	ttgtaataag	ataatgaatg	tattgttcag		4560
gcttaactcc	atttgggaga	ttaaattggt	ttatttttcc	ttccgctgcc	gcttttaact		4620
cataagttcg	tgattctgtg	cgggtgaaaa	ctttatcaag	agcagcttcc	ttttcatttt		4680
ctgtggagta	tttatcgcca	tcaagaatat	aaagtttatc	agatagatta	tctccacgaa		4740
taagtgtact	ggcaagtaga	gtgaatgcgt	ttgaagctgc	gccaaattta	aatattttca		4800
catatctgct	ggccttaagt	gaagaacata	ttttatttat	tattgcaaca	gcaagatcat		4860
ctccacata	tatttcaatg	ggagttggtg	atttacctgt	taatctgttt	atagcatcag		4920
gttttgtttc	ttcaaatgaa	taactacggc	cttgaatggt	tacgacgtgt	cttatattta		4980
tcttgtctga	taaagtgggt	accattttctc	tatgggtagt	gaagatgatt	tgtttatttt		5040
tatcttcggc	atgagttgat	atgacgtcta	ttaacttttt	caatgcttcg	tcatgcaaca		5100
gcaaactctaa	ttcatcgatt	aatattaagg	cgttcttgtc	cgctttta	attgtttcca		5160
gaattaaaaa	tatcttttgc	tctcctgcgc	tcatacttaa	tgatgagtag	gccagtcctt		5220
ctgactcaac	tccaatcaat	atttttccat	tgggttgttg	atgttgattg	aaacttgtat		5280
atggtttatt	aagtatatag	gagggcgtaat	gaagaatggt	tgttattaaa	tcattactga		5340
cactgctggg	ttcactactga	atattattct	ttttttctga	ttctattata	ggaacacatt		5400
tatcaatgcc	aagatagtaa	acttctctta	aaggacgacg	agcataaatc	tgaatccatc		5460
gtgagcctcg	aacatcagct	tttcataat	tttttaattc	attttcaatc	attacacat		5520
ctttacgata	agttaaattt	acaatgaagt	cactgccggt	ccattcagca	tgtggactgc		5580
gtggaaaaaa	atgcattaac	cgatgggtctt	caccggggaa	acctttttca	ggcatgtata		5640
tgcttgctat	ggcatggagt	attggtgatt	ttccgcttcc	atgttgacct	aaaattgcgg		5700
ttaacgcatg	aggtttaaaa	ataatctcgt	ttaatccatt	tatacatttt	agtttggtta		5760
ttttaatgga	gttcaagact	tgaccagtaa	tagttttttc	ttttttctg	ccatttttaa		5820
atcctagcat	tatggtgggg	gaattcacca	tgtaattcag	aaacatataa	ctgtgaacag		5880

-continued

gggatataac	aaatcctttt	aatattctat	tttgacagt	attctacatc	aggcctcttt	5940
tatgctacag	actttttgag	atgtctgtaa	ttttagactt	aatgttatga	ctgatcatat	6000
ctcctatcca	ctggtggcgc	aggaaagtta	accggctgcc	accatgggat	gatgtgtaaa	6060
ccgtgcacag	gcgtgttctt	acggagcggc	actttcattt	atctgtacgc	gaacctccat	6120
tccggcatca	tgacaggcct	gcagccactg	cgccacttcc	agcggatcgc	cctcccggcg	6180
taccacctg	ccttctttat	tccataactg	cagacaggtg	ctgccgtcga	gacgcaccac	6240
aaaatcccca	cggcaggcct	gatacgtcat	gccgttcage	tccaccgcca	gatcagtggc	6300
agaagtgcct	tctgcgggca	gacctgcggc	cgggaccagc	ggtagtacga	cgacttctgc	6360
cgcacgctgt	tctgcccgga	ggcggctctg	ttctgcctgc	agcagaggct	gtgccacggc	6420
ccggccggcg	tccgtcagct	cgacagccag	ctgcagattc	ggggcgcgca	gggtacgcag	6480
ccagccggca	tcctccagac	gacggcagga	cgcgcgcagg	tttggcccgt	agatcggggc	6540
ttcccgcctt	cgctccagca	cccgttccag	gtcccgcgtc	agcacggggc	ccggccgttt	6600
ttcatcaagc	gcagccagca	caatcagcac	tctccgctgc	agtggcgacg	gtcggcggct	6660
ctgggtcatt	acctgtcatc	ctccggccag	atgaggtttc	tgaggcgctg	aaagtcggcg	6720
tcaatgagct	cctgtctctt	tatggcattc	attgaggcat	agccatttat	ggccagttca	6780
tgccagaaga	tcagcacggc	tccggctttg	gctgactcgc	agagataaat	cgcgcctctg	6840
ctgtccagat	tgattcccgc	gatgcgtcgt	tccgcaaacc	gggtcagttg	ttcatagctg	6900
agtgaaaacg	tcatttctctg	atccatcctg	cacgctccat	ctgataatgt	tctgacaggt	6960
aaaaatcata	tcattgtatga	tttatgtact	cttgatttct	gataatatca	gatattgttt	7020
catttttaat	gatgaaaatc	atatctgata	tgattttatg	tgtatttctt	aattatcata	7080
tcatttgcgt	cttttctgcc	gcgcagatcc	ggtttccggc	taacacggag	ataataggtt	7140
agggtggttct	gttgttaggg	tatggagaac	atttctcgag	ccgagcaagg	gaaattactc	7200
acaccatttg	ctatgctaac	ggccacacta	accagccttt	tttcggggta	atacatgccg	7260
ttagcacaac	tgaagcgtga	cactctttcc	cttgtaagc	taaatggcga	caggactgat	7320
gggataaaaag	gaagtgttca	aaagaataag	attttcatta	gccggagcga	tattgctatt	7380
gaaaaggggg	atctgcttat	acgcagtatg	ccgcatggcg	gtactgaaga	atatattgta	7440
atcgaaacct	acttcagaat	gggtgtaggc	ggatctcctg	cgacctatca	ggctgaggtg	7500
atactgaagg	aaaatacaac	taccgaggaa	atgacatcat	ccccttccac	agcagtaccg	7560
gaagcagtta	ttgccactgt	aaatacatc	attgctctgt	gtgtcaccat	tgtaaatgag	7620
ggcgcaccaa	gtcctgataa	atatgcttcg	cagttttatc	gcttgcgtca	ggaattactt	7680
gaactcgata	atattatcac	cattccttca	tggatcagat	tctccatgtc	accgctgac	7740
attaagaata	atgttggttt	aaacgtcaca	ggtggcgatg	gagcttgggg	gcgaagacga	7800
cagtatttac	agagcgaatc	tattaaata	ctttcaagct	ataaaaccgc	accaattatt	7860
gagcattctg	ttagtgagaa	taaaataaaa	aatactgagc	aagtcagcgg	gttgacaacg	7920
atggcaagcg	atgcagggtt	aaacatgaag	aagaaagtat	tcattgtcca	tgggcacgat	7980
gataaactaa	aaaacgaggt	ttacatthtt	ctggcaaatg	aaggthttca	gcctgtcata	8040
cttcatcatg	aagccaatga	aggacagacc	ataatcgaga	agcttgagaa	gcatatcgac	8100
actgtatcct	atgcagtggg	gctttatact	gcctgtgatg	aagggaaagc	caagaatgaa	8160
actgaactaa	aaaaagagc	ccggcagaat	gttgttttag	aacacggctg	gctcatgtcc	8220
aagctatcgc	gtaaattcgt	cgctgcgata	gttgaagatg	gcgttgaatt	tcctggagac	8280

-continued

ctgtccggag	tggtcagaat	atctgcatca	gactggaaat	atgatctgtc	taaagaatta	8340
aaagtgtca	ataattaaat	tgtattcagt	gatgtaagga	tactattatg	ggatacacca	8400
gaaatcagca	catgctctca	cagtggtttc	tcaggaactt	ccgcagtgat	gatacggcac	8460
agagtccgaa	ggagaagcaa	cgggtctggg	cccacgttgt	ggttectacg	gcagaaggca	8520
aaaatgacat	aaaggacatc	ccgctaccga	tatccagcgt	ggccgtctgt	aaggactgct	8580
ttcgtcttac	cgacggtgac	acaggcgagg	tttttgatat	cgagcatgag	ctcagtgatt	8640
atgaacagga	tatggctttg	cttgtccggg	atctggttca	gaaccataat	ttcgcgcgtc	8700
tggtactg	tgacactgat	gattttccgg	tagagaagct	tgcaagtttt	gctatatttc	8760
agatgttact	taacctcaat	aaccgcgaaa	gcagatttcc	gggtaaaaat	gagttatttc	8820
agtcattcat	taacctagta	aaaaacaacc	ttcagcatat	catttccgaa	acaatttctt	8880
tgtctgacgt	tatgccggag	ttggcggtt	taagtatcta	tcagaaactg	attcgtatag	8940
ctcgttcttc	ttctggggat	gacgaaaaag	ctaaggccat	gtttgtatta	ttttcccttc	9000
tcgcacttca	gggtaaaata	acaatgattg	acactatggc	ctggctacgc	ggagagggtt	9060
tttccggaat	acatcgtgtg	gatatatttc	ataccgggca	ccacttttac	agtacagaac	9120
cacgtccggt	atttacagta	tcacctaata	tattttgcaa	aatgacagaa	gaacgcgtcc	9180
tgtaccttcc	ccttgctcat	aatttggttc	ttaagtttta	tcagtaccgc	gaacacgggt	9240
ttttcaccct	actggaaatt	aatgtattca	gcccggacct	tcagaaacta	cttacaaaag	9300
acatgtcacg	aatcaaagtt	tataaatgct	cctatgatta	tattgatcag	gttatgtcaa	9360
caattgatat	gtataacgtc	ggattttcaa	atattattta	ttctagctgg	cagctcagtg	9420
atgttgaaaa	ttatctgagg	ctacagaacg	aacatcatga	tacttattat	cttccggaac	9480
atcccgtttg	ctggactgta	tccagggaga	aagggtgatg	gccctgacct	cggaacagat	9540
aagttgccga	cagcagctcg	tggcaatggg	tgacttcaat	gcccataccc	tgctgcccgg	9600
agaggagtgg	accaggccag	aaaacgctga	tgtccggcac	gttctgtcgc	tgatccccct	9660
gacggacatc	cagctggcta	accggctgga	tgtggacgaa	cgcaccatcc	gcaaggggaa	9720
atccggcgag	accagtatgg	tattcaccac	ttggtgctgc	ctgtgctggc	tgccggggct	9780
gggaatgctg	ctggaagaac	cggcttagcc	ggttctgatg	cgtttccaga	ttcttttgag	9840
tatgaagcgt	cgctgatatc	gccattgtga	acggtagata	tgggggagtc	gatcatagtt	9900
cttccaaaac	aaggtccagc	ctttatagcc	atcaacaagt	agggcaatga	gagagccagt	9960
ttttaagagg	ccaaagaaaa	cggccatgag	aaatacagtc	atacgatgtt	ccttatgtaa	10020
aactgtattt	aggaaatccg	aagcggcctt	taaggccggg	tgatgaaaat	gaactgaaaa	10080
aagtttctct	ggcctatttg	ttgccatttc	aggctagctc	tttcgtgaat	tttgcctctc	10140
aggcaataat	ccactcatca	caacaattca	ccgtttttag	tgcttatcct	gcaaaaatct	10200
gtttttttcc	cttctgaga	tccgaaaact	tatttaagag	gatcacttgc	agccggcaac	10260
aggaagggtt	tacattgatt	tgaattatgc	cgtttctttt	cctcctgcct	tgaaaaggat	10320
atctgaatgc	acttttatgt	ggatgaaaca	ggccagactg	gccgaaacct	ttttgacaaa	10380
accagccaa	tcctctccta	cggagtctcg	tcctcagagg	ctgacctaga	taaggttgct	10440
gaagcggatc	ttgccgatt	acgcaaaact	ctggcgctgg	agegcctgca	cgctgcggaa	10500
ctggcgctgc	accgcctttc	agaagttgtg	gatacgcctg	tggtcctgca	gaaaaatcac	10560
cggatacggg	ttgatatctg	gcaggtgggt	aagcgcgatc	acgccattat	ttcgttcttc	10620

-continued

gaccaggtgt	ttgatcagg	actgaatccg	gttgtgccct	ggagtgccta	ctggaccct	10680
ctgcgctatc	ccctgctgct	gaatctgtct	aatctgtttg	atgatgagct	ggctgaaaa	10740
gcgtggcgtg	cccgtcttga	ggctcatgat	gaacgttctt	gctcattatt	cagtgaggtt	10800
tgtggagtgc	tgcttcagcg	cgttcactct	ctgggtgatg	cccgttcagt	tgaactcatt	10860
accgatgccc	tatcttgggc	gatggccaac	tttgatgagc	tggggtaaaa	ctgcaaaacc	10920
aataaggaaa	agttgcagat	catgcccaat	atgattgggt	ttcagtcctg	tttgcacggg	10980
atctgctctc	gtctgggggc	accgaaccgg	aaagcagata	tcattgttga	ccagcagtca	11040
cagttcaaca	ccaccagcg	ggagttgaac	gagttttact	accagatccg	cgaacagccg	11100
tgggcactgg	ggcggggtt	gcctgtcatg	gatatgaaga	acatgccagc	aaaaccgctt	11160
gtcttccagt	cgggaacgat	gagtgcggg	ctggaactgg	ttgatattta	tctctggatc	11220
ttcaaacgat	acatggaacg	gaaggaactg	acaaaacccc	tctcccgcct	cgtctacacc	11280
aatcttaaaa	cagcgagAAC	tgacagtgtt	tctctgcagt	cagttgcaaa	gaggtttaag	11340
gagttttttg	aaaaactttc	tgaaccaacc	gcagaaatga	tagaaaaagc	aatgaactc	11400
agggccgtgg	aagaaacgcg	ccgtcttgcc	catcgtgtac	aaagtgtgtc	gcaatcctga	11460
tcagaaagg	taaccgcata	tgaaggcaga	aatgcccg	caggttcagg	ggctgataga	11520
actagagaaa	tttaaccctg	aaacactgtg	ctcggggcag	agctggatgg	caccttcagc	11580
cagtgaagtc	agcgtgggtc	gggcgctgat	cccgcctaca	gatatccagc	tggccaaccg	11640
gctagatgtg	gacgagcgca	ccatccgtaa	gtggaaatcc	ggcgagacca	gaatgggtgt	11700
caccacctgg	tgctgtctgt	gctggctggc	cgggttgggg	atgctgctgg	aagaaccggc	11760
ttagccgggt	ctgatgcgtt	tccagattct	tttgagaatg	aagcgtcgtc	gatatcgcca	11820
ttgcgaacgg	tagatatggg	ggagtgcgac	atagttcttc	cagaacaagg	tccagccttt	11880
ataaggctcc	gtttcccaaa	cggagccctg	agtcgctgac	gccggaattc	tttactacga	11940
attagtattg	aggcgagcgg	ccaaaacaat	atgctgcata	tcctgggtgcg	tcggcttaaa	12000
gcccagacgc	tctaggttta	tttcagcaac	cacttcatct	gggccacccc	agatagtatc	12060
gccagcctgt	tccagtaggt	cgagtttgcc	acaataagct	tcaggcttac	cagcggcatt	12120
tagctgatac	tccagttttt	ccccatgaat	tttcatgacg	ttaatcagca	cgctattccc	12180
cagagccata	tagagccaga	tatatatgcc	gccagcggtc	tgctgcgtat	cgcttacaac	12240
gacaccataa	tgtgccatga	ttagccggta	tacgtgctgg	gacagtttta	ctgccctata	12300
ttcatcgccg	acaaatgcac	tgataacctg	cggaatacga	tcaggaaaac	cctctggagc	12360
ttccagagca	aactcaagca	tatagtttgc	ggaaacttca	tttgactcga	tatgacgcaa	12420
gtaaagacgt	gcttgcttgc	cgatgtcttc	aagaatgacc	tcgtgcttaa	agcctgcgtc	12480
gtcagtgatg	ttttctaatt	tttggttaga	ctggcccgtc	tcattgagat	cttcaggcca	12540
gattaatttt	ttatcgtgtt	cgcgatttat	cagtgggtgac	atgccagatt	accgtgctca	12600
ttccattgaa	aaaattctat	cgcgcgggcg	ctgaaatcag	ccagattcac	cgattttgat	12660
agctcggttt	ctttctgttc	tatgcatttc	ttacggccat	cttcttcaaa	ctgaacaaca	12720
accagcggca	caacacggtc	gcgacggggt	gcttgcctgc	agttttcatg	caccacgatc	12780
agcatcggac	gcttctcgcg	ggattatttt	gaacgtactt	cgaatttacc	ctgaacgcca	12840
ggtatgcaaa	aactacccaa	aagagcatag	ttatcagcaa	tagtgaatgg	tgaatgagtg	12900
atcattggca	cctccgcaaa	ttcaaagtat	tcagtaagat	ggcggaaaacc	cttgacgcgc	12960
aagtggttga	cgcttacgtc	agtatacctc	atagaaatat	tcggacaata	atattgttta	13020

-continued

cgatttcagc ggcgttcgta taggaaaagc catcctcag gatggctttt ctcgtttcag 13080
 aacgtcagaa aacagaccgt tctgtgggcg gcaggcgcag tgcttgccgt atctggtcga 13140
 ccatgtccag aaaatcccct tctttctgca ggaagaacag ttctttatgc actctgatta 13200
 gcgtcggtaa atcgcgcgga gcagcctcaa tgaagagggc aaacgccagt gacgtgccat 13260
 gcgggatatg ggtgatgcca ggtagctgtg cggcgcgcag ttcaagcagg ggaacgccgt 13320
 tacgcataat atgctgcaga tcttcttctt tataaatgcc tagtaaacgg caccaggccc 13380
 ggttttcagc gagcgtctgg gcgctgtcat accagtaatc ggcgagggct gccttcatca 13440
 ttgtggccac gtctttatcc atcagcgcca cgaggccatt tccgcgcata aagttaccga 13500
 tcagatcccc gaaggaggct gagaggaatt ctttgacaaa atcacttttt gactttcctg 13560
 ccgccctcgc ctgttccgtg atttcgttat ccacatcaaa aggcattgtt cgcacggcca 13620
 gcgtgcgtgt ggatcctttt tcggcatttt cattctgttc agtcatttct ttctccgaag 13680
 gacgtgacac tctcaacatc caccacttgc attgaaataa gatgtttgtt gtttaagatat 13740
 ttattttgc tcccgatttc aatatgtgaa ttcataatga taaaagtggg gctaagcaag 13800
 ataaaattta accaggcgtg aggagaactc ctcatcttca gcactgagat ccgaaaaccc 13860
 caagttacgg atccgcggat ccttcgctgc cgcccgtgg tccgcttca caggatgtgg 13920
 tgtcccgcctc cgctgacatg aactgtatg ttgtgtttct tcccgtgttc ccgagccagt 13980
 catcagcggc agaaaagatc gcttcgctta ttcactgatc ctgattcact tccggaaagt 14040
 tgtaaatacg cagtaaactg gatcatctga aaaccactgt tcgataattt aatggagtgg 14100
 ttatatgcct gattattatt tcaatatgtg aaatccattt ttgtgaaagt cactttctca 14160
 acagagtagc actcatctgg cgatgattga ggtgtggtaa aattgcacgg ctaactattc 14220
 aactgaggaa atgacatgtt tactgcattc aatgagagaa atgatttcag ttatgccttt 14280
 gaaaaaatc gcaatgcgat ttccgcgcca ggagaaaata atgtttatgc tgccacagaa 14340
 ttaggtcttg gcattctgct ccgtaaatac gagcagtttc gccgggagct ggatgtggcc 14400
 ggtgagctgg gaaactggga atacgatctc gatacctaca atcactgtat tgccgtgctg 14460
 caacgttact tcaactggca tccatccgga ctgacagaac gtgacgccc gatttacagt 14520
 cagtacctgc agactgagca caaaggggtt gtgaagctgg ctgaagaact ggccgctgac 14580
 cgctgaatac atacagtagg cgggatttcc ggataaggta ccgaaccggg gctgttaaaa 14640
 gattctggag ttgaaatgaa aaagggaaaa acgttagaac cggggctgct ggccagcgac 14700
 agcgactggc acaataatgc ctgcctgaat tacatgccgg atcatggtac agcttacacc 14760
 gaaggttaca ggcgagctgc tgatattctg attaaccaca ttgatgaatc cgggcgggac 14820
 caggattttc tggtttatcc ggtgttgttt ctctaccgac atcacttga gctccttacc 14880
 aaacaaatta tcggactggc ccttgcactg gcagaagacc cggataaaca ccagtacaaa 14940
 aaagatgacc ataacctgaa taatctatgg ccgctggcac aaaagctgat cctggaagtt 15000
 gatgacagct accggccttc cgattttaa atcgtcaaag aggtgggtta agctcttcac 15060
 caagcggatg aacgggcgac agatttccga tatgccagga gaaatgacgg caccgggagc 15120
 cttgaaggaa ttcattacgt caacaccgca cgctttgggg aaaaaatggg agaggcttcc 15180
 gatttacttg acggggtcga caatagcctc cggtagctgc tggactgtaa agccgaatgg 15240
 aatcaaattc tggacagctt ctgacagcca gaaacggcgc gaaaaatcca tcagacttac 15300
 ctgaacaact aatgatactg agataccgat catgactggc ctcatacctt cagctacttc 15360

-continued

tcagggccca	atggccgccc	tgccagtgac	catcgactat	cccgcagcac	tggecttgcg	15420
gcagatggcg	ctcgttcagg	acgaactacc	gaaataacctg	ctggcgccgg	aagtgagcgc	15480
cctgctccac	tatgtgcccg	atctgcaccg	taagatgctg	ctggccaccc	tctggaatac	15540
ggcgccccgc	attaacgagg	cgctggcgct	tactcgaggg	gatttttcgc	tgccaccgcc	15600
atatccgttc	gtacagctgg	ccacgctgaa	gcaacgtgcc	gagaaggctg	ctagaacagc	15660
aggacgtctg	cccgcggca	gtcaggccca	tcgtctggtt	ccgctatcag	acagccagta	15720
cgtgaaccag	ttggaaatga	tggtggccac	gctgaagatt	ccgctcgagc	gacgtaataa	15780
gcgtaccggc	agaaccgaaa	aggcgcgat	ctgggaggtc	actgaccgga	cggtaccggac	15840
ctggctgaat	gaagcagtgg	agaatgcggc	cgctgacggg	gtgtcattct	ctgtgccggg	15900
tacccacat	actttccgcc	attcctacgc	gatgcatatg	ctgtatgctg	gtattccgct	15960
gaaggtgctg	cagagcctga	tggggcacaa	gtcgattagt	tcgacagagg	tgtacacgaa	16020
ggtgtttgcg	ctcgatgtgg	cagcaaggca	cagggtgcag	ttttcgatgc	ctgagtccga	16080
tgctgtcaca	atgctgaaaa	acagacacgc	ataagtcaaca	aatcataatt	atgaattgtg	16140
atattattcta	taaaagaaga	gaccactgca	atatgtgatc	tcttgtatgc	aagggtgctt	16200
aaacagtgtg	aattcacaag	tgtgatttca	taagtaataa	cttcttgatt	attacgtag	16260
tgtttttaag	tattgctcaa	gggtactct	gacgatggca	cttacatttt	ttggatcttt	16320
accattgctg	ttattcctca	atgccagatc	ttctattgtg	acaagcatgc	ttccaccaag	16380
agagattgtc	gtccgacatt	gtttttctgg	ttcgggtttt	tccggcgcg	cgtatggttt	16440
atccgcaagg	cgctgagcca	gagcctctgc	ttgttctacc	gtaactgcag	ctctgtttaa	16500
tgcttgctgg	ctgggtttct	tcaccatggg	ccaaatacct	cattcattaa	atgttcaatt	16560
tctgctctgg	ctgctgtatt	gttcgtttct	actacaccgg	tgccgttgct	catgcaatcg	16620
cgatagactt	ttctgaaaca	aataactgaa	tccaggactt	gaattgttgg	gaattcttca	16680
agatattcaa	ggaattcttt	tctctcattt	cccctcaaaa	ccggattggt	tggtgccata	16740
ctttgtaaac	aataaacctt	aagttccggg	ttaaggttac	gcattgcgtc	tatctgttgt	16800
tctagttctg	taagagtatc	cagatctggg	tgagaacact	gtagtggcgc	aattatttga	16860
tgtgcgacaa	ctccactcgt	tatgaattcc	tttgagtttc	ttcctgcgac	atccactatt	16920
acatcatcga	acttttcatt	cagagcctgt	agtgtttgtg	tcaggttatc	aaatttctca	16980
acaagggtta	ttgctggtaa	cagtcctgca	gcttctcggt	ccgcatgatg	ttttgcccgt	17040
gttcggttga	gatctccgtt	taacaggcag	acttcttttc	ctttatttgc	gagagcaata	17100
gccaggtttg	atgcaatggt	agttttccct	gaaccacctt	tgttcccacc	aactacagta	17160
atcattgcaa	cctcataaat	gtgatgtgtg	aagtatgatg	atattttgac	acggtaacct	17220
gatgtgtcaa	catgcattca	tatttatgaa	gtatgaaata	tgaagtatgt	catgtgatgt	17280
aataaatatt	acttgtgttt	tgtgatttca	taactatgat	agtgtctaaa	ttgagtatta	17340
ccttgcaacc	agaaacagtg	atttactcag	attgagtatt	taaggggcta	tagatgaacg	17400
tatactgcga	tgatggttca	acaacaatca	agttggcatg	gaatgacaat	gggaaaatct	17460
gtaagtcggt	gtcgcaaac	tcatttcgtc	atggatggaa	ggttgacggg	ttagggattc	17520
gccagacatt	taactatgaa	ctggatggta	aaaaatacac	gtatgatgaa	gtagcaacc	17580
aatctattct	tacgactcat	attgagtatc	aatatacgga	tgtaacctg	ttagctgtgc	17640
atcacgcttt	actgaatagt	ggattagcgc	ctcagcctgt	atcattgact	gtgactttgc	17700
ctatcagtga	gttctacacg	aaagagtgtc	aaaaaatga	actcaacatt	cagcgtaaaa	17760

-continued

ttgagaattt aatgaggccg attcgtctta ataaaggcga tgttttcacc attgaacacg 17820
 ttgatgtgat gcctgaatca ttgccagctg tgttttctcg tctggtcacg gataaagttg 17880
 gtcagtttga aaaatcgctg gtagttgata ttggcggcac tacgcttgat gttggtgtta 17940
 tcgttggtca atttgactct gtaagtgcc aatcatggtaa ttctggcatt ggtgtgtctt 18000
 cagttacgaa agctgcaatg agtgcattgc gcatggcacc cagtataacc agtttcctcg 18060
 ttgcagatga attgattaaa cgtcgtaatg acccggactt tgttcggcag gttataaatg 18120
 acgaaacaaa aactgatctg gtccttaata ccattgaggg ggctattgcc agtctggggg 18180
 agcaagtagt caatgagctc ggtgattttc atcatgtgaa tcgtgtttat gttgtcgggtg 18240
 gtggggcccc gttgatctat gattcgataa aaacggcagc gcaccatctt gggcaaaaag 18300
 tagtgatgat ggagtcgcca cagacagcac tgggtgaagc tatcgcggct ttcaaagagg 18360
 agtaaatattg tggacgatga acggaaaagg aaaaaattca cactttatct gcatccggaa 18420
 aaagctgcag actttcaaac tttggaagcg atagagtccg ttccgcgttc tgagcgtggt 18480
 gagctgttcc ggaatgcatt tatttctgga atggcgttac accaacttga tctctgcctg 18540
 cctgtattgc tgactgcat tttgagcag gagttttcag cagatcaggt tgtaacctta 18600
 ctcagtcaga cgacaggatg gaagccttct caggccgata tcagagctgt gttgactgaa 18660
 ctcggtgctt tgcaatctgc tgaaaaaatg cctccttctg ctactgattc ggtgcaggag 18720
 gcaatgaatg atgtgcgct taaaatgcaa aaattattct gatatacag aatgaagcaa 18780
 tggggatctc agtccattgt gttgtatacg aaggcgagag catttcccg ttcatttgcc 18840
 attcaggggc ggttccctgc cccgcaaacc aactttccc tttccagac tggttcagtt 18900
 catcgagtgt tttcattaac ttttcgctgt ttttaagggg ctggatctca tcaaataatc 18960
 ccgctgcgc tataccgat ggtgtgaaat cagccagcat gactcctgcc ttcatatagc 19020
 ggtacccttc acgccagaca tggtttaacg ctctgcatgc tgcggcaata atgtcccggc 19080
 tgcctgtgt gggtaatgga agcttttcca cagcggcatt gctgtaacag agttctttta 19140
 ctgcaaaggg ggatgtccgt acaaatgtcg tcacctgccc gcaatactga cgctccccac 19200
 gtagtttctc tgcggcccgc tctgcatact gaacaacagc ctggtgcatg gcatctttgt 19260
 ctgtgattcg ttcacaaaa ctgcgactac agacaatctg ctgttttgcc ggtggtgctt 19320
 cttccaggga tatgcaggac tgcgcgttga gttcgcgtac cgtacgctca agaatgacgc 19380
 tgaagttttt ccggatgaat gccgtgtag cctgcgccag ctgcagtgt gtgtaatac 19440
 ccagcgcatt cagcttttcc gtcagtctgc gtcctactcc ccagacctca ccaactggct 19500
 gcagccccag tagcttcaag atccgattac ggttttctgc cgtcagcgcg accacaccgg 19560
 aaaactgtgg ccattgcttt gttgcccact gtgcactttt agccagcgtt tttgtaggcg 19620
 caatgcccac cccatggtg agtctgtcc agctctttac ctgttccctg agctgatgac 19680
 caaaaacctc cggagagatg caatgattta tccccgcaa atcaatgaac atttcatcaa 19740
 ttgagtaggg ctcaactgcg ggagaaagcg actccagaac agccataacc cgttggtca 19800
 tgctgtggta cagcgcataa ttgctgaaa atacatgtat tttcttctcc aggcgcatct 19860
 gtctcacctg aaaccagggc tgccccattc tgatgccaag ggcttttgcc tccgggctgc 19920
 gcgcgatcac acagccatcg ttattgctga gtacgattac cggttcgttg cgaaggctccg 19980
 ggcggaaaac tttttcacat gaggcgtaga aactgttgat atcagccagt gcaaacatca 20040
 gcgtaactcc cgcgtcctgt gtatcacgtg agtgacaaca ccaaaaatac agatgttttc 20100

-continued

cggatacagt	gtgcggaact	cggggctgtc	tgaaacccggc	tccagtgccg	ggcgtgggcg	20160
caacagcagt	cgtttgacgg	tgaactcacc	gtcgatctca	gcgataacga	tgtccccgtg	20220
ttgtggtttt	tgggccctgt	ccactaccag	cagatcacca	ttctgcacgc	cagcctgggt	20280
catcgattca	ccgctggcgc	gcagaaagaa	ggtggctgca	ggtctgctga	tgcaatagct	20340
gttcagatcc	agttcctgct	cagcataatc	agtggcaggc	gaaggaaaac	cggcctggca	20400
acgatcggca	aacaacggtc	gcacgtaact	gtcatcgctc	gaagggtcag	ccggacggtg	20460
ataaacggta	ctcatgctgc	aggcagccag	ctgtcgtcct	gccagatttc	ttccagcaga	20520
gacaggatac	gttctttatc	cttgtcgttg	cgggctcctg	tgacagatac	agacggggcg	20580
ctgccctggg	ctatacgcag	ccagatttcc	gggtagtggt	gtttcagacg	ttgttcgatt	20640
tcattctgta	gcgctgaag	tgtgcctgat	ttgaggtttt	ttgtgctctg	gcggtcgaaa	20700
agaatttcaa	tgcggatcat	gttctcatct	cccttttctt	ttgctgtatg	catatacagt	20760
atcctaataa	ctgaatccac	acacagtcaa	atgtcattgc	tctgactaaa	aatgtctcaa	20820
ttctctgaga	gtgtggctgt	atgcctgctg	tggagtgctg	tgtccagctt	atccacagca	20880
ttttgtgcac	ggttctgtgg	acaaaatacc	tggttaccca	ggcctgcccg	gcacgttaac	20940
cgggctgcat	ccgatgcaag	tgtgtcgtcg	tgcgccgctc	cctcaccggy	tcacgtttcg	21000
tcgttctctc	tccacgcgct	gcggtctcgg	ggccgcacct	gcattcgtat	gcggtcgccc	21060
ggttacaggg	gcggcacggc	ctgatggagg	ccgcattgta	gaggagaatt	cccatgccaa	21120
actggtgctc	aaatcgatg	catttttctg	gtgaaccagc	acagattgct	gagattaaac	21180
gactggccag	cgggtgcagtc	acaccatttt	atcgccgctc	cacaaatgaa	ggtattcagc	21240
tgtttctggc	cggaagtgcc	ggacttctgc	agaccactga	agatgtgcag	tttgaaccgt	21300
gccccggact	gacggctgcc	ggacgtgggt	ttgtatcgcc	ggagaatata	gcgttcaccc	21360
gctggctgac	acacctgcag	aacgggtgtc	tactggatgt	acaaaactgc	ctgatgctgc	21420
atgaactctg	gctgcagagt	ggtactggcc	agcgtcgtcg	ggaaggatta	ccggatgagg	21480
tcagggatac	catcaccgca	cttttcaccg	caaaaagagg	tgactggtgt	ggcttctgga	21540
gtaacgagga	tgtatcgggt	tgggtggaacc	gtctgtgtga	caacgtactg	ccggaaaaaa	21600
ccatgcogtt	tgacctgctg	acggttctgc	cgaccgcctc	ggatggtgaa	gtgaatggct	21660
ttaacgggtg	tgttctgaac	ggtgttctct	ctgcatatca	ctggtatacg	gaacgggatg	21720
gcgtgaagtg	gcctgtgggg	tatgaggtga	atatcagtag	tcaggaagac	aacttcattc	21780
aggttgattt	cgacacgccg	tgggtgcagc	cggaaagcga	cgttattgca	gaattaagcc	21840
gccgtttcag	ctgcacgctg	gagcactggg	atgccgaaca	gggctgtgat	ttctgtggct	21900
ggcagttgta	tgagcgcgga	gagctcgttg	atgcgctgtg	gggggaactg	gaatggctct	21960
ccccgacaga	tgacgatgag	ctgccggaag	tcaccggacc	tgcgtggata	gtcgacaatg	22020
tggcgcatta	tggcggatga	agtatgacgg	agacggggcg	gcaaccgccc	gtttcttttc	22080
cgacaaagga	tgtcgccgtg	ctcctctttt	tactgcgccc	gctgacgcgg	cgcggcagga	22140
acgctgcctg	tggtcagtgt	cccgcgtccg	gcgggcaagg	gacggggcgt	tttaccgctc	22200
ccgctggcgc	tcggtgacag	tgtacgccag	cccgtcggcc	ttttctgatg	aacgcccttc	22260
aagccgcttt	cgcggcataa	ccttgccgct	agaaagacga	cggctgcggt	attccacggt	22320
cggcctgacc	cgttaccgga	cgcgggtgaa	agcccacagg	cagcggggaa	cgggcaccac	22380
aggggtgccc	tcccgggtgc	ctctgtaaga	gaaggagttt	ggtatgtccc	gttttgcctc	22440
cgtaactgct	atcgatgta	tggcccgtat	ccctgataac	gccattgatt	tcacctcac	22500

-continued

cgacccgcca tatctcgtcg gtttccgtga ccgttccggg cgcaccatcg ccggcgataa 22560
 aaccgatgag tggctgcaac cggcctgtaa tgaatgttc cgcgtactga aaaaagacgc 22620
 gtaaatggtg agcttctacg gctggaaccg cgtc gatcgc tttatggccg cctggaaaaa 22680
 tgcgggattc agcgttgttg gtcacctggg cttcaccaaa aactacacat cgaaggccgc 22740
 atatgtgggc tatcgccacg aatgcgccta catcctggca aaaggccgtc cacgtctgcc 22800
 acaaaaaccg ctgccggacg tgctgggctg gaaatattcg ggcaatcgcc atcaccgcac 22860
 ggaaaagccc gttaccagcc tgcaaccgct gattgagaac ttcacacacc cgaacgcaat 22920
 tgtgctggac ccgtttgcag gcagcggctc aacctgcgtc gccgccctcc agtccggacg 22980
 ccggtatata ggtatcgagc tgcttgagca gtatcacctg gccgggcagc aacgccttgc 23040
 cgccgtgcaa cgggccatgc agcagggggc cgcgaatgat gactggttta tgccggaggc 23100
 tgcgtaaagc aactatgcag gacacgaaaa actgcgcgcc gaagtggcgg aggtggccaa 23160
 tgccatgtgc gacctgcgta caaccatgaa tgagatggag cagcggtaga gctttaatgc 23220
 cgacaccctg ccggaacgtc tgggtgcgta gacgctgttt cgcgcaaacc gcctcctgat 23280
 ggaggcatat accgaaatc tggaaactgga agcgtgcttt aaagattgag aaggagacga 23340
 gaatgtacgg aacatgcgaa acgctatgcc gggagctggc agtaaagtat ccgggagaca 23400
 tgccgctgat gctggttatc tgggtccccg aagagattca ggccctcgct gacggaatgg 23460
 atatttccct gtccgatcat gaaatcagaa ccgtcctggc gcgcctggag gacatcccgg 23520
 aagaccagcg gactgaatcc ggtatttctt ccggcgtggc gatggagatc atcaataacg 23580
 tgagcgaaaa ccgccaggtg accgtccctg ctgaaactgct ggcgtccctg attcagaccg 23640
 ctgaaacggc attgtggaaa cgtgaaatggg ccgcccgga tcatggcctc gccgtcccgg 23700
 aatgcgtcac ccgccgtcag gcggtgatta atcaggcccc caccctgctg aaaaacaaca 23760
 gacacgaaaa cgactgatgt tatcgccgcc tccgggcggc gattcaggga gaacgattaa 23820
 tcatgaacga aaacacaaca ctgaacgcac tgatttgcg tcacgcccgc aacctgctgc 23880
 tggcgcaggg ctggccggaa gagacggatg ttgaccagcg gaacccgaac aatccgggct 23940
 ggatcagcat ttatgttctg ctggatgcgc cccggctggc gacgttactt atcaaccgtc 24000
 acggcggcgc actgccgccc ctectggcct ccgccattca caaactgacc ggaaccgggg 24060
 cggaaactgt actgtccggc agtcagtggc agtcgctgcc ggtacttccg gcagacggaa 24120
 cgcaggtgtc tttcccgtat gccggtgagt ggctggcaga ggacgaaatc agggcagttc 24180
 ttgatcggtg acgcgatgca gtacgctgtg tcagttacca ggtggcagaa gatacgccc 24240
 gtatccgggc gccgctgacc accaccggtc agacgttact gaccgccag acgcgccgct 24300
 ttcgctggg cgtgaaggag agcgatcacc cctgctggct cgatgaggac gacgaaaacc 24360
 tgcccgtggg gctcgacgcc atcctgaacc ggggcgcacg ttttccggc gtggaaatgt 24420
 atctggtcag cgattgtatt gaacatatcc tgtccagttg gctggcctgg gatgtgctgc 24480
 gtataccgga tgaaccgccc cgcgctggg ttgaccgtgg tgttctgcgg gaggtggccc 24540
 gggaaagccc gaacgaaatc cgcagcatgg ccgatgcctt ggcaaaaatc cggaaatgat 24600
 gacactggcg gggtaaacc ccgcctttt cctgccggtc cccggacaga gcacaaagga 24660
 cgtcgcgcc gccctcgctt taccggcca tgcagggcat ggccttggg ttttccagtt 24720
 atgtggccgc cgtgtcgtgt gcgggctgtg ccgtgcctcc atcttagccg ggctggcagg 24780
 gatgcaaggg tacgcttcgc cgtgcggtc acccggtccc tcttcccgt ctgccgtgat 24840

-continued

tttcggtcg	ttcaccgct	cagatttcgc	ggtctcacc	tccaactccc	gccagccgtg	24900
tgcgtcaggc	tgcggcttc	cttgccgccc	gtgcatcccc	accttatcgc	ccggctttta	24960
tggaggcacg	gcaccgccc	gtgtcgcgga	atatgtgaac	aacggaggaa	aacatcatgc	25020
aatatgcgaa	acctgtcact	ctgaacgctg	aagagtgcga	ccgtctgtct	tttctgcctt	25080
acctgtttgg	ccaggatttt	ctgtatgccg	aagcgtctgt	atacgcgctg	gcgaaacaaa	25140
tgatgcogga	atatgaaggc	ggattctggc	acttcatccg	cctgccggac	ggtggcgggt	25200
acatgatgcc	ggatggcgac	cgttttcaca	tggatgaacg	tgcaaactgg	tttgaccgta	25260
ccgtgagtgc	tgatgccgca	ggcatcatcc	ttacctccct	tgtgattaac	cgccagttgt	25320
ggctgtacca	cgacagcggg	gatgcaggac	tgaccagct	ttaccggatg	cgcgatgcgc	25380
agttgtggcg	tcacatcgaa	tttcaccctg	aatgcaacgc	gatttacgca	gactggact	25440
gattaacgga	cggggcccga	atgccgcccc	tgtaaaggag	acgagaacat	gtactgtact	25500
gttaaagaaa	ttatccgca	tgtactggat	acagacgtgc	cggacagtga	atgcgttttt	25560
gccgtggtgc	tgaccctggg	ggatgtgcgc	cacatagccc	aggactggag	tctgacagac	25620
gatgagctgg	aaaccgtcat	gcagcggctg	gacgatgcct	ttgaatatgg	tgcggatgtc	25680
agcgttggtc	acggcgttgt	togtgaactg	atggaagaaa	agcgcgccag	ccgtcaggtg	25740
acagtcccgg	cggtgatgct	ggaaaaagtg	ttggcgtggg	caggcagtga	aatgaagcgc	25800
ctgtatgccg	tccggagtga	gaacggggggc	gacggatgat	cgttcgtcag	ggaagaacgc	25860
gaagcaatgg	acgttgtgtt	acaggcgtcg	gacggggagc	acatgtcatg	aatatcagca	25920
cagaaaccgg	cgaaattctg	cgcaattaca	aagccgtgat	taatgcgcgg	cgctcgtgaaa	25980
tggggcagaa	accgctcacc	actgcgcaga	ttgttgatga	aatctgcgat	tttgtggcga	26040
atcagcaggc	ggttttcctc	ggtggtcact	atatccttca	gggcagcaga	aacaggatgat	26100
acagggcagg	cggtggaggc	cgccgtcag	cccgcgcgaa	aaccctggc	aggctgacgc	26160
ctgccgga	tgcgggggtgc	agcgcctgcg	gcgctgccgg	cccggctttc	cggtcagaag	26220
gtagtgatg	gctgtatgca	gggaacagg	gtgatattcc	gtgacactgt	caccgtttct	26280
ggctgtcttt	tattgcgccc	acttcggctc	ccggctgcct	ggcggcatcc	ggtcgtcagg	26340
cccgactccg	acaggcagct	gctggcgcac	ccgccagtct	ccgccgaacc	cgctggcgcg	26400
gtttcgggct	gccgctacgg	tccgatgcgt	gaaaaccggg	cttgacagca	ccgttccggg	26460
cgcccgccc	ctgtcgcgcc	gtgacctgcg	ctccctgcac	acctgacggt	gtgtgaggaa	26520
actgcgcctg	atggcgcagc	agtcttccct	cctgccgcca	cccctgcggc	ctgtttcccc	26580
ctgtggactt	tccggggggc	agacgtaacc	ccctccggtt	ccatctgtcc	agggtgagat	26640
gcaccggcca	caaaattttt	agccatgaac	ccggctaaaa	atthtgcgtc	cgccccgga	26700
cagctgtccc	gtgaggcgg	aaacggggccc	ccatcgga	ggtccactgc	ggggagaaac	26760
ccctgtgaag	tggacggcag	gaggagcttt	cgctcctctg	aaggggcaca	tgaacgtccc	26820
gtcgcgggta	tccggtttat	ctcacatctt	tcagtcagga	ggttcttatg	agtgcacgtg	26880
gtatcaacaa	ggtcatcctc	gtcgggcgtc	tgggcaatga	tccggaagtc	cgttacatcc	26940
ccaacggggg	cgcagtggca	aacctgcagg	tggccacatc	agaaagctgg	cgtgacaaac	27000
agacggggga	gatgcgggag	cagacggaat	ggcaccgcgt	ggtgctgttc	ggcaagctcg	27060
cggaagtggc	aggatgaat	ctgcgcaagg	gtgcgcagg	ctacatcgaa	ggtcagcttc	27120
gcaccgtag	ctgggaagat	aacggatca	cccgttacgt	caactgaaatt	cttgtaaga	27180
ccacgggcac	cgtgcagatg	ctgggacgtg	caccacagca	gaacgctcag	gcgcaaccga	27240

-continued

agcctcagca gaatgggcag ccacagagtg ctgacgcgac gaaaaaaggt ggcgcgaaaa 27300
 cgaaaggccg tggacgtaag gccgcgcagc cagagcctca gccgcaaccg ccggagggggg 27360
 aggattacgg gttttcagac gacatcccgt tctgatcggg ctgactgtga caaccgcccc 27420
 gccctgtgcg gggcatcacc ggagatatga ggatgagcga atatttcaga atacttcagg 27480
 gactgccgga cggctccttt acccgcgaac aggcggaagc cgttgccgca cagtaccgga 27540
 acgtctttat cgaggatgat cagggaacgc attttcgcct ggttgtccgt caggatggca 27600
 cgttgatctg gcgctcctgg aattttgagg acggtgccgg gtactggatg aaccagtaca 27660
 tcagggattt cgggattctt aagtaagaga ggtgccggac gcgcgaacgt ccggcaggac 27720
 ataagcaatt ataaggggat gattatgcct gtaacgaagt gtgaaccaga aaccacccgc 27780
 aaagcaagcc gtaaactctgt aaaaacgcag gaaactgtcc tgtctgcctt gctggcgcag 27840
 acggaggaag tgagcgtgcc gctggcctcg ctgattaaat caccgctgaa tgtgcccacg 27900
 gtgccgtatt ctgcccagtc cgtcagcga ctggcggagt ccattaaggg cgtcggactg 27960
 ctgcagaatc tggtegtgca taccctgcct ggtgaccgtt acggtgtcgc cgcagggtgt 28020
 cgccgactgg ctgcactcaa catgctggca gagcgtggca tcattccggc tgactggcct 28080
 gtacgcgtga aggttattcc gcaggagctg gcgactgccg catcaatgac tgaaaacggg 28140
 catcgtcggg atatgcacc tgcgaacag attgccgat tccgtgcgat ggcgcaggaa 28200
 ggcaaaacgc ctgcacaaat cggtgatttg ctgggctatt cgcgccgcca cgttcagcga 28260
 atgctgaaac tggcagacct tgcgcctgtc atcctcgatg cgctggcaga agaccgcatc 28320
 accacagagc actgtcaggc gctggcctg gagaacgaca ccgcgcgtca ggtgcagggtg 28380
 tttgaagccg cctgccagtc gggatggggc ggaaaaccgg atgtacagac cattcgtcgt 28440
 ctggtgaccg aaagtgaagt ggcgggtggcg gggaacacta aattccgctt tgtgggggct 28500
 gatgccttct cgccagatga actgcgcacc gatttgttca gcgacgacga ggggtggctat 28560
 gtggactgtg ttgcgctcga tgcctgcctg ctggaaaaac tccaggctgt cgctgaacac 28620
 cttcgggaag ccgaaggctg ggaatggtgc gccggacgca tggagcctgt cggtgagtgc 28680
 cgtgaggatg ccggaacata ccgcagctc cggagccgg aagcgggtgt gacggaggcg 28740
 gaagaagaac gcctgaacga actgatgacg cgttacgacg cgctggaaaa tcagtgtgag 28800
 gaatccgacc tgctggaagc agaaatgaag ctgatgcgct gcatggcgaa ggtcagagcg 28860
 tggacgccgg agatgcgttc ccggaagcgg gtggtggtgt cctggtgtta tggcaacgta 28920
 tgtgtccagc gtggtgtgca gttgcgcagt gaggatgacg tggctgacga cgctgaccgc 28980
 acggaacagg tgcaggagaa agcatcagtg gaggaatca gtctgccgtt gctgacgaaa 29040
 atgtcctcag agcgcacgct ggcagtccag gcggcactca tgcagcagcc ggacaaatct 29100
 ctggcactgc tggcatggac gctctgcctg aatgtgtttg gcagcggggc gtacagtaaa 29160
 ccagcacaaa tcagcctgga atgtgaacat tattcgtgga ccagcgtgc gccatcgggg 29220
 aaggaagggt ccgcattcat ggcgctgatg gcagaaaaag cccgtcttgc tgccctgtta 29280
 ccggagggat ggtcacggga catgacgaca ttctgtcac tcagtcagga ggtgctgtta 29340
 tcctgctca gtttctgcac cgcagcagc cttaacgggt tccagaccg tgagtgtggt 29400
 cacacgtcac gcagtcgct ggattcgtg gaaagcgcga tcggctttca catgcgcgac 29460
 tgggtggcagc cgacaaaagc aaacttcttc ggacacctga aaaagccgca gattatcgca 29520
 gccctgaatg aggcaggact gtccggtgcc gcacgggacg cggagaagat gaagaaaggt 29580

-continued

gatgcggtg	aacatgcaga	gcaccatatg	aaagacaacc	gctgggtgcc	tggtgggatg	29640
tgtgcaccac	atccacagac	agatgccact	gaacgcaccg	ataacctggc	tgatgccgcc	29700
tgatgaacaa	ccacaccgcc	ccgccggaga	cggggcggca	gcaagggaga	tacctgatg	29760
aaaactgaac	tgacctgaa	tgccctgcag	tccatgaacg	cacaggaata	tgaagatc	29820
cgtgctgagg	gaagcgatat	gcgcccgaat	ctcactcagc	aggtgatgag	tgaagtggac	29880
gcaccggcta	actggatgat	gaatggcgag	tatggcagtg	agttcggggg	ctttttcccc	29940
gtccaggtec	gtttcacgcc	agcccacgaa	cgtttccacc	tgccattatg	ttcgccggga	30000
gacgtctctc	agctctggat	gctggttctg	gtgaattgtg	gtggacagcc	tttcgcccgc	30060
gttcagggtc	aacatatctt	cacgcctgtc	gctatcagtc	acacgctggc	gcttgccgag	30120
acacttgatg	cgaggggta	cagtgttaac	gatatcatcc	atctcctgat	ggcagaagga	30180
ggtcaggcat	gagcgcacgt	tcacgggcac	tgatccccct	cagcgcagag	caacaggccg	30240
ccatgcaggc	tgtggctgtc	accgaacaac	gtcgtcgtca	gggacgcaca	ctttcagcat	30300
ggccttatgc	cagcgccttc	tttcgctgcc	tgaatggcag	tcgcccggat	tcgctgaccg	30360
atctccgctt	ttttgctcct	gcgctgacga	aggaggaatt	tcattggcaac	cgtctcctgt	30420
ggtggtctgc	cgtggataaa	ctgattgaaa	gttttgggtga	agtctgtgtt	cttcccctgc	30480
catccgatgc	ggggcatcgt	ctgttcccgt	ccgttccttt	tcgtgaaggt	gagcggcgctc	30540
gtcagaaaac	cacgctgaca	gagcagaaat	acagccgcca	gcgggaacgt	gaggcagaac	30600
gacgggaact	ggaataccag	acatgttttg	ctcaggcgca	gattgacctt	gcgtttcata	30660
ctccctccac	ggtcggaaag	tggttgtccc	gctggtctgg	tgttgttgag	gagcatgatc	30720
tggaaacgat	tttctggggg	tgggtcgggc	gttttccatc	actgtcatca	tttgaccggt	30780
ttttctggca	ggaggaacca	ctctggcggc	tgatttttga	agctggtgag	gccggtcgtg	30840
gtgcaccggt	acaggtacgt	gcacttgagc	agtggatgat	cccgaacaag	ctggagaacg	30900
caatatgatg	aatcagacg	aacaatatca	ggttcccgtg	tggatgcgac	ctctgttgcc	30960
gttgcctctg	aataccggtg	gtaatgatcc	ggaggaactg	ctgaatgata	cagaaaccac	31020
cgccagtgcg	aatattgtcc	gttatgtact	gatagttgca	gtgcggctgc	agattgatct	31080
gctgcagcta	ctgtacagga	aaggactggt	gcgcacagag	ataccagggt	gcttttcacc	31140
ggaagaagcg	caggaactcc	tggataatct	ggtgcgcagc	catatcagca	aggcgtctgc	31200
gggtgagcga	atggcagccc	gtgacagaaa	tgccgatctg	acctggattc	gccagcaact	31260
ggtcgatgcc	gcctggtttg	tccgtgccac	actggaagcg	catgggatgg	gcgtcgga	31320
tgagagtccc	tctgctccgc	cggagacaat	gccggacata	cagacacggg	aactggttat	31380
gttgatcaag	cgactggcat	catcgctgaa	agcggtgaaa	cccagacgta	gcgtggtgag	31440
tgaagcgcag	gactggctgt	gcgacagaaa	acttgtggat	atcacagata	ttctccggtg	31500
aaccagacat	gtatatttta	cgcagggaca	cgccgatcat	gatcgtttca	tatcaggggt	31560
ggtctggagg	tcatgcggcg	tgtcctctgc	actcgcggga	ataaggaagt	cgccggcggc	31620
tccgctttta	cccggccatg	cggggcatgg	ccttgtgggt	tttcagctct	gtggcctcag	31680
cgctgtgtgc	gggctgtgcc	gtgcctccat	cttagccggg	ctggcagggg	tgcaagggta	31740
cgcttcgccc	ctgcggtcac	ccggtccctc	cttcccgtct	gccgtgattt	tccggtcgtt	31800
caccgctca	gatttcgagg	tctcaccctc	caactcccgc	cagcctgtgt	cgtcaggctg	31860
cggcttccct	tgcgccctgt	gcacccccgc	cttatcggcc	ggcttttatg	gaggcacggc	31920
accgcccggg	gccgcagaac	atgtgactat	ggaggattcg	ggaatgtctg	ttgttgacc	31980

-continued

tgctgtatac gttggaacct ggcacaaata caactgtgga agcatcgccg gacgctgggt 32040
tgacctgacc acgtttgatg atgagcgcgga ctttttcgcc gcctgcegtg ctcttcacca 32100
ggatgaagcc gatcctgaac tgatgtttca ggattatgag ggattcccgg ggaatatggc 32160
ctctgaatgc catatcaact gggcctgggt tgaaggcttc cgccaggcac gggatgaagg 32220
ctgcaagag gcttatcgtc tatgggtgga ggataccggt gagacggatt ttgacacctt 32280
ccgcgatgcc tgggtggggcg aggctgacag tgaggaggct tttgcggttg agttcgccag 32340
tgataccggc ctgctggctg acgtgccgga gacgggtggcg ctctattttg actatgagggc 32400
gtatgcgagg gatttatcc tggactcctt cacctttatt gacggtcatt tgttccgtcg 32460
gtgatttact cccccgctcc ggcgggggta tggcctgccg ggcgcgcca aaaccctggc 32520
aggcttacgc ctgcctgaaa tgcaggaggc ccgcgcctgc ggcgctgcc ttctgcccg 32580
tcatggtgtg aggcattttt ctggtatgtc gtttctgttg ttctgatttc cggaggcggg 32640
gacaccttcg gctcccggct gcctggcggc atccggtcgt caggcccgc tccgacaggc 32700
agctgctggc gcaccgcca gtctccgccc aaccgctgg cgcggtttcg ggctgcccgt 32760
acggtccgat gtctgaaaa ccaggcttgc agcgaccgt ccggtcgcgc cgcctctgc 32820
gcgcccgaac cggcgctccc tgcacacctg acggtgtgta aggccactgc gcctgatggc 32880
gcagtcaacc cttccgccc caccctgcg gcctgtttcc cgctgtggac tttccggggg 32940
ctggagtaac cacatcccgt ttcagcagtc caggggaaga tataccgtcc aaaaaattt 33000
tagccataaa cccggcaaaa aattttgctg ccgcccccg acagctgcc cgtgacgtgg 33060
tgacggacgc cccatcggaa aggtccactg cggggagaaa cccgaagaa gtggacggca 33120
gaaggggctt tcgcccctcc ggggagcaac cggtcggccc ggcgacctga ttcagcagaa 33180
ggagacgttt tcatgactgt cagcagcacg atttccgttt tttgccgca cgggggtgtc 33240
cgtaccgttt actgccacct gcacggtgag ccgacctgga acggtcgcatt cctgcatacc 33300
cactatgcca ccggtcagca ggccgaagcc ctggttgaac acggtgatat ccggtgcctc 33360
ggccccgtt gcgacaaacc cgcgggcat acgcttcaga acccggtgga cgggtgtgacg 33420
gcttattacg gacgtgacag tggtttccgg atggacagtg aggcgctga gtaccgttct 33480
ttcaggagg ctattgccac tgaagcact gaagaggtgc gcttcatta tgtgttcac 33540
gacggctact ggaaggtgat gtaccgcacg ccggaaggct ggaagatgaa agcgtcgcg 33600
ctggcactgc gtcgctgtcc gaaatgaaaa aaaggcaggc cgataaacc tgctctctc 33660
cgccggcgct tccccgccag gaagtccggc atctcaatca ctatctatgg agattatgcc 33720
atgagaccat caattatctt cgcaaccgcc gattatgtaa agcgtctgcg tgaagagtgc 33780
ctgcccggaga ataaaccct gcaccgcat acccgcttca gacgtcagga gctggcacag 33840
gatgagatta acccgacgt cctggcgatg agcggccata tcgccagacg ctgcagtgag 33900
cagaagcggg tgcgtatccc cgctatgaaa gtcagcgaat ggggccacct gctccgcgcg 33960
cttgaaattg agcgggtctg ccaactgatta acccttgcg tctgcctgtg caggcggcag 34020
gatacgttca gacatctcac caggaggaac cgtgagtaag aagaaaacca ccacgacgcc 34080
cacgccgat gatgccgct tccggctgct cctggcgaat cccgacgtcg ccagagattt 34140
tctggaactg catcttccgg cggagtaccg gcagttgtgc gacctgtcca cgctgaagct 34200
ggaaccgccc acctttgttg agccggacct gcatcagtac gccagcgata tcctctggag 34260
tgtgaaaacc accgggggtg aagatggcta tgtttatag ctcacgagc accagagcac 34320

-continued

cgaaaatctg	tacatgcctt	tccgcatggt	acgttacagt	gtggcggcga	tgcagagaca	34380
tctggagcag	cacaaaacgt	tgccactggt	cattccgggtg	ctgttctatc	acggtgagcg	34440
cagcccgtac	ccgtacagca	tgaactggct	ggactgtttt	gagaatccgg	cgcttgccggc	34500
taaaatatac	acaaagccgt	ttccgctggt	tgatatact	gtcgttgatg	acaatgaaat	34560
catgaacat	cgccggatgg	ccgcactgac	gctgctgatg	aagcatatcc	gccatcgtga	34620
catgatggag	ctgctggaca	aactcccgca	ggtcatgggtg	gaaatttcag	acgagcaggt	34680
gctgtttctg	attcattaca	tcggtaacgc	aggggactct	gtatcaccgg	aatttatgcg	34740
ggcgtggct	gagcgtctgc	cgcagcatga	ggataaactg	atgactatcg	cagaacgtct	34800
tgagcaaaaa	ggtcgccagg	aaggcaggat	ggaaggacgc	atggaaggac	gcatggaagg	34860
agcgttgaa	aaagccctgg	ctattgctg	ccagcttcag	aaaatgggga	tgacgccgga	34920
gcagattaag	caggctaccg	gactttccga	tgacgaaactg	aagaaaatct	ctcactgagt	34980
aaacatcaca	gcccggcaaa	atgccgggct	ttttgtcag	caggagcaga	gcaaacagca	35040
tgacgattgc	agaacgtctt	attcaaaaag	gcgcacttga	agtggcgcgg	gaaatagcct	35100
gccggctgcg	ggatatgggc	tggacgccgg	aacggattca	ggaggcaacc	ggactttccg	35160
gtgaagaact	gaaaaagctg	tttctgatg	agcagtagcc	tggcattcag	ccaggctgtg	35220
aatcacgctc	acacatcctc	tgccgtttcc	cccagttcat	tttccagtcg	cctgatgata	35280
tctgccttac	gcatcccctg	catgtgaggc	agcaggtcac	ggactgaaag	tgccctgggtg	35340
gtcctccaga	cggtgacgtc	cacctgttcc	gcattttccc	aggcgtgcca	tgttctctgc	35400
gtcacgccaa	attctctggc	cgctttttcg	cgtgaccaga	gcatgctttt	tcgccagatt	35460
cgcagttccc	agccggatcat	aaaacacctt	tgaaaaagtg	aaaaaacttc	actttatttt	35520
atcatcacia	ttgccaatc	agcgcgataa	ataagtgtaa	aaaagtgaag	aaatttcact	35580
ttttttgctt	gtaaagtctg	tgcggttttc	tctgttttca	cctgtgcggg	agtgggtgtg	35640
cagtgaaccac	cacatgccat	tgttgtgccg	tcgtttttct	tcagtcgcgc	cgtatgcggc	35700
gtccctgca	caccttacgg	tgtgtaaggc	cactgcgcct	gatggcgcag	ctgtctctgc	35760
ctgtctgccg	ccgcactgcg	gcctgtttct	cgcagacgga	ctttccgggg	gtacatacat	35820
gaccacatcc	cgtttcagtc	gtccagggga	gagatgtacc	agccacaaaa	ctttttgccg	35880
caggcgtcaa	aaacttttgc	gtctgcccc	ggacaactgc	cccgtgacgt	ggtgagcgtc	35940
ccccgtcgga	aaggccact	gcggggaaat	tcccgaagac	ccggacggca	gaaggagctt	36000
cgctcctccg	ggaaatgacc	tggctgacct	ggcagtcgtg	acgatgagga	gacaatgtga	36060
tgaatcagac	tttaccact	gctgacctga	atactgccgg	tacgacagat	gttattccgt	36120
ctgtggctat	cgaccgcac	atcgcgcagc	gtaacgaagg	tattgcactg	ttcatgcagg	36180
cgatggaatg	cctggcgaca	gcgcgcaaga	ttctgctcga	tgcgtcaggt	gatatttttc	36240
tttacgggtt	tgaagactgc	gtgactgatt	ccgttcgtcg	catagataaa	ccggaagaag	36300
cgaaaaggaa	tatccccgt	cttgccgacc	ggaaaatctg	ggaccgctg	atgacagata	36360
cgggcatgta	caccttcag	agttcatgcc	agcgtgatga	gtggaacagc	cagctgatga	36420
gcgacacctg	tcctgaaatc	accctggaca	atgtactggc	aacattccgc	catctgaatg	36480
cctgcaagat	gcagacattt	gaacagggac	tgattgatgt	ctaccgaaa	ttgtcatggg	36540
attacagaac	caataatccc	tgccgtctgg	gtaagaaaat	cattattgaa	aacctgctgt	36600
accgctggag	taacggggct	gtgacgctgg	actgcagcgg	acgggagga	ctggatgacc	36660
tggtacgtcc	gttttatctg	ctggaggggc	gcaacgttcc	tgacttcagg	aacagtatcg	36720

-continued

gggcgcagta	tggtgaattt	ctcgggaacg	gcgacaatgt	cggtaaactg	ttagaagggg	36780
aatattttac	ggtgcgtggc	taccagaaag	ggaccgtaca	cattgtcttt	aagcgttctg	36840
accttggtga	aaaactgaat	gatattattg	cacggcatta	tccaggtgca	ttgccgccac	36900
gagtctgatt	aaacagaaaa	gccctgggat	ttatgccggg	gctttttttt	ctgtaatcat	36960
cataatctca	gaacacgatg	tgacattgtc	acatcaatta	ttgttcatat	cgatgccatc	37020
tttctgcct	gaatctgtct	ttttaggtgc	tgttttagag	gaagaacggc	gggatggttt	37080
tttcgattct	gcttcccga	taatgtcacg	aagtgccttc	tctcctactt	cataccctgc	37140
atttttgagc	gtgtcacgaa	catctgccag	tgtataaacc	tttgcctta	ccaggacaat	37200
aatgtcatca	cgaatggcat	caagaaaatc	acgcaatgtt	ttccgttgag	cggtgagatc	37260
tggcaattcc	gataaagcag	cttttgccag	ctggatgtca	tcatctgagt	aaaatttttt	37320
agaagccatt	ggcactttct	ctccgtttca	tgttgaagtc	tgattttatc	atcaaaaact	37380
gactcctggc	agggctgccc	cctgcctctg	ccgtctgcat	aagactatga	tgcacaaaaa	37440
taacaggcta	taatggcctg	aaaaacggga	caggatgtgc	aattgtaata	ccgtcacacg	37500
cgacgctatt	acaattgcca	tctggtcagg	gcttcgcccc	gacaccccgt	aaggagcctg	37560
aagtgagtga	tagtgtggta	agaaaaaaaa	gtgaggtacg	gcaaaagaca	gttgtcagga	37620
cactcagatt	ctctcctgtt	gaggatgaaa	ccatcaggaa	aaaagctgaa	gattccggac	37680
ttactgtatc	tgcttacatc	cgaaatgcag	cactgaataa	gcgaattaac	tcccggacag	37740
atgatgcttt	tctgaaggag	ttaatgagac	tgggaaggat	gcagaagcat	ctgtttgttc	37800
agggaaaaag	aaccggtgac	aaggaatacg	cagaagtgct	tgttgccata	accgaactta	37860
caaatacatt	gcgtaaacag	ttaatggaag	gttgaggatt	ctccggtgaa	tgcaagtcatt	37920
ccgaaaaaga	gaagggacgg	aaagtcttcg	ttcgaagacc	tggtatccta	cgctctctgc	37980
cgggatgaca	tgaccgatga	ggaactggat	ttatctcctt	cttcgcaggc	tgaacaacca	38040
taccgaagcc	gcttcagtcg	ccttgttgat	tatgcgacac	gtattcgaaa	tgagttatct	38100
gtggcgctgg	ttgatgtcat	gaaggacggc	tgcaaatggg	tcaactttta	tggtgtcacc	38160
tgctttcaca	actgtacttc	tcttgaaact	gccgctgcag	atatggagta	cattgcccgg	38220
caggcacact	atgcaaaaag	tgacactgat	cctgtttttc	actacatcct	ttcctggcag	38280
tcacatgaaa	gcccgcgtcc	ggaacagatt	tatgacagtg	tacgtcatac	gctaaaatca	38340
ctcggccttg	ccgaccatca	gtatgtctct	gccgtgcata	ccgatacaga	taatctgcac	38400
gtccatgtgg	ctgttaaccg	ggtacatcct	gaaaacgggt	atctgaatcg	gttatcctgg	38460
agtcaggaaa	aactcagtcg	tgccctgccg	gagcttgaac	tgaagcatgg	ttttgctccg	38520
gataacgggt	gctgggtcca	tgaccggggt	aatcgtatcg	ttcgcaaac	tgccggtgaa	38580
cgtgatcgcc	agaacgcatg	gacacgtgga	aaaaaaciaa	cttttcgca	gtatggtgcg	38640
cagacagcgg	tcgctggttt	acgcagtgaa	cctgtacatg	actggttatc	cctgcatcgt	38700
cgtcttgccg	aagatggtct	gtacctgtct	cagatggacg	gaaaatttct	ggtgatggat	38760
ggtgggatc	gcaacaggga	aggtgtacag	cttgattcgt	ttggtccctc	ctggtgtgca	38820
gaaaaactca	tgaaaaaat	gggtgactac	acgccagtac	caaaagacat	ttcagccag	38880
gtggaagcac	caggacgcta	taaccgggac	tttattgcag	ctgatgttcg	cccgggaaaa	38940
atcgtgaaa	cagaaagtct	gcagcagtat	gcctgtcgtc	atcttgaga	acgtctgccg	39000
gaaatggcac	gggaaggtcg	gctggaaaac	tgccaggcta	ttcaccgcac	actggctgaa	39060

-continued

gtgggattat	ggatgcgtgt	tcagcatggt	cacctgggta	tctgtgatgg	ttatgatcat	39120
accagactc	ccgttcgtgc	tgacagcgta	tggcactgc	tgacgctcga	caatgtgaat	39180
caactcgatg	gtggctggca	gcctgtacca	acagatattt	tccgccaggt	tacgccaaca	39240
gaacgcttca	gtggtcgtcg	tatggagagc	tgtcctgcga	ccgataaaga	atggcacctg	39300
atgcgtacag	gcacggggcc	gcagggggct	atcaaacgcg	aactgttttc	tgacaaagaa	39360
agtctgtggg	gatacagcat	cagccattgt	agccctcaga	ttgaagaaat	gatcacacag	39420
ggtgagttta	cctggcagcg	ttgtcatgag	ctgtttgcac	aacagggact	gatgctacag	39480
aaacaacatc	acgggcttgt	tgtcgttgat	gcctttaatc	atgagcaaac	gccggtgaaa	39540
gccagcagca	ttcatcctga	tctgacactg	aggcgtgcgg	agccacaggc	cggacctttt	39600
gtgagtgcc	cagcagattt	gtttgacagg	gtgcaacctg	aaagtcgcta	taaccgggag	39660
ctggctgtca	gtgacaggta	cggggtcagc	agtaaacgtg	acccaatgct	gcgccggcag	39720
cgacgtgaag	ccagggctga	ggcccgtgct	gacctgcgtg	cccgctatct	agcatggcgt	39780
gaacaatggc	gtaaaccaga	tctgcgttat	ggggaacggt	gtcgggaaat	tcatcaggca	39840
tgccgtctgc	ggaagtcaca	cattcgtgcg	cagtacaatg	atccggcatt	acgtaagctg	39900
cattatcaca	ttgcagaagt	tcagcgaatg	caggcattga	tcaggctgaa	agaagacatc	39960
agggatgagc	gacagaaact	tattgctgac	gggaagtggg	atccaccttc	ttaccgtcag	40020
tgggtcgaaa	ttcaggctgc	tcagggagac	agggctgctg	tatcgcagtt	gagaggctgg	40080
gattatcgcg	atcgccgtaa	agacaagtca	cgacaacga	cgacagaccg	ctgtgtcgtg	40140
ctttgtgaac	cgggcggaac	gccggtatac	ggtaataccg	gtgatcttga	ggctcgtctg	40200
cagaagaacg	ggagtgttcg	tttccgtgac	cgtcggacgg	gagagtggg	ctgtacggat	40260
tatggtgaca	gggttgtttt	cogtaatcac	catgaccgca	atgcgctggc	agataaactg	40320
tatttgattg	cacctgtatt	gtttgagcgt	gatcccagaa	tgggctttga	accagaagga	40380
aacgatggac	agtttaatca	ggtctttgct	gaaatggtgg	catggcacia	tgtgacggga	40440
ttctctgaac	atggaaatta	cgttattact	cgaccggacg	tagatcagca	caggggaagtg	40500
agtgagcggg	gctatcgcaa	ttacatggat	agtaaacctt	acagagatgg	aactcagcca	40560
gttcaggata	gtgagaatcg	ctgggaacct	ccaacaccgg	tgtaaagaat	gttataaacg	40620
ggagattggt	atggcttatg	tcgatgattt	taaagaagca	atcatcagga	ctcggcgggt	40680
acaacttgca	caacccttg	atztatgtga	gacgcatact	cgcataatga	acgataaacg	40740
aatccgccat	ttgggaggaa	ttatacgtcc	tgtactggat	ctgaattctg	ggtatgaaca	40800
actggttgcg	cgatgatgc	ctgttcatct	tcaagccaga	cctttggttg	aagaatggct	40860
gggatgtcct	gtttatttta	cgttgggatg	gattgatgat	gggaccccaa	aaggatggtt	40920
caggtttgat	gaggacttta	ttactgatac	attgaaaaat	ggttatacag	gagatactgt	40980
caatcttcat	gcatggctaa	ctttaccag	tatggaaatt	atagatatca	cattatcaac	41040
aacaatttct	atggttcagg	ggcataagaa	tcagttagcc	ggtgttatta	tcaagagagc	41100
tgatgatatt	aaaggattct	catataagcc	aatgcttatt	ggtgatgaat	tctgtcaaaa	41160
atctggtata	ttgcataagt	ttacatatct	agaattgaac	tagtgatttt	taaataaact	41220
ggttttttga	cgttcttata	tctgttcaga	aatcacctcc	tgttgggggtg	attatttata	41280
ttatgagttc	tggcaggtcg	atatgttatt	tccgaaaagt	gaccatctct	cagatacaga	41340
actctgtctg	cggatgctat	tgtttctggg	cgatgagcta	ttaacagaac	aggaattccg	41400
agttggcgta	atgtctggct	tatttctatt	tcactttcca	catcaagatg	actggttgct	41460

-continued

tcgtccagta ataatagacc gggtttttta tacagtgtct ttgccagtag aatacgttgc 41520
 ttctgaccac ctgaaagtcc ccctccgggt tctccaagta atgtttgata gccattggc 41580
 attgccataa tctactgtc tataagtgcc agacttgccg atttacgcat gtgttcatga 41640
 tctctaattt cgctaaaaaa cattatatta tcagctatag aaccttgaa aagatagtca 41700
 tcttgcaata cagtccaat tcgttgacga acctgaaaat aatcagaatg tgtatgtggt 41760
 atgccaaatg cattaattct tccttcactt ggtgtatgaa ttccaagaat aagctttacc 41820
 aatgttgatt tgccacatcc tgatttacct gttattgcta atatttctcc aggaaagagc 41880
 attagtgacg cgttatccaa tatgggttta tctgcgccct tatggctaaa tgttattttt 41940
 tcgataagta atggtggatg ggtattatca tatttatggt ctctgtactg gcttgcatg 42000
 attgtttcat tatggtttgc ccaatgggtgc tgattctggt gaccttctg tgggtgtagc 42060
 acaatatcgg caagtctctc gttataaaca tcaagcatgc gccaggaaaa aaagttatca 42120
 gtcagattgc ttatactgga tgaaaaacgc atctgatagg ataagtaagc aaccaacata 42180
 cccacggtaa atgtccatc cagcacttct actgctccct gccacaaaat aatggctgaa 42240
 actacacttt ccgtcagtgt atgcgtcagt tcatagctca tttgtaaagc attctggcgt 42300
 agctgtgtgt ttctgctgggt aacgttgagg ttcagccagg ccgcttctct gtgaatagtt 42360
 acaccgttga ttctcagact ctgaatgccg ttaagggttt cgagaaaatg ccccgactcc 42420
 ttagttcctg catcccagac atcttcaaca gattgccgta aagccggata ccacaatgct 42480
 ctcagtgcgc catatataat agctgcaatt actgcgatta atgtcattcc tgggctatac 42540
 aacagcatca tgcaaagagc agtcacaata agtagcatat ccagaatgcc ttcaagaacc 42600
 tgcgttgca ggcctgctg gattatatct actgcttcaa aacgggcatt aatacttctc 42660
 ttacttoggg catcgaacca tgcaagaggg agtcttacia gatgatggaa aactctggca 42720
 gtccattgca tgttaaaatt gacggataaa ctgatcggtg cccattgtcg tgctagggag 42780
 agtaataatt gtatgagtga taacaacagt agtgccacta taatgacata caatagactt 42840
 ctgtctgctg cgaccagaac ttcatacaatt accagttgat taagaagtgg accacctaaa 42900
 gccagaatct caagggccag agcaaaaata ataatttttg tcattgatgc taaaagcccc 42960
 ggggttttcc ctgtcagttg acgcaggtgg attttttttc tctcgttccg gggggtgaaa 43020
 tcaactggctg gagttaattc cagtgccact cctgtaaaat gcttacctgc gtccaacaga 43080
 cttattgtaa ttttctctct gtccggatca tggatgtata accggtttcc ccgaacttta 43140
 tggagaacga cgaaatggtt catatcccag tgcagaatag atggaagatt aagacacctc 43200
 agatcttcgg gttccagacg aactgcacgt gatgataaat ggatggacgc tgcacattcg 43260
 atcaaccttt gtagegtcat tccctgaata cctatattga aacgttcccg taatgtcgat 43320
 aaatctgttt tcagtccatg ccagcaggca atcatagcca gacacgccag accgcattca 43380
 gctgattcgg tttgacggat aacgggtagt tgtttcctta ctttccagtt tattgattcc 43440
 attacagatt tcctttcatg ctccataggg gctctgtcag ccattcccat aaatgacgag 43500
 tatcaagggt gacgtctcct tccagagtca tgctgggtct tagcggttct ttttttccgt 43560
 atgcaaatat aatgtattt tcaggttcaa caataacgcg ataatgcctc tcgttttctt 43620
 tccatgtgac gggtgaaact ggtaataagt cggaaggagc cagagtcgta tgactgattt 43680
 tacgaattgt gccgtactgg ataccaaatt tctgataagg gaaggccgaa aacttcagag 43740
 ataccggtg acctggtcgg ataaaaccgg ctttctggct ggtagcataa agctcaattt 43800

-continued

gtaaagagc	attatcggga	atgagagtca	tgaccggttc	agatgctttc	acagactgcc	43860
cctgtttgat	cagtacagca	gcaatagtc	cggatactgg	agccctcagt	gtaaattttt	43920
cttgccggc	gagttcatcc	tggtgtgtt	ttagcacctg	caattgtctg	tcgagttctg	43980
ctttacggct	ttccctga	acaataagat	gatttagttc	atctttggct	gtgtccattg	44040
cagtatgtaa	ctggagaagc	ccctgacgct	gatcttcaac	gtttgttga	gcggcagaaa	44100
catcaatttg	tttctgttg	aattcgatat	ctgacacata	atgcgtacca	gccaaatttt	44160
tatagcgttc	catgacggat	atagccagtt	ctgcctgacg	ttcagcaagc	tgaagtcttt	44220
gttctgcact	tcttatttg	ggctcaagt	atatcatcct	ttgccgtatg	gcttctctgt	44280
gttgactatt	atctecgac	tcaaaggatt	gctgggagge	caacataata	tactgagtct	44340
tcagggaaat	actcatcgtt	gctaatgtgc	cagttccggt	accgttataa	tgttctccac	44400
ttatatgata	gagttgtgtc	cctgcagtta	cgtgttctcc	ttcggataca	gtcagttgtg	44460
ttacatatcc	tgcatattga	ggaattatth	ttaccagtc	tgatgagggc	atgacgatac	44520
ctgtaagatg	cgcttccctt	gtatagctac	cgtaatatat	gaatacagtc	agacttaaca	44580
taatgaataa	tgtaactggt	gcacatacgg	ataggctaaa	tgatgttggg	aaaataatgt	44640
caccatattc	agtgtcatta	tgatgttcta	ttgcttccct	tctgaatata	ttcattatth	44700
ttaatacaat	aagtaacctt	tccgtcaaca	agaggggttg	gttgaataat	attgatatth	44760
gatatacatc	tgacctgtgt	gatgttaaag	ttttatacta	taatataat	aacaataata	44820
caaagccggt	tattcccgca	tgtaacagca	ttggatagaa	aatccctta	ctgcaaatcc	44880
ttatattcaa	caataacatt	gacataataa	acagaataat	ttgatcagcc	acattataat	44940
actgccgatg	catcaggcag	aaaaataaag	atgtacacac	gcagggggta	aataattctt	45000
ttttataagt	cgtacataga	agaccgaata	gacatgttcg	gtaaacaatt	tcttcataat	45060
acggaactgt	caggaccagt	ataaatatth	caatccaatt	aagtgaagtt	gattcactat	45120
tgttcaaatt	gtctctataa	gcaaaaataa	gcagttgcat	gagagcaatc	acagcaaatg	45180
atattactaa	tagctttaat	gttttcgcat	ttgtctttat	gggtgattta	caacctggta	45240
ttcttcttaa	gtaaaaaata	taaaatgaag	ttgacattaa	aatttcagta	ataaagacaa	45300
aggaaaatgc	cagatccaaa	ccaatatatt	gtatggtgaa	tgccggtgtg	aatatcacia	45360
ctgttgatat	aacaacaagt	agaagaaacg	ctatcgcatt	atctttacta	tatttatata	45420
tgttatcatt	cataatgcta	tttcgaggag	attgttctta	ttttttctat	gatatagtcc	45480
atgaatcttg	ccgtggaaaa	aagagtgatc	agcatgacta	caatctttga	aaactcggaa	45540
ggtagtgaaa	accagtataa	atcaataaca	gaggagccac	tcaatagtgc	aatcccagt	45600
aacaaaccac	atataaagga	aagtaattta	ataaacatag	tagegcctc	cattatatct	45660
atttatcggg	tacatgttcc	gccaacatta	ttacctgaac	aactactgga	acttctctg	45720
ttaccacttc	catttccact	accatgatct	gagagacatt	gaccaacaac	ggctccacca	45780
atggtacctc	ttgccattcc	tatgggacct	cctttgatcg	caccaccaat	cattccacta	45840
aatacagcgt	tagegcattt	tacagtgtt	ggatcactat	aaatatgagt	tggtgcgth	45900
cgaccagtg	agttacgagc	cccactggaa	cggtcattac	ggggccacc	ttcaaagttg	45960
ctgtttgctg	ttcctccgct	gacaagcgtt	atctcatcta	aagttaattc	tcttatatth	46020
gccatatcat	atttcccta	tcggtgtgtt	gttatthtgt	gcgttcaaga	tagccaataa	46080
caaaaatgta	atgaaagtga	aattgtgtga	ttaaatgtaa	atatgtgaaa	aaattgtat	46140
gttttcgagg	ttgtgtaatt	acaaaaatat	catcgtgtga	agatataaaa	ccgttccagg	46200

-continued

gctggcaccg	cctctgttca	gtacatctcg	ttccagtcog	aacggttgtt	ttttctgat	46260
gaaaccagtt	tacaggacgc	cctgtcgggt	ggttattgtc	ctgtgggagc	gttaacaggt	46320
ttatattggc	ttttctgct	ctcactgata	tctgattttc	ctcttttgtt	tcaggtgggt	46380
ctggtctggt	cagcgtgata	tagcgaattc	gtcgtctctc	cagtgtggtc	gttttaagcg	46440
tattcacccg	tgtttccac	aaggcacttt	cacgtgcggt	gatatccgtg	tcgtactctt	46500
ccagcattgc	catagctgcc	tgacgtcctg	caatgcggtg	ctggaatgta	tccacgatcg	46560
tgtgcggctc	tgtgcgaatt	tttctgtctt	ttctggaggg	ttttgcagtc	aggacgcca	46620
tgatggcact	gacattttcc	ggtgacggga	ttcgcggttg	agctgtacgg	ggaacaagac	46680
ggcggagacg	gtccaggcgt	ggcgcattca	cgctgatata	cctgtttata	acaacgggat	46740
cgctgctgca	gcttttctca	tcgtcagggg	tgaagaatga	tgctgatggt	acggtttctc	46800
cccggaatat	agaaaagaac	tcgccaggat	gaagttcaat	caactcctga	acatctatct	46860
tactttccat	caggatgctg	atgtgtgggc	tgtcaatcca	tgattcacca	aatatgccgt	46920
cctgacgctg	caggttgttc	atcctcgcgc	tggtctcttc	accggcggcg	cttttcagcg	46980
ttctggccgt	actgccctcg	ctgacaatcc	tgccggcaaa	ttttgtcccc	gtgttctgca	47040
tcagtgttgc	agtattcgtg	gctgttgtct	gtccttctat	acgttctctg	tcctgtgcca	47100
tcaaaatcag	agcaaatcc	agtgaacgca	cctgagtggc	ttccacagca	atacgggtccg	47160
tatagtatgc	ccccacttca	tcaaggaaac	acagataagg	gaaacgcccc	ttatattttt	47220
tgacttccag	tgcatcggaa	tcagttcctt	cgaggcggta	gccccaatca	cgggcgagaa	47280
tcatactttt	ctgggtgata	aacattcgtc	ccagagcaga	cgttgtatgc	gctgatgtat	47340
ccagagcggg	gatcattacc	atcagaatcc	tgtcgtctg	aatgctgtca	cggatatacg	47400
tatcacogga	atcttcagca	aaaatatccc	cgaatgcttc	cgtgaatgtg	ctgaaagttt	47460
cagaaaactg	cccggagaga	taagcatggt	gttttctggg	ttcttccgtc	caggctgatg	47520
gtgtcctgac	cagcgacagg	tcgaaaccgg	gaacgtcctg	aaggtagtta	cgtaatggtg	47580
cgatagcttc	ttccggccac	tgatcatcga	ggccatgaca	gtaaagtttg	gccattcctt	47640
cgagagtcac	atgttcacgg	agcatctgca	gcgacattgt	tttgccttcg	cgcacacacc	47700
agaatttagt	accaaatacc	agtgccttgt	tcatggcaat	ggcccgggac	tgccactcgc	47760
ccccctggac	gttctggggc	agcattgact	gcattgtctc	cgctgtgaat	gcctcagtgc	47820
tgtaacagaa	gggattccag	gtatttgact	gaggacgcgt	ttttcacca	ctcagaatga	47880
tttactgcg	ggattttcct	ccgttcatga	agttgatgac	ttccacatcg	tcttcacgac	47940
caaagcgtct	ggccagatac	cagatcgctc	ttgccgtatc	attctgtgcc	ttgccatcga	48000
caagggtgaa	tcctcttgcc	cagcaaagcg	ggttaatcgc	ccaggcaaag	atggtttccg	48060
ttttaccccc	accgggtggtg	gcgaaaaaca	ttatatggcg	ggtcagatcg	tccatactca	48120
gccacaactc	ccgacctata	tccctgacgc	gttgataaacc	aacataaaat	atgccgctgg	48180
ccggtgactc	caggatgacc	tcatactgaa	acagagttgg	ccagaagctg	aaaaggcttc	48240
ttttaatcat	tctgtcctgt	gacgggtcag	cacattccag	cgatcatggc	atacgaagag	48300
ggcagcgcga	tcgctgcaga	ctaaatacca	gcacgttat	cagtgtgaac	aacagacatg	48360
ccggtaatgc	aagtggccag	ataaaactgg	ccacaagact	tgccaccagg	caaaagccat	48420
agatattgag	actctggagt	gcattccaga	caggatttcc	ccaggctgta	cggtgtaaaa	48480
gctcgggggt	aacgcgatgt	tcactcatgg	ccagactcgc	tgctcggttg	tttcaggaat	48540

-continued

aaattaagcg	tgccagtttc	ctgcagaatt	ccagtaggca	gatgccagcc	cgtgtcggac	48600
agtacccatg	gggtaccggc	aatccgaac	ttacggaagg	cgacattggt	aacatcaatc	48660
gcagctctgg	ccgctttcag	gcatgtttca	tctgcaggcg	ttgtttcttc	tgatggcgtc	48720
atcattccgt	tatctgcgga	atacagtcgg	tgccagccgg	cagcacgttt	ctgagcatct	48780
ttttcacaca	gcagtggtgc	cacacggtcg	gtggattcct	ctccaccaat	aactgaaacc	48840
gggtagataa	cgacattgaa	ggcgctggcc	aggcgtttta	aggctggctc	cagaagtctg	48900
cagttaggac	aggcaggatc	gagaaatgcg	taaagggttc	gttcatgacc	ggatgacagg	48960
ttgacggtaa	acattccccg	atcggcggtc	cgcttcagaa	cagcagccag	attatgtcgg	49020
gcagctgceg	cttccggatt	tttgcttggtg	agtgttttat	ccggtacctg	gacgtctttt	49080
ttcggggtaa	ccgggagttg	aatgccttca	tttaatggca	cggtgtgatt	caggtgaggg	49140
gggagcagtc	gtggctcacc	tgccgtctgt	actgcttcag	gcgttgatc	atcccagaat	49200
acacgatcaa	catagcggaa	cagagagacg	gcaatcgttg	ccattacgaa	cagtacaacg	49260
ctggcgatta	ttgcacggaa	caaaggcggt	ctgctgaagc	ggcgttccat	caggtattca	49320
aggcgcagac	aggaatcaat	agctgtaagt	atctggtcag	cgttatgctc	ctgcttgtea	49380
atcaggacgg	tttctctgtt	acgagtgcc	atggcgtcaa	aggctatatg	aatcagttga	49440
ttgtttcgtg	ttaccagccc	tgacagggca	tcccggtgaa	ggacggcaat	aatttctgtc	49500
ctgctatccg	gccagattgc	ctgcacggaa	atatgttttg	caatgcgtgt	tgcaaagtac	49560
tcgattgtca	ttttcagttc	tccggataat	cagaattcgt	tgtctgtagc	aggtgtgceg	49620
ggcaggatgt	cgtcggtgag	ggaccagttg	gtcagaatgc	ggcgtttccg	gtcgcgatct	49680
ggttggtggt	catcccagat	aagaccgaga	ctgagcatat	cccgccgtaa	gccttcacc	49740
gcttcatcaa	cacaggggtc	agggcagggg	aggccttca	gcatggcttc	ggcctctgca	49800
cgtgcaacgg	ccaccacgcc	agcgccttca	ataaatcctt	tcgtggtatt	ggcgcggtgt	49860
aatgcataaa	acagcgttct	gtccacgcct	ttcagccaaa	tccagttggg	tggcgtaagc	49920
cgcaggtcat	gtgcatacag	ccagaccagc	ccactgcgga	cgtagcgatg	ttgcttcagc	49980
cattgctgtg	ctccatcgct	tttaatcact	cttttgaatg	cagatttggc	cagtgaataa	50040
actggggtac	agaatttccc	actgtcccgt	ttgcttttaa	ttctgcatga	gaggttcagt	50100
gtatccatga	gctttaatgc	tgccctacga	tcatccagga	aatactgaag	gccaaatatg	50160
gcaaagagcg	ctttttcatg	tggtgccatg	tctttccagg	acgttaaagg	tttaccacac	50220
tggtgccatga	aacatcgtct	tgagctgca	acatcgagct	gcatattggt	gatgagagta	50280
tgctgctcga	caaatgcttc	cggggtgaga	gcaaccgcc	gttcaggtcg	tttgccacca	50340
tgaaagagtt	tttccggtc	accatctgcc	agtacagggg	cgatagcagg	ggacaacgaa	50400
gcaaagatgt	gtggcagtcg	ggtaatatct	actggtctgc	gggtgaaacg	actttgtccc	50460
ggatggtgat	accactccca	caaacaccag	agtgtcacag	gtaagaggta	catccacaga	50520
atacctatgg	tctgctccat	gacgttaacc	cactggctat	agcttatggt	ggcggcgttg	50580
ttaccggtca	tggcaagcag	gttgatcgt	ggtgctgcat	agttatgaaa	tgggtccccag	50640
tcaaccagtc	cccataaggt	atgaagaatc	aggcagctgg	cgtaaaccac	ttccggcaag	50700
aataaccata	taacgaatag	cagcaggata	agaaggacac	caacagcgcc	ccatatctgc	50760
ataggatctt	ctgcgacagg	ctgtcgattg	taagacatga	caaagtctcc	atctctggaa	50820
tttaaatcaa	acggaaaggt	taaaaattta	tttgacggcg	ataagagcta	accagaggaa	50880
ttagccgtgc	gataaaagga	ttggtgcaga	tacgaaagtc	gttagaatag	ctgcgggcgc	50940

-continued

ttgaggctgt atgccgaaag cgttttgtgg acggtataca gcagaaagcc cctggagatt 51000
 tttttatcaa tcaaccaagg gctctactgt aatgcttoga caacattata gtagcccgat 51060
 aaccgccgta aggcaatgga ggggctatga tgccacagcg aacattttta atgatgttga 51120
 tcgtcgtctg tgtgacgatt ctgtgttttg tctggatggg gagggattcg ctttgccgat 51180
 tccggctcca gcagggaaac acagtgcttg tggcaacggt agcctacgaa gttaaacggt 51240
 aacgggcaac acggcggcag gttttctgcc gccgctttgt tgccaaggct gacctcattg 51300
 cgccctttct tcttcaatga agcgtatccg gtattgtttc atttcccctg aagccgatta 51360
 gctccagccg aatgcctttg ccatcggggg ccacgttctg catttcgcag ataccacgtc 51420
 gggatcatgag tgtgaaggct gtcattgcca gcatggctaa cgcattttcc tcgcttccgc 51480
 tgcgtttctc gagagcatcg gcaatttctt ctatgctccc cacctgaaag caagagtcga 51540
 attctttact ccacttttct gacatcggat tttctctctg tatttatggg tagttatcga 51600
 actgaatgtg ccagtttttt caggagacga caaagttgag atggctgatt caggttcaga 51660
 gcatgagttt ccccggtgtg acgggcatgg cggggcggat tttgcagata caaaagacgt 51720
 aaaaaaccg actggtgagg ccggcttttt tactgttacg ctacaaagt gatgactctg 51780
 accagaaaag agctgtctat aactgacgct aaaaatgata atttgttcta cctgattaat 51840
 gcaacatgcc ataagtttac gggaaaggct gaccacctga tattgttgca aaatacgaaa 51900
 gtcgtcaaaa tcgcggtggg gagcttgagg ctgtaagctg aaagttgaaa gcgtttgtga 51960
 aagcccaggg agattgttct atcaatcaac caagggtct actgtaatgc ctagacaaca 52020
 ttatagtagc ccgctgacgt cctccacgcc agagggagct tgctacgtac agcttgctcg 52080
 tactcagaag taataaatgt aaaaaaacg actgatgagg tcggttttct tactgttccg 52140
 ttacaaagt ggtggccctg actggaggaa atctcttttc aactaacgtt cttataatag 52200
 tgttctgttc atttgataac aaccaccctt ataatccgca ggttaacact gtcgcgcgac 52260
 acttctgtcg tgatgaagg aaccagaaca tgagtcttcc cgggtgaaca ggcattggtg 52320
 ggcgatttg cagaaacaac agatgtaaaa aaaccgactg gtgaggtcgg cttttttact 52380
 gttccgctac agagttggtt gctctggacg ggaaaagaca gtctgtatct aacataatca 52440
 attctatgct ttgtcccaca ctatgtcaaa aatcctgcta atcaagtagt atacaaaatg 52500
 ttagctctac tgattgtctg agttcgacaa ctgacggatt tgtaagtcc tggtcgggat 52560
 aacaggtggg gctgcttccg gtgctctggg cggagtgagg cagtctgtat ctaacaatag 52620
 aggcaaccgt agtgacaggc agcccatgag taagctgagg tgtttcgtc ccttatcaag 52680
 ggaaaacgga tgattaatct gttaatcatc gttctcaggg cagtgggtgc cgttgcaaac 52740
 gcgctgattg ctgttctgga actgatccgg gaacttgctg accgataagc ccggaaacgt 52800
 aactaagggc agggagttac cgcttctgc ccttaacaa aaagagatct cacgttaaaa 52860
 atttgtacc ttccttaact tccagtgcct gctcctttga gtcaaacatc agtcttgttt 52920
 ttccgggaac accccatgaa atgtattcga catctatcca ccattttcca tattcttcat 52980
 atggcccgga tattactttt ttgacaaagg cgtctaccag attcattgtt ttttcctttt 53040
 tattttgaaa ataattaatg ccagagcaca gcgaaaataa tgaatgact ggctgtgata 53100
 attgcgattt tctcccatat gatatttttc tcatgggagt ttctgaggag attatttctt 53160
 cgcattggaa tatattggat atgtttatc atgaataaga gcaggtgtgg gatttctctg 53220
 tcttttgtt ggcgttattt tacatgcttc cagacagaag ccggtacttt gtctgacaat 53280

-continued

ttgttcattg	tcagttccgc	aaggcgatga	tcaactgcag	agttgaatgc	ttctatttta	53340
tccgagacca	aagtgccttg	gttttttagca	ataattttct	caagtgtctt	taagctggaa	53400
cagcgacgta	attgatataa	ccattcctgt	tttgtttttg	ccataaatag	gtccttgggt	53460
ttatttaata	cggcataagc	tatgtggtgt	tgcaaacaaa	agccggctca	tctgaaccgg	53520
cagttatgga	ggctgcttat	cttaaaatac	ttcagctaca	ggcatacctg	caatctgctc	53580
ccactcotta	cgcttttctt	gaatcaggcg	aggaaagtcg	acagggtaat	cgtatcctct	53640
ttctgccatt	gcgtgtaatg	tgtttgcaat	agaacgagca	gagttaacac	caatagacaa	53700
ttctaacatt	ggcatattga	catactttgt	gtgtatttcc	atacagtttt	ctcttactac	53760
tgcccggtg	aaattatcaa	tatcaatgcc	aatgacatct	aatgttttat	tggggtaaag	53820
ccgaatatat	aacgcagtac	cttttttgat	atcaattccg	aaatataatg	atgatattga	53880
tttgtgttcg	taagatgggt	ctggatcgaa	tgcatcatga	cattcggctt	ttatctgttc	53940
taagatatta	tttatgattg	ctcttttctt	tcttcttctt	ttatatccgg	agtatagtag	54000
taatccagtt	gggattactg	ctagtcccca	actggtaggt	gtattccaaa	tgattagtaa	54060
tgggacggcg	aaaataatgt	agaaaagtgc	gaatgcgatc	acgcataatt	cttttttaga	54120
atgggtgccg	ccacggtttg	catatgctcc	aatcattata	tatgacctcc	ataaacactt	54180
tttgatattt	taatctctcc	aagtgtatat	ggcaagtcac	atattaagtt	attatccctt	54240
tattccatcc	ttattgttgt	cgttattcat	tcttttaatt	tgctcctctc	ttatattagg	54300
tgctgtctct	atgtttctat	tgctgccagc	aaaaatctct	tttattgaac	cagccatatt	54360
gccaagcgtg	tttacaccat	cacgtcctcc	taggaaatta	attacatggt	ctgggaggta	54420
tgcttgtaag	gcaaatgctg	cggtacaat	ggttggtgca	cttctagcat	aaagaagtaa	54480
gaaacctgcg	aggctaaata	tacctgtaaa	tgaacttatt	tgtacattgg	tcagtgcagc	54540
accgaataaa	aagttaata	tagtacctat	tgctataatg	gctacagagg	caaaaaagaa	54600
tccgaaaacc	atgataggag	gtcttatcat	gctgtctatt	aaatataat	aaccgtaggc	54660
agcacgactc	cctctgtcct	gtgaggtgcc	tagatgagtt	gccccccaca	gagggtccagc	54720
tgtacatccg	attaatacac	taatgacca	gttaccaatc	ccagtcaccc	agaaaataaa	54780
cgaataaat	ggtaataaaa	tagataaaga	gaatcctgca	caaacagca	gtagtaacag	54840
aaagtatacg	gggggcgcta	aggcctcaag	taaggcattt	agtgttgaaa	tagcacttgt	54900
cgtaaatct	atgaatttac	caaatataga	actcccagtt	cctgaagtaa	taactctagc	54960
agatgtataa	gtaatccaaa	taccctctgc	agcgaccata	gttttatcac	caatattttt	55020
catttttatc	agtggattaa	cttgattgct	acttgtacct	gaatcagtc	actcgggtggc	55080
aatattgttc	gtaagccatt	gccccaaact	ctctgtgggc	ttgattaaag	catcttgtgg	55140
cgtgcttggt	tttgaaagta	gttgttcgtc	tgctgaagtt	atagtaccta	aagggtgggt	55200
ataagttgaa	ttctgcaatt	gggtccttga	tgccccata	acagcactaa	ataaatcagt	55260
gtcgccaact	tccccagtg	atgacattga	agttacagct	ggagctctgt	cagccagctc	55320
tgccagacgc	tggtagcag	tggcaaaggt	ctgataccac	gcgccaagcg	ttaccatcc	55380
ataggttgtg	agataagact	tgagagcttc	tttctggat	tgttctccgt	tatcaatagg	55440
tagcgatttt	tgtacagcac	gctcactctc	gtcggctgct	ctctgaatcc	gtgtctcgat	55500
atccggcaat	gttccgttgc	cagaatttct	ttttccaga	aatgttgta	caaacctact	55560
ggcagcgttg	tccatgtcgc	taatcatatt	atccatggct	gcacgttggt	ctgagataac	55620
accgctgtat	tcgtttttac	tgaagggtt	aaagaatttt	ccaatcgtcg	attgatctgt	55680

-continued

tgttccgttt ccttctactg acaggctggc tgaaccacag ataccgctgc cattggatac 55740
 cgtgacagtg taattaccac tggcggtttt agctgattct gtcacagtg aagtcgagga 55800
 tttggccgctc tgattaaaat catttagtcc tgcgttaacc gcatacttac acagttccat 55860
 ttcaaaaatg ccacgcgctg ctgttcgtgt ggatgcctga actggctgta cagtcattga 55920
 ataaccattt gcgatattat cagcggcaag ttgcaccatc acattggcgg acccaacccc 55980
 cattatcgat gcgccccata acataatgag ctgagcgata ctccagccat ttccggttgg 56040
 aacgatcatc agaaaacctg caacgacact cagtgtgccg acgatatcgc gtccgggtgct 56100
 gaatacctgt ccctgatgcc ccgaacgcac aacatgacgg ataccaatga acataaacca 56160
 gacaacggca agtacggcga tgatactggt gaacgccccg aacatgcttc cgatcagagt 56220
 gggggcgctg gttgacagtg gattgggtgac tacatcacccg aatatacgtga ccagcgctg 56280
 gcgggacaga tcgtcaggat tgggtggcagc agacacaata tctgatagg tcaactgaagc 56340
 cattgccggc agtgaggata tagcaaggcc tgcacagagt gcgcaagta aaattttcac 56400
 agtaactccg gaatagaatt gcgtatgggc aaaggccaca caggatttaa ttaaggggga 56460
 tggcgacatg ccagtgttac tggcatctgg acgtgatcag tattgtttac tggttacggc 56520
 aattaatgtg gcattgcgcc agccattgcg gtcgttcaga aaatcacgga aagtcccctg 56580
 ctccgggttcg ctgacttttc gttcatgcaa ctgccagagg cggatgtaa caatcagtgc 56640
 tctggaagca caaagagcga cgctgacag tatcaacaca agagtgctga tggcgcgta 56700
 cagagtcgta agaggaatg aagaggcggc aaagagcata ccaactgagaa acaaagcgat 56760
 ggccagcaga ctccagcaac agaatcgcca tactgttctg cgccggcgga aacgacgatc 56820
 cagatcgtct actgacatat ggctggcctg cagagcttct tcccacgtga ggtggagtgt 56880
 cgctttttta ttattacct gacgaaatct gtccagcctg cgtttttgtt gttccagcat 56940
 atgctgtaca gaattcgta tcaggcgagt ctccatcaga ggaacaaaaa tgtaataat 57000
 ccccgggtg gctatgcggg ttatggatgg tgattttttg acgtttttcg tctggtctga 57060
 attttccggt aacttattca ttttttcagt cctgttctga cgtcagcttt caacgtgcgt 57120
 ttgctgatt gattgttttc tcaaggctac cgagttgttt ttcataatac tggcgggcag 57180
 tcagagccag ttgctggcca gagataacat taccctggcg gatctgttct ttcagatcgt 57240
 tcagctgcca gttcatttgc gcagtgatc ttaccagttc acggagcagg ttatccccct 57300
 gcatttctg taaatccacc aggtatgctg tgttggcgta gcgccggcca gcctcaaaag 57360
 cttcaaaactc acgggtactc atatatcccc gtgcttttgc ttctgggtgaa gccacctggt 57420
 cgaagtaagc ggccgctgag tctgactgca gtgtttcagc cagtgcctta cgtgtgcttt 57480
 cattagcgt gctgtcagca atcaacgtca gttggggatt cgacgcagaa tcaatgatgc 57540
 cgttgattc gttctggagt ccgacgtagg ttcgcccact ctgggtattc acttctcctt 57600
 taccagagc acgaccggca gagggcgagg aagtgttttt catgtaagca gtcgctgcat 57660
 ctatttgctt ctgatcccat gtcagtgccg cagggtgtgc cgctgtacct gcgccgtggt 57720
 aaatcgagcg tacctgactg tctccacctg gtatttcgcc cacagaagga caaacggcgg 57780
 ttctccaaa acgtgcatat tctgcttctg tacagtaact ggcgtgatg gccgcgcat 57840
 cataagcttc ccgcacggga gagtttctg cgctggccag acggtcgagg atgctacgg 57900
 tgctcacacc gccaccttca ctgagttttg aggtgcgga tgctgaggca cttttgcttt 57960
 ctgttgcaat ccctgatgcg gattcactgc agatggagtc tggcacggtg aagcttttcc 58020

-continued

gtgcctctc	gagcgctga	gtttcattac	tgaaaatcat	ctgctgacgt	gtcgctgtc	58080
cgttctgggc	aatgacactt	gccagctttt	cagagtctcg	attgatagcg	gtaccctggg	58140
ctgtctgggt	actcagtatg	tactcagca	cacctttgat	ggcctccatt	ctggggacga	58200
cctgctgttc	aacgggacgg	ctggcgacga	cggtgactga	ataagcatga	gcctgggatg	58260
ccgttccatt	caggatagct	ataagggctg	cgagtaatgt	ttttctttgc	attttattgt	58320
ctcctgctcg	gggtggagca	caaggtcagg	aaggctgtcg	tattttctgt	cttcaggtag	58380
tggggccagt	gggaaacact	gatatcgctt	ggtgatataa	cctttctctg	tccggttatc	58440
gatgatgctg	aaagaacgac	gtctgacgcg	ccgtaagggtg	gaagggtcag	tatccataac	58500
aggccagtca	ccggcactca	gtgccggcgt	tccgggaacg	gatggccata	accaggatc	58560
atcggacatc	agcgaagtca	gcggtgaagg	gagtatccac	tggatgacat	gctgaacgtc	58620
gaatggtgct	tcatccggga	cagaaacctg	ccatattgcc	gttggtatca	gctcatctgt	58680
gctggacggc	aacaacagcc	gcatgcctgt	aacctttccc	tgtgttctgg	catccgaggc	58740
gtatatcact	ctgggattgg	gggccggatg	taacctgaag	acacgtgacg	gcagagtgaa	58800
tgagaaactg	tcacctttta	cctcaagttt	tttaagaaat	acctgccctc	tggcaggctc	58860
ccggcagcgt	ggggtgatat	gaattgtaca	catcagagat	tgtatccctg	ttttcggatg	58920
agctccgagg	ccagttcttc	aataacattg	tactgttat	gttgccccgc	ccggtgctca	58980
attaatgacg	ttgcagaacc	tctggggaag	ttttcggcca	gaatcttacg	tgcccgaact	59040
gaacctaaact	tatttgtcag	tgttttacgc	aggcactgt	cttttggcga	tgagttcagc	59100
gcccatagct	ccagtggacc	gacggtaaata	ttgagtattc	tcgcaagcgt	gccacttttt	59160
acctgaata	ctcccagaac	aggaacacca	ctaccatctg	gtgccgggcc	ttccggcatt	59220
ttcaggaagc	gtttcagcat	aaattcagga	acgttgaagt	tatccctcag	tacggggata	59280
tcttcggggt	tgtagcgcag	taaccagaga	gtatttctg	acttaagaac	gctttccggg	59340
tagtccctca	gatactgctg	actcagaacc	gtgcggatag	caaacttgcg	ttgctcacgc	59400
tcttgggtat	ccagattttc	ccagatgaag	tcaatgcccc	gggcgttatg	cagttcatca	59460
taaacttttg	tcttaacctc	ctgatcaagt	tggtaatac	gtttaagagc	gatttcatgg	59520
tattccogtg	gaagctgctt	taacacttca	tcctgtatt	gtggcagggt	gaagtcacca	59580
ccggcgatct	gacctgcaag	caggtacatg	atgccggtt	taagcctgcc	tgcaggcgtt	59640
ttgtcaccgg	caacattatt	cagatcgaca	gcgatgacct	gggtttccgg	gttgatcata	59700
aaccgggtat	accgggatat	catggggtag	tcgttatgct	cctgctcgag	cgcgggcgcg	59760
atgtagtcca	gcagaagttc	gtttgaacca	tcacgctgaa	cagtaccgaa	aacatccctg	59820
agactgggat	ggcccagcat	cgaggacact	tcgggaagct	ggggcattgc	ctgataatgt	59880
gcccgtgag	ccgcatgat	ataccggca	ttgtggagca	tatcccgac	ttcgaaccag	59940
gttgatctgg	cccaccaggt	tgcacatgt	ttttcataca	gtcccagtc	ctgcagtgct	60000
gaatccacca	gttcttccgt	tgaggcgcg	taaagtccg	gattattttc	accgtactct	60060
ttaaaagcca	gctcgataag	ctggttgata	atgtgtcggg	tgtctccggg	gttacagggt	60120
tgaccggtac	cggtatcgac	acagagagca	cacagcaccg	atgacatgaa	attcttttcc	60180
ggcgtaatag	gctttttagc	gccgtacatc	acgtcaaaaa	ggttacgggt	gtattccgga	60240
tcattgctca	gaataatacc	gacagcttcg	tcttttcttt	ccggaggaag	actgtcgcga	60300
ataagctgaa	ccagtcctg	agcactgtat	cccttatcga	tataggcaat	gaagggcagg	60360
ttttctgag	cagatgatat	ctgtatttcc	gacaatgtat	taatcagaac	tgatttacc	60420

-continued

```

agtccccgat cgccctggtgc gagttctgta tgtttatttt gttgggatga cgccagacca 60480
acctcaattg cgggaaccgtc ttctgtatgt aacataagat tccctttacc tcgccagaca 60540
gagcctgccc tgtaagcgg gaaaagcgg atggcatgtg acaacggggg atacagggga 60600
accgggccgg agcctccgga tgccgcgaga atggtattca cccaggcgcg tcggggatcg 60660
ccaaatggtg tcgtggtgcc acatacgccc cagccttcaa tggctgattt cagaatggcc 60720
tggtttcgtg tgcataattc acgtgttttt cccacgtgg aggccatgat ggtcattatg 60780
cagacaggtt ctttttcac cgttgccgcc agggccataa cggattcata cattggacga 60840
acggcagaaa tgaagctgct gtaagtcaga agcgttttct tcagattaag agccttcac 60900
ccgccgggca tcagatccat tctgatgcgc caggggactg cgccggggac ggcacggacc 60960
agtccgtaa acgtctgcag attttgcgga ggtaaagtaa tcgataccat tccgtgccag 61020
agtccgccc cctgaaccag gttgcctgt gtggtcacct gagtggtgaa taactgcaa 61080
tgcaatgaag gagcatgtag tacggattca tcgtcagtc agcgatatcc cgctggctgg 61140
gcatcttcag gcaggtgggg ttgccagtta cgcggtgtgc tgtgcccgttc tgtctgacga 61200
cgtatttcac gcccgacctc gtgtatatcc agtagccgga gaatcaggcc atcagatgaa 61260
tgtctcagtg cctgttcac attatcaaga aaagcttctg ggcggatttt cagtgcagat 61320
aaggtccact gccaggggga ctgggcaaag cgtgctttcg gtaccgcttc agccagtctt 61380
ctgacaagct catcatgggc ggtgcgatcg ctggtgctga taaggctcggg tccactccag 61440
atgccagcc agcaacgctc ccggaccagc catggggaca gtggtgtgac tttctcatcg 61500
accacatcct gtaactggat acctgtatta gccagtgagc gcttttgtgg ggcgaccatg 61560
tcttogattt cttctttccc catgtcagga tcacgctcaa aaacgaagct gattttatga 61620
ccgctgtttt tatatgccgt attcaggctg tcaactcatgc tggatgatcag cgattccagt 61680
gaacctgggc cagtctggtc ggatgcttca tccatttccc tgaaagcacc gctgacttca 61740
aagacagaga gatattctcc acgctttgtg gctgcaatat agggcgaatt cagccatggg 61800
cgacgttcac gatcctgtct gtccagacca attacagtac gtaaategca atactcaaca 61860
aaactgcttg cgacagagaa acgggatagc gtgttcagac agtcttcgat agtgaagatt 61920
aaacggttta tgttcatagg tgagggaaact ccggacttac aggaggaggg tttgtgcagt 61980
ttgatTTTTT taatgccacc ccgctgtgga gtggcatgaa gaaaaatcaa tcaacgtatt 62040
cttttttgat gaatgaatct ggtgtcagaa tcagggcaat cccgttcatt ttttcacgca 62100
ggggcgaaac accggaaggt ggatagcgac gaaaaacgtc agcgaaatcg gccgggcgga 62160
aactgcggaa tttatcctca accgccagtc tgttttgcac cagtgcagag agcgttccc 62220
gtccccgccc gaccgggaaac ttatcattac tgaaaacttc ctgtaatgaa cgacgggtaa 62280
gggccaacgac cgtggatgga tgaaggctcg gtagccacac cataacgccc tgtgctgcgg 62340
cataaccatt cagtgaatgc caggcgtggc agaaagcaca taagctgtaa ggccggccgt 62400
cttcatgaaa cagttcctgc tctttctctg acaacgactc tgtactggtg atttcagctt 62460
tctgtacatg gcggagtgaa agacgtctgg cagacagacg ggcctgctca agcgcctgtt 62520
cagcggcttt tactgccgtg ttgtactttt ccttttcgcc ggttgcgact ggttcaccac 62580
gcttttttaa cttatccaga tgttctgtgg ccttattaag acgaactcgt gtgtcactga 62640
ttgtgtcggg aagctgtctg agtggccatg agtcatccag tctgaaacgg tgctgacgt 62700
tttgccggca gcagatacat cgaccgggcg ttgttaattc cggttccggt aacagtggct 62760

```

-continued

cctgtgatg	aaccacatca	atctctggaa	agggatacaa	ccacaagtct	ttaatgctgt	62820
gttgcacgag	caggctccgt	actgggtgtaa	cgtttcacgg	cttccagaat	gatgtttgcg	62880
atctcatcgg	aacagcattc	tgcaaaaatg	aattcctgat	cgtcccgact	gtcgtgggca	62940
atcacattgc	cgttttctgt	tcgtcgtaac	gttatgtgct	ccgggctcca	ggcagacata	63000
tgtgcctcct	tgtattgccg	aacaggaagg	gcaccggata	aatgccagtg	ccctggacaa	63060
gattagccaa	tggaaattgt	ggaaatcccc	agctgtttct	ggctgcgact	catcatttca	63120
ggtcggcgga	caagtagcgc	cccaatgacg	atagatacaa	tgcaaccagc	cagtcccatc	63180
cccccttgtt	tcccactttt	tttcaggcca	atcaggcccc	cgagaaacag	aattacgccg	63240
atgaactgcg	caatagtcag	tgatgatgac	tgtgctgttt	tggcaccttg	ttcgacattg	63300
cgaaccatat	cggcaagatc	tccatcggca	agaacggctt	tgggcagcaa	catcatggga	63360
atgagcagca	ggaacttagt	cagtttgctc	cggcatgaca	ttacaaacag	ttgtgcgtgg	63420
ataaatgceg	cgtacagacg	ggccgctacg	acacgaatac	gtgacatagt	ttctccttaa	63480
atggatatat	cagtggttta	tatgaagggtg	aaaaaatca	gaagacgatt	ccaatgcttg	63540
ccagcagggc	attgaggaca	cgatcgataa	agaccagcag	gacgccggca	ataaatttga	63600
cgtttccctt	actgacggat	tcaactggcac	tcagtgcggg	atgtccatcg	agtccggcct	63660
tgcgccagat	ggatatcccc	ttcattacaa	atccaacacc	ggccagcttg	gccagcgaca	63720
gaactgcatt	tgctgcgcca	gcagcagcgc	caaacgtctg	aggttgtaca	tatgcaatcg	63780
ggccaaatga	gtcagccctg	aatcccattt	gtacgcctcc	ggcgtaatc	attgccggga	63840
gtgatacgag	catgcagctg	gttaacatcc	ccgcaataaa	ttttccggga	gacattttta	63900
ccggaccggc	tgaacgggcg	cgggcaaaaca	gggtaatcat	gctgatcacc	ccgatgaatt	63960
ctcccaggt	aaacaggaaa	tccattccgg	cactgaaaat	actgctggca	aagttctcaa	64020
tggcggtcag	ggcatccatg	ttcatcagcg	taacgtccct	gcactggtga	tgatgggccg	64080
ggtcgtcgga	tcaatccgct	ggatcaccac	attgcccaga	gtctgacctt	ctctgacagc	64140
ccaggtacta	ccctgccagc	gaatccaggc	catgccagtt	tccatcgaca	tgattttcat	64200
tccgttaagt	acagacgacg	tttttttctt	tgctggatgc	gggtgtggaag	aggattcggg	64260
gacgcttttc	tgtgtcatca	ttccgttcag	gtggctccgg	atatcatcca	gctgacggcg	64320
cgtttcctgt	gcgtattctt	catccttttt	tatagcttcg	cccagcttgt	taatgctgtc	64380
gtgaagcata	ttcagtgttg	cctgaatfff	ttcatcggcg	ttatccagct	ctgtttttac	64440
atcccgggca	agctggetca	tatcttctcc	tgtccggaca	gtcatggtct	cagtggactg	64500
aacggaagg	gatgattctt	gtgtggtttg	ccaggctctg	acgccagcat	ccgcatcatt	64560
aaacggaggc	atgcctgttt	ccgatgggtg	tctcaggaac	agataccata	tggtgcgag	64620
caatcagact	gcacatagcc	cccatgttgc	tacagatc	ccccagacgg	aacgtttcca	64680
gaaaggggcg	ggtttctctt	cgggttcacc	gaagctgccg	gtttcatcta	tttctgtttc	64740
aggtttcatt	atggtgtctc	cggttgttca	tcataccgac	gttgcatcac	agcttttctt	64800
tgctccatgg	ctgtctgcat	tcgtgcctgc	gagcgttggtg	ccgtctgtga	tgtacgatta	64860
actgaagggg	aaatgccact	ggaaagggaa	gatgacctgg	cgctgtttgt	cattaccggg	64920
tcaacaaaca	gaattgatac	gacttcatgc	tgatacactt	ctacctgttt	atagggctca	64980
ctttctgcct	ggcgggttaa	tatctgactt	cctctttccg	ccataccacc	ggcaataacg	65040
cccgaacag	cttcaccact	gggcattccc	acgcgtccgg	taaccgtgcc	atagttaccc	65100
tgaataacct	gcgtgttggc	atctttataa	agtgtgcaa	tactgccac	acctcctaac	65160

-continued

actgacggca gaatgatatg tttaaaccag cgtgtattca cattgctggc cacggatgac 65220
atcaggttgt cttcccgttg agcatatgca ttgaccttaa ggtccatgcc gttccagctc 65280
atccggtcga aatggatctc cacgccgta cccaccagtt tgactcccgg actgaacagc 65340
gttgcccctg cccagggggc agcgggaatg gttgcgataa ccttggatga cgggttatca 65400
gaatccactg cagtatcaat atatgccggg atacgggtca gagcaggtat cagttgtatc 65460
cctttttctg ctacaggcgt ggacaggctg gcattctgta atgcgaattg ctgcgtagca 65520
ttctgcccctg ttgtttctgc cggagattta ttccacatag tcgttgctat ggttggtgta 65580
ctaccggcag gatgctgatc ttttattctt acaatcagct tttgcagccg ctccatacgt 65640
ttttcaactg ctgctcgatc ctctgtggt gtgccggaag cctggcgatg agcatagttt 65700
tccggttttg ctgcaggctg ttgttgcttt tccggagtgt ccggaatc aagcccctgt 65760
ggaagactgg caatgaacgt ctgattattg cgggctgcag ctgcggcccc tcgttcatta 65820
tccgctctta acagttcacg atagtgaggc gtttcggtaa cgctgcgcgt tccgccgctt 65880
gctgcaactg taatgttac ggctgactgc atatcgctgt tactccctga tagtttgaa 65940
aacgcgatat agcccgcgc aaataagatg atgctgcca gtccaagcag ggcagccagt 66000
ttctttccgg atttaccggc atcctgttca gcactcatga ttactccagt tctggtgtca 66060
cgtgaacgga ctggccattc acagagaaag tcagtagtgg ggtgacggga agtttccaga 66120
gatgagttcc gtcggcagag gacaaggctt gttcaaattc atcgcgcaac atcgcccggg 66180
aacgaaccag aaggctcatc cctgtgtgcc agatcgttgt atccgggaca ttacctgtga 66240
atctcagcct cttactgaa ggggtcccggg gaggaatacc atccagaaat gcctgtaatg 66300
ttgcatcatg cagggcgatc ttatccgtcg ggatggagac aactgggctg gttggtccct 66360
gccgtggtat tcgcagatcc agacgactgt ccatttctctg actggatgac ggcgtatctg 66420
tttcgccact ggttacgttc aggatgaccg gtaccgacag acctttcagg tagacagaaa 66480
tatttccgga tgcccatggc cgcaatggtg tgattgtcac catgttctcg ttgtactgca 66540
catcaaagag ttttgggtgcc gcgttataag gaggatcgga ttgtggccat ggtgaaccgt 66600
tgatcctggg aatgtcacc acgctcaggt tgttcatggc tgtgcgaaca agaggaaggg 66660
tggcaccggg ggacagatta actgtcagag agctgatacg gggtaacaaca ctggtgatgg 66720
gcgcatgatg ggcccgtctg ttatccgcca tgagactgcg tagtgagcga atctcatcgg 66780
cggagagctc agaatcaagc cttgccgcat cctgtaccag cgggctggcc tgcccggggg 66840
caggcagctc accttttacc agtggtgccc gaacacctcc ggtgttttgg gaggcgttct 66900
gaacgtgatc gctggcagaa tttgtcgctt gtggtgtgcg tgcgttctgc catcctgcgt 66960
tatctgcaga cgtggcggcg ctgcacacca ggagcagtg gctcagtaa taacgtgatt 67020
gcatattact tatctcagga gttcgggtccg gcgttacggg agatcatctg ccggatttcc 67080
ataccggatg gtttcagtct ggggtcaaca cgctggatgg tgatttcgaa aacaaaagac 67140
tgttctggct tgctggtgt ctggccgacc agacgcatac ggacaggata ctggaatgct 67200
cagaaccata cgccgtcggc catttgtccc tgtcgtacca gaacgccagc acctgtcgtg 67260
gcggtcagat tcatcttctc tttcttgatc gtctccagaa tgtagatgc ctgtaatgca 67320
ttcacatata cgacaaaacc ttcgtcagaa aaacgcggag acagggagga gatctgtgaa 67380
cgatagtgca caaatccag gttgaatgcg gtcgccagtg cctggctgcc aaaggccatt 67440
gcatcattct gactccatgc tggctgactt gttggtgcca gcctgaccag acgaccattg 67500

-continued

tctgtagcga	aatattcgcg	ctccacattc	gttgagtgcc	agtactgaat	ggcgttacca	67560
gtaatactga	taagaagaca	tgtgcccgta	cataaaagcg	cttttatcag	cgcagggaca	67620
ttatttgccc	gctgttctga	ctgcttcata	gccctgattg	tgctcttcag	tatctccggg	67680
tcagggtgcc	gatgtgatgg	cgaggatggc	tcggtatctt	cggtcatagg	ttgtagtcct	67740
tccagggatc	aatattcccc	ggcagctttt	cattcacctt	gtccacgacc	gcgtcgcaga	67800
cctggttttc	cagctgcgac	agaatgtcgt	caaggctggg	gaactggggg	aggtttatgc	67860
tgatTTTTTT	gattcgtgac	agacaggact	gcagggatga	ggaaacatcg	ttttcacggt	67920
gtgaccatgc	atccgcagct	gcacgtgctc	gctcatatcc	tgtattacta	ccggcctgtg	67980
ccgcgctacc	cgcacgacag	gttgcagcac	ttgccgtgga	tgaaatcagg	ataaggccga	68040
gcacggcaac	cagagactta	tgcattgtca	tatggcttcc	ttaccggctc	atcggccggg	68100
gctgtgggag	agatcctgat	gcagagtttt	ttcctgcctg	tcctccggct	tttggctggt	68160
ggaccactgc	tgccatgact	gctcgaagcc	caggttccgg	tacaacgcat	caggttggtt	68220
ttccggcgtg	tagacagcag	caaaaagcgg	ttcttcccg	gttttcagat	gaaactgcat	68280
aagctccggg	gcagggcgat	tcgtgctgtc	agcatcgtgg	tttaccgctt	caccataacc	68340
tgcaaagcgt	aaacctttgt	cggtcagcgc	attgataacc	agctgactgt	tgtcggctga	68400
tgggggtggc	agtgccggat	acaatgtgcc	gttcagccgg	accacaccct	gcagatgttc	68460
atcggcactc	tggacaagta	gcaggttgag	ttcacgcgta	tccttatcca	ctgatcccag	68520
aacaggtgtc	agcttgtcag	gggctgcgct	ggttatctct	gttacctgat	ttgcgttctg	68580
tggcgcggag	accggatgtc	ggtcttcacc	gataaacaga	tgtgagccga	cgttttctgg	68640
catacgtaac	gctttcatct	cttcgggcca	ccctggctg	atttgcgcag	ccactttcat	68700
aaaggtttcg	accggaatcg	cctgaatacg	ctgaccttta	tccggattat	catgtgatac	68760
cgagatcccg	ttggtaactg	actccatgga	ccacttatcc	cggaaacgtg	ctttttgctc	68820
tcctgggagg	atgaattggt	cgcggttctg	aagtgtcagt	gtcaccacgt	cacctttctg	68880
atggtttttg	accagacttt	ccagttgttc	ccccagtag	agtttgctgc	cactgcgggt	68940
tttaagctca	acaaagaaac	tctctccttt	gccgggtgca	tattcagcac	gacaaaaatt	69000
gtgcagtacg	gcagtcacgc	tctctcccgg	gcgaagtttt	cctggtggtt	cttcaccttg	69060
tgccgcatct	gccgttttgc	caggttcagc	cggatgatgat	gcagggacgg	tgctgacggg	69120
tgatgcttca	ggggctactg	gggacgccgg	ggattgtgtg	gcttcttttt	cctgaacagg	69180
gtctgggact	gctggttgtt	caggggtatt	ccggttaagt	tccgggtgtt	gcttatgggt	69240
gacaacagta	tctttaccga	cagccatttc	cttgcgtaat	ttttcgagcg	ccgctcgtcg	69300
atccgggaat	ttcatgcgca	ctttgatggt	gtgctcgatg	atcaactgca	tcgctttttg	69360
cttaaaggca	tactgcccgg	tcagctcaat	gacaccacca	taaaaatcag	tggccacagc	69420
aagtgcagcc	agaacactgc	gatcgtcatt	gctggcaccg	ttgaccattt	ccagccgggt	69480
taccgggtca	atgaaggcag	gtttgccatc	cagtttgtag	aggacgggtc	tgtctgctcg	69540
ttcttcacct	tccagcgatt	taatgatttc	gtccagattg	agcgatatcg	gtgcatcagg	69600
gcgttccggg	gcgtagacaa	tactgtcagg	tgccggtgtg	gtcgtcgtgg	tttccgggtg	69660
gggtgtggga	tactgttctc	catgcgcctg	tgaatccggt	tttttacgcg	taaaaagcc	69720
acgcgctttg	tcgagaaacg	atgaagtatt	atcagaagat	gatgtgctct	gaacagggtt	69780
ctgtggagtg	ggggcatccc	ggacagccgg	ttctactgta	tctgttgtgg	cctgaagttc	69840
tgactcatca	gcctgaacgt	ggcctgtgtc	cggttgcgac	ggcatatcac	tgttttctcg	69900

-continued

cagatgctca ggattttcat tgttcatcag ctctgatata gcgctgtagt tttcgtattc 69960
ttcggggcca tctgactcag gaaggaacgg ctctggctga aggggaatgt cttcagttac 70020
atggttgacc gcctcttccc ggggagtatc cggggatatt ccggtgcttt gtttgcatac 70080
aggctccgtc atcacggcca tttcctcttt gactgcatca ggggaagggtg atggctcggc 70140
tgattcattc atggtttcag atgagggact gtcttcaggg gatgcggtgg tggcagcagg 70200
ggccggattt tcaggtgaag tgccggattc ctgttgtagc tcgttttttt ccggttgtaga 70260
cagttcggct tcaaattcac gccagtcttt atctgtggcc accgagacaa ctttttcggg 70320
aggttccgcc ggatgagcgg gttcatcagg ggcagacgcc gttgtacttt ccggggacgc 70380
cggtgattct gcaggggagt cctgaactac agagctttcc gtttgcgcct gaacgttatc 70440
agcgtgccgc tcatctttgc cgttatcttc agtggcgtga ctggtaaag actgtgtttc 70500
atcagcaatg ttactgctgg aagcagctgg ttgttctgct tgcgtggcgg acggcagaga 70560
aggccctgg tcattggctgt gccctgtatc gggatgatgt tcaggatatt ctgtcggagt 70620
catggttttt tctcagtggt ggaccgggtg aaaaacgagg ttgcctatca ccagtgcctc 70680
gcgcatcttc ggggtgttac tgttgggggt ggaaaccccg atgtgttcta actgggcgtt 70740
gatgacatgc tgaagagcgg cccgtccccg gcttgctgctc aggtcattga aatcggtcag 70800
cccctgcgct ttttcggcat cggatgaacgc agaaagatg accgatcctc ctgtcagttc 70860
tgcggctttt gttgactga cgataccttt gtaaaccccg attgcatgat cgttgctcggc 70920
acagaagata aaggggcttt gcgtccactt ttgccgggca ttttcggcaa cggcaatcat 70980
gttgccctca tccaccgtca tcagtaccgg aaggcccggtg gcttcgtgca gggaggccgc 71040
agtggcatag ccctcggcaa acagtaccgg ctgaccgttg cgcggtgtgc ccagcgcgaaa 71100
ccagttaccg gttttctccg aatctatcag gatgcgggca tctttcccc ccggtgaccgg 71160
aatacgtgg taagagcgtc tcgcccgtt acggttactg aaggaataa ccagttcatt 71220
ttgttggtt acccgcacc ccggtgcagc ctgaatgctt tccgggtca ggtattcatg 71280
tgctgtggcc tgcggccatt tgttgatata gcggcgggca tacgcccct gtcggttgta 71340
ctgtgctttc agttcccgt cgcgctctc cctgcgttgc attgaatgcg ctttcaggtg 71400
gagtcttgcg cggggatctg tctgttctcc gccggagaag gtccaggatga tcggcgaatt 71460
atccgcgctg cgataatccc tgtaccagcc ggcaggtctg ccgtccagga agccgcgata 71520
tgcgccactt ttttgcctt ttttgcatac ggcggtcggg acacggtgga ttttcccgtc 71580
catgaccggc agttctttca gaaccagtcc ggcattctcc agaacctggg caaactcggg 71640
gaccggatca ctgccgttca tggagacgct ctgtggccgg ggcagccagc ggtccagcct 71700
ggacaggtcc gccccgggc gggcgaacca gattttgtgc tcttctccc agatgacggg 71760
cgtgtgcccg tcatcgggg gatgtgcttt ttgagatct tctattcat ctgcaggcac 71820
ggcaagccag gtgcggtagc gggatacaga cggcatgagt gcttctcctg aaaaaagacg 71880
gaaaaaaacc accgccgga gccgaggggtg gctgggggga tagaaaatcg ggggagaaat 71940
gtttgtcagg gtctccagtc tgtaccctta ttccagcagat cctgccagtg ttcaagatat 72000
tgtgcggcta catccggcat attcttgagc acaacgacat tctctgaatt cttgcgtgca 72060
gcagcacgag agaagttata ggagccagtt tcaaccgtgt tccgctaac aatgatgact 72120
ttgtcgtgat ggatggggaa ggcattctca gtccggagag gaatgtccag caggttgata 72180
ttgtcaacga cggatgaaaa gtgatccact tatatctcca ccaacggccc aatattgatc 72240

-continued

caccgtttta	ctcaggatta	gcttctgcta	taaccccggc	ctttcgtttc	tgtctgagtc	72300
gatagctttc	tcctttgatt	tgaacgacat	gtgagtgggtg	taagatacgg	tccagcatcg	72360
ctgaggtcag	tgctgcatca	ccggcgaacg	tttgatccca	ctgcccgaac	ggcagattgg	72420
atgtcaggat	cattgcgctc	ttttcgtaac	gtttagcgat	gacctggaag	aacagctttg	72480
cttcttctcg	actgaacggc	agatagccta	tttcatcaat	gatgagcagg	cggggggcca	72540
ttactccacg	ctgaagcgtc	gttttataac	ggccctgacg	ttgtgccgta	gataactgaa	72600
gtaacagatc	tgctgctgtt	gtgaagcgaa	ctttgatacc	tgacaggact	gcttcatagc	72660
ccatcgctat	tgccagatgg	gttttcccca	cacctgatgg	ccccagtaat	acgatatttt	72720
cattacgttc	tatgaagctg	agtgagcgta	acgactggag	ttgcttctgc	gggtctccgg	72780
tggcgaatgt	gaagtcatac	tcttcgaacg	ttttaccgc	cgggaaggct	gccattcggg	72840
tatacatcgc	ctgtttacgt	tgatgacgtg	ccagtttttc	ttcatgaagc	agatgctcca	72900
ggaagtccat	ataactccat	tcctgggtcta	ctgcctgttg	tgacagcgca	ggcgtgctgc	72960
ttataaggct	ttccagttgc	aactgcccgg	cgagcaccat	cagtcgttga	tgttgacggt	73020
ccatcatcac	gccactcctc	tgacagaatga	gtcgtagatg	gagagtggat	gatgcagggg	73080
gtgtttgtcg	aagttcacca	gattttcatc	aagatgcacg	tcatactctt	ttttctccgg	73140
aggcagtgcc	agcatggact	gctgctcttc	gagccagcga	tcgcagggac	gtgcctggat	73200
tgtttcatgc	tttcgttggg	tagcgacatc	gtgcagccag	cgcagaccgt	ggcggttggc	73260
tgtttcaaca	tcgacagtga	tccccatcgg	gcgcagggca	gtcattagtg	ggatgtaaaa	73320
actgttacgg	gtgtactgca	ccatccgttc	cacctacct	ttagtctgtg	ccctgaaggg	73380
gcgacacagt	cggggagaga	agcccatctc	cttgccgaac	tgccacagcg	aaggatggaa	73440
ccggtgctga	ccggtctgat	atgcgtcacg	ttgcagaacc	acagttttca	tattgtcata	73500
caacacttcg	cgcggcacac	caccaaagaa	gcggaacgca	ttacgatggc	aggtctccag	73560
cgtgtcataa	cgcatattgt	cagtgaattc	gatgtacagc	attcggctgt	atccgagaac	73620
agcaacgaac	acgtgaagcg	gtgagcgacc	attacgcata	gtgccccagt	caacctgcat	73680
ctgtcgtccg	ggttcagttt	cgaaccgaac	ggcaggctcc	tgctcctgag	gaaccgagag	73740
agaacgaatg	aatgcctctga	gaatgggtcat	tccgccacga	tatccctggg	ctctgatctc	73800
gcgagcgatt	accgttgccg	ggattttgta	aggatgagca	tcggcgatgc	gttgacgaat	73860
ataatcccgg	tattcatcca	ggagtgaagc	aacagcaggt	cgcggcgtat	atthttggcgg	73920
ctcagatttt	gcctgcaaat	aacgtttaac	ggatattgctg	gagatcccca	gttctctggc	73980
aatcgcocgg	ctactcattc	cctgcttctg	caggatttta	atthccataa	ctgtctcaaa	74040
agtgaccata	agctctcctg	aatcaggaga	gcagattacc	ccctggatct	gatttcaggg	74100
gttgggtgtg	gatcactatt	gcaccgttcg	tgacagatat	atthcatcgc	ttcctgactt	74160
gcccggttcg	tattcccctt	gtcatcaaca	acaatacggg	cgtccactcc	gcgttttttc	74220
gcttttgcca	gcgcatgcat	tacatccggg	tcggtgaagg	aatatgcat	catcctgatg	74280
gagctttccg	cactgttgat	tgtgtcaagc	accagagcgg	atgcgcttcc	ttcaggagaa	74340
aagccgacct	tcacggatgg	cgtgtcgatc	attgcaaacc	atgggtgctg	gaacagtaac	74400
gggcatgcca	gtagcgatac	cgggagcaga	gtaacgatag	tttttttacc	tgacataaag	74460
actccagaat	ttaatcgagg	ccagtccagt	ctcgtgggtg	ttccgtatgg	tggcgatacc	74520
accatggacg	accggaggcg	atggcccctc	tcagaatgct	gaaaatgcga	gtacagatcg	74580
tcctgacagt	ccagcctgaa	cggtcgagaa	taacgaaaaa	taaaatgatg	ccggtgcaaa	74640

-continued

tccagaaggt	tgttttggag	ggaaaggggc	atataaacag	ataaatcatg	gtgaacggca	74700
gaggtacgcc	ctggatgttg	actggcggtg	ttgcatatcg	ccagaaacct	tctcttttca	74760
tgaccgtaac	tcccctggcg	ggataaaaag	aatcgcttct	cttcggtcaa	cttcattccg	74820
gatatacatt	tccagaatct	ggteccggat	acggcgcttc	tctgcccga	ttatggcatc	74880
aatgtgatgc	ccccactctg	catgtggcat	tccggaaaga	ttgtcgcgaa	gctcatcggt	74940
aatgacgata	tattcccgga	cggctttacg	accaccgtca	tttgttctga	ccagaacctg	75000
aaccagaatg	aactgcaaca	gtgacaggac	agcccaggcc	atcgaatccc	tgatgacagg	75060
gggaaacagc	ccaagaagac	gtgccagcgt	ttcaccagga	gatttcgcat	gcatgggtgct	75120
caggcagtaa	tgcccgggtg	tgectgectg	taccgctgcg	tccggcggtt	cgttatccct	75180
gatctcacca	acaccgataa	tttcgggatt	acgtcgtaca	gcagaacgca	gtccggcagc	75240
aaaactgacc	acatcacgcc	cgattttctgc	ctgatgcggt	gggagcagat	cgtttttcat	75300
tcccaggata	tattccaccg	ggctttcata	tgtaacgatt	ttggcgtcgg	ggaaattgtc	75360
cataatgtaa	cggtagctg	ctgaacacag	cgttgatatt	cctgaccggg	tttcaccaca	75420
tacaaatccc	agaccgcttt	tgacagccat	tgcttcaagc	agatctggtt	caatgttcat	75480
ggagagaatg	tccggatatt	ctgtcgggat	gacacgcgat	gttattgaga	ctgctttctc	75540
ctccgcacca	gatgtgccct	gaatgaggtg	agagcgtaac	cggatgcggt	ctccgcggtt	75600
aagaccatag	cgaccggatg	catccccggt	aatctgtatc	gtcctgtcaa	ccggattgcc	75660
tgccagaacg	cggggaatga	cttcccagcc	gaacagttca	tcaatcaggg	aggacatgag	75720
tgtggttggg	aacgttgcac	tggaacaacg	cacccgtcgg	ccaaagcgac	tgacagatac	75780
aggtgaccca	cgggtcagat	ccacatcact	gactttatgt	gccggcacacc	agacaaagaa	75840
atgccgtagt	tcatctgcag	tgaaacgctg	aaacggaaaa	agaccaaact	catcaggaat	75900
attcatcggg	agcctccttc	agtgcctata	agcggacgcc	agtgagattt	ctgaagattg	75960
aattccgcat	gatttttaag	gcgacgaaca	cgatctccag	tgaccagttt	tttcccgtca	76020
cctgtaacgg	tttgcatctg	atcagaaaca	tccggacggg	tgatcatgcc	ctgacgccag	76080
agaagtgagt	acagcatcat	gccccggtaa	tcacgggtga	gggttttctg	gttggcttca	76140
agcgtcagg	cggcgttttg	tcttccttcc	tgccatccct	gcccgaatgc	ggtttccacc	76200
acttttcggt	gcacgctgtc	ttctggaacg	acgctgcctt	ctgtaccggg	agtggctgtc	76260
gttgaaagcc	cccggagaag	ccagtacgcg	cagcccggtg	gattgctgac	aaagcgttca	76320
gggcgaatga	tggtccagac	ccgggaagag	gtccggattt	gatctggcgt	gatatgagct	76380
acgtcctgtg	cttcatcaat	aaccgggtgg	agccagcctt	ccgggcta	cagtggccgg	76440
aaatcgtata	aggcattaag	tgtgctttcc	cgggcgttga	gtgcctgaat	cagctcccat	76500
gaacgctgag	ccttgccacc	acgaaatcca	agcgttttac	ctgcgtcggg	cagcattttc	76560
cagcgtggtt	ctgacagact	atccggcttt	tcacttcgtg	gtttaagcca	tgcattaatg	76620
tcagggtggtg	gcgatttgac	cccacctggc	gagatggtag	gggaagaaga	acaaccagta	76680
agcagtatta	ctggcaaaat	gagagaggtg	agtgccttca	tttttccgg	ttctccggct	76740
gcatgaagct	gacctgtaac	aagcccggat	attgatggat	tggtgctctc	caggctgtct	76800
gggcttcaat	aagtctcaac	gtattggaaa	acgtcatatc	ccggacgtga	aggttgactg	76860
gtaacggcag	gccgacacca	ttgtagttaa	actgcatccc	cctgactctg	gccagttcgt	76920
tcagtaattc	aattgcatca	ccttcccag	caaaggaaag	gcgatcgtctg	ttagctgtca	76980

-continued

gaagatgaga	ccccgttgaa	accggaagtt	ggccggaaaa	cacacctttg	tcccataatg	77040
tgtactgagt	gtgccgggta	accgccacat	cagaggcagc	accgtagtta	cgcggaacag	77100
gagtatgctg	agaaggggaa	ttgcagccag	ccagaaaaag	ggcggcaaga	caccccgcag	77160
gtataatacg	gttcataata	attcctgagt	agttaaataca	gaatgggata	taccggtgct	77220
ccggtacaga	caggatgatg	tttgtttccg	gctatacttg	cgttaccgga	aataaatgcc	77280
agtgtggcca	ggtaaatagc	ctcatagttt	actgaagggtg	attattcctg	atactggctg	77340
gttgatgtgt	cgtcagacat	aaaacgaata	tgagcgtaat	ctttaacgct	ccgcgcccga	77400
tcgatccatg	atggatgact	cgacgattta	tgaatcgaac	gtaccggcgc	ttgtccctga	77460
aacagttccc	ggccctcgtc	cggataacct	gcaattcaga	caggcacatg	tgcccgtaca	77520
ctcttgatc	ttactgagta	tatcagaatt	tatgtaaatt	caaatacct	ctatgactct	77580
ttgttgatt	ttccgtcaag	tatgagccgg	gtaccatcgt	aatgcatgat	cagggcatca	77640
aggtacgccc	gtttgaattt	cttgccgagc	ctatctctgg	ccagaaatga	taaacaatga	77700
ttatgtgtca	ttattactat	gttcctttta	tgagattctc	ttgcgattga	ttcaagcgtc	77760
ttataaagat	cattattgca	gtctgataaa	ctgtccataa	cgacgggttc	tttaccggag	77820
aagaattttg	cagtttgtat	ggttcttacc	gcattgctgg	agtaaatac	atattcactg	77880
aagattgttg	cgaacttaat	accttctgct	tgtgctttct	ctgtaccggt	aatagtgatt	77940
ccgcttttat	ccgaatagca	tggcatatct	gaacggtcgc	aacgttctcc	atggcggaaa	78000
aggaaaataa	cggtgttata	agcattaatt	tcttttgctt	gttccagggt	gatatcggga	78060
agcgagcttt	ttgcttttgt	cactgccgct	accaggaaaa	cagaaaataa	aagaatgaat	78120
gctgtttttg	aataagaaga	acgtggtttc	atcatgttat	ttaaactgaa	tataaaaata	78180
ccccggggtt	tagtgccggg	ggcggggact	gtaatcagaa	agtgaactga	agttgtgcca	78240
ttgcaccgta	atcggtgtca	gttcctacca	ggccggaaac	atcgatatgt	acgacgtcaa	78300
atggagagat	accaacgcca	gcggtgaagg	cgcttccgga	gtttgatgcc	atgttctgac	78360
gataaccggc	acgcaattgc	gcccatttcc	atgctgtaaa	ttcagcacca	acacttgcaa	78420
actgacgttt	gctgtcagaa	gtgaagccac	tggcaggagt	cagatcaacg	tcaagagcag	78480
tggtaaacag	gtcattatgc	caggatacac	cggcggttgc	ctgtggacga	actttgaagg	78540
tttctttaa	gccattgacg	actttagtat	caatactgcg	tggaatgatg	ttctgggcaa	78600
caagaccgac	agtccagttg	tcattcaggt	ctgtataagc	accaatatcg	gcggtgaatc	78660
cgtttttctg	gttggtgtac	ttgtcaccgt	caaaatcgtc	tttgtcgtaa	tcaagaccg	78720
ttacgttgta	gttaaacagg	tccacacgct	gatattttgg	tgtgacgcca	agagaccatt	78780
tttgtccggc	cgtttccagt	tctttggcaa	atgaaattcc	gacgtcggta	attacagctg	78840
cacgcccga	tgccgctgag	gtcagggcat	tcttatcgac	gtcggtaatt	gttccattgg	78900
caactttgtc	cagataatcc	aggtctgcat	cgtttacttt	tccgtttacg	ctgacagttc	78960
cgtaagactt	gaccataagg	gcaaacggca	gagtgtcatt	tgccatggct	gctacagctg	79020
atacacctac	ctgagcatct	gcattgatat	tgccggaattc	ctgcagacga	tgtttaagat	79080
ttgccgctgc	ctgttgtagc	ccatgctggg	tatctacagc	actgtcaaac	aaatcccagt	79140
catctttaac	atcatcagct	ttatttgata	catcatcagg	atcagcaact	tgtgcccaca	79200
cagacggcag	aagaaggctg	aaatcatcat	tgctgttggtg	ctttgtcagt	aaagctgggt	79260
ttgccagagg	tgccacacca	taatgggaag	atgctacccc	ggtgccaccc	attgcatcgt	79320
tacgcgcttc	aaaatatgac	gtcgtgctg	cagcgtaaaa	ggaaaataat	acagcagatg	79380

-continued

caatgatggt gcgggtaata tgatTTTTct tcatcattta atttcctggt tadcagaatt 79440
 tagacaaaac aacgctatga cacggatgtg ccgtaatttt tactttggta ctatctggta 79500
 tttaccaggg taataaagac gtattaaata agctaacagg tagtatttgc cctgtaataa 79560
 ggttcccggc aaggccaggt ctcaacgtga cgcgtcgcaa agacattggt gtattctgcc 79620
 tggttgtata ttcagttaac cattttcttt tttcatcggt cagaagtgtt ggtgataatg 79680
 atagtgccgg atatattaca gagccattta tttctTTTT ctgtctcaat attaccccg 79740
 aatattctct tttcgtggtt cctgcgaagg ggaaactatg ccagaaaata acttcagtgt 79800
 tgctgctatc attaataagc attctgaaat tadcagcagt atctggccat tcaccggaca 79860
 acgctatcgg atagtTTTca tggccattca gccagtcggg attgagatta aaacattcag 79920
 caagatgttc gagagcgtca gctgaaagat agtctgcaag tctggccggg tctgtataa 79980
 ccgtggagcg gatattccat ggcgacagca atgttgccag taatggcgca tttatatcat 80040
 gcgacagcat gatgtattca attctgctta ttatgtttcc tgtggtgta tccgcaggca 80100
 taaacatatt atgaagagca tctcaagca ggattcgggt taaatcagcg gtggatatgg 80160
 ctaattgttc gctcattatc cccagaactt ctcttcccc ttgtgggtaa cggacctgca 80220
 gtggtgtcgg gtttatctga cgaccgttga tgagtTTTT gccgattgct tttttgtcca 80280
 gcgagagcat cattcggggc gcaataccgg tcgtattcag tctcattggt cctccgactg 80340
 aaaaagtctt ttcagctcat gtggttattg tatcttcggg gttttttctg gtgaaacgaa 80400
 taatttcgat catgcagatc gaatgtggtt ggcgagttgt tgcaactcgc ctttctgtat 80460
 gtgttttgaa tgatgtttac agcgggggtg tgcccgggtt cagagggcaa atcataatgt 80520
 agtcagggtc gttaacaggt aacgctccgg gagatgggac acgttcgcct ttctgtgctg 80580
 caatggccag tgtacgcaac aaaacctcac tggcgcgggtg aactgcttcc tctttcgttg 80640
 tggcagtgac gtgaaggta tcaaaatcac cgatctcaat acgatgcgct ttctgcccc 80700
 tttcttcatc gatggtcgtg atatgggcag gatccggcac aaacctgct gccacttttt 80760
 gtgtctgccg ccggcgggca tcaagtttac tgaccagttg ccatgcacga agatgagtat 80820
 accgtttcag catattcatg gaacgatgtc ctgatattgc agcaatctcc attacattca 80880
 ggctaccag ttcgaagaag cggcttattg ctcatgccg tagatcgtga aaatgcaggt 80940
 cctcgatgcg aagtcgttgt gtggctattc tccaggcatt tttaaagccg gatgagggtg 81000
 aatcaaaaac attgccgtgg agattaacgg gcatcatctg aagaaagtta cgggcacgct 81060
 tggacagagg aacatcccgt gagtgaccgt ttttggtttc aggtaaatga gccacaccgt 81120
 ggcgcaaatc aatgtgctcc caacgtaagg ccagtatttc gccctgccg atggctgtct 81180
 caagggcaag atggaaaatg acatacaaca tcagattttt ttcgcggaaa tagcgagaaa 81240
 ggcgacgttc ttctgaagac gttagccggc gatctcgtcc ggaggatact ttggccttgc 81300
 gaaccagttc aaccgggtta gtacgacagg ttccccatc aacacgagca atattgaaca 81360
 gagatgacag aagggcgagt tcaagacgta cagtattacc tgtaatgggt ttaccgcttc 81420
 gggggttgat ttctgctaaa cgaacgtctc tgatgtagc aatatcaac gttgttattt 81480
 cgtccatatt ccgaagggca atgggatatc gcttgataac attgctccgg taaaactcct 81540
 gttgatgccc tttcttgtgt acagaaactg tttcaggta cttatccagt gcgcgtgaca 81600
 gggacatttt acggatgcgt ggagacggca tgctaacctc aaaagaggca aaaaataatg 81660
 ccaacaatca ttctctgcaa gcgtgccaat ccggtacctg gcgtaaaagc aattctggta 81720

-continued

gtacggtgat	aactggtcgt	atagcaaatg	gtcagcaaat	accgctgcca	acaggatfff	81780
ctgccagtca	gtgctcatgg	agtgtgagca	atgcagaaaa	ccctcaaggt	tggaagccga	81840
attactttgc	gggatcagtt	gcaacttatg	atgcaaatcg	aattgttaaa	tgtgggtttt	81900
atgatgaata	caatttccat	aaagggacat	ttagagctga	tttaaccgga	aatgtagtt	81960
atgtcgtcgc	gtgtcagaac	tgagattaaa	ttgctggcgc	tgctggccta	cgtgccaatc	82020
cggtagctgg	ggcgctccta	aaattcaatt	cacaacgcag	acctacaaca	tagctaaaaa	82080
cactcgtaat	ttaaggtcgc	gggtccatgc	atattgctca	tgacttacc	tgaatggctc	82140
accctttggt	ggttttcaac	aggtatattc	cgacccaaac	aacgtttggg	atgagagtaa	82200
ttatgcttgg	ggaaattatg	agtctgggtg	gaccatatca	gtcacatgcc	tcaatcttcc	82260
tggtgctgga	gtttaattaa	aggggcaaca	gtaggcacgc	acatgttcc	catcaacacc	82320
atcaccaata	cgtacatgc	gtgttccagt	cataatgtat	ccagtcggac	attgaatcgg	82380
cttgaatag	atcgaaccac	cactcttacc	gccgataaag	tgattcattg	ctacggatga	82440
tttgtaccaa	ttacatgctg	agtaattaat	tttattacc	cctgaccacc	gaccggattg	82500
gcacgtaggc	cagtgccaat	cccggtagct	gggggacaat	aggtggaaaa	ctcaaagtta	82560
ctcagctttc	caccacaggt	tatctggggc	aattcgactt	ctgtgccatt	gccagaatgg	82620
gcaacgcaga	ggatgcccc	tactgccagg	tagttgagag	cccagcaggt	tcacgtaaat	82680
ggtacaaaata	cgagcataag	acaggttgta	ttgcgtcgtg	tgtaacgctc	aattaagttt	82740
gatatccaaa	tactgaaaat	accccgccac	cacatgatgt	atcttctgtt	ggataggatg	82800
ttatctgata	ggaagtacct	gcaggtacag	caaagctgat	aaaggctgtt	tttccatatg	82860
cagggttatt	gctggcattc	acgctaatta	gcgtcccacc	aacatatccc	tcagtcggg	82920
atgtatttgc	acatgcacct	ccggcagatc	ctccattacc	tccagatgca	taaataaaca	82980
atgtactgcc	ccctgaattc	cgccctgaga	atgaacctct	atgtgaacct	aagtttgtgt	83040
aagaaccatt	gagcgaacca	gaagtcttcc	aggtaccgga	ttggcacgaa	agtattgccc	83100
ctgtattatc	gcgccctaca	aggccgtag	gcgaacatga	tgccccagca	acggcagttc	83160
tttccagttg	taagtattca	ccagtataaa	ggcgaccatc	agcccgaaca	gaaccgcctt	83220
tcacctgacc	gccggtatag	atgcccttgt	tgtttacct	tcgaacctat	gatccatcgg	83280
acataaaaa	tccgccaccg	tgagtttcat	tgagccagcc	tttgcgtgta	cgagtaatta	83340
accaaccatt	attacttctg	atatcaccgc	cagcggtagc	atctacgtca	aagtttccgc	83400
tattgccttt	tacctgaccg	ctgaaagtgc	catttacacc	atcacattg	ccgctgaaat	83460
taccagtctg	ggcatttact	gccccaacgt	tattcaggtt	atctgatccc	atatcaatgg	83520
ctgtgtgcat	tttgtttaag	tcagggcgac	cattgacctg	gaatctgtaa	agacgatcag	83580
tgctctcagc	tgaccacta	agttcatctg	tcgataaaaa	tacggcaata	tgcccgttac	83640
cgcttttggc	accataatta	cttaaagcta	ctgaccagga	acgtaatgca	cctgtggctg	83700
ttttgcgctc	ctggatata	ccaccaagac	cagtggtaat	atccttagcc	atctggataa	83760
gtgctttcac	tgataaaggc	gtgccaccac	tgatacaaac	cattgcctgt	agtaattccg	83820
ggttttgggc	gtttcgaacc	acatatgcct	gtaaccgctg	cccctcgctg	tttgtctcag	83880
taaaccogct	ggacaaaaag	ccggtatfff	tcagcatggg	tgctcgtgatg	acggcaggag	83940
ttgttgggt	actactgcc	tgagagtcg	tatagttfff	ccctatgtaa	gagcgggccc	84000
cactggcca	gctgctgaca	agacgtgctt	cagtttgcca	cccttttgtt	tgaatatagt	84060
cctgccat	gcccgtccc	caggcaatca	ggagcataac	aatcaataaa	gccgcgccag	84120

-continued

ttccagcga	tgcccagcct	cggtcatatt	tttcatcag	attaccata	gtggttgata	84180
aagattatcc	agcagcaaaa	ggacatggcc	aaaacatagc	catggacca	gagggccttc	84240
tttatgcctt	tttatgcacc	atggtgaatg	ccataagaca	aatcctcctg	tgcccagcaa	84300
cacacacat	atggcggtat	ataaccctga	ccatgctgta	ataccgcaa	taagccacag	84360
gtctccagtg	ccaatattaa	gacgatggcg	gttaactaat	ttatgaagac	agaataagac	84420
aattgcagca	gtggcaaatt	ctggtgtacg	gaaccacat	atatcagtcg	tgatttgca	84480
tagcattcct	gcaattaaaa	aacgctgtgt	gaatgttctt	ggtaataaac	ctgtcagtcg	84540
atccgttacc	gccatttgca	gtatgaacga	aagaataagg	acagcatgaa	tacggtagag	84600
cagtggatg	gatgataaaa	taattaacgc	cacagctata	ctgtatagcc	atattcctga	84660
cagaacagca	gggtgtgtct	tataccagag	atgtcccgta	tcagataaaa	aatgacgaac	84720
tctgaatagc	agagtctgtc	caataatgga	aaatgtgaac	atcaatggca	gtatataaac	84780
aggggataga	cttatgccta	cgattgtctg	catgctctgc	ctccctgtcc	gggaagacat	84840
atccctttca	tgtaacgata	aattctccat	attttattgg	catattgctc	tcttgtttca	84900
tgtctgtcct	tacggaatcc	ggcattgtat	gaccaaggc	aattccagct	gacgccacat	84960
atctgaaaat	gtcttgccag	tatccagctt	cctatatgga	tattaaggca	tggtttggta	85020
attaaatcct	cagacttttt	tattacgccc	atatttacca	gctttggaat	atgggttgag	85080
tttatttgca	tcaaccata	atccgtgcta	ctggctttac	ctgttttttt	gtccttattt	85140
atattaattg	cgcccggcct	caacgaagat	tccccggcag	aatagcctt	caataataat	85200
ggttcaattt	gatagcgcgc	gccggcagcg	gcaaagcaat	tgtcccactt	gttgggccag	85260
atctgtttgg	gagctacgta	tgaagctcgg	gcggttgga	taagagaaaa	aagcaggatt	85320
aatgaaataa	gtctgagggg	tactgtaccc	cctgacatta	aaactcctta	accattgatg	85380
gtgaagataa	gtttgtttgt	accagtgtg	ccattatctg	ccttgcaattg	cgtactggct	85440
tcttcagtag	tgacttttcc	atcactgtga	gcagtactgt	tcagggtaat	gccgttagtt	85500
aaaccagttt	tactgatctg	tgtggcaatc	tggatacagg	catcctgtgg	gactttatca	85560
taggtaacgg	taaaaccggt	gttgaaccct	gatgttgaag	ccggggcaac	agttacagca	85620
ccgccccatg	cgttatagag	cgttgctgta	ccagatgttt	tgtegccttg	tacggtcac	85680
ccagagggaa	tgacacccat	ctgaatgagg	gcacctgtca	ttttggcact	gctggtaaat	85740
gtatatccat	cgctaccttt	tagcaggctc	tgggcacttg	tgataattgt	ttgtatattt	85800
gcggtttcag	ttgccacatt	ggctcttgta	cgcaacgcat	acaaactacc	cagaacaacg	85860
actataacaa	aaagaacaac	gagcgtatt	gttccctgct	ccaaaattgc	ccatccttta	85920
tcatgaggct	cattcttctt	attatttcca	gttaaagtgg	tattaatatt	tttactaac	85980
ataaatatcc	tcgttttgtt	taaaagttac	ccatgctggt	gtcactaata	gactgaatat	86040
ccataatggc	aaaaaccagt	aacatgagag	acatgacaag	aaatatcagc	ataattaaac	86100
gaatcacggt	tgcccgtttc	tttacacggt	gaagtgtttg	actaagccat	cgttgaccat	86160
aattgctgat	tagctctggt	gcccactctc	cctgtaataa	agacaggaag	ttggctgctt	86220
ccctggatgg	gaactgataa	ccgcactgac	gcaaagccag	tccaagatga	tccccctggc	86280
ggacgcggta	aataatgctg	tcaagacgtg	tgcttaacca	tggtgatgca	aactcctgaa	86340
gaatgtttag	cgagttgagc	gtcgtcattt	tgctttcag	aagtgcagcc	atattcagga	86400
gaaatgttgc	tcctgtata	tctgataaa	tactccatgg	cattatcttg	tcggcaaaag	86460

-continued

tacgaacact	gtcagggctt	ttccagtttg	gcagagacca	tgatattaaa	cctgtgatca	86520
ctgcaaaaag	aacggcacat	atagcgccgt	aattatcgac	aaaaacagat	aatccataaa	86580
gaaaaccaag	agcaccactc	catgaatcgg	gggagcttat	tttgetcagt	tcaggtatta	86640
gctctgtatt	cagaacatat	aatgtccccg	tcatcatgat	taacaatccc	accggataaa	86700
tagccatttg	ccatatagcc	tgatggattt	gttcttttgc	atctgtaaga	gtggtggcga	86760
attgcagtgc	atccacaatt	gaaccacttc	ttatcccggc	gctgattact	gcggcctctt	86820
cctgaggaac	ccataaacta	agagtatatt	ccagagagtt	ttcgccactg	ttttcacgaa	86880
gagactcaat	gcagtctgtg	gccagttcag	caaagggatg	ccattttcgt	ccaaagtctg	86940
tccaggcacc	ccgcatctgt	tccagtgcgg	tctttaatgg	ctgtttattt	tccagcagaa	87000
aacgcagggc	ttcgtaaaac	tgcaccctgt	agggggcgct	gaacgttttt	ctgacaatga	87060
aacgcctcag	ccgttgactg	aaattcattt	cacgcatggt	gttctcctgt	tagacatcat	87120
cgatgctgag	gcgctcgtct	togtccagag	ggatgattct	gtcggcttca	agagggctca	87180
ccagaccttc	attgatacgg	cgaagaagat	gctctacacg	actgatgcct	ttcatgtttt	87240
ccagccagta	tttacgtgct	gcaactttgc	cgcggtgttt	cagaatctga	aataagcggg	87300
tatcaggttc	tatcacctca	gcaattacag	tcttgcgggt	gaggccttta	cctatttcac	87360
cgcgctttct	gccgttaatg	attacgtcgt	gattacatcc	agagcatccg	tgatgatttc	87420
ggaaccagat	attatctgta	ctgcagagtg	aatctttatt	gcagtgccgc	tcaaggtaat	87480
cacgctcgtc	gtcgctaagt	tcaggtgctc	gcttttccca	tggaatacgg	caggagggac	87540
acagagttgg	tacaaggcgc	tggctgatca	tccaatcag	taattgcgca	tcgcaaataa	87600
gatcggcatt	catacccatc	gtaatcattc	gctccggtat	accagagct	gagtttgtat	87660
gtaatgtcgt	cagaactatg	tgcccggtct	gtgccgcgta	ggtggttgac	atcatcgaga	87720
taagatcgcg	catttcccct	tccatgatgg	catcagggtc	aagtcgcatt	gccgatgaaa	87780
tagcccagct	ccatgccagt	ttgacggcat	cttcgtcgga	tttgtcgag	ataatcggag	87840
tctgtgttgc	tcccagtatc	tgtccttcca	gcgatcttc	gattgttagc	aggtgtcgcc	87900
cctgattatc	gtcaagatat	acacggcagg	cgctgcgtaa	cgttgtcgat	ttaccggaac	87960
cggttgacc	tgacaggact	attttccctt	ccggcgggcg	cagcattatg	ttcagcaacc	88020
ggatttgttc	cgggataaag	cccagttggt	taaacgtggg	aactttatct	ccgtcatcgg	88080
gtatcaggcg	cataactgca	atcagaccgt	ctcccgtagg	tctgtgactg	tagcgtgcac	88140
caaatattcc	tatttttcgc	attaattgtg	gggacaggcg	cgcatcctgc	tccctttgag	88200
ggaagaaact	ggtttcagtg	acatcagcca	ttgacagaat	ggctgttgcg	caaagtgaat	88260
agcccagtg	tggttgatct	tcatctacag	tctgcagttc	accgaatatt	ctcatgcgaa	88320
ctttgaaaat	agactctgaa	attaagaaat	gaatatctga	agcaccaagt	tttctggcag	88380
tttcaaaaata	agatagaact	ttcttctcac	tttactgac	atcagcaagg	tctttcagat	88440
gaataattcg	ttctttcggg	cctctgtttt	tctcatcctg	acctgectcc	tgtaactccg	88500
acaacgagac	tacttttggg	ttgatatccg	gatataattt	tagcagctcc	tggagattac	88560
tttgtacgtc	aggccttgtc	cgctggtttg	tttctataag	aatttcatgg	gtgtctcccc	88620
tggatataaa	aaggagagca	tccttcagat	tatatttatc	catatcacgt	tactcagaaa	88680
gtaaggggtg	tgccatcact	taacgtgacg	ccagacaatg	agategactt	cactgtgacg	88740
gatgtgectg	gaagctggct	gccagtggtg	acgcttgtct	gacgtccatc	agccatgcga	88800
agaacggcat	taagacgttt	atctttgccc	tttatttcca	taatgatggg	caattccttt	88860

-continued

ctgttttttag atgtcggctg ctctgaaact gatggcaaag aggcagtcac accagagaaa 88920
cctgaaacag tttcagatga tgaagtaaca tctgattctt cgagttgttt ctgtagctgt 88980
gcgccctgaa cttttgcctg taaaagaata ttccggtttt gttgtgcttc aagttctcct 89040
attgtgacaa gaggttgtgt tgttgcaaat gaaaaaccgg agaagaaaaa tatggatgga 89100
ataatgagta atttacctgg acgcataaat atgaccttct gaggaataac tgaaagtacc 89160
gccgtttaat tcaaaatgga tattgctcag acgaaccccg gtatcctgaa ataaagggaa 89220
caactcatca ggatttacag gcgttgataa actgaactga tattctttcc atttctgaac 89280
aggggctggg tcaccatcgt tacctggtaa tggttccggg atggctattt cattaatggc 89340
cggcgtaaac tgttttttct gaaaccacgt gaacacccgc atcagttgtt ctgagggggg 89400
agggactgcc tcacccctgc ggggcagggg aggcagtggc cggggtacag aagccaggcg 89460
tgcaccatct ttaaggtaaa agtcaggaat aacattaaag atttctttgc ttcttgccag 89520
aaagccttca atagttctc ctggctgtcg ttcgtaaatac agtgtgaatg tctcgggagt 89580
acatgttcca ccggtaagtt tccagccttc tagcgcgacc ggtgatgggt ttcgaaggtc 89640
cgcgaggct ttcagaaaat cactgattac aggttgtgat gcccatggat gcgggagttc 89700
tggcgggtga tggggctttt taaactgcaa tcttgcccgt gcagctatct cctcgggcgt 89760
cggtacgaca tccggctctg gctgagtcac ccagaataca gtgcctgcgc cggtctgtac 89820
taaaaacagt acggcaggca gtgtgaattt gctgcgattg ccgacagtaa gtttgcaacg 89880
gcggagatct gctgatgata accgggtaat aatactttcc cagttatcag gatgttccag 89940
aggagatacg acctgccatt tttcgggggg ctcttcggtc atcgtcagaa aaagactgac 90000
cttttgagca acatcagcat catttctga cagatcagcc ataacggcag gctggccatt 90060
aatggaggca aggaataaaa gtcctttatc gctgtaccgg aagacgccgt atccatttct 90120
caccatgag cagaaagcca gagcaaggga aaaataatga ttgcgctccg gcctggccag 90180
tattcctgtg ccggtaatgc ggctgatctt cccacgggaa cttctgctgc ctacagtcac 90240
tttcagagag gtaagccgtc tggattttac atggggcttg tgtttctgat gagaagggac 90300
tcgctgtttt tttacgacag gactccattt aagacaggct gccacacgc gatgatttac 90360
tttaggatct gcgagaagca caaccgggtt gatatcttca tcagccattg ttgcctcctg 90420
acgggaaagt cggggaatg atgattacaa gcgtgctgcg ttcatttttc ccggtttgtg 90480
aaccacaaa taatggattt gctggcgtaa acgtaccggc tttacttgtc gtcgtattgt 90540
tctgatcgaa accagtaacg acaagtgatt gcccttcttt cagattgacc ttctggctca 90600
gtgaacgcag tttggtatac ggcatttcga tgtaactggt tccgtctttt gacgtaaagc 90660
tacggattgt tgggggatct gacagattaa aattcatctg caactggaga ttgcccgttt 90720
tctgaattaa aggcagcagg gtcatttga atccggtggt gatcatgcc ggcgtaatg 90780
ttgttgttgc tectacatcc gtagtcggtt ttgttctgta ctgggcgacg taaaccgtct 90840
gatctgccat ctggataggt accggcgtca ggtttgtagc agtgctttct tgtgaagtca 90900
caacactgac atgcacctgt tcaactcagc cttaaatcag aagactggaa ccgctgaatt 90960
tggcggcatt ccctgttgc gtatccagaa ttgatccgcc tgcagatgta gcgcctgtaa 91020
aatctccgct tgcattgttc aacgttctc cggcggaatg tagcgattta taaacaaggt 91080
tccagtccag accgaactgt tcgtttctgg tattgctgac gctcagaacc tgtacgttca 91140
gggctacctg gcggttcata atactgtttt gttcgtccac atatcgtgag acggcttct 91200

-continued

ggacagctgg	agtatcagtg	acagtcagcg	ttgagctcga	tgcagataac	cagtaacggc	91260
ctttttctgg	tgtcagcatt	gcttcaatag	ttttccggat	gtcttcatac	agatcgtatt	91320
cctgaccaac	ggttgtgctc	tgagaggacg	ttgcatcacc	ggatgctgag	ttatcctggc	91380
ctcctgttgc	ccccattgtg	cttggtgagc	cagagctgac	actggaactg	ctgctggttt	91440
tgggtttcag	catatgaagt	ggatacgttc	tggtttcagt	cagatagaat	acaatccgac	91500
cattatccat	gcgccagtac	agaccactcc	ggctggccat	cagatccaaa	agaccattga	91560
tatctccctg	ccacatgagg	ttattcagcg	ttaatggctg	agtggaggta	gtcattgttg	91620
tgctgcccag	gctgcttaac	ggtagacgcc	cattttcatc	tgggtgctgt	agtgttcctg	91680
tcatctggcg	ggtagcgctc	ccttcaagag	ttgaattggc	tgcgtcaggc	gtgatgatca	91740
cagggatgcc	gcatacggca	gtaatacggt	gcccagttc	ctgcagagtg	atctctcctt	91800
ttcttgectg	cgtgatgtag	caggccggag	ctgtttgttt	tttctctctt	gatacctgag	91860
cgaccggaac	agggtttatc	cattgattat	cgagccaggt	aagagcctgc	gatttacggg	91920
ccgaaagggc	tgataccttt	tcccgtgcat	gtgctgagtc	ttcctgtgct	tttttctgca	91980
ttttgttgat	ttcgtgaaa	gtacatccgg	agatggaaa	agcgacggcg	atcatgcagg	92040
ggagcaccgc	cagcttcatt	gaacgctggg	gtgatttttt	catgaatata	tccagattag	92100
ttaacgtaga	cgacagaacc	agcagtaatg	cctgccgggg	gtgtcagacc	ggttgcagtt	92160
cctgatagcc	aggtgagtg	cccgttttgg	aagatcccta	ttagtgcaga	accacgactt	92220
tttgaacgca	aagtttcaac	aagacctggg	tgttcaggca	tccataccca	cagacgcccc	92280
tgttgtaact	gatgtttaat	tcgggagtc	ggagtgcag	ggagagccag	tttatctgag	92340
gaaattactc	cgtcctgctg	gcctgatacg	tatctgatat	cattgattct	gtagcaatc	92400
attagtatct	gacttgccca	tacagacgca	cttgcattat	gctgggctgt	tgtggtttca	92460
gacatcttct	gattctggta	gctaccagtg	ataatcagaa	tggtcaggcc	gacggccatg	92520
accagccatc	ccattagcga	ccatctcttg	tatcagaaac	tgtaatgatg	caactgcatgc	92580
gagaagcctg	tgcgtataaa	ggtttttgcg	cagtccgata	taactcaaat	acctgctcca	92640
tggttgattc	aatgatccc	cggaacatta	aaggcgcctc	cagacggtaa	tcggttacag	92700
aaagtggcca	tatgaccatc	cagtgcgctg	atgccatgct	ttcgcatttt	gtttcttctg	92760
cccacttgat	aatgttctct	cttaatgtgg	tgctgcggg	cgcacgccac	tctttaccct	92820
gagataccgg	tttaacaggc	gttccgggtc	tgagcgggat	cgacttgact	gtggagccgg	92880
ttggagtcgg	ggtagggcg	ggcgttgacg	aagatacgtc	gtttccctg	aatggatttc	92940
gtggtttgtt	ttggctattt	gctgtcgttg	gagattcagg	gtaagtggat	gtggttacca	93000
tggctgctgg	cgagatagtg	gttgccgtgt	cctgtgccgg	tgcagcagct	gatggtgtga	93060
cggtcaacgt	tttattatc	cagtccagat	ggcccagag	gtggtgttct	tccagcaacc	93120
ggttcagaga	acgggtccac	tgatcattgg	cagaccatga	aaccagtttg	gtattcagct	93180
tgggcgtggc	tgcattctct	tgtctgaatt	tccatccttc	cggtagtaat	gtttttatcc	93240
actgactgac	ggccgggtta	cgggcccgtc	gcgatagtgt	tacaggggcg	ctaccaggct	93300
tgctgtaaat	gattaaccgg	gagaaattct	gacttattgt	tgggtgaagg	aacggtcggg	93360
atcgcctaac	aggctgtgct	gtttttactg	tctctggcac	gctgactctc	ggggggggag	93420
ttattttagg	tggagaaaga	cgttggttgc	taagtgccag	aacgccagca	ctttcactga	93480
tttgtccgtc	aacaaaaacc	agagcaggcg	tatctgatgg	tgccacgtta	ttgctgccgg	93540
aaattccggc	acagccggac	aataatgacg	gcagtataag	tgctcagacag	ttttttttca	93600

-continued

taacggagac tccgtgttcg tatatacgtg tttgttaatt ggtgtgaggc ggctggagag 93660
gacgaatgac gactgtcatt ccgtccgaat gcaaatgcgg gagagaccac tgaataaga 93720
gatatacaaa aggaattgat aatTTTTcat acagacttgt tttccgtggg catgtaataa 93780
cagagaaatt caaacataa gattccagtc tctttataag tttatttatt cttgcaggag 93840
taaagagatg tgaatgcata acaatggttt catcattatt aattgctttt gatatcagaa 93900
aaagtaacac atcccagtgt ttctcattg actccgggca acgtgtatcg gcataggggc 93960
taagatgat gcttgattct ttactgccat tttttttcgc aaagaatgtg aagttgtatt 94020
tagatacaga ccttacgata agaagcacgc atctgaaaag tagtggggaa aagcaataa 94080
taaccactat acagaaatat aatatataag atagtgatat gtggtcagtg tatagataac 94140
ggaagtattg ccacggggta gtgatgtaca ggcaaacgt acaccaaagt aacatagat 94200
ataatggtac gttattattt ttcatgtag ttgatgccgg cgactaagat aacagagtaa 94260
gggggattaa ctgtttaatt ctttgaacg aaaaaatgca gttcctgaac atcacacacc 94320
attatttcca caggcttacc atttttatcc agtaaatttg aattggtttc aaaagatttg 94380
cagttgtttt tacttttaa tgaatcaagg tacaggggtg taatgtcaga ttcgtcatct 94440
gttgtttctc ttgaaataat actgttttct atcaccacat tttcatgtac ctcatTTggc 94500
atTTgtact gttgcaata ttgttggcgg cggatgcgtg cctgttact gctttctatg 94560
aacaccaccg tgatgattgc ccagtacatg ataatcagga aaaccagaa atcttttggg 94620
atcttccaaa aaagtgcgga cagtttgta tctgatgaaa ttaaaatcgg aaaaggatt 94680
gcaaagacaa tcaaaatcgc gatggtaat taaataaaa acgacatggt cccctcctgt 94740
tttgacgagg tcttttgtt ttgttgtttt tacgacagcc agtctgcag gtgctgatgg 94800
cgggagcggc tacccttgcg ccagcggcag tggctaccgg gtgcacgttc caggcggaac 94860
agaaatcggg tgttgcatag taccaccaca aggcagttat ccggcgtgca gaagcgtcgg 94920
gcaagctcat cgggatctgt ctgtgttttc gttgaaaaca gcttgcgttt gcagtgcgtg 94980
tcgacgacca gtacctgtag tegtccggga tgttgcgtg gcatcaaaga ctcttccgg 95040
aacggggaaa aaaagcagct gtaccgtcat aactgcaggt accggttgcg aaaaaacgg 95100
cacaagcgag tggtgacaga aagaattccg gaaacggcag aaagggcggg acaggctgcg 95160
aagacgggaa acgggttggt ttgggaatta acgcacgtga ggtgtgatga gaacgacgcg 95220
cttttcgcca gctccgtctc cgggtaatcc attcacgaca agggactgtt ccggctctgag 95280
agaaatgctt tgttcaacag tctgttttcg tttctggtct gtggtcgaga gtgcagaggt 95340
gatatttccg ggcgcaccgt gaatatccgg tgatacctgc attctgacac cgggagagac 95400
atctgcagtg aaggtatccg gacctacgga cgttaccagt gattcaacac agggcgtatt 95460
ctgtatcatc ccgtggagcg tttcaggtgt cagcgtcagg ctgtcattaa aaaatgcact 95520
gctgaaata ctccctgag caccggcaaa caggtccgga tggcgtcat taagaaggct 95580
tccgtatttt tccgccaggc agattgggtt gctggccgtt gtgtctgttc gcacggatc 95640
gaccgtgaat gtcacctgcg ggtgatgttc cctgtggcct gtgcagccgg acagcagtgc 95700
ggcggctatc gtcacccaga gtagtggtt ttttttcatg ctgttaattt cctctcaggg 95760
taaaaagaaa gactcgcacc gtcatgtcga tggggccgc ttgcgaaaa atggcacaag 95820
cgagtagtga cagaaagaat gtcggaaacg gcaggaaggg cggtacaggc tgcgaagact 95880
ggaaacgggg tatgccggg attacacatc ctcaagttaa tgtgatagtc gtctgctcct 95940

-continued

gtgttgacc	ccagacatct	tctggcaggc	tgggcagccc	gataaatagg	gtgtgaaaga	96000
gggtttctct	gcgttcgatc	ccgaattgat	gttcgtatcc	tctcaccacc	tgaaatcctt	96060
cgctcgagaa	tattaactct	gccgtttcca	gaagctgcat	agttttgcgg	tgtagtggag	96120
tgatcagctg	caacgtaact	ggtgccctca	tatcgctgt	cggtagaaaa	cactcttcgg	96180
tgcgacttag	ttgtagcaga	tgacgtttcc	cggaacaggc	ccgttcaatg	gattcattga	96240
acaccctctc	aggccatggg	cagacatatg	tgcgccagcc	tgctttctgt	aatttaccca	96300
gtgcagcccg	aaaacgaaac	aacggacatt	ccccgacagt	ggcagagctg	agaaagagcg	96360
tattcagcgt	tccgatgatg	ggaatattgc	gatctttttc	ggccaatgct	tttaacgcca	96420
tgatttcgcc	agggagacta	cggaactcag	gatgtctgct	ggcaccagaa	agccattcaa	96480
gcaggtaatg	ccgtaatccg	gtttcactgg	ttatattgtg	gttttctgt	gccgttttca	96540
gggcattcag	tgacaccag	agcaactggc	gcacgggatg	ttctgtcgtg	gtcatgcgaa	96600
tgtcctactg	tgagatgaaa	agaagaccgg	tatccgctct	ctccgccaca	cgtgatggca	96660
cgggccggcc	tttgataaaa	cgaatcaata	ctctgggggtg	aagcctttta	tttctttcgc	96720
cattaagaaa	tacacgattc	catcaaaaaga	cagggggagt	ccatgggtggg	gatggcttcg	96780
tgacggcttc	actccagaat	attctctgaa	ttgaaaaaag	cccggcccga	aggccgggaa	96840
atactggcta	tgggatgttt	acaaggcgct	ccataaagcc	gtgatgttcg	gcatttgata	96900
ccagttccag	gagcagggat	atcctcgact	caggctggag	agtattttcc	attctgagga	96960
gatactgata	ttgtgctttt	gtcagccata	tgetggaagc	cgcattcagc	tcttcctgg	97020
ctcccggatt	tagcacaggg	tccgggtaaa	tcttcattaa	tccatcaaca	atatctttat	97080
tgacgggttt	tatttcaccg	ccaaacttca	cgaatcaat	gaaggcgcta	tggcgacgta	97140
atgccgatac	tggttgaatg	tcaaaattag	ccagaataaa	aaagtaccct	ggaaaaatag	97200
cgaatattct	ttcacggtaa	cagcgctgg	agtctgcccg	tcttatcttt	cttgttatta	97260
atggagtcca	tggtagcagc	ttttgctcat	tcagccatga	gaataaagat	tctctgtttt	97320
tgccggctgt	attatattgc	gcaagatacc	agttccgggt	attcaggtgt	tctatattca	97380
cgaagtcca	cgctccgcgc	aaaaccgatc	catgatggac	gattttgcga	tgtcaggcga	97440
atatgctaaa	tcatatgtct	gaagcagtgt	ccagcccata	tctggataaa	ctgcagttct	97500
gacaggcata	taaccagcag	actctagtag	gttctgtatc	ggtgatttgg	cgaactcaca	97560
gataaagaac	ggctaagcac	taatatcagc	aatacagtg	cacagtattg	tgatacgcga	97620
aataaaacat	cagcagctca	gttcagagta	agatcgccat	atategggca	tgagccagat	97680
acaataaact	gggacaccgt	ctgaagtgat	ttgctttatt	aaagtaactt	gtgcttgggtg	97740
tttatgttta	tcaatttggg	atcgctgta	aagtcaaaa	tgcaatttcc	atgaaagtgt	97800
cccctttaat	ggggacacct	gttcacattt	tttctgtttc	tttagctgta	ttgctaatca	97860
tgaaaaocgaa	agttcgcac	agcacagcag	agcgaagtgc	atcatatcct	tccagattta	97920
aattcttcag	gcttcgcttc	aggtaggttc	gtaccgtttc	gggagaaagc	cgacagttct	97980
gagcaatggc	gtcgtaaagga	acaccattg	cgtaaaaaac	gcagacttta	agctggtttg	98040
ttgatagctc	gggaaacatg	ccttccaaca	gagtgatggc	cgggagtttc	tgtatcagtt	98100
gaggtgacat	agcaaaggtc	tccgatgaca	actaaaaacg	ctatcaccca	gttcctacgc	98160
tcatgtgtga	tagcccagac	gggggtagga	ataccggcgt	catcggaac	cgccaggtct	98220
aatgcctgcc	ccgctgagc	taccatagat	gacgacaaga	aatacaagtt	cctgtcttta	98280
tggtagggca	aaaaacgacg	ccaaatgaag	aaattaactt	ctgcgccgac	gatgactacg	98340

-continued

```

cgggttcccta cgccccgatca cagttttgcc tgtgaccagt aaaggggtact tagtataacg 98400
caccgagtcactaacagct taaaaaacat acaaaaaagc gtcaaaaactt aacgctccgc 98460
gccgaagcga tccaggcatg atgcttctgc tttgtggcgt tcgaacatgc tgggtccatat 98520
gcacgaaacg gtgtctgacc ctgccccaga caatccgcag ttctgacgaa catatgaaca 98580
aatatgctct tgtagaggct gttgttacac aattggcggg ttgtgtaaca aatggtttta 98640
tcttctaaga attattctat ttacgatcga atgatctaca aaatgatttt ttaaaggttt 98700
tttagatcgt ttaattacat taaaacagaa tattattctg ttaggtggat cggttgtaag 98760
ataaatgatc gtgagtagga caaaagtcga tcttttaatc caaaagaag 98809

```

<210> SEQ ID NO 34

<211> LENGTH: 4773

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 34

```

tcacctcctg ttggggatgat tatttatatt atgagttctg gcaggtcgat atgttatttc 60
cgaaaagtga ccatctctca gatacagaac tctgtctgcg gatgctattg tttctggtcg 120
atgagctatt aacagaacag gaattccgag ttggcgtaat gtctggctta tttctatttc 180
actttccaca tcaagatgac tggttgcttc gtccagtaat aatagaccgg gttttttata 240
cagtgtctct gccagtagaa tacgttgctt ctgaccacct gaaagtcccc ctccggtttc 300
tccaagtaat gtttgatagc ccattggcat tgccataata tcaactgtcta taagtgccag 360
acttgcgcat ttacgcatgt gttcatgatc tctaatttcg ctaaaaaaca ttatattatc 420
agctatagaa cctttgaaaa gatagtcatc ttgcaataca gtgccaatc gttgacgaac 480
ctgaaaataa tcagaatgtg tatgtggat gccaaatgca ttaattcttc cttcaactgg 540
tgtatgaatt ccaagaataa gctttacca tgttgatttg ccacatcctg atttacctgt 600
tattgctaatt atttctccag gaaagagcat tagtgacgcg ttatccaata tgggtttatc 660
tgcgccctta tggctaaatg ttattttttc gataagtaat ggtggatggg tattatcata 720
tttatgttct ctgtactggc ttgcagatat tgtttcatta tggtttgccc aatgggtgctg 780
attctgggtga ccttctctgt gtgtagcac aatatcggca agtctctcgt tataaacatc 840
aagcatgccc caggaaaaaa agttatcagt cagattgctt atactggatg aaaaacgcat 900
ctgataggat aagtaagcaa ccaacatacc cacggtaaat gtcccatcca gcacttctac 960
tgctccctgc cacaaaataa tggctgaaac tacactttcc gtcagtgtat gcgtcagttc 1020
atagctcatt tgtaaacgat tctggcgtag ctgtgtgttt ctgcccgtta cgttgagggt 1080
cagccaggcc gcttctctgt gaatagttac accgttgatt ctgagactct gaatgccgtt 1140
aagggtttcg agaaaatgcc ccgactcctt agtctctgca tcccagacat cttcaacaga 1200
ttgccgtaaa gccggatacc acaatgctct cagtgcgcca tatataatag ctgcaattac 1260
tgcgattaat gtcattcctg ggctatacaa cagcatcatg caaagagcag tcacaataag 1320
tagcatatcc agaatgcctt caagaacctg cgttgctcagc gcctgctgga ttatatctac 1380
tgcttcaaaa cgggcattaa tacttccttt acttcgggca tcgaacctg caagagggag 1440
tcttacaaga tgatggaaaa ctctggcagt ccattgcatg ttaaaattga cggataaact 1500
gatcgttgcc cattgtcgtg ctagggagag taataattgt atgagtgata acaacagtag 1560
tgccactata atgacataca atagacttct gtctgctgcg accagaactt catcaattac 1620

```

-continued

cagttgatta	agaagtggac	cacctaaagc	cagaatctca	agggccagag	caaaaataat	1680
aatTTTTgtc	attgatgcta	aaagccccgg	ggttttccct	gtcagttgac	gcaggtggat	1740
TTTTTTTctc	tcgttccggg	gggtgaaatc	actggctgga	gttaattcca	gtgccactcc	1800
tgtaaaatgc	ttacctgctg	ccaacagact	tattgtaatt	tttcctctgt	ccggatcatg	1860
gatgtataac	cggtttcccc	gaactttatg	gagaacgacg	aatgggttca	tatcccagtg	1920
cagaatagat	ggaagattaa	gacacctcag	atcttcgggt	tccagacgaa	ctgcacgtga	1980
tgataaatgg	atggacgctg	cacattcgat	caacctttgt	agcgtcattc	cctgaatacc	2040
tatattgaaa	cgttcccgtg	atgtcgataa	atctgttttc	agtccatgcc	agcaggcaat	2100
catagccaga	cacgccagac	cgcattcagc	tgattcgggt	tgacggataa	cgggtagttg	2160
tttccttact	ttccagtta	ttgattccat	tacagatttc	ctttcatgct	ccataggggc	2220
tctgtcagcc	attcccataa	atgacgagta	tcaaggttga	cgtctccttc	cagagtcatg	2280
cctggtctta	gcggttcttt	ttttccgtat	gcaaatataa	atgtattttc	aggttcaaca	2340
ataacgcgat	aatgcccttc	gttttctttc	catgtgacgg	gtgaaactgg	taataagtcg	2400
gaaggagcca	gagtcgatg	actgatttta	cgaattgtgc	cgtactggat	accaaatttc	2460
tgataagggg	aggccgaaaa	cttcagagat	accctgtgac	ctggtcggat	aaaaccggct	2520
ttctggctgg	tagcataaag	ctcaatttgt	aatgagcat	tatcgggaat	gagagtcatg	2580
accggttcag	atgctttcac	agactgcccc	tgttgatca	gtacagcagc	aatagtcccc	2640
gatactggag	ccctcagtgt	aaatTTTTct	tgtccggcga	gttcatectg	ttgttgTTTT	2700
agcacctgca	attgtctgtc	gagttctgct	ttacggcttt	ttccctgaac	aataagatga	2760
tttagttcat	ctttggctgt	gtccattgca	gtatgtaact	ggagaagccc	ctgacgctga	2820
tcttcaacgt	ttgttgagc	ggcagaaaca	tcaatttgtt	tctggttgaa	ttcgatatct	2880
gacacataat	gcgtagcagc	caatTTTTta	tagcgttcca	tgacggatat	agccagttct	2940
gcctgacgtt	cagcaagctg	aagtctttgt	tctgcacttc	ttatttgctg	ctcaagtgat	3000
atcatccttt	gccgatggc	ttcctggtgt	tgactattat	ctcgcgactc	aaaggattgc	3060
tgggaggcca	acataatata	ctgagtcctc	agggaaatac	tcatcgttgc	taatgtgcca	3120
gtccggttac	cgttataatg	ttctccactt	atatgataga	gttgtgtccc	tgacagttacg	3180
tgttctcctt	cggatacagt	cagttgtggt	acatatcctg	catattgagg	aattatTTTT	3240
accagtctctg	atgagggcat	gacgatacct	gtaagatgcg	ctttccttgt	atagctaccg	3300
taatatatga	atacagtcag	acttaacata	atgaataatg	taactgttgc	acatacggat	3360
aggctaaatg	atgttggtaa	aataatgtca	ccatattcag	tgtcattatg	atgttctatt	3420
gcttcacttc	tgaatatatt	cattatTTTT	aatacaataa	gtaacctttc	cgtcaacaag	3480
agggtttggt	tgaataatat	tgatatttga	tatacatctg	acctgtgtga	tgtaaagtt	3540
ttatactata	atatatttaa	caatataaca	aagccgttta	ttcccgcag	taacagcatt	3600
ggatagaaaa	tccccttact	gcaaatcctt	atattcaaca	ataacattga	cataataaac	3660
agaataattt	gatcagccac	attataatac	tgccgatgca	tcaggcagaa	aaataaagat	3720
gtacacacgc	agggggtaaa	taattctttt	ttataagtcg	tacatagaag	accgaataga	3780
catgttcggg	aaacaatttc	ttcataatac	ggaactgtca	ggaccagtat	aaatatttca	3840
atccaattaa	gtgaagttga	ttcactattg	ttcaaattgt	ctctataagc	aaaaataagc	3900
agttgcatga	gagcaatcac	agcaaatgat	attactaata	gctttaatgt	tttcgcattt	3960
gtctttatgg	tgattttaca	acctggtatt	cttcttaagt	aaaaaatata	aatgaagtt	4020

-continued

```

gacattaataa tttcagtaat aaagacaaaag gaaaatgccca gatccaaacc aatatattgt 4080
atgggtgaatg ccggtgtgaa tatcacaact gttgatataa caacaagtag aagaaacgct 4140
atcgcattat ctttactata tttatatatg ttatcattca taatgctatt tcgcgagat 4200
tggtcttatt ttttctatga tatagtccat gaatcttgcc gtggaaaaaa gagtgatcag 4260
catgactaca atctttgaaa actcgggaagg tagtgaaaac cagtataaat caataacaga 4320
ggagccactc aatagtgcaa atcccagtaa caaacacat ataaaggaaa gtaatttaat 4380
aaacatagta gcgcctcca ttatatctat ttatcggtta catgttccgc caacattatt 4440
acctgaacaa ctactggaac ttctctggtt accacttcca tttccactac catgatctga 4500
gagacattga ccaacaacgg ctccaccaat ggtaccttt gccattccta tgggacctcc 4560
ttgatogca ccaccaatca ttccactaaa tacagcgta ggcatttta cagtgttgg 4620
atcactataa atatgagttg gtgcgtttcg acccagtgag ttacgagccc cactggaacg 4680
gtcattacgg gggccacctt caaagttgct gtttgcgttt cctccgctga caagcgttat 4740
ctcatctaaa gttaattctc ttatatttgc cat 4773

```

```

<210> SEQ ID NO 35
<211> LENGTH: 102
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli

```

```

<400> SEQUENCE: 35

```

```

Asn Ala Asn Ser Asn Phe Glu Gly Gly Pro Arg Asn Asp Arg Ser Ser
1           5           10           15
Gly Ala Arg Asn Ser Leu Gly Arg Asn Ala Pro Thr His Ile Tyr Ser
20           25           30
Asp Pro Ser Thr Val Lys Cys Ala Asn Ala Val Phe Ser Gly Met Ile
35           40           45
Gly Gly Ala Ile Lys Gly Gly Pro Ile Gly Met Ala Arg Gly Thr Ile
50           55           60
Gly Gly Ala Val Val Gly Gln Cys Leu Ser Asp His Gly Ser Gly Asn
65           70           75           80
Gly Ser Gly Asn Arg Gly Ser Ser Ser Ser Cys Ser Gly Asn Asn Val
85           90           95
Gly Gly Thr Cys Asn Arg
100

```

```

<210> SEQ ID NO 36
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer

```

```

<400> SEQUENCE: 36

```

```

tgctgcgatg gaaaaacgtc 20

```

```

<210> SEQ ID NO 37
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer

```

```

<400> SEQUENCE: 37

```

```

ttctggacgc ttgcgatctt 20

```

-continued

<210> SEQ ID NO 38
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 38
 cttgcagacg tcttgagtc ttaaggggac tggagc 36

<210> SEQ ID NO 39
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 39
 gccttgccgc ctgccctaag gcaagccgcc agacgt 36

<210> SEQ ID NO 40
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 40
 atcgctgtag gtctgggtct 20

<210> SEQ ID NO 41
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 41
 atgtcctgcc agcgttctac 20

<210> SEQ ID NO 42
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 42
 aatatcagaa cgtaactaa atagaggcat tgtgct 36

<210> SEQ ID NO 43
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer
 <400> SEQUENCE: 43
 ctaccgtaat aaattcagac atcagcccct ccctcc 36

<210> SEQ ID NO 44
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 44

agcggcagga tgcattatca 20

<210> SEQ ID NO 45
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 45

gggaagatta ctggctgcca 20

<210> SEQ ID NO 46
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 46

gtgaatattc acgggcttta tgtaatttac attgaa 36

<210> SEQ ID NO 47
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 47

aattaacacc tatgtattaa tcggagagag tagatc 36

<210> SEQ ID NO 48
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 48

caatggcaga tgaagcgagc 20

<210> SEQ ID NO 49
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 49

tgcaaatggg ctggatagca 20

<210> SEQ ID NO 50
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 50

aactgcgcac tctatgcata ttgcagggaa atgatt 36

-continued

<210> SEQ ID NO 51
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 51

 caggaaaaaa gcgctcccg c aggagcgctg aagga 36

<210> SEQ ID NO 52
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 52

 cgctatcagg gtaacgggag 20

<210> SEQ ID NO 53
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 53

 agcactttca cggtagcgaa 20

<210> SEQ ID NO 54
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 54

 gttgtcagaa tcgatctggt tgatgatgta gtcaac 36

<210> SEQ ID NO 55
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 55

 gtgatcgtcc ctgctctggt agtagcaggt actgca 36

<210> SEQ ID NO 56
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

 <400> SEQUENCE: 56

 tgttgcaac ctttgggagt 20

<210> SEQ ID NO 57
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide primer

-continued

<400> SEQUENCE: 57
agcaaggtga cgatgagcaa 20

<210> SEQ ID NO 58
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 58
gggcaaatga acttcgtggc gagaagcgca atcgcc 36

<210> SEQ ID NO 59
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer

<400> SEQUENCE: 59
cttacaatt gttgcgaacc tttgggagta caaaca 36

<210> SEQ ID NO 60
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer site

<400> SEQUENCE: 60
tgtgtaggct ggagctgctt cg 22

<210> SEQ ID NO 61
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer site

<400> SEQUENCE: 61
catatgaata tcctcctta 19

<210> SEQ ID NO 62
<211> LENGTH: 66
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 62
gaaaacatac aaattttttc acatatttac atttaacac acaatttcac tttcattaca 60
tttttg 66

<210> SEQ ID NO 63
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide F1

<400> SEQUENCE: 63
tttacttttg gttacatatt 20

-continued

<210> SEQ ID NO 64
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide F2

 <400> SEQUENCE: 64

 ttttcttttt gaaaccaaat 20

<210> SEQ ID NO 65
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide F3

 <400> SEQUENCE: 65

 ttatctttgt agcactttca 20

<210> SEQ ID NO 66
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide F4

 <400> SEQUENCE: 66

 gttacggaat attacattgc 20

<210> SEQ ID NO 67
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide C1

 <400> SEQUENCE: 67

 ttacatttt gaaacatcta 20

<210> SEQ ID NO 68
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide B1

 <400> SEQUENCE: 68

 tttacattta atcacacaat 20

<210> SEQ ID NO 69
 <211> LENGTH: 19
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide B2

 <400> SEQUENCE: 69

 ttcactttca ttacatttt 19

<210> SEQ ID NO 70
 <211> LENGTH: 18
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide B3

-continued

<400> SEQUENCE: 70

tacaaatttt ttcacata

18

<210> SEQ ID NO 71

<211> LENGTH: 120

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic McsS

<400> SEQUENCE: 71

Met Ser Asn Ile Arg Glu Leu Ser Phe Asp Glu Ile Ala Leu Val Ser
1 5 10 15Gly Gly Asn Ala Asn Ser Asn Tyr Glu Gly Gly Gly Ser Arg Ser Arg
20 25 30Asn Thr Gly Ala Arg Asn Ser Leu Gly Arg Asn Ala Pro Thr His Ile
35 40 45Tyr Ser Asp Pro Ser Thr Val Lys Cys Ala Asn Ala Val Phe Ser Gly
50 55 60Met Val Gly Gly Ala Ile Lys Gly Gly Pro Val Gly Met Thr Arg Gly
65 70 75 80Thr Ile Gly Gly Ala Val Ile Gly Gln Cys Leu Ser Gly Gly Gly Asn
85 90 95Gly Asn Gly Gly Gly Asn Arg Ala Gly Ser Ser Asn Cys Ser Gly Ser
100 105 110Asn Val Gly Gly Thr Cys Ser Arg
115 120

<210> SEQ ID NO 72

<211> LENGTH: 103

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic ColV

<400> SEQUENCE: 72

Met Arg Thr Leu Thr Leu Asn Glu Leu Asp Ser Val Ser Gly Gly Ala
1 5 10 15Ser Gly Arg Asp Ile Ala Met Ala Ile Gly Thr Leu Ser Gly Gln Phe
20 25 30Val Ala Gly Gly Ile Gly Ala Ala Ala Gly Gly Val Ala Gly Gly Ala
35 40 45Ile Tyr Asp Tyr Ala Ser Thr His Lys Pro Asn Pro Ala Met Ser Pro
50 55 60Ser Gly Leu Gly Gly Thr Ile Lys Gln Lys Pro Glu Gly Ile Pro Ser
65 70 75 80Glu Ala Trp Asn Tyr Ala Ala Gly Arg Leu Cys Asn Trp Ser Pro Asn
85 90 95Asn Leu Ser Asp Val Cys Leu
100

<210> SEQ ID NO 73

<211> LENGTH: 105

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic MccL

<400> SEQUENCE: 73

-continued

Met Arg Glu Ile Thr Leu Asn Glu Met Asn Asn Val Ser Gly Ala Gly
 1 5 10 15
 Asp Val Asn Trp Val Asp Val Gly Lys Thr Val Ala Thr Asn Gly Ala
 20 25 30
 Gly Val Ile Gly Gly Ala Phe Gly Ala Gly Leu Cys Gly Pro Val Cys
 35 40 45
 Ala Gly Ala Phe Ala Val Gly Ser Ser Ala Ala Val Ala Ala Leu Tyr
 50 55 60
 Asp Ala Ala Gly Asn Ser Asn Ser Ala Lys Gln Lys Pro Glu Gly Leu
 65 70 75 80
 Pro Pro Glu Ala Trp Asn Tyr Ala Glu Gly Arg Met Cys Asn Trp Ser
 85 90 95
 Pro Asn Asn Leu Ser Asp Val Cys Leu
 100 105

<210> SEQ ID NO 74
 <211> LENGTH: 90
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic Mcc24

<400> SEQUENCE: 74

Met Tyr Met Arg Glu Leu Asp Arg Glu Glu Leu Asn Cys Val Gly Gly
 1 5 10 15
 Ala Gly Asp Pro Leu Ala Asp Pro Asn Ser Gln Ile Val Arg Gln Ile
 20 25 30
 Met Ser Asn Ala Ala Trp Gly Pro Pro Leu Val Pro Glu Arg Phe Arg
 35 40 45
 Gly Met Ala Val Gly Ala Ala Gly Gly Val Thr Gln Thr Val Leu Gln
 50 55 60
 Gly Ala Ala Ala His Met Pro Val Asn Val Pro Ile Pro Lys Val Pro
 65 70 75 80
 Met Gly Pro Ser Trp Asn Gly Ser Lys Gly
 85 90

<210> SEQ ID NO 75
 <211> LENGTH: 99
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic MccE492

<400> SEQUENCE: 75

Met Arg Glu Ile Ser Gln Lys Asp Leu Asn Leu Ala Phe Gly Ala Gly
 1 5 10 15
 Glu Thr Asp Pro Asn Thr Gln Leu Leu Asn Asp Leu Gly Asn Asn Met
 20 25 30
 Ala Trp Gly Ala Ala Leu Gly Ala Pro Gly Gly Leu Gly Ser Ala Ala
 35 40 45
 Leu Gly Ala Ala Gly Gly Ala Leu Gln Thr Val Gly Gln Gly Leu Ile
 50 55 60
 Asp His Gly Pro Val Asn Val Pro Ile Pro Val Leu Ile Gly Pro Ser
 65 70 75 80
 Trp Asn Gly Ser Gly Ser Gly Tyr Asn Ser Ala Thr Ser Ser Ser Gly
 85 90 95
 Ser Gly Ser

-continued

<210> SEQ ID NO 76
 <211> LENGTH: 75
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic MchB

<400> SEQUENCE: 76

```

Met Arg Glu Ile Thr Glu Ser Gln Leu Arg Tyr Ile Ser Gly Ala Gly
1           5           10           15
Gly Ala Pro Ala Thr Ser Ala Asn Ala Ala Gly Ala Ala Ala Ile Val
           20           25           30
Gly Ala Leu Ala Gly Ile Pro Gly Gly Pro Leu Gly Val Val Val Gly
           35           40           45
Ala Val Ser Ala Gly Leu Thr Thr Ala Ile Gly Ser Thr Val Gly Ser
           50           55           60
Gly Ser Ala Ser Ser Ser Ala Gly Gly Gly Ser
65           70           75
  
```

<210> SEQ ID NO 77
 <211> LENGTH: 84
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic cleaved mcpM

<400> SEQUENCE: 77

```

Arg Asn Ser Leu Gly Arg Asn Ala Pro Thr His Ile Tyr Ser Asp Pro
1           5           10           15
Ser Thr Val Lys Cys Ala Asn Ala Val Phe Ser Gly Met Ile Gly Gly
           20           25           30
Ala Ile Lys Gly Gly Pro Ile Gly Met Ala Arg Gly Thr Ile Gly Gly
           35           40           45
Ala Val Val Gly Gln Cys Leu Ser Asp His Gly Ser Gly Asn Gly Ser
           50           55           60
Gly Asn Arg Gly Ser Ser Ser Ser Cys Ser Gly Asn Asn Val Gly Gly
65           70           75           80
Thr Cys Asn Arg
  
```

45

We claim:

1. A composition comprising microcin MccPDI having one or more of a sequence of SEQ ID NO: 77 or a functional variant thereof and/or SEQ ID NO:24 or a functional variant thereof, wherein said functional variant has a sequence at least 95% identical to SEQ ID NO: 77 or SEQ ID NO:24; and an oxidizing agent.

2. The composition of claim 1, wherein said composition further comprises at least 10% oxidizing agent.

3. The composition of claim 1, wherein said composition further comprises at least 20% oxidizing agent.

4. The composition of claim 1, wherein said composition further comprises dimethyl sulfoxide (DMSO).

* * * * *